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CLEC-2 is a member of the 'Dectin-1 cluster' of C-type lectin-like receptors and was originally 
thought to be restricted to platelets. In this study it was demonstrated that murine CLEC-2 is 
also expressed by peripheral blood neutrophils, but only weakly by bone-marrow or elicited 
inflammatory neutrophils. It was also shown that on circulating neutrophils, CLEC-2 can mediate 
phagocytosis of antibody-coated beads and the production of proinflammatory cytokines, 
including TNFa, in response to the CLEC-2 ligand, rhodocytin. CLEC-2 possesses a tyrosine-
based cytoplasmic motif similar to that of Dectin-1, and it was shown using chimeric analyses 
that the activities of this receptor are dependent on this tyrosine. These data therefore 
demonstrate that CLEC-2 expression is not restricted to platelets and that it functions as an 
activation receptor on neutrophils. 
Like Dectin-1, CLEC-2 can recruit the signalling kinase Syk in myeloid cells; however, it was 
found that stimulation of this pathway does not induce the respiratory burst. This suggests that 
there is another component / pathway stimulated by Dectin-1, in addition to Syk, that is required 
for the induction of the respiratory burst. To explore the mechanism of Dectin-1 mediated 
induction of this response some preliminary experiments were performed and it was found that 
the tyrosine within the ITAM-like motif of Dectin-1 is crucial for this response, whereas the 
membrane distal tyrosine is not required. Furthermore, a number of chimeric receptors which 
will be used to further investigate the underlying mechanisms were generated. 
Podoplanin is a transmembrane mucin-like sialoglycoprotein that is expressed on a variety of 
cell types. It was recently described as a CLEC-2 ligand and its expression on myeloid cells was 
demonstrated for the first time here. Inflammatory macrophages and neutrophils were found to 
display high levels of podoplanin expression. In contrast, resident alveolar and peritoneal 
macro phages, and bone marrow derived macrophages were found to have negligible 
podoplanin expression. Furthermore, it was shown that certain TLR agonists and cytokines 
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The concept of homeostasis refers to the ability or tendency of a system to maintain internal 
equilibrium. In physiological terms, this is an exceptionally dynamic process during which intemal 
change continuously compensates for external change to keep conditions relatively constant. The 
human body consists of several systems which together function to maintain homeostasis. Each 
system is composed of cells which are progressively organised into tissues and organs, and the 
concept of homeostasis can be applied at all levels. At the most basic level cells perform functions 
that are essential for their own survival, in addition to specific tasks that playa part in the 
maintenance of an organism's overall homeostasis. Membrane proteins such as those that form 
channels, serve as carrier molecules and act as enzymes or receptors; are all crucial for a cell's 
role in this system. Cells express a wide range of surface rec ptors which are involved in a variety 
of functions, including differentiation, growth and survival, adhesion, migration, phagocytosis, 
activation and cytotoxicity [1, 2]. Even though there has been a rapid development of powerful 
technologies which has resulted in an ever increasing list of membrane proteins, the entire 
repertoire of membrane expressed receptors remains to be determined. Nonetheless, there has 
been a vast amount of research devoted to their characterisation and their roles in homeostasis 
and host defence. 
1.2 Receptor classification 
Although protein families have long been grouped according to structure and function, the 
extraordinary explosion in protein sequence, structure and functional data in recent times, makes 
classification a significantly complex and dynamic process [3]. Structural classifications derive 
groups on the basis of molecular similarity in terms of primary or tertiary structure, whereas 
functional classifications derive groups on the basis of functional similarity. Family members 
grouped according to structural homology frequently have related functions, but may also be 
functionally divergent. Structurally homologous receptors are usually derived from a common 
ancestor and are likely to have been generated by genetic changes such as exon shuffling, gene 
duplication, retroposition and gene fusion [4]. An example of a structurally defined group is the 
immunoglobulin (Ig) superfamily (lgSF). This superfamily is one of the largest in vertebrates and its 
members can be diverse in terms of sequer:lce and structure. However, all proteins of the IgSF 
possess a common Ig-fold which has a sandwich like structure formed by two sheets of antiparallel 
I)-strands [5]. The members of the IgSF are involved in immune functions, recognition, binding, and 










receptorrToll-like receptor (TLR) superfamily and the Tumor Necrosis Factor (TNF) superfamily are 
other examples of major groups defined by their structural domains. 
1.3 Receptors linking homeostasis and immunity 
In vertebrates, a complex immune system has evolved to defend against the potentially detrimental 
effects of microbial infection. This immune system consists of two branches; innate and adaptive. 
Innate immune recognition is based on the recognition of conserved, invariant structures that are 
unique to microorganisms. This recognition is mediated by the pattern recognition receptors 
(PRRs), a family of functionally related germ-line encoded proteins [6, 7]. According to Charles 
Janeway's original hypothesis, PRRs evolved to recognise microbial ligands and functioned to 
distinguish infectious non-self from non-infectious self with the resultant initiation of adaptive 
immunity [7, 8J. For a long time this theory seemed to hold true, and reports emerged that various 
PRRs such as TLRs, C-type lectin receptors, nudeotide-oligomerisation domain (Nod)-like 
receptors (NLRs) and retinoic acid-inducible gene 1 (RIG-1 )-like receptors (RLRs). did recognise 
pathogen-associated molecular patterns (PAMPs) and could induce immune responses. 
TLRs were the first dass of cellular PRRs described and are present at the cell surface or within 
endosomes. They recognise specific microbial components and playa crucial role in immunity that 
has been reviewed extensively elsewhere [9, 10]. C-type lectins comprise both soluble and 
transmembrane receptors and can recognise a wide range of mainly carbohydrate structures on 
pathogens. NLRs and RLRs are intracellular cytosolic receptors involved primarily in the detection 
of bacteria and viruses respectively [11-13]. As our understanding of these receptors has 
deepened, it has however become necessary to reconsider Janeway's original theory. For 
instance, it is now known that the bacterial ligands recognised by TLRs are not unique to 
pathogens but are also present on commensal microorganisms. For example, studies have 
revealed that TLR signalling induced by commensal bacteria has an essential role in maintaining 
epithelial homeostasis, and protection from direct epithelial injury [14-20]. Furthermore, growing 
evidence suggests that PRRs respond to endogenous ligands which are released from, or exposed 
on the surface of dying cells. For example the C-type lectins, Minde and CLEC9A, were both 
shown to recognise ligands on necrotic cells with the resultant activation of adaptive immunity [21, 
22]. It has also been demonstrated that TLRs can respond to endogenous ligands which are 
released during inflammatory responses and tissue damage. One example is the induction of 
signalling and dendritic cell (DC) activation via TLR2 and/or TLR4 recognition of hyaluronan [23-
25]. Finally, it is becoming increasingly apparent that the recognition of endogenous ligands by 
certain PRRs contributes to immune homeostasis. This is particularly apparent in the case of C-
type lectin receptors [26]. A select example is DC-SIGN, which in addition to recognising several 
pathogens, also binds endogenous proteins and in this way mediates adhesion between DCs and 
endothelial cells during DC migration, and between DCs and T cells during antigen presentation 
[27]. We have learned a tremendous amount about the immune system in the 20 years since 
Janeway proposed the idea of PRRs and it has become clear that his hypothesis does not 











complete and (the) pattern recognition concept will continue to evolve and eventually integrate with 
other concepts into a more general theory' [28]. Furthermore, our growing knowledge raises 
interesting questions about the evolution of such receptors and Siamon Gordon, amongst others, 
has speculated that the further identification of endogenous ligands and an increasing appreciation 
of homeostatic requirements will result in the realisation of the innate immune system as 'primarily 
a self-regulating, physiologic system, with defence as a secondary, albeit vital, by-product' [29]. 
1.4 C-type lectin-like domain superfamily 
The term 'C-type lectin' was originally used to describe a group of Ca2+ -dependent carbohydrate 
binding proteins containing a conserved carbohydrate recognition domain [30, 31]. Other proteins 
containing the same domain were subsequently identified, but carbohydrate ligands have not been 
identified for many of these proteins. To clarify this ambiguity, the term C-type lectin-like domain 
(CTLD) was introduced to refer to such domains [32, 33]. The C-type lectin superfamily is now 
defined as a large group of proteins that are characterised by the presence of one or more CTLDs. 
It should be noted that the use of the word 'lectin' to describe this family is in fact misleading, as the 
definition of a lectin is a protein with carbohydrate binding capabilities. It was proposed by Zelensky 
in 2005 that the family instead be referred to as CTLD-containing proteins (CTLDcps) [34]. 
However, several reviews published since then have continued using the term 'C-type lectin' and 
as this is the more common usage in the current literature, it will be used here. 
The CTLD is a structural motif which was originally identified as a protein fold in the carbohydrate 
recognition domain of mannose-binding lectin [35]. It consists of two antiparallel ~-sheets and two 
a-helices. A ~-strand divides the structure into two loops, the upper and the lower. The lower loop 
is formed by the vertical [3-sheet and both a-helices. The upper loop consists of the long loop 
region and the second anti parallel l3-sheet, and three distinct core hydrophobic regions are 
present. A WIGL amino acid (aa) sequence (aromatic aa, aliphatic aa, glycine, aliphatic aa) which 
is extremely well-conserved in CTLDs, is involved in formation of all three hydrophobic cores which 
stabilises the overall structure [34, 36]. Disulfide bridges at the bases of the loops are formed by 
four cysteines [34]. 
Initially, the superfamily was divided into seven groups based on their domain architecture (Groups 
I to VII) [37]. This grouping conveniently correlated with the results of phylogenetic analysis and 
incorporated functional similarity. The classification was modified some years later with the addition 
of seven new groups (Groups VIII to XIV) [38]. Subsequently three new groups were added to 
incorporate novel proteins identified in the interim (Groups XV to XVII) [34]. The latest classification 
is shown in Figure 1.1 [34]. Despite the presence of a highly conserved domain, C-type lectins are 
functionally diverse and have been implicated in various processes including, cell adhesion, tissue 
integration and remodelling, platelet activation, complement activation, pathogen recognition, 











CTLDs recognise a range of ligand types, including carbohydrates as the superfamily name 
suggests, but also proteins, lipids and inorganic compounds [34]. As mentioned previously there 
are now many C-type lectins which have not been ascribed any carbohydrate binding function. 
Nevertheless, the recognition of carbohydrates by these receptors is relatively well studied and is 
worth considering. Many C-type lectins posess four Ca2+ binding sites, although Ca2+-binding site 2 
is the important site for carbohydrate binding [34J. Residues with carbonyl sidchains are involed in 
Ca2+ coordination at this site and together with the Ca2+ atom are direcly involved in carbohydrate 
binding. These highly conserved motifs contributed by the long loop region of the CTLD are Glu-
Pro-Asn (EPN) or Gln-Pro-Asp (OPD) and generally have specificity for man nose or galacotse 
respectively [44]. A second highly conserved group of residues is a Trp-Asn-Asp (WND) motif and 
is contributed by a ~ strand in the upper ~ sheet [36]. These characteristic residues have been 
widely used in the literature as indicative of whether a C-type lectin with unknown binding function 
is likely to bind carbohydrates (EPN/OPD and WND present), and furthermore whether it would 
preferentially bind mannose or galacotse type carbohydrates (EPN v OPD) [34J. However, this 
approach has some limitations as it is based on the assumption that Ca2+-dependent binding is the 
only major mechanism of carbohydrate binding by CTLDs. This is known to be untrue, as 
demonstrated by Dectin-1, a C-type lectin which does not contain the motifs described above and 
binds a carbohydrate ligand in a Ca + -independent manner [45]. Furthermore, it also should be 
noted that the presence of these motifs does not guarantee carbohydrate binding functions, as 
there are several examples of CTLDs containing the conserved motifs that are not known to bind 
carbohydrates [34]. 
1.5 Myeloid C-type lectins 
A prominent role for C-type lectins in immunity was originally identified in Natural Killer (NK) cells, 
where they were implicated in controlling NK function in response to transformed and virally 
infected cells [46]. The functions of NK cells were found to be controlled by paired C-type lectins 
which delivered activation and inhibitory signals, the balance of which controlled NK cell function 
[47]. The identification of C-type lectins on myeloid cells raised the possibility that they may serve 
similar functions in controlling cellular activation in these cells. Of particular interest to our research 
group are myeloid expressed C-type lectins belonging to the Group II, V and VI subgroups, many 
of which have been implicated in innate immunity and homeostasis. In several instances their 
functions have been linked to the presence of signalling motifs in their cytoplasmic tails, or to the 
ability to couple with signalling chains. For example, Mincle (discussed below) induces cellular 
activation by associating with Fc receptor y chain (FcRy), an immunoreceptor tyrosine-based 
activation motif (lTAM) containing adaptor. An ITAM consists of a short amino acid sequence 
containing a duplicate of the sequence YxxUI with six to twelve intervening residues (YxxIlLx(s_ 
12)YxxI/L, where Y is tyrosine, L is leucine, I is isoleuine and x is any residue) [48-50J. The 
conserved tyrosines and leucine/isoleucine residues, and the spacing between them are critical for 
the biological function of an ITAM [51]. Immunoreceptors which activate intracellular signalling 
through ITAMs include T cell receptors, B cell receptors and Fc receptors. Signalling via this motif 
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tyrosines by Src family kinases. This phosphorylation promotes recruitment of Syk family kinases 
which initiates a series of downstream signalling events [49, 50]. 
ITAM signalling often results in the activation of cellular responses, including cell migration and 
adhesion [52], proliferation and differentiation [53, 54], and phagocytosis and degranulation [55]. 
This activation may be kept in check by immunoreceptor tyrosine-based inhibitory motif (lTIM)-
containing receptors [49, 50]. An ITIM is a cytoplasmic sequence consisting of the amino acid 
residues INIUSxYxxI/LN, where I is isoleucine, L is leucine, S is serine, Y is tyrosine, and x is any 
residue [56, 57]. Generally, ITIM containing receptors are tyrosine phosphorylated by Src kinases 
in response to immunoreceptor engagement. This results in recruitment and activation of protein 
tyrosine phosphatases such as SHP-1, which inhibit cellular activation by dephosphorylation of 
various immunoreceptor-regulated substrates [56, 57]. 
The concept of paired receptors, one activatory and the other inhibitory, working in collaboration to 
ensure controlled cellular responses was prevalent for some time and seems a plausible model of 
regulation [58]. This model certainly appears to hold true when one considers the tight regulation of 
NK cell function [47]. However, in recent years a number of examples have emerged which have 
questioned this paradigm [49, 50, 59]. For instance, it has been shown that ITAM signalling under 
certain conditions can induce negative responses. One example is TREM2 which associates with 
the ITAM containing adaptor DAP12. TREM-2/DAP12 signalling was shown to trigger nitric oxide 
production by macrophages [60], cytokine production, antigen uptake and maturation in DCs [61, 
62], and differentiation of osteoclasts [63]. However it was also shown that in certain contexts, 
TREM-2/DAP12 signalling can negatively regulate TLR and FcRy signalling in macrophages and 
inhibit inflammatory cytokine production [64, 65]. There are also examples of ITIM-containing 
receptors that function to activate cellular responses. For instance, TL T-1 was shown to enhance 
FCERI-mediated calcium signalling, an outcome which was dependent on its association with SHP-
2 [66]. To add further complexity to ITAMIITIM signalling models, ITAM-like motifs which vary from 
the traditional consensus sequence have now been identified in a number of receptors. Dectin-1 
exemplifies an ITAM-like motif containing receptor and its mechanisms of signalling will be 
discussed later. Such examples of non-traditional ITAM-signalling are becoming increasingly 
common and demonstrate a flexibility of the mechanisms of signalling [49]. 
1.5.1 Dectin-2 cluster: an example of myeloid expressed C-type lectins 
An example of myeloid expressed C-type lectins is the Dectin-2 cluster of receptors which are 
members of Group II of the superfamily [67]. The group consists of Dectin-2, DCIR, DCAR, BDCA-
2, Mincle and Clecsf8. These receptors are encoded by a cluster of genes within a single large 
region known as the 'natural killer gene complex' (NKC) that occurs on syntenic regions of mouse 
chromosome 6 and human chromosome 12 [68, 69]. Mincle, Dectin-2 and DeAR have ali been 
shown to associate with the ITAM-containing FcRy, (and BDCA-2 with FCERI), which triggers 
intracellular signalling via Syk [21, 70-73]. Mincle provides a further example of a receptor involved 











Minde acts as an activating receptor that senses damaged cells and in this way has a homeostatic 
function [21]. On the other hand, it has also been shown that Minde mediates recognition of 
Candida albicans and Ma/assezia species and is involved in the immune response to these fungi 
[74, 75]. In a similar vein, Dectin-2 can recognise hyphal forms of various fungi and is capable of 
inducing innate immune responses via coupling to FcRy [71]. Another member of the group, DCIR, 
is an ITIM-containing protein and although neither endogenous nor exogenous ligands have been 
identified, it has been shown to act as an inhibitory receptor [76]. It is possible that under 
physiological conditions, DCIR may function in concert with Minde, and/or other activating 
members of the group to modulate signalling. 
1.5.2 Oectin-1 cluster 
The Group V receptors, identified only in higher vertebrates, are almost exclusively encoded by 
genes within the NKC [68, 69, 77, 78]. They are type II transmembrane receptors meaning they 
have a single membrane spanning region, with the N-terminal domain extending into the cytoplasm 
and an extracellular C-terminal domain. Within the NKC, another cluster of genes encode a 
subfamily of related Group V receptors known as the 'Dectin-1 cluster', that are expressed 
primarily, but not exclusively, on myeloid cells (Fig. 1.2) [77, 79, 80]. These type II receptors 
contain a single extracellular CTLD which lacks the typical residues involved in Ca2+ coordination 
required for carbohydrate binding by other C-type lectins. Although this group of receptors show 
considerable similarity in structure, they nevertheless recognise a diverse range of structurally 
unrelated ligands and mediate an assortment of functions that contribute to both immunity and 
homeostasis [79, 81]. Table 1 lists the members of the 'Dectin-1 cluster' and includes the approved 
gene symbol and approved gene name as designated by the HUGO Gene Nomenclature 
Committee 1 (European Bioinformatics Institute, Cambridge, UK). ConSidering the structural and 
evolutionary relationship to CLEC-2, each of these receptors will be considered in turn here. I will 
summarise the current literature for each receptor under the headings: identification, structure and 
expression; ligands, and function. However, in the case of Dectin-1, I will enter into more detail 
because the sequence homology of the cytoplasmic tails of Dectin-1 and CLEC-2 was what 
instigated this project, and knowledge of Dectin-1 function directed the initial stages of the 
investigation. The order in which the receptors are discussed is based on the type of signalling 
motif present in the cytoplasmiC tails. CLEC-1 and LOX-1 do not contain any characterised 
signalling motifs and are the first two receptors discussed. Next, I consider MICL and CLEC12B 
which contain ITIMs in their cytoplasmic tails. Finally, I discuss the ITAM-like containing members 
of the cluster, Dectin-1, CLEC9A and CLEC-2. Cartoon representations of the typical structures of 
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Table 1 Members of the Declin · l cluster of C·type lectin proteins 
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1.6 CLEC-1 (CLEC1A) 
1.6. 1 Identification, structure and expression 
CLEC-1 was originally identified through a computational screen of myeloid cells for C-type lectin 
receptors homologous to those expressed by NK cells [82]. CLEC-1 displays the typical structure of 
Group V C-type lectins and it contains a cytoplasmic tyrosine within the sequence YSST which may 
represent a novel signalling motif [82]. In addition to six cysteine residues in the extracellular region 
that are typical of C-type lectins, it also contains two more cysteines in this region which may 
mediate receptor dimerisation. RNA blot analysis of various human tissues revealed expression of 
CLEC-1 in placenta, lung, thymus, heart, pancreas, kidney, bladder, prostate, testis, ovary, small 
intestine and colon. RT-PCR analysis of cellular distribution revealed expression on unstimulated 
as well as TNF or CD40L-stimulated DCs, endothelial cells and weak expression in monocytes [77, 
82]. The expression of rat CLEC-1 has also been examined and RT-PCR analysis revealed high 
expression in the lung, lymph nodes, spleen and aorta and lower expression in the heart and 
thymus [83]. In terms of cellular distribution, rat CLEC-1 was found at the protein level on the 
surface of bone marrow derived DCs and to a lower extent on endothelial cells. Furthermore, it was 
demonstrated that rat CLEC-1 expression was down-regulated by inflammatory stimuli such as 
LPS, and increased by immunoregulatory mediators such as IL-10. It was also found that CLEC-1 
expression was up-regulated on myeloid cells and endothelial celis in various models of allograft 
tolerance. This study also suggested that the action of regulatory T cells (Treg) enhanced CLEC-1 
expression in tolerated allografts which in turn moderated allogenic T helper 17 (Th17) responses. 
These findings led to the suggestion that CLEC-1 may be a potential therapeutic agent for 
modulation of immune responses in transplantation, autoimmunity or cancer settings [83). 
1.6.2 Ligands and function 
CLEC-1 is the least characterised of the Dectin-1 cluster of receptors. No ligands have been 
identified and limited functional studies have been carried out. As referred to above, it has been 
demonstrated that CLEC-1 moderated Th17 differentiation in an experimental transplant model 
[83]. As for the other 'orphan' receptors of this cluster, the identification of ligands will potentially 
provide direction towards clarification of the physiological function of CLEC-1. 
1.7 LOX-1 (OLR1) 
1.7.1 Identification, structure and expression 
Lectin-like oxidised low-density lipoprotein receptor-1 (LOX-1) was originally identified by screening 
a vascular endothelial cDNA expression library for receptors for oxidised low-density lipoprotein 
(OxLDL) [84]. LOX-1 is a type II transmembrane protein with a single CTLD connected by a stalk to 
a transmembrane region and a cytoplasmic tail which does not contain any known signalling motifs. 
The receptor contains the characteristic six cysteines of CTLDs which form intrachain disulfide 
bonds [85]. Human LOX-1 (hLOX-1) also contains a cysteine residue in the stalk region that 
mediates homo-dimerisation which is important for effective recognition of certain ligands [86]. 
Furthermore, evidence suggests that dimers of hLOX-1 may form noncovalently associated 











been determined [86, 87]. In contrast to hLOX-1, the rat and murine forms do not have a cysteine 
residue in their stalk regions. Interestingly, both rat and murine LOX-1 have longer stalk regions 
than the human form, consisting of triple repeat sequences [88, 89]. Sequence similarities between 
these long-stalked LOX-1 forms and the myosin tail, which is also highly repetitive, have been 
noted [89]. The spacing of hydrophobic and charged residues in myosin allows dimerisation to 
occur by two a-helices wrapping around each other to form an a-helical coiled coil [90}. Rat and 
murine LOX-1 may form dimers in a similar way, even though they lack the cysteine in the stalk 
region that mediates dimerisation of human LOX-1 [86]. 
In humans, alternative splicing generates an isoform which lacks exon 5 and exhibits functional 
differences to the full length form. This variant is called LOXIN and contains a stop codon in the 
open reading frame which leads to premature termination and generates a protein that lacks a 
large portion of the extracellular domain [91]. LOX-1 is glycosylated, although precise glycosylation 
patterns and chain length vary between species and cell type [85]. It can also be proteolytically 
cleaved at the cell surface and released in a soluble form [92]. IL-18 can stimulate this shedding of 
LOX-1, and ADAM10 is involved in the cleavage process [93]. The function of soluble LOX-1 is 
unknown but it was found to be elevated in obese patients and in the serum of patients with acute 
coronary disease and diabetes [94-96]. 
LOX-1 is widely expressed with highest levels in placenta, lung, marrow and spinal cord [97]. In 
terms of cellular distribution, LOX-1 is present at low levels on endothelial cells, monocytes, 
activated platelets, smooth muscle cells, fibroblasts, macrophages and immature DCs [84, 98-102]. 
However, expression can be enhanced by several pathological conditions including hypertension, 
diabetes and hyperlipidemia [98, 103-105]. LOX-1 can also be rapidly induced by pro-inflammatory, 
pro-oxidant and mechanical factors such as OxLDL, angiotensinII, TNFa, shear stress and free 
radicals [101, 106, 107]. 
1.7.2 Ligands 
As mentioned, LOX-1 recognises OxLDL [84]. In addition to this 'modified self ligand, LOX-1 
recognises several other structurally unrelated macromolecules including advanced glycation 
endproducts, aged and apoptotic cells, heat shock protein-70, Gram -positive and -negative 
bacteria and C-reactive protein [99, 108-111]. The diversity of LOX-1 ligands highlights this 
receptor as yet another example of one which functions in both pathogen recognition and 
homeostasis. 
1.7.3 Function 
Even though LOX-1 does not contain any classical signalling motifs in its cytoplasmic tail, it can still 
mediate a range of cellular responses. For example, LOX-1 can mediate endocytosis of OxLDL by 
a dynamin-2 dependent, clathrin independent mechanism which requires a cytoplasmic acidic 
motif, DOL [84, 112]. The receptor can also mediate phagocytosis of aged/apoptotic cells, possibly 











a mechanism that includes the downregulation of antiapoptotic proteins c-IAP and Bcl-2, the 
release of cytochrome c and Smac, and activation of caspase-9 and caspase-3 [113. 114]. LOX-1 
can also mediate activation of NF-KB and the production of reactive oxygen species via a pathway 
that involves MT1-MMP, and Rac-1 mediated NADPH oxidase activation [115-118]. Binding and 
endocytosis of HSP-70 by LOX-1 can induce DC mediated antigen cross-presentation [99]. 
Although the pathways leading to these cellular responses are not understood in their entirety, 
other various downstream components have been implicated in LOX-1 signalling including PKC, 
p38 MAPK and PTK [119, 120]. The fact that LOX-1 can bind bacteria and induce superoxide 
generation suggest that it plays a role in immunity. However, a precise function in terms of 
protective responses has not been shown directly and further investigations are needed to clarify 
its role in the immune response. 
1.7.3. 1 Function in vascular disease 
Much research on LOX-1 has focused on its involvement in vascular disease states. OxLDL is a 
key contributing factor to atherosclerosis [121, 122J, and it mediates several of its adverse effects 
via LOX-i. Several other lines of evidence support a role for LOX-1 in vascular pathology. For 
example, LOX-1 is highly upregulated in human and animal atherosclerotic lesions [103, 123, 124]. 
and many of the previously mentioned factors which upregulate its expression are associated with 
atherosclerosis and other vascular disease. OxLDL ligation of LOX-1 results in upregulation of 
adhesion molecules E-selectin, P-selectin, VCAM-i and ICAM-i, which have been shown to have 
a role in artherosclerosis by facilitating entry of leukocytes into the artery wall [122, 125J. 
Additionally it was shown that OxLDL triggers the CD40/CD40L signalling pathway through LOX-i 
[119]. This signalling system is known to playa central role in the development and progression of 
atherosclerosis [126]. Furthermore. LOX-1 mediated uptake of OxLDL in macrophages results in 
the formation of lipid laden cells that are similar to foam cells which are present in atherosclerotic 
lesions [127]. Other evidence which indicates a role for this receptor in cardiovascular disease is 
the observation that the deletion of LOX-1 in mice limits atherogenesis despite a high cholesterol 
diet, at least in part by preserving endothelial function and integrity [128]. Finally, LOX-1 allelic 
polymorphisms can confer an increased risk of heart attacks [129, 130]. Interestingly, subjects 
homozygous for the 'non-risk' haplotype showed a small increase in LOXIN expression [91]. 
Further in vitro studies demonstrated that hetero-oligomerization of LOX-1/LOXIN isoforms 
impaired OxLDL binding and uptake [131J. This suggests that hetero-oligomerisation between 
naturally occurring isoforms of LOX-1 may be a mechanism of LOX-1 regulation [131]. This would 
constitute an elegant control system and it is tempting to speculate that the existence of receptor 
isoforms that mediate self regulation may be a feature of the Dectin-1 cluster of receptors. 
However, this is purely conjecture and further studies involving the various receptor isoforms are 
required to investigate the idea. 
1.8 Myeloid inhibitory C-type lectin-like receptor (MICL) (CLEC12A) 











MICL was originally identified through data base searches for molecules homologous to Dectin-1 
[80]. Subsequent studies by a number of groups described the same receptor, but used the 
altemative names C-type lectin-like molecule-1 (CLL-1). Killer cell C-type lectin like receptor L 1 
(KLRL 1) and Dendritic-cell associated C-type lectin 2 (DCAL-2) [132-134]. Alternative splicing 
results in at least three isoforms of human MICL (hMICL) which have been designated MICL-a, 13 
and y [80J. hMICL-a displays the type II transmembrane structure characteristic of Group V C-type 
lectins and contains an ITIM signaling motif in its cytoplasmic tail. The transmembrane region is not 
present in hMICL-I3, suggesting that it may be either secreted or withheld in the cytosol as has 
been described for other equivalent C-type lectin isoforms [135]. The hMICL-y isoform is unspliced 
at the second intron, resulting in the introduction of a stop codon after 18 codons. Although hMICL 
contains cysteine residues in its stalk region, which in other cases mediate dimerisation by forming 
disulfide bridges, this receptor appears to be expressed as a monomer [80]. hMICL is also highly 
N-glycosylated, although the precise level of glycosylation varies between cell types [136]. In 
contrast, no isoforms have been identified for murine MICL (mMICL) and its N-glycosylation is not 
as extensive as that of the human form. Furthermore, mMICL is expressed as a dimer [137]. 
Both murine and human MICL are predominantly expressed by myeloid cells (granulocytes, 
monocytes, macrophages and DCs) [136-138]. hMICL is also present at low levels on CD4+ T cells 
[136]. mMICL is expressed on B cells and at low levels on CD8+ T cells making it more broadly 
expressed than its human counterpart [137]. One study described expression of MICL on NK cells, 
but other studies have definitively concluded that MICL is not present on these cells [134,136-138]. 
hMICL was also identified as a marker for acute myeloid leukemia [132]. Expression of MICL is 
downregulated following inflammatory conditions, including those triggered by microbial 
components [80,136,137]. 
1.8.2 Ligands 
There have been no ligands identified for MICL to date. However, a cellular reporter system based 
on BWZ.36 cells and related to the one used in this thesis (see Chapter 5) shows that MICL 
recognises an endogenous ligand that is broadly expressed in many mouse tissues [137J. 
1.8.3 Function 
MICL can inhibit cellular activation, a process which most likely occurs by signalling though the 
ITIM motif located in its cytoplasmic tail. Accordingly, it has been shown that MICL can associate 
with the signalling phosphatases SHP-1 and SHP-2, but not SHIP [80, 137]. This is consistent with 
other ITIM containing C-type lectins [139]. It has also been reported that MICL inhibits NK cell 
cytotoxicity, although this was shown indirectly and is unlikely to be a true function as NK cells do 
not express MICL [80, 134, 137]. Furthermore, antibody cross-linking of hMICL in DCs has been 
reported to result in antibody internalisation and to influence cytokine production and receptor 
expression. Studies also suggest that MICL can selectively interact with TLR signalling pathways or 
the T-cell signal CD40L, to alter cytokine production by DCs and thereby regulate downstream T-
cell activation [133]. Although the phYSiological role of MICL has not yet been identified, the 











homeostasis [137]. Its ability to inhibit cellular activation suggests a regulatory role and 
furthermore, the various isoforms may also function cooperatively in order to maintain some type of 
regulation. 
A recent investigation examined whether targeting of MICl could induce immune responses. This 
study concluded that antigen targeting of MICl in the presence of minimal amounts of adjuvant 
resulted in the mounting of a robust humoral response, but only moderate cytotoxic T-Iymphocyte 
(CTl) responses [138]. lahoud et al postulate that the poor induction of CTls may be a 
consequence of inhibitory signalling through the MICl ITIM motif or alternatively that antigen 
delivered via MICl may be inefficiently shuttled into the cross-presentation pathway. The authors 
also suggest that there may be scenarios in which the induction of a humoral response without the 
activation of CTls is desirable, in which case immunisation via MICl may be a useful strategy 
[138]. 
1.9 ClEC12B 
1.9.1 Identification, structure and expression 
CLEC12B was identified during a data base search for proteins with a high homology to the 
extracellular domain of the activating NK cell receptor NKG2D [140]. It is a type II transmembrane 
receptor with a CTLD, a transmembrane region and a cytoplasmic tail containing an ITIM 
sequence. RT-PCR analysis in human tissues showed that ClEC12B is widely expressed at low 
levels. Alternative splicing generates a variant which lacks exon 4. This transcript is present in 
mammary gland and ovary and is predicted to yield a non-functional protein. In transfected cells, 
ClEC12B formed disulfide-linked homodimers. Expression of ClEC12B was detected on 
differentiated human macrophages and on a stimulated human pro-myelocytic cell line, but there 
was no expression detected on freshly isolated monocytes or any other leukocyte population [140J. 
1.9.2 Ligands 
To date there have been no ligands identified for ClEC12B. 
1.9.3 Function 
Like MICL, ClEC12B can recruit the inhibitory phosphatases SHP-1 and SHP-2 and it was shown 
to be capable of inhibiting certain cellular functions via its ITIM in an experimental in vitro system 
[140]. An obvious speculation is that such ITIM containing receptors function to downregulate and 
control cellular activation. In this context it is possible that ClEC12B and indeed MICl function as 
the inhibitory counterparts of ITAM containing receptors in this cluster. The identification of ligands 
and further functional investigations will give more insight into the role of this receptor. 
1.10 Dectin-1 (ClEC7 A) 
1.10. 1 Identification, structure and expression 
Dectin-1 was initially identified as a DC specific receptor that modulated T cell function through 











glucans following a screen of a murine macrophage cDNA expression library with zymosan, a ~­
glucan rich extract of Saccharomyces cerevisiae [143]. ~-glucans are carbohydrate polymers with 
well-characterised immunostimulatory activity that are found primarily in the cell walls of fungi, but 
also in plants and some bacteria [143, 144J. 
Dectin-1 is a glycosylated type II transmembrane receptor with a single extracellular CTLD 
connected by a stalk to a transmembrane region and a cytoplasmic tail containing an ITAM-like 
motif (described later). Like the other members of the Dectin-1 cluster, it lacks the residues for 
calcium ligation. The murine form of the receptor is expressed by many cell types, including 
macrophages, DCs, monocytes, neutrophils and a subset of splenic T cells [145]. There are at 
least two isoforms of murine Dectin-1, encoding the full length receptor and a stalkless version and 
they exhibit differences in their ability to recognise zymosan and to induce cellular responses [146]. 
Both murine forms are N-glycosylated at two sites in the extracellular region [141]. The expression 
of human Dectin-1 differs slightly in that it is also expressed on B celis, eosinophils and mast cells 
[147, 148]. Human Dectin-1 mRNA is also alternatively spliced generating eight isoforms (isoforms 
A-E), of which only two are functional for l3-glucan binding (isoforms A and B). hDectin-1 isoform E 
lacks exon 3, which results in a variant that does not contain the transmembrane and stalk regions 
[147]. It has been shown that this isoform is retained in the cytoplasm and is capable of associating 
with a Ran-binding protein, RanBPM, although the functional relevance of this interaction is 
undetermined [135J. Of the two ~-glucan binding isoforms, the most predominant lacks the stalk 
region and has no glycosylation sites. The other form contains one N-glycosylation site in its stalk 
region [147, 149]. It has been shown that glycosylation contributes to Dectin-1 surface expression 
[150], and the two major human isoforms are expressed differently in various cell types, although 
the significance of this remains unclear [147]. The highest levels of Dectin-1 expression are on 
inflammatory cells and at sites of pathogen entry such as the lung [145, 151J. It has been shown 
that the level of Dectin-1 expression in murine macro phages can be influenced by various 
cytokines and microbial factors [152-154]. For example IL-4, IL-13 and GM-CSF cause Dectin-1 
expression to be highly upregulated. In contrast IL-10, LPS and dexamethasone cause down-
regulation of Dectin-1 expression [153]. 
1.10.2 Ligands 
Oligosaccharide microarray technology has shown that Dectin-1 specifically binds ~-1 ,3-linked 
glucose oligomers [155]. The Ca2+ independent mechanism for recognition of carbohydrates by 
Dectin-1 is still unclear, however it is known that at least two residues flanking a shallow groove on 
the protein surface, Trp221 and His223, are crucial for ~-glucan binding [156]. By way of its ~­
glucan specificity. Dectin-1 can recognise a number of fungal species [157-165]. Recent studies 
have also shown that Dectin-1 interacts with various mycobacterium species; however the specific 
ligand(s) recognised by Dectin-1 on these microbes remain unidentified [166-169]. Although ~­
glucans have been detected in bacteria such as Brucella, Agrobacterium and Rhizobium [170. 
171]. their presence has not been described in mycobacteria. As briefly mentioned earlier, Dectin-1 











proliferation [141, 142, 147]. It is more likely that this T-cell ligand is a protein rather than a 
carbohydrate because it is sensitive to protease but not glycosidase treatment [141]. Based on the 
similarity of Dectin-1 to other NK-cell-receptor-like C-type lectins, it has been suggested that the 
ligand may be an MHC class I molecule or related protein, or another C-type lectin [45]. Studies 
using cell lines also showed that Dectin-1 recognises a ligand on apoptotic cells [172J. 
1.10.3 Function 
Signalling from Dectin-1 following ligand binding can induce many cellular responses including the 
production of various cytokines and chemokines, the respiratory burst, production of arachidonic 
metabolites, ligand uptake through phagocytosis and endocytosis, and DC maturation [45, 173]. In 
recent years, several studies have sought to decipher the Oectin-1 induced signalling pathways 
that underlie different cellular responses. Before discussing the findings below, it is worth noting 
that as evidence of cross-talk and branching in various systems is emerging, the traditional 
visualisation of a linear signalling pathway is giving way to the realisation that these pathways are 
in fact much more intricate [174]. This holds true for Dectin-1 induced signalling which in some 
cases can trigger a response directly but in other cases requires cooperative signalling with 
MyD88-coupled TLRs. This is complicated further by recent evidence which shows variability in 
Oectin-1 signalling in different myeloid cell types [175, 176J. 
1.10.3.1 Oectin-1 signalling through the ITAM-like motif 
Oectin-1 signalling is mediated through a cytoplasmic ITAM-like motif. It contains two tyrosines in 
its cytoplasmic tail that are positioned in an arrangement that is similar to an IT AM but does not 
conform exactly to the consensus sequence. The two tyrosines are appropriately spaced, but the 
N-terminal tyrosine resides in a YxxxL sequence (or Yxxxi for mouse), as opposed to the traditional 
YxxL ITAM sequence. The membrane proximal tyrosine resides within a YxxL (Yxxl for mouse) 
sequence conforming to the traditional ITAM motif [45, 49]. Studies revealed that the membrane 
distal tyrosine was dispensable for signalling [157, 177-180] and this suggested that a single 
tyrosine based motif was sufficient for mediating signal transduction. Subsequently, it emerged that 
CLEC-2 and CLEC9A (discussed below) also signal via similar single tyrosine based motifs. The 
convention now is to use the term 'ITAM-like motif to describe this type of sequence, and in the 
case of Oectin-1 the designation pertains to the tyrosine containing YxxL sequence and excludes 
the C-terminal tyrosine. This motif has also been referred to as a 'hemiTAM' motif [42], although 
the term 'ITAM-like' will be used here. 
Following ligand binding, Oectin-1 becomes tyrosine phosphorylated by Src kineses, thereby 
providing a docking site for Syk which initiates downstream signalling [180]. This is reminiscent of 
traditional IT AM signalling where ligand binding similarly results in receptor phosporyation by Src 
kinases and thus promotes the recruitment of Syk kinases as described above. However in 
contrast to IT AM receptors where dually phosphorylated tyrosines are necessary for Syk 
recruitment, phosphorylation of only the membrane proximal tyrosine is sufficient for Syk 
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ligand binding. receptors become tyroSine phosphorylated by Src kinases, 
thereby providing a docking site for Syk which initiates downstream 










1.10.3.2 Syk-dependent activation of NF-KB 
Signalling initiated via Dectin-1 results in activation of NF-KB through both the canonical and non-
canonical pathways (Fig 1.5) [192, 193]. Before discussing the details below, it is first useful to give 
a brief overview of the two established pathways of NF-KB activation (for review see [194]). In 
mammals, there are five members of the NF-KB family: p65, ReIB, c-Rel, NF-KB1 (p50/p105) and 
NF-KB2 (p52/p100). NF-KB1 and NF-KB2 are both synthesised as large precursors (p105 and p100 
respectively), which are post-translationally modified to become p50 and p52 respectively. The NF-
KB family members form numerous homo- or hetero-dimers that are associated with differential 
regulation of gene transcription. Usually in unstimulated cells, NF-KB is retained in the cytoplasm 
by IKBs (inhibitors of KB). NF-KB1/p105 and NF-KB2/p100 precursors contain the inhibitory function 
of the IKB proteins in their C-terminal halves and also function to retain their partners in the 
cytoplasm. Two major signalling pathways result in translocation of NF-KB dimers from the 
cytoplasm to the nucleus. The canonical (or classical) pathway is mediated by activation of an IKK 
(inhibitor of KB kinase) complex which catalyses the phosphorylation of lKBs resulting in their 
ubiquitylation and subsequent proteasomal degradation. The released NF-KB dimers translocate to 
the nucleus and activate gene transcription. In the non canonical pathway (or alternative) pathway, 
NF-KB2/p100 (which is most commonly associated with ReIB), is targeted through the successive 
activation of NF-KB-inducing kinase (NIK) and IKKa, which catalyses the phosphoryation of p100 
and its ubiquitylation. This results in the proteasomal degradation of only the inhibitory C-terminal 
half of p100 and the remaining p52 protein is released resulting in translocation of the dimers 
(usually p52-ReIB) to the nucleus [194]. 
In terms of Dectin-1 mediated activation of NF-KB, studies in DCs have demonstrated that 
recruitment of Syk to Dectin-1 results in activation of PLCy2, leading to the engagement of the 
caspase recruitment domain (CARD) containing protein, CARD9, which together with Bcl10 and 
Malt1 signal for activation of the transcription factor NF-KB (Fig 1.5) [193, 195, 196]. The signalling 
events that link PLCy2 activation to CARD9 recruitment are still not known. However in 
lymphocytes, signalling through ITAM containing proteins leads to recruitment of Syk tyrosine 
kinases that activate PlCy, which in turn catalyses the hydrolysis of membrane phospholipids 
generating diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3) [197]. DAG activates PKC 
isoforms which then activate the CARD9 related protein, CARD11, allowing the formation of a 
signalling complex consisting of CARD11, Bcl10 and Malt10 [197]. It is likely that a pathway 
analogous to this one culminating in CARD11 activation in lymphocytes, results in CARD9 
activation in myeloid cells [195]. How signals are transmitted from the CARD9/Bcl1 O/Malt1 complex 
to NF-KB is also not yet described. However if one looks again to defined pathways in other celis, it 
seems reasonable to consider that the direct interaction of Malt10 with the adaptors Traf2 and 
Traffi may lead to activation of IKK, which in lymphocytes results in translocation of NF-KB to the 
nucleus where it influences gene transcription [197, 198]. Dectin-1 is also the first PRR shown to 
induce Syk dependent activation of NF-KB in DCs via the non-canonical pathway. Previously, this 
activation of NF-KB had been reported for only a few members of the TNF receptor superfamily 
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The intricacies of the pathway which relays signals from Syk to the activation of Re1B-p52 dimers 
remain undefined at present. Ligation of Dectin-1 also induces a Syk independent, Raf1 signalling 
pathway which integrates with the Syk pathway at the point of NF-KB activation (Fig 1.5) [192J. 
It has recently come to light that Dectin-1 signalling via Card9 is differentially regulated in myeloid 
cells [175, 176J. For example, bone marrow derived DCs, resident peritoneal cells and alveolar 
macrophages activate NF-KB and drive TNFo production as described above, whereas bone 
marrow derived macrophages, thioglycollate elicited macrophages and Flt3L-derived DCs fail to do 
so. This failure to drive proinflammatory cytokine production is in spite of Dectin-1 induced 
activation of the Card9/Bcl1 0/Malt1 signalling complex [175]. This variability in Dectin-1 signalling in 
different cell populations is potentially a novel mechanism by which myeloid cells can be tweaked 
to regulate immune responses and may have implications for therapeutic uses [175, 176]. 
1.10.3.3 Syk-dependent activation of NFAT 
Apart from activation of NF-KB in DCs, ligation of Dectin-1 also triggers activation of the 
transcription factor NFAT in macrophages and DCs (Fig 1.5) [196, 201J. The role of NFAT and the 
sequence of events leading to its activation are most well defined in T cells. The signalling pathway 
induced by ITAM containing T-cell receptors in lymphocytes (discussed earlier) branches after the 
generation of DAG and IP3 . As described, DAG initiates a cascade of events resulting in the 
activation of NF-KB. The action of IP3 initiates another signalling pathway by triggering the release 
of Ca2+ from intracellular stores which in turn triggers the opening of Ca2+ channels in the plasma 
membrane resulting in the maintenance of the increased levels of intracellular Ca2+. This results in 
the activation of the phosphatase calcineurin which dephosphorylates NFAT transcription factors, 
leading to their nuclear translocation and regulation of gene expression [202, 203]. Although the 
signalling events linking Dectin-1 signalling with NFAT activation have yet to be elucidated, it is 
possible that NFAT activation in myeloid cells occurs via a pathway analogous to the one described 
for T cells. This is all the more likely since zymosan has been reported to trigger calcium flux, and 
Dectin-1 is known to signal via Syk in macrophages and DCs [196, 204, 205]. Dectin-1 mediated 
activation of NFAT regulates cyclooxygenase-2 and prostaglandin production in macrophages, and 
the induction of IL-2, IL-10 and IL-23 in DCs [201]. 
1.10.3.4 Syk-dependent, CARD9 independent signalling 
It has also been shown that certain cellular responses controlled by Dectin-1/Syk signalling are not 
dependent on CARD9. For example, in DCs there is Syk-dependent activation of ERK, a mitogen 
activated protein (MAP)-kinase, through a CARD9-independent pathway [206]. Another example of 
this type of signalling is the induction of phagocytosis via Dectin-1 in DCs. Although this pathway is 
not fully understood, it is known that it is Syk dependent but does not require CARD9 [177, 193]. In 
macrophages however, Dectin-1 mediated phagocytosis is induced in a Syk independent manner 
(see below). An artificial system which demonstrated the phagocytic capacity of Dectin-1 by 
expressing the receptor in normally non-phagocytic fibroblasts, showed that Dectin-1 signalling 











around the particle [179J. It also showed that PKC was required. The precise role of PKC in 
phagocytosis is unclear, however one of its substrates, MARCKS (myristoylated, alanine-rich C-
kinase substrate), possesses actin cross-linking activity that is involved in zymosan phagocytosis 
[207]. 
1.10.3.5 Syk-independent signalling 
Dectin-1 is also capable of inducing signalling via Syk-independent pathways. In macrophages, 
ligation of Dectin-1 results in phagocytosis. This response requires the ITAM-like motif and a 
triacidic DED sequence, but does not require Syk and is possibly propagated by a novel kinase [45, 
177, 179]. This is in contrast to the Syk requirement for Dectin-1 mediated phagocytosis by DCs 
discussed above. Recently, it was found that Dectin-1 induced a signalling pathway through the 
kinase Raf-1 that was independent of the Syk pathway but integrated with it at the level of NF-KB 
activation for regulation of cytokine production [192]. 
1.10.3.6 Interactions between Dectin-1 and other proteins 
Continuing research in the field of pathogen recognition and the receptors involved in mediating 
immune responses has highlighted that receptor collaboration, as opposed to receptors functioning 
in isolation is an important facet of controlling infection [208, 209]. This holds true for Dectin-1 
which collaborates with various TLRs to promote anti-fungal and anti-mycobacterial responses. In 
addition to l3-glucans, there are a number of PAMPs in the cell walls of fungi that are recognised by 
several PRRs whose cooperation is required for efficient anti-fungal immune responses [210]. 
Dectin-1 has been shown to collaborate with TLRs for optimal cytokine production and 
enhancement of the respiratory burst. This collaboration depends on cell-type. For example, in 
macrophages, collaborative signalling by TLRs and Dectin-1 is required for TNFa production [157, 
178]. On the other hand, in DCs, Dectin-1 signalling alone can trigger TNFa and IL-10 production, 
although collaborative signalling with TLRs enhances these responses [208, 211]. In macrophages, 
it was shown by a recent study in which I participated, that the Syk kinase pathway triggered by 
Dectin-1 is required for collaborative signalling with the TLRs which induced sustained IKB 
degradation resulting in enhanced nuclear translocation of NF-KB [208]. In fact, Dectin-1 can 
interact with several MyD88-coupled TLRs (TLR2, TLR4, TLR5, TLR7, TLR9) to induce production 
of multiple cytokines [173, 208, 212]. In addition to Syk, integration of TLR and Dectin-1 signalling 
requires the adaptor Raf-1 [192]. Functional cooperation between Dectin-1 and TLR2 has also 
been established during phagocytosis, ERK1/2 MAPK activation and the secretion of pro-
inflammatory cytokines by macrophages and dendritic cells [165, 168, 210, 212, 213]. Indeed, a 
study which examined bone marrow derived macro phages challenged with Mycobacterium 
abscessus or zymosan, showed that Dectin-1 physically interacts and colocalises with TLR2 [167]. 
Apart from the TLRs, Dectin-1 also cooperates with a number of other plasma membrane proteins. 
In human DCs, costimulation of Dectin-1 and DC-SIGN triggers the arachidonic acid cascade [214]. 
In macrophages, Dectin-1 also cooperates with SIGNR1, the murine homologue of DC-SIGN, 











tetraspanins, a family of proteins that have been shown to modulate signal transduction by 
interacting with many other transmembrane proteins to from 'tetraspanin microdomains' in the 
plasma membrane [216]. Dectin-1 associates with the ubiquitous tetraspanin CD63. Furthermore, it 
has been shown that phagocytosis of yeast particles by DCs was accompanied by a decrease in 
CD63 expression, which was inhibitable by a soluble l3-glucan, laminarin [217]. Although the 
functional significance of a Dectin-1-CD63 interaction has not yet been elucidated, it may represent 
part of a signalling complex that could influence phagocytosis. Dectin-1 also interacts with the 
immune cell specific tetraspanin CD37 resulting in stabilisation of Dectin-1 in the cell membrane 
and inhibition of Dectin-1 mediated IL-6 production in response to zymosan [218, 219J. Whether the 
tetraspanin-Dectin-1 interactions are involved in Dectin-1 collaboration with TLRs is not known, 
although there has been speculation that tetraspanins may directly link the Dectin-1 and TLR 
signalling pathways [218]. 
1.10.3.7 Dectin-1 and innate immunity 
l3-glucans can constitute up to 50% of fungal cell walls and as mentioned, Dectin-1 recognises a 
number of fungal species by way of its l3-glucan specificity including Candida, Pneumocystis, 
Saccharomyces, Aspergillus, Coccidiodes and Penicillum [157-165]. Many studies have shown that 
detection of various fungal species by Dectin-1 results in the initiation of protective immune 
responses such as fungal uptake and killing by toxic reactive oxygen intermediates, and the 
production of protective inflammatory cytokines and chemokines, including TNFa, CXCL2, IL-113, 
IL-1a, CCL3, GM-CSF, G-CSF and IL-6 [45, 220]. Dectin-1 also induces the production of IL-2 and 
IL-10, cytokines whose role in fungal infection is less clear. IL-10 in particular has been shown to 
have inhibitory effects on anti-fungal immune responses [221}. These cytokines also contribute to 
the development of Tregs, the implications of which will be discussed later. 
In vivo studies, although not wholly consistent, have supported other evidence that Dectin-1 plays a 
role in antifungal immunity. Loss of Dectin-1 in mice with a 129Sv background resulted in increased 
susceptibility to systemic infection with C. albicans and invasive pulmonary infection with A. 
fumigatus as a consequence of inflammatory defects and decreased fungal killing [162, 222]. 
Interestingly, Dectin-1 deficient mice with a C57BU6 background showed no increased 
susceptibility to C. albicans, but did exhibit increased susceptibility to Pneumocystis carinii due to 
defects in the respiratory burst [159]. This disparity is most likely because of the genetic 
backgrounds of the deficient mice, but could also be due to differences in the fungal strains and/or 
routes of infection used. Further evidence to support a role for Dectin-1 in fungal infections is the 
recent identification of a polymorphism in human Dectin-1 that is associated with an increased oral 
and gastrointestinal colonisation with Candida species [223]. 
1.10.3.B Dectin-1 and adaptive immunity 
In addition to triggering innate immune responses, Dectin-1 signalling can also induce adaptive 
immunity and was the first non-TLR PRR shown to do so. Dectin-1 activated Des can 'instruct' the 











C.albicans and Mycobacterium tuberculosis [211, 224]. It has been shown that Raf-1 signalling by 
Dectin-1 is a crucial determinant in the induction and regulation of the relevant polarising cytokines 
[192, 211]. While it is generally accepted that the generation of a Th1 response is required for 
protection against fungal infection in healthy hosts [225], the role of Th17 cells in anti-fungal 
immunity is rather more controversial. A number of studies have shown a detrimental role for IL-17 
in anti-fungal immunity [226. 227}. On the other hand, mice that are unable to mount Th17 
responses are very susceptible to oropharyngeal candidiasis [228, 229J. Furthermore Th17 
deficiency in humans is also associated with increased susceptibility to C. albicans infection [230, 
231]. Conditions such as route of infection and inocula used may account for the observed 
differences; however, IL-17 like other cytokines can have opposing roles in disease [232}. For 
example, in periodontal disease IL-17 may be either host-protective or destructive depending on 
how chronic and severe the disease is [233, 234]. It has also been shown that vaccination induced 
IL-17 producing T-cells are critical for the rapid recruitment of protective CD4+ T cells upon 
challenge with M. tuberculosis [235]. This suggests that the Th17 responses induced by targeting 
Dectin-1 may be a means of enhancing the efficacy of future vaccines to this pathogen. 
Interestingly, Dectin-2 was recently identified as another SyklCARD9-coupled C-type lectin that 
mediates DC activation and induction of Th17 immunity in response to C. albicans [236]. Dectin-2 
has a positively charged residue in its transmembrane domain which mediates association with the 
IT AM containing FcRy chain and allows coupling to the Syk pathway [236]. Despite this distinct 
difference in Syk recruitment, Dectin-2 and Dectin-1 may be representative of a novel class of 
myeloid expressed receptors which signal via Syk and CARD9 to initiate immunity, as the authors 
pointed out [236]. 
Activation of DCs via Dectin-1 can also convert selected populations of Treg cells into IL-17 
producing T cells that cannot be classified as either Treg or Th17 cells [237]. Furthermore, 
costimulation of Dectin-1 and TLR2 contributes to Treg expansion and function [238, 239]. Tregs 
suppress T effector cells and have protective effects in certain infections by means of their anti-
inflammatory function [240}. They have also been shown to be essential components of the 
memory protective immunity to certain pathogens [241, 242]. On the other hand, Tregs were 
demonstrated as immunosuppressive during disseminated candidiasis [243]. These adaptive 
immune responses mediated via Dectin-1 remain somewhat unclear in terms of their contribution to 
host protection or immunopathology; however, it may turn out that Dectin-1 has a central role in 
balancing the pro-inflammatory and anti-inflammatory responses during fungal infection [173]. 
In addition to driving CD4+ T cell differentiation, Dectin-1 stimulation can also induce CDS+ T cell 
responses. DCs which were stimulated with curdlan, a selective j3-glucan agonist, were found to 
promote the expansion and differentiation of CTL precursors in vitro [244]. The precise role of CTLs 
in direct antifungal responses is unclear, however it has been shown that CD8+ T cells are 
activated during fungal infections and can playa protective role in some cases [245-248]. Curdlan 











response that was sufficient to protect against tumor challenge [244]. This may explain the 
antitumor activity of l3-glucans which are used in cancer therapy in some countries [249], and this 
study suggests that Dectin-1 agonists may be beneficial as immunotherapeutic agents. Antibody-
mediated targeting of Dectin-1 also resulted in the induction of CTL responses as well as CD4+ T 
cell and Ab responses [250]. This study demonstrated that targeting to different DC subsets using 
receptors can induce qualitatively different immune responses, with anti-Dectin-1 preferentially 
triggering a CD4+ T cell response but anti-DEC-205 favouring induction of a CD8+ T cell response 
[250J. 
1.10.3.9 Dectin-1 and autoimmunity 
Dectin-1 mediated responses have also been implicated in driving autoimmunity. SKG mice, which 
are genetically susceptible to develop autoimmune arthritis, did not develop arthritic symptoms in a 
pathogen free environment. However, treatment with zymsoan or purified l3-glucans induced 
severe chronic arthritis in these animals which could be inhibited by blocking Dectin-1 [251J. This 
may be as a result of dysregulated generation of IL-17, a cytokine which has been shown to be 
involved in the pathogenesis of various autoimmune diseases in mice [252]. Furthermore, blockage 
of Dectin-1 could prevent experimental autoimmune uveoretinitis, a Th1ITh17 disease and it has 
been suggested that Dectin-1 will be implicated in various other autoimmune diseases in future 
[173J. 
1.10.4 Dectin-1- summary 
The expression of Dectin-1 on myeloid cells allows for the recognition of fungal and mycobacterial 
species and the subsequent induction of all branches of immunity. Dectin-1 was the first Syk-
coupled non-TLR PRR shown to drive such responses and it may be the prototype of a new class 
of receptor. Furthermore, Dectin-1 was the first example of a PRR which induces intracellular 
signalling via a single-tyrosine based ITAM-like motif. Further research into the role of Th17 and 
Treg responses in fungal and mycobacterial infection is required before we will fully understand the 
role of Dectin-1 in these immune responses, but studies suggest that Dectin-1 is potentially an 
immunotherapeutic target. The potential role of Dectin-1 in autoimmunity is also an area that 
requires further research and the identification of the endogenous Dectin-1 ligand(s) on T-cells will 
assist in the elucidation of the role of Dectin-1 in homeostasis. 
1.11 CLEC9A 
1. 11. 1 Identification, structure and expression 
CLEC9A is a type II transmembrane protein with a single CTLD, a transmembrane region and a 
cytoplasmic tail containing an ITAM-like motif similar to that of Dectin-1 [253,254]. It has also been 
described as DNGR-1 mC, NK lectin group [eceptor-1) [254]. In mice, alternative splicing 
generates at least five isoforms of CLEC9A. Similar to related C-type lectins one of these isoforms 
contains six exons, and this form is expressed as a non-glycosylated monomer at the cell surface 
[253]. Conversely, a seven exon version which contains an additional exon in the CTLD is 
expressed as a dimer at the cell surface [254, 255J. The various murine isoforms may display 











Investigation of cellular distribution has only been carried out for the seven exon version of murine 
CLEC9A. It was found to be expressed at low levels on plasmacytoid DCs and on CD8a+ DCs in 
the spleen, lymph nodes and thymus [254, 255]. The CD8a+ DCs are specialised for, and are by far 
the most efficient at. presenting exogenous peptides on MHC class I molecules, a process known 
as cross-presentation [250, 256-258]. 
In humans, CLEC9A (hCLEC9A) is present as a glycosylated dimer at the cell surface and RT-
PCR analysis showed that it is broadly expressed as a single transcript in most organs, with 
highest expression in brain, thymus and spleen [253]. In peripheral blood, hCLEC9A expression is 
restricted to BDCA3+ DCs, a small subset of CD14+CD16- monocytes, an unidentified population of 
CD14"CD11b"CD64+ cells and B-cells [253, 254, 259]. Little is understood about the BDCA3+ 
population, although they are known to express multiple TLRs and are thought to be immature 
precursors of interstitial DCs [260-262]. These cells also express high levels of CD62L and it has 
been suggested that this may mediate the migration of BDCA3+ DCs from the blood into lymphoid 
tissues [262]. Functionally, little is known about the BDCA3+ DCs but based on the expression of 
CLEC9A and several other surface markers, it is believed that they may represent a DC lineage 
equivalent to the murine CD8a+ DC subset [253. 254, 259, 263, 264J. CD14+CD16" monocytes are 
considered 'classical monocytes' and are believed to migrate to sites of inflammation where DC 
differentiation occurs [265, 266]. 
1.11.2 Ligands 
Specific ligands for CLEC9A have yet to be identified. However, it is known that CLEC9A acts as a 
receptor for necrotic cells and it is thought that this is mediated by recognition of a ubiquitous 
preformed acid-labile ligand(s) that is normally sequestered in healthy cells but becomes exposed 
following disruption of membrane integrity during necrosis [22J. 
1.11.3 Function 
As mentioned, CLEC9A contains an ITAM-like motif in its cytoplasmic tail, YxxL, and it induces 
intracellular signalling via recruitment of Syk [253, 254]. It is possible that Syk associates with 
CLEC9A in a similar way to that which has been proposed for Dectin-1; via a bridging interaction 
between two CLEC9A molecules (Fig.1.4) [177, 181, 253]. As mentioned, it was recently 
demonstrated that CLEC9A acts as a receptor for necrotic cells [22]. CLEC9A also regulates the 
cross-presentation of dead-cell associated antigens in a Syk-dependent manner [22]. This 
investigation found that although CLEC9A is not required for uptake of necrotic cell material, it is 
necessary for efficient cross-presentation of dead-cell associated antigens by CD8a+ DCs [22]. 
As mentioned earlier, another Syk-coupled C-type lectin in addition to CLEC9A, Mincle, has also 
been shown to recognise necrotic cells [21]. It may be that CLEC9A and Mincle are part of a family 
of Syk-coupled proteins that are involved in sensing and mediating the response to dead cells [22]. 
Mincle has also been described as a fungal PRR as mentioned previously [74,75]. In light of recent 











emerging of Syk-coupled myetoid expressed C-type lectins that mediate recognition and initiate 
cellular responses to pathogens and necrotic cells. 
Because CLEC9A is an endocytic receptor that is largely restricted to a specific DC subset that 
importantly is common to both human and mice, it holds some promise as a candidate for delivery 
of antigens to DCs. This potential was explored recently by two independent groups. Sancho and 
colleagues demonstrated that antigen epitopes covalently coupled to an anti-CLEC9A monoclonal 
antibody were selectively cross-presented to CD8+ T cells in vivo and induced potent CTL 
responses in the presence of adjuvant [254]. They also determined that targeting of antigen to DCs 
via CLEC9A did not result in presentation by plasmacytoid DCs, a result which they attribute to the 
fact that CLEC9A is expressed at very low levels on these cells and that plasmacytoid DCs are 
nevertheless understood to be inefficient at cross-presentation. They then proceeded to explore 
whether CLEC9A targeting could be used for tumour immunotherapy. In a cancer model, they 
tested the efficacy of antigen targeting via CLEC9A to either prevent or treat tumors. In their model, 
tumor derived peptides were covalently coupled to anti-CLEC9A and administered to mice in the 
presence or absence or adjuvants either before or after tumor challenge. They found that the CTL 
responses mounted resulted in both tumour eradication and tumor prevention [254]. Caminschi and 
colleagues also showed that targeted delivery of antigens to DCs using anti-CLEC9A monoclonal 
antibodies induced a striking enhancement of humoral immunity, and enhanced CD4+ and CD8+ T 
cell proliferative responses [255]. Interestingly all of the responses in this investigation were 
observed in the absence of additional adjuvants. 
It will be interesting to see whether CLEC9A turns out to function in pathogen recognition as has 
been described for Dectin-1, Dectin-2 and Mincle. The studies described above which use CLEC9A 
to target antigens to the CD8a+ DC subset indicate that CLEC9A is a promising target for 
therapeutic applications and further research in mouse models could possibly translate to an 
immunotherapeutic strategy for cancer in clinical settings. 
1.12 CLEC·2 (CLEC1 B) 
1.12. 1 Identification, structure and expression 
CLEC-2 is a type II transmembrane receptor displaying an extracellular CTLD, a single 
transmembrane region and a short cytoplasmic tail that contains an IT AM-like signalling motif. 
CLEC-2 was originally identified through a computational screen of myeloid cells for C-type lectin-
like receptors homologous to those expressed by NK cells [82]. This study identified human CLEC-
2 (hCLEC-2) and its murine homologue (mCLEC-2) which showed approximately 60% identity with 
the human form. RT-PCR analysis of full length hCLEC-2 showed transcripts in PBMC, bone 
marrow cells, monocytes, DCs, granulocytes and in a few NK cell clones [82]. RNA blot analysis of 
CLEC-2 on different human tissues also showed selective expression in the liver [82]. In mice, two 
further splice variants in addition to full length mCLEC-2, have been identified. One, named 
mCLEC-2B, lacks exon 2 which encodes the transmembrane region. The other, named mCLEC-











252bp [267]. The various isoforms of mCLEC-2 showed different expression profiles and 
subcellular localisation. All three transcripts were expressed in PBMC and monocytes. However, 
only mCLEC-2B and mCLEC-2C were detected in a T-cell line, a B-ceilline and a macrophage cell 
line, and furthermore, only mCLEC-2C in peritoneal macrophages and a fibroblast cell line [267]. In 
transfected fibroblasts, full length mCLEC-2 was expressed on the cell surface, while mCLEC-2B 
and mCLEC-2C were retained in the cytoplasm. This is consistent with the cytoplasmic retention of 
other type II transmembrane receptors which have been alternatively spliced to generate variants 
lacking the transmembrane region, for example human Dectin-1 isoform E [135]. Surface 
expression of CLEC-2 has been shown in platelets where it has been shown to undergo differential 
glycosylation [268]. During the course of this study I also described surface expression of mCLEC-
2 on peripheral blood neutrophils [269]. 
mCLEC-2 can be cleaved by serine proteases releasing a soluble form of the receptor. Soluble 
CLEC-2 has been shown to exist as disulfide-linked homodimers which led to the suggestion that 
full-length mCLEC-2 also exists as homodimers, although this has not been directly shown [267]. In 
fact, the structure of the extracellular domain of hCLEC-2 has been solved to 1.6-A and this 
analysis revealed that hCLEC-2 appears monomeric [270]. However, as is the case with MICL, it 
may be that the murine and human forms differ in terms of their dimerisation capabilities. 
The crystal structure of the extracellular region of hCLEC-2 revealed that its basic core consists of 
key features of the CTlD, with two antiparallel j3-sheets flanked by two a-helices. A semi-helical 
long loop region dominates the upper surface of ClEC-2 and there is a 3-10 a-like helix contained 
in this region. Mutational binding analYSis identified the long loop as important for ligand binding 
[270]. The residues which typically coordinate a calcium ion in related carbohydrate binding 
proteins are not present in ClEC-2. 
1.12.2 Ligands 
Both endogenous and exogenous ligands of ClEC-2 have been identified. The first exogenous 
ligand described was rhodocytin [268J, a toxin purified from the venom of the Malayan pit viper 
Calloselasma rhodostoma. It was long known that rhodocytin elicited powerful activation of 
platelets [271] but the exact mechanism was unclear until an investigation by Suzuki-Inoue and 
colleagues. This investigation used rhodocytin-affinity chromatography combined with mass 
spectrometry analysis to reveal that ClEC-2 was the receptor underlying platelet activation by 
rhodocytin [268]. It has been speculated that as rhodocytin is multimeric. ligand binding may initiate 
surface clustering of ClEC-2 on platelets causing localisation of cytoplasmic signalling domains 
and augmentation of signal transduction [270]. ClEC-2 is likely to recognise a proteinaceous ligand 
on rhodocytin, as the venom protein is not glycosylated which rules out the possibility of a CLEC-2-
carbohydrate interaction [270]. 
Podoplanin, a transmembrane sialoglycoprotein involved in tumor cell-induced platelet aggregation, 











for CLEC-2 and it has been suggested that their interaction may be involved in tumor growth and/or 
metastasis [272-274J. Using recombinant glycopeptides to study the interaction of hCLEC-2 with 
podoplanin, Kato et al concluded that the interaction was carbohydrate-mediated, and that a di-
sialylated core O-glycan sequence on Thr52 of podoplanin was essential for recognition by CLEC-2 
[273J. This is in agreement with a structural study which indicated that an endogenous ligand is 
likely to be a protein with a predominantly negatively charged binding surface [270J. However, it 
remains unclear whether the oligosaccharide sequence alone is sufficient for CLEC-2 binding, or 
whether any of the flanking peptide region is also involved. 
CLEC-2 was also identified as a HIV-1 attachment factor that may capture and transfer infectious 
HIV-1 in cooperation with DC-SIGN in platelets [275]. The structures recognised by CLEC-2 on 
HIV-1 particles are so far unidentified. However, binding of HIV-1 to CLEC-2 occurred in the 
absence of the envelope protein which led to the suggestion that CLEC-2 may recognise a cellular 
factor which is incorporated into the viral envelope upon budding from infected cells [275]. It is well 
known that a vast array of host proteins can be incorporated by HIV-1 during viral budding [276, 
277]. It is therefore a plausible idea that CLEC-2 may recognise an HIV-1 incorporated host factor. 
In fact, there is evidence that HIV-1 can infect renal cells where podoplanin is expressed and it has 
been suggested that podoplanin may be incorporated into the budding virion leading to recognition 
by CLEC-2 [272, 278, 279]. 
1.12.3 Function 
A number of studies have explored the downstream signalling pathways initiated by ligation of 
CLEC-2. CLEC-2 signalling is critically dependent on both SH2 domains of Syk, similar to Dectin-
1/Syk signalling [181]. Furthermore, it was also proposed that a single Syk molecule forms a bridge 
between two CLEC-2 receptors, a  has been suggested for both Dectin-1 and CLEC9A (Fig. 1.4) 
[181, 253]. It was also shown that in addition to Syk phosphorylation, stimulation of CLEC-2 results 
in tyrosine phosphorylation of PLCy2, Vav1/3, LAT, SLP-76 and Btk [181, 268, 280]. Indeed, 
platelets deficient in Syk, and CLEC-2 transfected T-cells deficient in Syk, Btk or PLCy2 failed to 
respond to rhodocytin, demonstrating a critical role for these proteins in mediating CLEC-2 
signalling in platelets [181, 268]. On the other hand, a significant but diminished response of CLEC-
2 transfected T-cells to rhodocytin was observed in the absence of BLNK or SLP-76, demonstrating 
that CLEC-2 is only partially dependent on the SLP-76/BLNK family of adapter proteins for 
signalling [181, 280J. Platelets lacking Rac1 display severely impaired CLEC-2 dependent 
activation demonstrating a role for this Rac GTPase in CLEC-2 signalling [281]. 
Over-expression of CLEC-2 in a cell line generated constitutive signalling via Src and Syk kinases 
that led to NFAT activation [282]. Co-expression of the ITIM-containing platelet protein, G6b-B. 
resulted in inhibition of both constitutive and agonist-induced CLEC-2 signalling. The authors of this 
study speculated that this may represent an important role of G6b-B and other ITIM containing 
platelet receptors in inhibition of platelet activation which is an essential component of physiological 











PECAM-1, on CLEC-2 signalling using both PECAM-1 deficient mice and antibody cross-linking of 
PECAM-1. This work demonstrated that PECAM-1 also had an inhibitory effect on CLEC-2 
signalling, although the results suggested that this inhibitory effect was mild and unlikely to be 
physiologically relevant [283]. 
Dectin-1 and CLEC-2 have an identical sequence consisting of four amino acid residues DEDG, 
preceding their YxxL motifs. Analysis in transfected B cells revealed that mutation of the glycine 
residue of CLEC-2 resulted in a significant reduction in signalling in response to rhodocytin 
demonstrating that the glycine residue is important for CLEC-2 signalling [181]. In a similar vein, 
mutation of this highly charged cluster in Dectin-1 was shown to abolish particle uptake [180J. 
Given the significance of the glycine residue in CLEC-2 signalling, the requirement of the OED 
cluster for Dectin-1 mediated phagocytosis, and the demonstration that CLEC9A which lacks such 
a sequence does not mediate phagocytosis [2531, it seems highly likely that the ability of CLEC-2 to 
mediate phagocytosis involves this highly charged cluster. 
Although many of the CLEC-2 signalling studies were carried out in platelets, the importance of 
CLEC-2 for platelet activation during hemostasis and in the course of thrombotic events was not 
defined until very recently. May at al demonstrated that antibody-targeting of CLEC-2 resulted in 
complete and highly specific loss of the receptor in circulating platelets for several days [284]. This 
study demonstrated that CLEC-2 is not required for adhesion of platelets to collagen during 
thrombus formation, but is necessary for subsequent stable aggregate formation. Furthermore, 
antibody-induced CLEC-2 deficiency resulted in increased bleeding times of mice indicating that 
CLEC-2 plays a significant role for normal hemostasis [284]. These results suggest that CLEC-2 
may represent a novel antithrombatic target. 
I have demonstrated that CLEC-2 is a phagocytic receptor expressed on neutrophils which can 
mediate the production of proinflammatory cytokines [269]. The expression of this receptor on 
neutrophils and the recognition of exogenous ligands imply a role in innate immunity. Although, a 
direct role in immunity has not been demonstrated, it is likely that future investigation of CLEC-2 
will reveal yet another example of a C-type lectin which functions in both homeostasis and 
pathogen response. 
1.13 Aims of this thesis 
CLEC-2 is the focus of this thesis. I originally embarked on this project in 2006 with the primary aim 
to carry out a functional characterisation of this receptor. At the outset of this work, CLEC-2 had 
merely been identified with some minimal analysis of expression [82]. However, quite a number of 
investigations of CLEC-2 have been published in the interim, including further analysis of 
expression and structure; and identification of ligands and Signalling pathways. The emergence of 
new discoveries and technologies, and the development of general concepts, especially within a 











My initial investigation into CLEC-2 was prompted by the observation that a short, but potentially 
relevant sequence, was present in the cytoplasmic tails of Oectin-1 and CLEC-2: OEOGYxxL. As 
previously outlined, the YxxL motif of Oectin-1 is required for its functionality and given the 
presence of this motif in CLEC-2 and the upstream homology between the two proteins, I sought to 
determine whether CLEC-2 was functionally related to Oectin-1. As I will describe in the 
forthcoming chapters, I found that in some respects CLEC-2 was functionally related to Oectin-1. 
However, I also established that unlike Oectin-1, CLEC-2 could not induce production of reactive 
oxygen species despite signalling via Syk. This observation initiated an investigation into the 
mechanisms that underlie IT AM-mediated activation of the respiratory burst and the role of Syk in 
this process. In addition, the identification of podoplanin as a ligand for CLEC-2 resulted in a facet 
of this project which aimed to characterise expression of this CLEC-2 ligand on macrophages. 
In summary the aims of this thesis were to extend the functional characterisation of CLEC-2, 
explore the mechanisms that underlie Syk-coupled IT AM-mediated induction of the respiratory 











2 Materials and Methods 
2.1 General reagents 
General chemicals of analytical grade were purchased from Gibcollnvitrogen, Sigma Aldrich and 
Merck. Distilled water was produced using a milliQ water purification system. 
2.2 Solutions 
• Cell lysis buffer for extraction of genomic DNA: dH20, 10mM Tris pH 7.8, 100mM 
NaCl, 10mM EDTA pH 8.0. 0.5% SDS (w/v) and 50j.lg/ml Proteinase K were added 
immediately prior to use. 
• Cell lysis buffer for immunoprecipitations: dH20, 25mM Tris pH 8.0, 140mM NaCI, 4mM 
EDTA, 1.1% (v/v) NP40, 10mM NaF, 1mM NaN04 
• Coomassie staining solution: dH20, 0.125% (w/v) Coomassie brilliant blue, 45.5% (v/v) 
Methanol, 9.2% (v/v) acetic acid 
• Coomassie destaining solution: dH20, 7.5% (v/v) glacial acetic acid, 5% (v/v) methanol 
• Coupling buffer: dH20, 0.1 M NaHC03, 0.5M NaCl, pH 8.5 
• ELISA stop solution: 2M H2S04 
• FACS block: PBS, 5% (v/v) heat inactivated serum, 0.5% (w/v) BSA, 2mM NaN3 
• FACS wash: PBS, 0.5% (w/v) BSA, 2mM NaN3 
• Formaldehyde fix: PBS, 2% (v/v) formaldehyde 
• Gey's solution: 20% A, 5% B, 5% C, 70% tissue culture grade dH 20. Filter sterilised. 
Gey's solution A: 3.5% (w/v) NH4CI, 0.185% (w/v) KCL, 0.15% (w/v) 
NA2HP04.12H20, 0.5% (w/v) glucose 
Gey's solution B: 0.42% (w/v) MgCI2.6H20, 0.34% (w/v) CaCI2 , 0.14% (w/v) 
MgS04.7H20 
Gey's solution C: 2.25% (w/v) NaHC03 
• Lidocaine/EDTA: PBS, 4mg/ml Lidocaine hydrochloride, 10mM EDTA pH8.0, filter 
sterilised 
• Paraformaldehyde solution: dH20, 4% (v/v) paraformaldehyde, 250 mM HEPES 
• Pervanadate solution: PBS, 20mM NaN04, 0.05M H20 2, prepared fresh for each use 
• PBS-Tween wash buffer: PBS, 0.1% Tween-20 
• Ponceau stain: dH20, 0.2% (w/v) ponceau S, 5% (v/v) acetic acid 











• 50S-PAGE loading dye (2X): 0.25M Tris pH6.B, 4% (w/v) SDS, 20% (v/v) glycerol, 
0.001 % (w/v) bromophenol blue. Reducing loading dye contains 10% (v/v) ~­
mercaptoethanol , non-reducing does not contain ~-mercaptoethanol 
• SOC medium: dH20, 0.5% (w/v) yeast extract, 2% (w/v) tryptone, 10mM NaCl, 2.5mM 
KCI, 10mM MgCI2 , 10mM MgS04. 20mM Glucose added after autoclaving solution. Final 
solution filter sterilised 
• Staining buffer (for sample preparation for confocal microscopy): PBS, 0.25% (w/v) 
saponin, 1 % (w/v) BSA 
• Thioglycollate solution: Boil 40.5g Brewer's Thioglycollate (DIFCO laboratories) in 1 litre 
of dH20 until dissolved, autoclave for 15 minutes and then leave for 1 month at room 
temperature. Thereafter store aliquots at -20°C. 
• Tris/EOTA (TE): 10mM Tris pH8.0, 10mM EDTA pHB.O 
• Trypsin/EOTA: PBS, 0.05% (v/v) trypsin solution, SmM EDTA, filter sterilised 
• Western blot transfer buffer: dH20, 25mM Tris, 90mM glycine, 20% (v/v) methanol 
2.3 General nucleic acid manipulation techniques 
2.3.1 Polymerase Chain Reaction (PCR) 
For general PCR reactions, 2X PCR Master Mix (Fermentas) containing 0.05u/lJl Taq DNA 
polymerase, reaction buffer, 4mM MgCI2 and O.4mM of each dNTP (dATP, dCTP, cGTP, dTTP) 
was used. PCR grade H20 (Sigma), 0.21JM of appropriate forward and reverse primers and 
approximately 100ng of template DNA per 20-501J1 reaction were added and reactions were 
incubated using a Gradient PTC-200 Peltier thermal cycler (from MH Research). Cycling 
parameters were dependent on primers and template size. However, standard parameters involved 
a denaturing step at 94°C for 2 minutes, followed by 30-35 cycles of denaturation, annealing and 
extension. Annealing temperatures were set at SoC below the lowest primer melting temperature. If 
TOPO cloning was to be performed, a final incubation at 72°C for a further 10 minutes was carried 
out to ensure that all PCR products were full length and 3'adenylated. When increased sensitivity 
was required, PCR reactions were carried out using the Advantage® 2 PCR Kit (Clontech) 
according to manufacturer's instructions. All PCR reactions were analysed by agarose gel 
electrophoresis. 
2.3.2 Agarose gel electrophoresis 
1 % (w/v) agarose gels were prepared by dissolving electrophoresis grade agarose (BioAmerica) in 
0.5X TBE (Roche) under high temperatures. Ethidium bromide (Sigma) was added to the dissolved 
agarose to a final concentration of 0.21Jg/ml. DNA loading dye (Fermentas) was added to the PCR 
samples before they were loaded onto the gel. DNA molecular weight markers (Fermentas) were 
loaded in parallel to samples for identification of fragments of specific size. Gels were run at a 
constant voltage of 90-1 OOV, to give a good separation of fragments. Gels were analyzed using a 











2.3.3 Purification of DNA from agarose gels 
Gel slices containing the DNA band of interest were excised and DNA was purified using the 
Wizard® SV Gel and PCR Clean-Up System (Promega) according to manufacturer's instructions. 
2.3.4 Topo cloning 
TOPO TA Cloning® (Invitrogen) provides a highly efficient, one-step cloning strategy for the direct 
insertion of Taq polymerase-amplified PCR products into a plasmid vector. Topo cloning of PCR 
products into the pCR2.1-TOPO vector was carried out according to manufacturer's instructions. 
TOPO reactions were then used to transform chemically competent Escherichia coli. 
2.3.5 Digestion of DNA using restriction enzymes 
Where required, DNA was digested using appropriate restriction enzymes according to 
manufacturer's guidelines. In general, 25-50ng of DNA was digested for 2 hours at 37"C. When 
indicated by the manufacturer, enzymes were then heat inactivated at appropriate temperatures. 
The success of each digest was confirmed by agarose gel electrophoresis and thereafter the 
digested DNA was excised and gel purified as described earlier. 
2.3.6 Ligation of digested vectors and insert DNA 
Ligation reactions were prepared according to Table 2.1 and incubated overnight at 16°C. Control 
reactions containing linearised vector DNA but no digested insert DNA were routinely included to 
analyse background from self-ligation of the vector. 21-11 of ligation reactions were used to transform 
chemically competent E.coli. 
Table 2.1 ligation reaction 
Component .. <. Volume/amount 
Linearised vector DNA 20-100ng 
Digested insert DNA 1 : 1 to 5: 1 molar ratio over vector 
10X T4 DNA Ligase buffer (Fermentas) 21-11 
T4 DNA Ligase (Fermentas) 0.21-11 (1 u) 
Nuclease free water to 201-11 
Total volume 201-11 
2.3.7 Transformation of competent cells 
One Shot® TOP10 Chemically Competent E.coli (Invitrogen) were thawed on ice from storage at-
BO°C. 21-11 of DNA was added to 15-351-11 of competent cells, mixed gently and incubated on ice for 5 
to 30 minutes. Cells were heat shocked at 42°C for 30 seconds without shaking and immediately 
transferred to ice. 2501-11 of room temperature SOC medium was added and the reaction was 
incubated at 37"C on a horizontal shaking incubator for 1 hour. 2001-11 from each transformation 
was spread on prewarmed LB agar plates containing 100IJg/mi ampicillin (Sigma) and incubated 











2.3.8 Analysis of transform ants by PCR 
Transformants were screened by PCR to confirm that the insert was present in the desired 
orientation. Single colonies were sampled from selection plates using a pipette tip, and transferred 
to a replica plate containing the appropriate antibiotic which was incubated overnight at 3rC. 
Thereafter the colonies were transferred directly to a tube containing a PCR reaction mixture with 
the appropriate primers. PCR and agarose gel analysis were performed as previously described. 
2.3.9Innoculation of cultures and isolation of plasmid DNA 
Single, well isolated colonies corresponding to transformants that showed the presence of the 
desired insert, were selected from the replica plate and used to inoculate 10-15ml of LB medium 
containing 100jJg/mi ampicillin. This culture was incubated for 12-16 hours at 37°C in a shaking 
incubator. The Wizard® Plus SV Minipreps DNA Purificiation System (Promega) was used 
according to manufacturer's instructions to isolate plasmid DNA from these cultures. DNA samples 
were checked for concentration and quality using a NanoDrop® ND-1000 Spectrophotometer prior 
to sequencing analysis. 
2.3.10 Genomic DNA isolation 
To confirm that newly generated cell lines were expressing the full correct nucleotide sequence 
introduced by retroviral transduction (described later), genomic DNA was isolated from these cells 
and analysed by sequencing. Cells were detached with lidocaine/EDTA, pelleted at 1000rpm for 5 
minutes at 4°C and lysed in cell lysis buffer which had been supplemented with 50jJg/mi Proteinase 
K (Roche) immediately prior to use. Celilysates were incubated overnight on a shaking platform at 
55°C. To extract the genomic DNA, an equal volume of phenol, pH 8.0 was added, followed by 
vigorous shaking and then centrifugation at 13,000rpm for 2 minutes at 4°C. Supernatants were 
carefully transferred to new eppendorf tubes and an equal volume of 
Chloroform(24):lsoamylalcohol(1) was added. Tubes were mixed by inversion and centrifugation 
repeated. The aqueous supernatant was transferred to a new eppendorf tube and 501-11 of 3M 
sodium acetate, pH 5.2 was added, followed by 500jJi of isopropanol. Tubes were inverted several 
times before centrifugation at 13,000rpm for 15 minutes to precipitate DNA. Pellet was washed with 
70% ethanol, air dried and resuspended in TE buffer. DNA samples were checked for 
concentration and quality using a NanoDrop® ND-1000 Spectrophotometer prior to sequencing 
analysis. 
2.3.11 Sequencing 
To confirm the fidelity of all constructs, purified plasmid DNA was analysed by sequencing at the 
Central Analytical Facility at the University of Stellenbosch, Cape Town, South Africa. Sequences 











2.4 Nucleic acid manipulations specific to this thesis 
2.4. 1 Generation of mCLEC-2HA and Dectin-1 HA 
Full length murine CLEC-2 (mCLEC-2) with a C-terminal hemagglutinin (HA) tag was generated in 
collaboration with Dr. Kevin Dennehy as follows: The complete CLEC-2 open reading frame was 
amplified from BALB/c mouse spleen cDNA by PCR using primers A and B (see Table 2.2). The 
PCR product was purified and inserted into TOPO vector as described (section 2.3.4) and the 
fidelity of the sequence was confirmed. Using primers C and 0 (see Table 2.2); recognition sites for 
8al1 and Xho1 were introduced by PCR. The purified PCR product was digested with 8al1 and 
Xho1 restriction enzymes (Fermentas) and ligated with annealed primers E and F (see Table 2.2). 
This ligation resulted in the introduction of the influenza hemagglutinin (HA)-tag at the C-terminus 
of the receptor. This short sequence (YPYDVPDYA) encodes a simple and convenient method to 
detect the expression of genes by flow cytometry. Western blot or immunoprecipitation. The 
mCLEC-2HA construct was then digested with 8al1 and Not1 restriction enzymes (Fermentas) and 
ligated with pFBneo or pMXs-IP vectors which had also been digested with 8al1 and Not1 as 
described (section 2.3). Full-length HA-tagged Dectin-1 (Dectin-1 HA) was available in the 
laboratory and was generated as previously described [157]. 
2.4.2 Generation of mCLEC-2IDectin-1 HA chimeric constructs 
A C-terminally HA-tagged mCLEC-2/Dectin-1 chimera in FBneo was generated in collaboration 
with Dr. Kevin Dennehy using overlap extension PCR. The chimeric sequence translated as CLEC-
i-27 I Dectin_144-244; generating a chimeric receptor consisting of the cytoplasmic tail of CLEC-2 and 
the transmembrane, stalk and CTLD of Dectin-1. A C-terminally HA-tagged chimeric ITAM mutant 
in pFBneo (mCLEC2/Dectin-1HA Y7F, referred to from now as 'Y7F') in which the tyrosine in the 
DGYxxL motif was mutated to phenylalanine, was generated by PCR using primer G (see Table 
2.2). 
2.4.3 Generation of a soluble FcCLEC-2 fusion protein 
A soluble fusion protein containing the extracellular CTLD and stalk region of mCLEC-2, fused to 
the Fc portion of human IgG1 was generated in collaboration with Dr. Kevin Dennehy as follows: 
The soluble Fc-mCLEC-2 chimera (FcCLEC-2) was generated by cloning the CTLD and stalk 
region of mCLEC-2 into the p8ecTag2 expression vector containing the mutated Fc portion of 
human IgG1, described previously [285, 286]. The mCLEC-2 CTLD was amplified by PCR using 
primers H and I (see Table 2.2). To generate soluble protein, the construct was transfected into 
HEK293T cells. Transfected cells were selected with 200l-lg/mi zeocin (Invivogen). Conditioned 
supernatants were harvested and FcCLEC-2 was purified by chromatography on protein A 
sepharose (GE Healthcare). 
2.4.4 Generation of chimeric constructs for respiratory burst assays 
C-terminally HA-tagged chimeric constructs (R08 chimera 1, chimera 2, chimera 3) were 
generated by peR from the mCLEC-2/Dectin1 HA construct using forward primers J, K and Land 











described and the fidelity of the sequences were confirmed. The constructs were then digested 
with Sal1 and Not1 restriction enzymes (Fermentas) and ligated with similarly digested pFBneo 
vector. 
2.4.5 Generation of CLEC-2 reporter constructs 
Reporter chimeric constructs consisting of the extracellular and transmembrane portions of 
mCLEC-2 or Dectin-1 fused with the cytoplasmic portion of the CD3~ chain were generated 
essentially as described previously [137]. Appropriate sequences were amplified by PCR and 
cloned into the pMXs-IP retroviral vector. The fidelity of all constructs was verified by sequencing. 
Generation of reporter constructs was carried out by Dr. Elwira Py:z:, University of Cape 
Town. 
Table 2.2 Sequences of primers used 
A 5'ATGCAGGATGAAGATGGGTA3' 








5'TCGAGTACCCAT ACGATGTTCCGGATTACGCTT AAGCGGCCGCTTT3' 
HA-tag nucleotide sequence Not I 
5' AAAGCGGCCGCTT AAGCGT AA TCTGGAACATCGT ATGGGTAC3' 
F 
Not I HA-tag nucleotide sequence (reverse complement) 
G 
5' ACGTCGACCACCATGCAGGA TGAAGATGGGTTTATCACTTT3' 
TIT codon codes for Phe 
H 5'GGGGGTACCTGGGGATCATGTCGG3' 
I 5'CTCGAA TTCAAGCAGTTGGTCCACTC3' 
J 
5' ACGTCGACCACCATGAAA T ATCACTCTCATAT AGAGAA TCTGGATGAAGATGGGTATATC3' 
Sail ROS chimera 1 
K 
5' ACGTCGACCACCATGTCTCATATAGAGAA TCTGGATGAAGATGGGTATATC3' 
Sail ROS chimera 2 
L 
5' ACGTCGACCACCATGGAGAA TCTGGATGAAGATGGGTA TATC3' 
Sail ROS chimera 3 
2.5 Animals 
C57BLl6, Balb/c, 129/Sv mice and Wistar rats were obtained from the specific pathogen free 











with institutional guidelines. All procedures were reviewed and approved by the animal ethics 
committee of the University. All mice were used at 6-12 weeks of age 
2.6 Cells 
2.6. 1 Cell lines 
All cell lines in this study were obtained from the IIDMM cell bank at UCT and are listed in Table 
2.3. 
Table 2.3 Summary of cells lines 
Cell line Description Media used Subculture Ref 
NIH3T3 
Adherent murine embryonic 
DMEM or X-VIVO as per ATCC guidelines fibroblast 
as per A TCC guidelines 
except cells were 
RAW264.7 Adherent murine macrophage RPM I detached by the addition 
of Iidocaine/EDTA for 5 
minutes 
EL4 
Non-adherent murine T 
RPMI as per ATCC guidelines 
lymphocyte 
Non-adherent Syk-deficient [287] 
murine B cell line established 
as per ATCC guidelines 
C35 from IIA 1.6, a FcyR-defective RPMI 
variant of A20 B lymphoma 
for A20 cells 
cells 
Non-adherent Syk-
as per A TCC guidelines 
[287] 
WT8 reconstitued murine B cell line RPMI 
derived from C35 cells 
for A20 cells 
Adherent ecotropic retroviral 
RPMI or DMEM [288] 
packaging cell line (a gift from 
containing 
as per ATCC guidelines 
Plat E blasticidin 
Professor Kitamura, University 
(10(Jg/ml) and 
for 293 cells 
of Tokyo) 
puromycin (1IJg/ml) 
Adherent derivative of the as per ATCC guidelines 
293T human embryonic kidney 293 RPM I 
cell line 
for 293 cells 
Non-adherent T-cell line [289] 
established by transfecting 
BWZ.36 
BW5147 cells with an NFAT-
RPMI 
as per A TCC guidelines 
lacZ construct (a gift from for BW5147.3 cells 
Wayne Yokoyama, 
Washington University) 
2.6.2 General cell culture techniques 
All cell culture was undertaken in a laminar flow hood using aseptic technique and following 
standard cell culture protocols to ensure sterility. For long term storage of celi lines, 1 to 2x106 
cells/ml were resusupended in cryovials in foetal calf serum (FCS) containing 10% DMSO (v/v). 
Cells were frozen in a freezing container containing isopropanol at a rate of -1°C per minute. The 











maintained in the appropriate media as indicated and unless otherwise stated this media was 
supplemented with 10% FCS (Gibco), 2mM L-glutamine, 100Ulml penicillin and 0.1mg/ml 
streptomycin (all from Cambrex). FCS was heat inactivated at 56°C for 30 minutes before use. 
Cells were subcultured according to ATCC guidelines and maintained on tissue culture plastic in a 
5% CO2 humidified incubator at 37°C. Dulbecco's phosphate buffered saline (PBS) without calcium, 
magnesium and phenol red (Gibco) was routinely used for cell culture applications. To determine 
total cell counts and viable cell number, cells were diluted with Trypan Blue Stain (Sigma). a dye 
that is taken up only by non-viable cells. In the case of primary macrophages, total cell counts and 
viable cell number were determined by diluting cells with Turks Stain which is specifically taken up 
only by macrophages. 
2.6.3 Primary cells 
2.6.3.1 Isolation of bone marrow cells and generation of bone marrow derived macrophages 
Mice were sacrificed by CO2 asphyxiation. Femurs and tibias were dissected from sacrificed mice 
and fresh bone marrow was flushed from bone cavities with sterile ice-cold PBS using a 26G 
needle. Cells were strained through a 70IJm nylon cell strainer before centrifugation at 850rpm for 5 
minutes. Cell pellets were resuspended prior to analysis by flow cytometry. If cells were to be used 
for generation of bone marrow derived macrophages, cell pellets were resuspended in RPMI 
containing 20% L929 conditioned medium (containing M-CSF, laboratory stocks available) and 
transferred to Petri dishes. Fresh media was added on day 3 after isolation. On day 7, cells were 
detached and plated according to experimental requirements. 
2.6.3.2 Isolation of peripheral blood leukocytes 
Mice were sacrificed by CO2 asphyxiation, and peripheral blood was collected by cardiac puncture 
using a 21 G needle, into 0.1 vol 100mM EDT A to prevent coagulation. Cells were harvested by 
centrifugation and resusupended in 50vol ice-cold Gey's solution for 5 minutes to lyse erythrocytes. 
Peripheral blood leukocytes were then recovered by centrifugation through 100% FCS at 300g. 
Celis were counted and cell viability was established by the exclusion of trypan blue. 
2.6.3.3 Purification of peripheral blood neutrophils 
To isolate neutrophils from blood, mice were sacrificed by CO2 asphyxiation and peripheral blood 
was collected by cardiac puncture as before. Samples were pooled and overlaid on a 3-layer 
Percoll™Plus (AEC Amersham) gradient 78%, 66% and 54% Percoll, respectively, diluted in PBS 
(100% Percoll:: 9parts Percoll and 1 part 10X PBS) and centrifuged at 3141rpm for 30 minutes at 
4°C (with acceleration and deceleration at lowest settings to avoid disruption of gradient). 
Neutrophils were harvested from the 77%/66% interface. After washing with PBS containing 1 % 
BSA, remaining erythrocytes in the neutrophil fraction were eliminated by lysis in ice-cold Gey's 
solution for 5 minutes. Cells were centrifuged for 10 minutes at 4°C and 1517rpm. Pellets were 
resuspended in FACS block or media depending on the following procedure. Cells were counted 











2.6.3.4 Isolation of alveolar macrophages 
Mice were sacrificed by cervical dislocation. Bronchoalveolar lavage was performed by insertion of 
a 23G lavage tube into the trachea and repeated washes with 1ml 10mM EDTA in PBS. Resident 
alveolar macrophages, the major leukocyte population in the lungs, were identified by size and 
autofluoresence using flow cytometry. 
2.6.3.5 Isolation of spleen and lymph node cells 
Spleens and lymph nodes were dissected from sacrificed mice. Organs were disaggregated by 
maceration and cells were strained through a 70IJm nylon cell strainer before centrifugation at 
1500rpm for S minutes. Cell pellets were resuspended and cells were analysed by flow cytometry 
as described below. In BALB/c mice, systemic LPS challenge was achieved by a single 
intravenous injection of LPS from Salmonella typhimurium (11Jg LPS diluted in PBS). Splenocytes 
and lymph node cells were harvested 20 hours after treatment as described above. 
2.6.3.6 Induction of sterile peritonitis and recovery of peritoneal cells 
To induce sterile peritonitis, mice were injected intraperitoneally with 1 ml of 4% thioglycollate broth. 
18 hours later (for inflammatory neutrophils) or 4 days later (for inflammatory macrophages), mice 
were sacrificed by CO2 asphyxiation and cervical dislocation. Inflammatory cells were collected by 
peritoneal lavage with ice-cold SmM EDTA in PBS. Lavage fluid was then centrifuged at 1000rpm 
for 5minutes and cell pellets were resuspended in RPMI. Viability was determined by the exclusion 
of trypan blue. Inflammatory macrophages were identified by their expression of F4/80 and 
inflammatory neutrophils were identified by their expression of Gr-1 and CD11 b. Resident 
peritoneal cells were harvested by lavage in the same way. 
2.6.4 Cytokine and TLR agonist stimulation of cells 
To test the effect of TLR agonists on CLEC-2 surface expression, PBLs were plated in 24 well 
plates and stimulated for 6 hours with Pam3CSK4 (TLR2/1, 100ng/ml), lPS (TLR4, 100ng/ml), 
f1agellin (TlRS, 20ng/ml), and FSL-1 (TlR2/6, 20ng/ml). Cells were then analysed by flow 
cytometry. 
To test the effect of LPS stimulation on podoplanin expression by RAW264.7 cells, 2x105 cells/well 
were stimulated with various concentrations of LPS for 24 hours. Cells were then detached and 
analysed by flow cytometry as described below. 
To test the effect of TLR agonists on podoplanin expression, bone marrow derived macrophages 
were stimulated for 20 hours with Pam3Csk4 (100ng/ml and 1IJg/ml), LPS (100ng/ml and 1IJg/ml), 
flagellin (1 Ong/ml and 100ng/ml), Pam2Csk4 (10ng/ml and 1 OOng/ml), FSl-1 (100ng/ml and 1 ~g/ml) 
or PolylC (1~g/ml and 10IJg/ml). (All TLR agonists were from Invivogen). To test the effect of 
various cytokines on podoplanin expression, cells were stimulated for 20 hours with Il-4, IL-10, 
GM-CSF. IFNy or TNF at the indicated concentrations. (All cytokines were from R&D systems). 











2.6.5 Generation of transduced cel/lines 
2.6.5.1 Retrovirus production 
Retroviral vectors containing genes of interest were introduced into an ecotropic packaging cell line 
which enabled production of infectious retroviruses with the ability to infect target cells and stably 
transmit the genes of interest into chromosomes. In this study, pFB-neo and pMXs-IP were the 
retroviral vectors used and the Plat-E cell line was the packaging cell line used. Genes of interest 
were introduced into vectors using standard molecular biology techniques described earlier. To 
produce retrovirus particles, recently passaged Plat-E cells were plated in six well plates at 2x106 
cells/well in a total volume of 2ml DMEM on Day 1. On Day 2, the medium was replaced without 
detatching cells, and cells were transfected with 1IJg DNA using Fugene6 (Roche) according to the 
manufacturer's instructions. On Day 3, plates were transferred to a 5% CO2 filled airtight container 
and incubated overnight at 32°C. On Day 4, supernatants were harvested and 5IJg/mi polybrene 
(Sigma) was added. Polybrene is a cationic polymer that acts to neutralise membrane charge and 
initiates virus aggregation resulting in an increased rate of sedimentation of virus onto target cells. 
Supernatants were filtered through a O.451Jm filter and were used immediately to transduce various 
cell lines. 
2.6.5.2 Retroviral transduction of NIH3T3 and RAW264. 7 eel/lines 
In parallel with retrovirus production, on Day 3, target cells were plated in six well plates (NIH3T3 
cells were plated at 1x105 cells/well and RAW264.7 cells were plated at 1x106). On Day 4, 
RAW264.7 cells were treated for 7 hours with O.21Jg/ml tunicamycin (Sigma) which inhibits N-
glycosylation and increases transduction inefficiency. Cells were then washed before 1.5ml of the 
viral supernatant was added. Plates were centrifuged at 2500rpm at 25°C for 90 minutes to bring 
viral particles into contact with cells. Plates were then returned to 3rC. On Day 5, media was 
replaced with fresh media and on Day 6, media was replaced with selection media containing 
O.6mg/ml G418 (Invivogen). Cells were monitored daily and fresh selection media was added when 
required. Cells were detached and transferred to flasks only when colonies became clearly viable. 
2.6.5.3 Retroviral transduction of A20 cell line 
In parallel with retrovirus production, on Day 3, A20 cells were treated overnight with O.21Jg/ml 
tunicamycin. On Day 4, A20 cells were washed, counted and plated at 7x105 cells/well in 24 well 
plates. The same day, 1.5ml of the viral supernatant was added. Plates were centrifuged at 
2500rpm at 25°C for 90 minutes to bring viral particles into contact with cells. Plates were then 
returned to 3rC. On Day 5, fresh media was added and on Day 6, media was replaced with 
selection media containing 11J9/ml puromycin (Invivogen). Cells were transferred to six well plates 
and then flasks only when colonies became clearly viable. 
2.6.5.4 Retroviral transduction of EL4, C35, WTB and BWZ.36 cell lines 
El4 cells, Syk deficient (C35) and Syk reconstituted (WTS) cells were retrovirally transduced 











cells. BWZ.36 cells were retrovirally transduced with chimeric reporter constructs by Dr. 
Elwira Pyz as described in [137]. 
2.7 Generation and purification of antibodies against CLEC-2 
2.7. 1 Coupling of FcCLEC-2 to cyanogen bromide activated sepharose 
Cyanogen bromide activated sepharose (1g, Sigma) was swollen with 100mls of cold HCL (1mM) 
for 30 minutes. The resin was then washed with a total of 200mls cold HCL (1 mM) which was 
added in several aliquots. Supernatant was removed by gentle suction with a BOchner funnel 
between successive additions. Resin was then washed with 200mls of dH20 followed by 50mls of 
Coupling buffer. The resin was immediately transferred to a solution of FcCLEC-2 (0.8mg of protein 
in 5mls coupling buffer) and rotated overnight at 4°C. Unreacted ligand was removed by extensive 
washing with Coupling buffer. Unreacted groups were blocked with glycine, pH 8.0 (0.2M) for two 
hours at room temperature. To remove the blocking solution, resin was washed first with coupling 
buffer (pH 8.5) and then with acetate buffer containing NaCL, pH 4.0 (0.5M). This cycle of high and 
low pH washes was repeated five times. Resin was stored in NaCI (1 M) containing sodium azide 
(10mM) as a preservative at 4°C. 
2.7.2 Immunisation of rats 
A purified polyclonal antibody, specific for CLEC-2, was affinity purified from the serum of Wistar 
rats after immunisation with FcCLEC-2. An emulsion of which 75% was FcCLEC-2 (20l-lg per rat in 
sterile PBS), and 25% was Titermax Gold (Sigma), was prepared according to manufacturer's 
instructions. This mixture was injected intraperitoneally. Booster injections were administered two 
and four weeks later. Four days prior to harvesting blood, FcCLEC-2 (30l-lg) was injected 
intravenously. Rats were anaesthetised and exsanguinated via the jugular vein. All injections and 
blood collection were performed according to standard protocols by Hiram Arendse, Animal 
Unit Manager at the University of Cape Town. 
2.7.3 Purification of po/yctonat antibody 
Blood was immediately centrifuged for five minutes at room temperature at 3000rpm. The serum 
layer was harvested and rotated at 4°C overnight with an equal volume of human serum to 
precomplex IgG. This mixture was then centrifuged at 3000rpm for 15 minutes at 4°C before 
filtering through a serum filter. Filtered serum was run through the FcCLEC-2 coupled sepharose 
column. The column was then washed with PBS before fractions (12 x 1ml) were eluted into 5001-11 
of Tris, pH 8.0 (1 M), using glycine, pH 2.5 (50mM). The concentrations of the eluted fractions were 
measured using a NanoOrop® NO-1000 Spectrophotometer, and those containing the highest 
antibody concentrations were pooled and dialysed against PBS overnight using a Slide-A-Lyzer 
dialysis cassette according to manufacturer's instructions. Quantification of antibody concentration 











2.7.4 Generation of monoclonal antibody 
A monoclonal antibody was generated and produced by Diego Mourio-Sa and Caetano Reis 
e Sousa (Cancer Research UK). Wistar rats were immunized 3-4 times with RBL-2H3 cells 
expressing mouse CLEC-2 fused to an HA epitope. Fusion of splenocytes with the rat myeloma cell 
line Y3 was carried out using standard procedures. Hybridoma screening was carried out as 
previously reported [254]. 
2.8 Flow cytometry 
In all assays, cells were stained prior to fixation to preserve sensitive epitopes and to analyse only 
cell surface markers. FACS was performed according to conventional protocols at 4°C in the 
presence of NaN3 (2mM) [290]. Cells were first blocked with FACS block buffer containing 5% heat-
inactivated serum (serum was from goat, rat, rabbit or donkey depending on the secondary 
antibody used). Cells were stained in V-bottomed 96-well plates. Primary antibodies were generally 
used at 10IJg/mi diluted in FACS block and secondary antibodies were used at 1/200 diluted in 
FACS block. Incubation times ranged from 30 to 60 minutes on ice. Cells were washed three times 
with ice-cold FACS wash after each staining step. All monoclonal antibodies used were compared 
with isotype-matched controls. Stained cells were fixed in 1 % formaldehyde prior to flow cytometry. 
Data was acquired and analysed using a BD Biosciences FACSCalibur and CeliQuestTM Pro. 
The primary antibodies used are listed in Table 2.4. 
Table 2.4 Primary antibodies 
Antibody Isotype Target antigen Source/supplier Ref 
CLEC-2 Rat IgG2b Mouse CLEC-2 See section 2.7.4 [269] 
CD61 (biotin) Hamster IgG1 ,K Mouse CD61 BD Pharmingen 
HA.11 Mouse IgG1 HA Covance 
2A11 Rat IgG2b Mouse Dectin-1 Gordon Brown, (UCT) [157] 
5C6 (FITC) Rat IgG2b Mouse CR3 Siamon Gordon (Oxford) [291] 
Gr-1 (biotin) Rat IgG2b Mouse Gr-1 Siamon Gordon (Oxford) 
7/4 (FITC) Rat IgG2b Mouse 7/4 Siamon Gordon (Oxford) [292] 
F4/80 (biotin) Rat IgG2b Mouse F41BO Siamon Gordon (Oxford) [293] 
CD3 (FITC) Hamster IgG Mouse CD3E Serotec 
Podoplanin Rat IgG2a Mouse podoplanin MBL 
Isotype-control antibodies were either obtained from the same suppliers or produced in house. 
Flow cytometric analysis with FcCLEC-2 and FcDectin-1 soluble proteins was performed using the 
Fe proteins at 10IJg/ml. Secondary antibodies used were PE-conjugated donkey anti-rat IgG and 
PE-eonjugated donkey anti-human IgG (Jackson). Biotinylated antibodies were detected using 











using the following equation: receptor surface expression after treatment (mean fluorescence of 
receptor specific mAb - mean fluorescence of isotype control)/receptor expression of untreated 
cells (mean fluorescence of receptor specific mAb - mean fluorescence of isotype control 
2.9 Confocal microscopy 
2.9.1 Preparation of acid-etched coverslips for confocal microscopy 
13mm glass coverslips were soaked in 55% nitric acid for 4 hours followed by several washes with 
dH20. Coverslips were then stored in 70% ethanol until use. 
2.9.2 Sample preparation and confocal analysis 
The preparation of samples is outlined in later sections. Confocal laser scanning microscopy 
was performed by Dr. Dirk lang at the UCT Imaging Centre. A Zeiss Axiovert 200M LSM 510 
META confocal microscope was used. Images were processed using Adobe Photoshop version 6.0 
2.10 Phagocytosis assays 
2.10.1 Phagoyctosis of zymosan particles by transduced NIH3T3 fibroblasts 
Transduced cells were seeded at 2.5x105 cells/well in six well plates the day before the assay. To 
inhibit phagocytosis, some cells were pretreated with Cytochalasin D (10IJM) (Calbiochem) for 40 
minutes before and throughout the assay. After washing, FITC-zymosan (1 to 5 particles/cell) 
(Invitrogen) was added and allowed to settle for one hour at 4'C. After washing three times with 
ice-cold media to remove unbound particles, cells were incubated at 37"C for one hour. Cells were 
then cooled to 4°C and detached using a cell lifter following 10 minutes incubation with Lidocaine-
EDTA. Cells were then transferred to a 96 well plate and blocked with FACS block for 30 minutes 
prior to the addition of zymosan opsonising antibody (1:1000) (Invitrogen) for 60 minutes at 4'C. 
Cells were then washed three times with cold FACS wash. Secondary APC-conjugated goat anti-
rabbit antibody (1 :200) (Molecular Probes) was added for 45 minutes at 4'C before washing three 
times with cold FACS wash. Cells were resuspended in FACS wash and an equal volume of 2% 
formaldehyde was added to fix. Using flow cytometry, FITC+ cell populations which had bound or 
internalised zymosan particles were gated and the percentage of phagocytosis was determined by 
comparing the APC' to the APC+ cell populations. 
2.10.2 FITC labelling and antibody coupling of Sheep anti-rat IgG Oynabeads 
Oynabeads Sheep anti-Rat (Invitrogen) are uniform, superparamagnetic polystyrene beads (4.5IJm 
diameter) coated with polyclonal Sheep-anti-Rat IgG anti bodes. 8x108 of these beads were washed 
with bicarbonate buffer and then resuspended in 2mls of the same buffer. FITC solution (Sigma) 
was freshly prepared in DMSO at 1 mg/ml. 901-11 of FITC solution was added to beads in 51J1 aliquots 
and rotated overnight at 4°C. The following day beads were washed twice with PBS and 
resuspended in PBS containing NaN3 (10mM), Beads were then recounted and analysed via flow 
cytometry to confirm FITC labelling. Anti-CLEC-2 (monoclonal) or rlgG2b isotype control (0.5I-1g per 
1x106 beads) were rotated with beads for 45 minutes at 4'C. Beads were then washed twice with 











2.10.3 Phagocytosis of anti-CLEC-2 coated beads by transduced NIH3T3 fibroblasts- analysis by 
flow cytometry 
Transduced cells were seeded at 2.5x105 cells/well in six well plates the day before the assay. 
Cells were cultured in DMEM as usual, but plated out using X-VIVO media as this was found to 
reduce autofluorescence and allow easier interpretation of flow cytometry data. To inhibit 
phagocytosis, some cells were pretreated with Cytochalasin 0 (10iJM) for 40 minutes before and 
throughout the assay. After washing with cold media, FITC-Iabelled anti-CLEC-2 coated 
Dynabeads (1 bead/cell), were added and allowed to settle for one hour at 4°C. After washing to 
remove unbound particles, cells were incubated at 37"C for two hours. Plates were then returned to 
ice and cells were washed three times with ice-cold media. Cells were then detached using a cell 
lifter following 10 minutes incubation with Lidocaine-EDTA. Cells were centrifuged for 5 minutes at 
1000rpm and 4°C. For the detection of external beads, cells were incubated with aPE-conjugated 
anti-rat antibody (1 :200) (Jackson) for 60 minutes at 4°C. Cells were then washed three times with 
cold FACS wash. Cells were resuspended in FACS wash and an equal volume of 2% 
formaldehyde was added to fix. Using flow cytometry, FITC+ cell populations which had bound or 
internalised beads were gated and the percentage of phagocytosis was determined by comparing 
the PE- to the PE+ cell populations. 
2.10.4 Phagocytosis of anti-CLEC-2 coated beads by transduced NIH3T3 fibroblasts- analysis by 
confocal microscopy 
Transduced cells were seeded at 2.5x105 cells/well on acid-etched glass coverslips in six well 
plates the day before the assay. Cells were washed with media and FITC-Iabelled anti-CLEC-2 
coated Dynabeads (1 bead/cell) were added. Plates were incubated for two hours at 37"C. Cells 
were washed three times with cold media and then fixed using a 4% paraformaldehyde solution for 
30 minutes. This solution was then removed and cells were incubated with a staining buffer for 30 
minutes at room temperature. The staining buffer contained saponin which causes permeabilisation 
of the cell membrane. Actin was stained with TRITC phalloidin (1 J..IM) (Sigma) for one hour, during 
which plates were covered with foil and shaken gently. Cells were then washed three times with 
staining buffer and finally with PBS. Coverslips were inverted onto drops of Vectashield (VECTOR 
laboratories) mounting medium containing Hoechst nuclear dye on microscope slides. Samples 
were then analysed by confocal microscopy. 
2.10.5 Phagoctyosis of zymosan particles by RAW2647 macrophages and Syk recruitment-
analysis by confocal microscopy 
Transduced cells were seeded at 2.5x105 cells/well on acid-etched glass coverslips in six well 
plates the day before the assay. After washing three times with cold media, FITC-zymosan (5 
particles/cell) was added and cells were incubated at 37"C for one hour. Cells were washed three 
times with cold media and then fixed using a 4% paraformaldehyde solution for 30 minutes. This 











minutes at RT. Actin was stained with TRITC phalloidin (1IJM) as before. Cells were then washed 
and coverslips were mounted as before. 
Recruitment of Syk was investigated similarly, except after addition of FITC-zymosan, cells were 
incubated at 3rC for only two minutes. Cells were then fixed and permeabilised as before. Syk 
recruitment was detected with anti-phospho-Syk (1:100) (Cell Signalling) for one hour at 4°C, 
followed by cyanine (Cy)-3-conjugated anti-rabbit IgG (1 :100) for one hour at 4°C. Coverslips were 
mounted as before. 
2.10.6 Phagocytosis of anti-CLEC-2 coated beads by peripheral blood leukocytes 
PBLs were obtained as described and 5x106 cells per sample were resuspended in RPMI. FITC-
labelled Oynabeads, coated with anti-CLEC-2. 2A 11 or istoype control Abs, were added at a ratio 
of two beads per cell and incubated with rotation for one hour at 4°C. To remove unbound beads, 
samples were layered over a two layer Percoll™Plus gradient- (40% and 70%) and centrifuged at 
3140rpm for 30 minutes at 4°C (brake and acceleration at lowest setting). After washing, cells were 
resuspended in 1001J1 RPMI in the presence or absence of Cytochalasin 0 (5IJM) and placed at 
3rC for 45 minutes to allow phagocytosis to occur. Cells were washed and external beads were 
detected by incubation with a PE-conjugated anti-rat antibody (1 :200) for 60 minutes at 4°C. Cells 
were then washed three times with cold FACS wash. Cells were resuspended in FACS wash and 
an equal volume of 2% formaldehyde was added to fix. Using flow cytometry, FITC+ cell 
populations which had bound or internalised beads were gated and the percentage of phagocytosis 
was determined by cornparing the PE" to the PE+ cell populations. 
2.11 Binding and cytokine production assays 
2. 11. 1 Zymosan binding and TNFa production by transduced cells 
RAW264.7 and NIH3T3 transfectants were plated at 2x105 cells/well and 5x10
4 
celis/well 
respectively in 24-well plates the day before the assay. Cells were washed three times with ice-cold 
RPM!. To block Oectin-1. glucan phosphate (1001Jg/ml, a gift from David Williams. ETSU, TN) was 
added to appropriate wells and cells were incubated for 20 minutes on ice. Following the addition of 
FITC-zymosan (25 particles/cell). cells were incubated on ice for a further 60 minutes to allow 
binding, and then washed extensively to remove unbound particles. For the determination of TNFo 
production from transduced RAW264.7 macrophages, cells were incubated for a further three 
hours at 3rC in 5% CO2 • Supernatants were harvested and TNFa was measured by ELISA using 
the OptEIA TM murine TNFa ELISA kit (BO Biosciences) as described by the manufacturers. The 
amount of FITC-zymosan associated with the cells was quantified after lysis with 3% (v/v) Triton X-
100. using a Thermo Fluoroskan Ascent FL. To account for any differences in cell density, control 
staining using Carboxyfluorescein diacetate succinimidyl ester (CFSE, Sigma) was performed. For 
this, untreated wells were rinsed with PBS. CFSE (10IJM) was then added and cells were incubated 
at RT for 5 minutes, before washing three times with cold media and lysis as before. CFSE is a 
non-fluorescent dye that passively diffuses into the cytoplasm of cells where it is converted to 











covalently binds to amino groups on intracellular macromolecules, anchoring the dye. The CFSE 
fluorescence reading for each cell line was then used to normalise the zymosan fluorescence 
readings. 
2.11.2IL-2 production by C35 and WTB cells 
For the analysis of IL-2 production by Syk-sufficient (WT8) and Syk-deficient (C35) B-cells, 1x106 
transduced cells were seeded in 24 well plates and stimulated with various concentrations of 
unlabelled zymosan (Sigma) for 16 hours at 3rC in 5% CO2. IL-2 secreted into the supernatants 
was quantified by ELISA using the OptEIATM murine IL-2 ELISA kit (BO Biosciences) as described 
by the manufacturers. 
2.11.3 TNFa production by purified peripheral blood neutrophils 
To examine cytokine production from primary cells, murine neutrophils were purified as described 
and plated at 3x105 cells/well, in 24 well plates. Cells were left unstimulated or stimulated with 
rhodocytin (15IJg/ml) or LPS (11Jg/ml) for six hours at 3rC. Rhodocytin was kindly provided by 
Johannes Eble, Frankfurt University Hospital. Germany [294]. Supernatants were harvested and 
TNFa was measured by ELISA using the OptEIA TM murine TNFa ELISA kit as described by the 
manufacturers. 
2.12 Protein determination 
2.12.1 SDS-PAGE 
Protein separation on the basis of mass was carried out by SOS-PAGE. Protein mixtures were first 
mixed with sample buffer containing SOS and ~-mercaptoethanol (Sigma) and boiled for 5 minutes. 
Using a Mini-PROTEAN® 3 System (BioRad). 1.5mm thick gels consisting of a 10% resolving 
polyacrylamide gel overlaid by a 10% stacking polyacrylamide gel were cast and submerged in 
SOS Running buffer. Samples were loaded into wells in the gel. A commercially available mixture 
of proteins having defined molecular weights was loaded in parallel. An electric current of 100V 
was applied across the gel, causing differential migration of proteins. Gels were subsequently 
stained with Coomassie staining solution for one hour. before destaining overnight, or were used 
for Western blots. 
2. 12.2 Western blotting 
Western blotting was used for the detection of particular proteins. In order to make the proteins 
accessible to antibody detection, samples were transferred elecrophoretically from acrylamide gels 
to Hybond C+ nitrocellulose membranes using the Mini-PROTEAN® 3 Cell System (BioRad). The 
uniformity and overall effectiveness of transfer of protein from the gel to the membrane was 
checked by soaking the membrane briefly in Ponceau S dye. The membrane was destained by 
several washes with water. After blocking overnight in PBS containing 0.5% BSA. membranes 
were probed with appropriate specific antibodies. After washing several times with PBS-Tween, 
membranes were incubated with an appropriate HRP-linked secondary antibody before washing 











antibody in use. Blots were developed with the ECl-plus kit (Amersham), used according to 
manufacturer's instructions. 
2.12.3Immunoprecipitations- RAW264.7 cells 
To perform immunoprecipitations from RAW2647 macrophages, 1x107 cells were stimulated with 
pervanadate solution (5\.11) for one minute at 3rC. Pervanadate is a protein tyrosine phosphatase 
inhibitor and it causes an increase in tyrosine phosphorylation and various cell signalling 
responses. Cells were lysed with ice-cold isotonic lysis buffer containing protease inhibitors 
(Roche). lysates were centrifuged and supernatants were added to streptavidin beads (Sigma) 
precoupled with biotytinylated tyrosine phosphorylated or unphosphorylated signalling peptides 
(25\.1M).The ClEC-2 signalling peptides were generated by the Peptide SyntheSis laboratory at 
Cancer Research UK and corresponded to the following region of the CLEC-2 cytoplasmic tail: 
MQDEDGYITlNIKPR. The Dectin-1 peptides corresponded to the following region of the Dectin-1 
cytoplasmic tail: MKYHSHIENlDEDGYTQlDFSTQ and have been described previously [177]. 
Beads were rotated for two hours at 4°C and washed five times with lysis buffer before boiling for 
five minutes in SDS sample buffer. The immunoprecipitates were resolved by 10% SDS-PAGE and 
stained with coomassie staining solution or transferred electrophoretically to nitrocellulose 
membranes. After blocking membranes overnight in PBS containing 0.5% (w/v) BSA, proteins were 
detected with anti-phosphotyrosine (clone 4G10), and anti-Syk (Cell Signalling) followed by 
appropriate HRP-Iinked secondary antibodies. 
2.12.4 Immunoprecipitations- A20 cells 
For immunoprecipitations from A20 cells expressing a HA-tagged version of ClEC-2, 1x107 cells 
were precoated with anti-HA antibody and then stimulated with pervanadate and lysed as before. 
Cell Iysates were added to Dynabeads Pan Mouse IgG (Invitrogen, dynabeads coated with a 
monoclonal human anti-mouse IgG antibody which recognises all mouse IgG subclasses and is Fc 
specific), and rotated for two hours at 4°C. Beads were washed and samples analysed by SDS-
PAGE and Westem blotting as described. 
2. 12.5 Mass spectrometry analysis 
Stained gels were provided to Caroline Jefferies (Royal College of Surgeons in Ireland) who carried 
out MS/MS analysis using a MAlDI-TOF system. 
2.13 Respiratory burst assays 
2.13.1 Respiratory burst assays in RA W 264. 7 cells 
For analysis of hydrogen peroxide (HZ0 2) generation, suspensions of RAW tranductants in RPMI 
(1x106 cells/ml) were loaded with dihydrorhodamine 123 (DHR 123, 2iJM) (Sigma). Cells were 
incubated in a 3rC water bath for 30 minutes before stimulation with zymosan (Sigma), particulate 
j3-glucan, or depleted zymosan (Invivogen) (all at 50jJg/ml). For co-stimulation experiments cells 
were incubated as described before stimulation with particulate j3-glucan (50jJg/ml) in the presence 











various time points and added to ice-cold PBS containing 1 % BSA (3ml). Samples were 
centrifuged at 1000rpm, 4°C for 5 minutes and cell pellets were resuspended in PBS (200J-l1). 
Conversion of DHR 123 to rhodamine was analysed by flow cytometry. DHR 123 is a non-
fluorescent reactive oxygen species (ROS) indicator that is oxidised by HZ0 2 to rhodamine which 
emits a bright fluorescent signal upon excitation by blue light. Cells loaded with DHR 123 but not 
treated with any stimulus were used to assess background levels of H20 2 production. Mean 
fluorescent intensity of untreated samples was subtracted from mean fluorescent intensity of 
treated samples. 
2. 13.2 Respiratory burst assay in primary cells 
To examine H20 2 production from primary cells following stimulation with rhodocytin, murine 
neutrophils were purified as described and resuspended in RPMI in 24 well plates at 3x105 
cells/well in the presence of DHR 123 (2IJM). Cells were unstimulated or stimulated with rhodocytin 
(15IJg/ml) or phorbol 12-myristate 13-acetate (PMA, WOng) for 1 hour at 3rC. Rhodocytin was 
kindly provided by Johannes Eble, Frankfurt University Hospital [294]. Aliquots (1501J1) were 
removed at various time points and added to ice-cold PBS containing 1 % BSA (350J-l1). Samples 
were centrifuged at 1000rpm, 4°C for 5 minutes and cell pellets were resuspended in PBS before 
immediate analysis by flow cytometry. Mean fluorescent intensity of untreated samples was 
subtracted from mean fluorescent intensity of treated samples. 
2.14 ligand screening 
2.14.1 Screening for interactions of soluble CLEC-2 with polysaccharides 
Carbohydrate microarray analysis was carried out in collaboration with Angelina S. Palma 
and Ten Feizi at The Glycosciences laboratory, Imperial College london. Microarrays of a 
total of 326 lipid-linked oligosaccharide probes, neoglycolipids and glycolipids were robotically 
generated and microarray analyses with FcCLEC-2 and FcDectin-1 were performed essentially as 
previously described [155]. The lipid-linked oligosaccharide probes were printed in duplicate on 
nitroceullulose-coated glass slides at 2 and 7fmol/spot as previously described [295, 296], and 
encompassed diverse N-glycans, O-glycans, blood group-related sequences on linear or branched 
backbones and their sialylated and/or sulfated analogs, gangliosides, and oligosaccharide 
fragments of glycosaminoglycans and polysialic acid. Also included were homo-oligomers of 
glucose and of other monosaccharides. For a comprehensive list of probes see Schallus et aI, 
Molecular Biology of the Cell, 2008 [297]. FcCLEC-2 and FcDectin-1 were tested at 20 and 51Jg/ml, 
respectively and binding of these probes was detected after two hours incubation, using 
biotinylated anti-lgG, followed by streptavidin-congugated horseradish peroxidise. 
2.14.2 Ligand screening using reporter cells 
For ligand screening, 1x105 reporter cells were co-cultured with isolated mouse primary cells, or 
RAW264.7 cells (1x106 cells), or PMA (40ng/ml) and ionomycin (1.5J-lg/ml) in 48 well plates for 20 
hours. Following stimulation, IL-2 released into the supernatant was quantified by ELISA using the 











cells were tested for induction of ~-galactosidase activity by X-gal staining using a commercially 
available kit [137]. X-gal (5-bromo-4-chloro-3-indolyl-[3-D-galactopyranoside) is a substrate for [3-
galactosidase and when cleaved by the enzyme it forms a visible blue precipitate. Following X-gal 
staining, plates were examined by microscopy and photographed. Photographs are shown in 
greyscale and (3-galactosidase activity is indicated by the presence of black cells. Initial ligand 
screening with reporter cells was performed by Elwira Pyz, University of Cape Town. 
2.15 Statistical analysis 
As a measure of the variability amongst samples and sample populations, statistical analyses were 
performed using GraphPad Prism. The standard deviation (SD) was calculated where it was 
necessary to give an estimate of the spread around the sample mean. In some cases it was 
necessary to employ statistical methods to determine whether differences between data sets were 
significant. Where there were only two sets of data, unpaired t tests were performed. Where there 
were multiple data sets, one-way analyses of variance (AN OVA) was performed to ensure the most 
stringent comparison of the data. Two-tailed P values (probability of the difference seen being due 






















3 Generation of tools and subsequent functional characterisation of CLEC .. 2 
3.1 Introduction 
The focus of this chapter is the functional characterisation of C-type lectin-like receptor 2, CLEC-2 
(also known as C-type lectin domain family 1, member B [CLEC1 B]). I previously mentioned that 
minimal analysis of the expression and function of CLEC-2 had been carried out when I started this 
investigation in 2006. However, CLEC-2 was since described as a Syk-coupled activation receptor 
on platelets [268]. Here, I have explored the expression and regulation of CLEC-2 on other cell 
types. I also previously referred to the fact that CLEC-2 and Dectin-1 share a short, but potentially 
relevant, amino acid sequence in their cytoplasmic tails: DEDGYxxL. The YxxL portion of the 
sequence is called an ITAM-like motif and is important for the functi nality of Dectin-1, as outlined 
in Chapter 1. The observation of a homologous DEDG sequence directly upstream of this motif in 
CLEC-2 and Dectin-1 raised the possibility that the receptors may be functionally related and 
initiated the work that is described here. As outlined in Chapter 1, Dectin-1 is a Syk-coupled 
activatory receptor that mediates phagocytosis and the induction of cytokines amongst other 
cellular responses. I therefore explored the possibility that CLEC-2 could also mediate 
phagocytosis and the induction of cytokines. I also investigated whether Syk is involved in CLEC-2 
signalling in other cells types. 
The work described here has been published in the Journal of Immunology: Kerrigan, A.M., et al., 
CLEC-2 is a phagocytic activation receptor expressed on murine peripheral blood neutrophifs. J 












3.2.1 The monoc/onal and affinity-purified po/yclona/ antibodies specifically recognise mCLEC-2 
Prior to this study, expression of murine CLEC-2 (mCLEC-2) had only been shown on platelets, 
although RT-PCR analysis did show transcripts in PBMC, bone marrow cells, monocytes, DCs, 
granUlocytes and in a few NK cell clones [82, 268]. I wanted to generate anti-CLEC-2 antibodies to 
investigate the expression of CLEC-2 on other cell types. To produce polyclonal antibodies against 
mCLEC-2, a highly purified soluble FcCLEC-2 fusion protein comprising the CTLD of mCLEC-2 
fused to the Fc portion of human IgG1 was generated. Wistar rats were immunised using FcCLEC-
2 as the immunogen and anti-CLEC-2 polyclonal antibodies were then affinity-purified from the 
antisera of these immunised rats. In parallel, my collaborators at Cancer Research UK, generated 
an anti-CLEC-2 monoclonal antibody. This was achieved by immunising Wistar rats with cells 
expressing mCLEC-2 and generating hybridomas by standard protocols. An anti-CLEC-2 
producing hybridoma was selected by screening. 
To confirm the specificity of these antibodies, I used EL4 cells which were transduced to express a 
HA-tagged version of CLEC-2. Anti-HA staining and analysis by flow cytometry established that 
mCLEC-2 was expressed on the surface of transduced EL4 cells (Fig. 3.1A). Subsequent staining 
with the anti-CLEC-2 antibodies and further analysis by flow cytometry demonstrated that both the 
polyclonal and monoclonal antibodies specifically recognised CLEC-2 expressed on these cells 
(Fig.3.1B&C). 
3.2.2 mCLEC-2 is expressed on platelets and peripheral blood neutrophils 
Using these antibodies, I then sought to confirm that CLEC-2 was expressed on the surface of 
platelets as had been previously described [268]. To do this, murine peripheral blood was collected 
and erythrocytes were removed by lysis. The remaining cells were stained with various antibodies 
and subjected to flow cytometric analysis. Analysis of CLEC-2 expression on CD61highSSCIow 
platelets [298J confirmed that the receptor is expressed on the surface of these cells as expected 
[268] (Fig. 3.2A). 
To determine whether CLEC-2 was also expressed on other cell types, I stained PBLs from BALB/c 
mice using a variety of markers to distinguish various cell populations. Expression of CLEC-2 on 
the surface of CD11b+Gr-1+ neutrophils was detected (Fig. 3.2B). This neutrophil expression was 
not dependent on mouse strain, as similar levels of expression were also detected on these cells in 
C57BLl6 and 129/Sv mice (Fig. 3.2B). CLEC-2 was not detected on blood monocytes 
(CD11 b +F480+SSCIOW) or lymphocytes (CD3+SSCIOW) (Fig. 3.2C). Thus these data demonstrate that 
expression of CLEC-2 is not restricted to platelets, and that this receptor is also expressed by 



















Figure 3.1: A) Anti-HA staining of transduced El4 cells, as determined by flow 
cytometry, showing expression of HA-tagged mClEC-2 (filled histogram) at the 
cell surface. The vector-only control cells are indicated by the unfilled 
histogram. Primary antibody binding was detected using PE-donkey anti-
mouse IgG. 8) The monoclonal antibody raised against ClEC-2 specifically 
recognises El4 cells transduced with HA-tagged mClEC-2 (filled histogram), 
but not vector-only control cells (unfilled histogram), as determined by flow 
cytometry. Primary antibody binding was detected using PE-donkey anti-rat 
IgG. C) Similarly the affinity-purified polyclonal antibodies specifically 
recognise El4 cells transduced with HA-tagged mClEC-2 (filled histogram), but 
not vector-only control cells (unfilled histogram). Primary antibody binding was 
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Figure 3.2: Peripheral blood leukocytes were stained with various markers to 
identif~ different cell populations. A) mClEC·2 is expressed on the surface of 
CD61 h ghSSCIOW platelets. B) mClEC-2 is expressed on the surface of CD11 b +GR-1 + 
peripheral blood neutrophils from different mouse strains as indicated. C) mClEC-2 
is not expressed on CD11 b +F480+SSC 'ow blood monocytes or CD3+SSClow blood 
lymphocytes. The polyclonal antibody was used for staining in A-C and is indicated 
by filled histograms. Primary antibody binding was detected using PE-donkey anti-










3.2.3 Expression of CLEC-2 on bone marrow cells and inflammatory neutrophils is low 
Under normal physiological conditions, the majority of neutrophils are located in the bone marrow, 
and only a small fraction of these cells are released into the blood, from where they can be 
recruited to sites of inflammation [299]. I wondered whether CLEC-2 was expressed on immature 
neutrophils located in the bone marrow and hence investigated its expression on CD11 b+Gr-1 + 
bone marrow cells from a number of mouse strains by flow cytometry. Anti-CLEC-2 staining of 
these cells revealed a much lower level of surface expression as compared with peripheral blood 
neutrophils (Fig. 3.3A). In addition I examined 18 hour thioglycollate elicited CD11b+Gr-1+ 
peritoneal neutrophils and found that these cells also had low expression of surface CLEC-2 (Fig. 
3.38). These results suggest that expression of CLEC-2 is upregulated upon neutrophil emigration 
from the bone marrow into the peripheral blood, but down regulated again following recruitment to 
sites of inflammation. 
3.2.4 Regulation of CLEC-2 expression 
As CLEC-2 expression was down regulated on recruited inflammatory neutrophils (Fig. 3.38), 
investigated whether stimulation of peripheral blood neutrophils with microbial agonists could 
induce regulation of this receptor, as had been described for other 'Dectin-1 cluster' receptors such 
as MICL [137J. P8Ls were treated for six hours with a variety of TLR agonists and CLEC-2 
expression on untreated and treated cells was then compared. I found that there was no significant 
regulation of surface expression of neutrophil-expressed CLEC-2 (Fig. 3.4A&8). However, 
stimulation with Pam3CSK4, a TLR2ITLR1 agonist, resulted in increased CLEC-2 expression on 
monocytes as defined by FSC and SSC profiles (Fig. 3.4A&8). Thus these results suggest CLEC-2 
is not directly regulated on neutrophils following microbial stimulation, but that these conditions can 
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Figure 3.3: Anti-ClEC-2 staining as determined by flow cytometry showing 
that mClEC-2 is only weakly expressed on A) CD11b+Gr-1+ bone marrow cells 
from various mouse strains and on B) thioglycollate elicited inflammatory 
neutrophils (Balb/c). The polyclonal antibody was used for staining and is 
indicated by filled histograms. Primary antibody binding was detected using 
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Figure 3.4: A) Regulation of mCLEC-2 expression on peripheral blood neutrophils and 
monoyctes following stimulation with various TLR agonists, as detected with 
monoclonal anti-CLEC-2 by flow cytometry. The histograms shown are gated on 
neutrophils defined by CD11b+Gr1+ expression, and monocytes defined by forward and 
side scatter profiles. Anti-CLEC-2 staining is indicated by the black lined histograms 
and isotype control staining (rlgG2b) is indicated by the grey lined histograms. Primary 
antibody binding was detected with PE-donkey anti-rat IgG. B) To allow easier 
comparison of the data, isotype control staining is omitted and only anti-CLEC-2 











3.2.5 CLEC-2 mediates phagocytosis 
Having identified CLEC-2 on peripheral blood neutrophils, my next line of investigation sought to 
determine the function of the receptor on these cells. As CLEC-2 contains a tyrosine-based ITAM-
like sequence which is similar to that used to mediate phagocytosis by Oectin-1, I explored the 
possibility that CLEC-2 might also mediate particle uptake. I initially examined the phagocytic 
potential of CLEC-2 using a chimeric receptor consisting of the extracellular and transmembrane 
regions of Oectin-1, fused to the cytoplasmic tail of CLEC-2 (Fig. 3.5). This chimeric receptor 
allowed triggering of CLEC-2 signalling using zymosan, a defined particulate ligand for the CTLO of 
Oectin-1 [143], and is a strategy that has been successfully used to characterise the phagocytic 
potential of other receptors in the Oectin-1 cluster [253]. To evaluate whether the cytoplasmic 
tyrosine of CLEC-2 contributes to its activity, a chimeric receptor construct in which the tyrosine 
within the cytoplasmic ITAM-like motif was mutated to a phenylalanine (Y7F) was generated (Fig. 
3.5). These chimeric receptors also contained a C-terminal HA-tag which, as explained before, 
would allow me to determine whether the receptor was expressed on the surface of transduced 
cells. NIH3T3 fibroblasts were transduced with the chimeric constructs described and Oectin-1; and 
anti-HA staining followed by flow cytometric analysis confirmed that the various receptors were 
expressed on the cell surface (Fig. 3.6A). 
Next, the ability of these normally non-phagocytic cells to bind and internalize zymosan was 
examined. To analyse zymosan binding, FITC-Iabelled zymosan particles in the presence or 
absence of glucan phosphate were added to the cells. The amount of zymosan associated with the 
cells was then quantified using a fluorometer. Glucan phosphate was included as it specifically 
inhibits Oectin-1 binding to zymosan [143, 147, 300]. As expected, expression of the chimeric 
receptors in the NIH3T3 cells conferred an ability to bind FITC-Iabelled zymosan, which could be 
inhibited by the inclusion of glucan phosphate (Fig. 3.68). This inhibition demonstrated the 
specificity of the binding and the functionality of the receptors. The binding level of zymosan to 
NIH3T3 cells expressing the chimeric receptors was equivalent to cells expressing Oectin-1 which 
were included in the experiment as a positive control. 
To analyse uptake, FITC-Iabelled zymosan particles were again added to transduced NfH3T3 cells 
and the cells were incubated at the appropriate temperature to allow phagocytosis. Samples were 
then stained with an anti-zymosan antibody, binding of which was detected using an APC-
conjugated secondary antibody. All FITC positive cells were analysed (all cells which had bound 
zymosan, whether phagocytosis had occurred or not), and the percentage of phagocytosis was 
determined by comparing the APC' to the APC+ populations. Where indicated, cytochalasin 0 was 
included to inhibit actin polymerization, and hence particle uptake. The results show that cells 
expressing the chimeric receptor were able to internalize zymosan particles in an actin dependent 
manner. However, mutation of the cytoplasmic tyrosine significantly reduced the ability of these 
cells to internalise zymosan particles (Fig. 3.6C). Similar results were obtained when these 
chimeric receptors were expressed in RAW264.7 macrophages and zymosan uptake was analysed 











Following a similar approach used recently to demonstrate the phagocytic potential of the C-type 
lectin, CD302, I used anti-CLEC-2 coated FITC-Iabelled Dynabeads to investigate CLEC-2 
mediated phagocytosis in primary cells [301]. I first confirmed by flow cytometry that anti-CLEC-2 
coated beads were specifically bound by NIH3T3 cells expressing full length CLEC-2 (Fig. 3.7A). 
To examine whether these beads were internalised, I incubated samples with aPE-conjugated 
antibody. Using flow cytometry and following a similar approach to that used previously, FITC+ cells 
were gated and the percentage of phagocytosis was determined by comparing the PF to the PE+ 
cell populations. Cytochalasin D was again included to inhibit actin polymerization. The results 
showed that anti-CLEC-2 coated beads were internalised by CLEC-2 expressing cells in an actin 
dependent fashion (Fig. 3.7B). Confocal images of these cells show the presence of actin-based 
phagocytic cups around ingested beads (Fig. 3.7C). 
I then investigated whether anti-CLEC-2 coated beads were bound and internalised by primary 
cells expressing CLEC-2. To do this I added antibody-coated beads to PBLs in the presence or 
absence of cytochalasin D, and incubated the cells at 3rC to allow phagotyosis to occur. 
Subsequent staining and analysis by flow cytometry showed that anti-CLEC-2 coated beads bound 
specifically to peripheral blood granulocytes, as compared with isotype-coated beads (Fig. 3.7D). 
Anti-Dectin-1 coated beads were included as a positive control and also bound to peripheral blood 
granulocytes as expected [290J. Upon incubation at 3rC, anti-CLEC-2 and anti-Dectin-1 coated 
beads were internalised by the granulocytes in an actin dependent fashion, as uptake could be 
inhibited by the addition of cytochalasin D (Fig. 3.7E). Collectively these results demonstrate that 
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Figure 3.S; Cartoon represent~tion 01 Dectin·!, CLEC-2 and the Dectin-lICLEC-2 
chimeric constructs used in this study. Note the presence of the extracellular and 
transmembrane reg ions of Dectin·1 and th e cytopla smic tail 01 CLEC·2 in the 
chimer~s. In the Dectin-lICLEC-2 Y7F chimera, the cytoplasmic tyrosine has been 
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Figure 3.6: A) Anti-HA staining of transduced NIH3T3 fibroblasts, as determined by flow 
cytometry, showing expression of HA_tagged constructs at the cell surface as indicated. 
Primary antibody binding was detected using PE-donkey anti-mouse IgG B) Quantitation of 
File-zymosan (zy) binding (25 particles/cell) by transd lICed NIH3T3 fi broblasts, in the preseoce 
Or absence of glucan phosphate (GP,100~glml). as indicated. The amolll1t 01 FITC-zymosan 
associated with the cells was quantified after lysis, using a Thermo Fluoroskan As~e nt FL 
RFU, relati~e fluoresc ent units. The data shown are the mean:!: SO and are representative of at 
least three independent experiments ... p < 0.05 vs control IStlldent"s t test). C) FACS·based 
analysis of phagocytosis, showing the eldent of FIlC.zymosan internalisation (grey 
histograms) by NIH3T3 cells expressing the constructs. as indicated. Cytochalasin D (10~M. 
unfilled histograms) was used to inhibit actin polymerization and served as a control in this 
assay. External zymosan was detected by the addition of a zymosan opsonising antibody. 
followed by an APC'conjugated goat anti-rabbit antibody. FllC' cell populations which had 
bound Or internalised zymosan particles were gated and the percentage of phagocytosis was 
determined by comparing the APC' to the APC' cell populations. The histograms shown are 
representative of at least three independent experiments, and the bars indicate the percentage 
of cells with internalised particles. OJ Confocal image demonstrating FITC.zymosan uptake by 
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Figure 3.7: A) FACS_based analysis of binding of isotyp~ co~t~d or anti·CLEC·2 coated FITC· 
dynabeads to NIH3T3 cells expressing mCLEC-2. B) FACS-based analysis demonstrating 
uptake of anti_CLEC·2 coated dynabeads (grey histogram) by NIH3T3 cells expressing 
mCLEC·2. Cytochalasin D tre~ted cells (10~M, black lined histogram) were included as a 
control. For the detection of external beads, cells were Incubated with a PE-conju9~ted anti· 
rat antibody. FITC' cell populations which had bound Or internalised be~ds were g~ted and 
the percent~ge of phagocytosi s was determined by comparing the PE' to the pe cell 
populations. C) Confocal image showing an NIH3T3 c ell expressing mCLEC_2 intern~lisin9 a 
FITC_labelled anti·CLEC_2 coated dynabead Inset shows the presence of an actin·based (red) 
ph~gocytic cup ~round the particle. 0) In comparison to isotype coated beads, peripheral 
blood granulocytes (identified by forward and side scatter profiles) specifically recognis e 
anti_CLEC_2 and anti·o..ctin·1 coated dynabeads. External beads were detected by incubation 
with aPE_conjugated anti·rat antibody. FITC' cell populations which had bound or 
intern~lised beads were gated and the percentage of phagocytosis was determined by 
comparing the PE to the PE- cell populations. E) Cells binding the anti_CLEC·2 coated 
dynabeads internalise these particles in an actin dependent fashion, ~s uptake could be 










3.2.6 CLEC-2 induces production of cytokines 
The cytoplasmic ITAM-like motif of Dectin-1 can also induce the production of cytokines, including 
TNFa [157, 178, 208] and I therefore decided to explore whether signalling via CLEC-2 could 
similarly induce cytokine production in neutrophils, as has been reported for other neutrophils 
receptors [302J. I found that the CLEC-2 ligand rhodocytin and LPS (included as a positive control), 
both induced the production of TNFo from purified peripheral blood neutrophils (Fig. 3.8). Although 
this suggests that CLEC-2 can mediate cytokine production from primary neutrophils, rhodocytin is 
known to be recognised by other receptors which may have contributed to the observed cytokine 
production [268]. I therefore attempted to stimulate cells using antibody crosslinking, and antibody-
coated Dynabeads, but specific responses could not be demonstrated in this manner due to high 
background levels of cytokine production in control samples (data not shown). 
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Figure 3.8: Addition of rhodoyctin or LPS to purified 
neutrophils induces the production of TNFo. *, p < 0.05 











Therefore, to specifically demonstrate that signalling from CLEC-2 is able to induce cytokine 
production, I used the chimeric CLEC-2/Dectin-1 receptor constructs expressed in RAW264.7 
macrophages. As described previously, these constructs were engineered to include a C-terminal 
HA-tag to allow for convenient detection of the receptors on the surface of transduced cells. Anti-
HA staining and analysis by flow cytometry confirmed that the full length chimera and the Y7F 
mutant chimera were expressed at comparable levels on the surface of RAW264.7 macrophages 
(Fig. 3.9A). Cells transduced with Dectin-1 were also included as a positive control for the 
experiments (Fig. 3.9A). Expression of these receptors conferred an enhanced ability to bind 
zymosan that was inhibited by the addition of glucan phosphate which, as explained before, 
indicated the specificity of binding and functionality of the chimeric receptors (Fig. 3.9B). 
Furthermore, in response to zymosan, the full length chimeric receptor induced high levels of 
TNFa, comparable to those induced by Dectin-1 (Fig. 3.9C). In contrast, the level of TNFa 
produced from cells expressing the Y7F mutant chimera in response to zymosan, was comparable 
to the levels from the vector-only transduced cells (Fig. 3.9C). Thus these data demonstrate that 
CLEC-2 can induce cytokine production and that this activity is dependent on the ITAM-like motif in 
the cytoplasmic tail of the receptor. 
3.2.7 CLEC-2 can signal via Syk kinase in myeloid celfs 
CLEC-2 signals via Syk kinase in platelets [268] and I therefore decided to explore whether it 
signals via this pathway in other cell types. I first performed immunoprecipitations from RAW264.7 
Iysates using tyrosine phosphorylated or un phosphorylated peptides, corresponding to the 
cytoplasmic tails of mCLEC-2 or Dectin-1. Subsequent Western blot analysis demonstrated that the 
phosphorylated CLEC-2 and Dectin-1 peptides could associate with Syk from the macrophage cell 
extracts (Fig. 3.10A). Anti-phosphotyrosine probing also revealed that the phosphorylated CLEC-2 
peptide associated with another tyrosine phosphorylated protein with a molecular weight of 
approximately 68kDa (Fig. 3.10A). Further analysis carried out by Dr. Kevin Dennehy 
demonstrated that this 68kDa protein was in fact Shp2, (src homology 2 domain containing 
tyrosine phosphatase) (data not shown). I also wanted to investigate whether cellular activation 
results in phosphorylation of the single tyrosine in the cytoplasmic tail of CLEC-2, as is known to 
occur with Dectin-1. I explored this by immunoprecipitating the receptor from pervanadate 
stimulated or unstimulated transduced A20 cells expressing full-length CLEC-2. Subsequent 
Western blot analysis using anti-phosphotyrosine as a probe, demonstrated the CLEC-2 was 
indeed tyrosine phosphorylated (Fig. 3.10B). 
Since I had now shown that CLEC-2 is an activating receptor with the ability to induce cytokine 
production and to associate with Syk, the next step was to determine if CLEC-2 could induce 
intracellular signalling via Syk. To explore this possibility, Syk-sufficient (WT8) and Syk-deficient 
(C35) B-ceillines were transduced with the HA-tagged chimeric receptor and the production of IL-2 
in response to zymosan stimulation was examined. This strategy has been successfully used to 
examine Syk-signalling in other receptors [253J. Anti-HA staining and anlaysis by flow cytometry 











cells (Fig. 3.10C). Although addition of zymosan to the Syk-sufficient cells expressing the chimera 
induced significant production of IL-2, the Syk-deficient cells did not show any response to 
zymosan (Fig. 3.100), indicating that the cytoplasmic tail of CLEC-2 can induce intracellular 
signalling via Syk. 
Finally, to demonstrate CLEC-2 mediated recruitment of phospho-Syk to the phagosome, 
RAW264.7 macrophages expressing the chimeric receptor were examined by confocal microscopy 
following a short exposure to zymosan. The activation of Syk around the phagosome, as measured 
by staining for phospho-Syk, was clearly detected (Fig. 3.11). This activation of Syk was absent in 
the cells expressing the Y7F mutant chimeric receptor (Fig. 3.11). Collectively, these data 
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Figure 3.9: AI Anti_HA s taining of transduc",d RAW264.7 macrophagM , u determined 
by flow cytometry, showing ~xpr~ssion of HA-tagged constructs at th e cell surface "s 
indicated. Primary antibody binding was detected by PE-donkey anti-mouse IgG. B) 
Quantitation of zymosan (zy) binding and C) zymosan induced TNFa production, by 
transduced RAW2647 macrophages, in the presencQ or absenc~ of glucan phosphate 
(GP, 100~gfml). ~ s indicated. Th e amount of File-zymosan associated with the cells 
was quantified afte, lys is, using a Thermo Fluoroskan Asc" m FL. RFU relative 
f luoresenct units_ The data shown are th~ m~an ± SD and are representative of at least 
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Figure 3.10: A) Western blotting of immunoprecip;tates from RAW 264.7 macrophages using 
phosphorylated (YP) and unphosphorylated peptides (Y), corresponding to th e cytoplasmic tail 
of mCLEC·2 or Dectin_1 B) Western blotting Qf anti_HA immunoprec ipitates from A20 ce lls 
expressing HA-tagged mCLEC-2. Cells were either unstimulated (US) or stimulated with 
pervanadate (5). Blots were probed with anti-phosphotyrosine (aPY) arid anti .Syk as indicated. 
C) Anli _HA staining of transduced B cell lines, as determined by flow cytometry. Bold black 
lined histograms represent anti·HA staining and Qrey lined histograms rep resent isotype 
contro l staining. Primary ant ibody binding was detected using PE-donkey a nti-mouse IgG. DIIL-
2 production following zymosan stimu lation of Syk.deficient (Syk·1 and Syk.sufficient (S yH) B· 
cells, transduced with the chimeric recepto r. The data shown are the mean :!:SD and are 
representative of M least three independent experiments. '. p <0.05 versus C35 Syk- cel ls 












FiQure 3.11: The upper panel shows a confocal image demonstr~ting the 
recru itment of phospho-Syk (redl by RAW264.7 macrophages express ing 
the chimeric rec eptor fol lowing stimulation with FITC_zymosan. 
Conversely. in RAW264.7 m~crophages cetls expressing the Y7F receptor, 
shown in the lower pane l, confoc~ 1 images demonstrate a lack of 











The study of the 'Dectin-1 cluster' of NK-like C-type lectin receptors has provided important insights 
into mechanisms underlying homeostasis and immunity. Arguably one of the most important 
discoveries has been the identification of receptors containing cytoplasmic IT AM-like motifs which 
can trigger cellular activation. These motifs possess only a single tyrosine, yet are able to recruit 
and signal via Syk kinase through a process which is not yet fully understood. One receptor 
possessing this motif is CLEC-2, a molecule previously thought to be exclusively expressed on 
platelets and capable of triggering the activation of these cells [268J. Here I have shown that CLEC-
2 is also expressed on murine peripheral blood neutrophils. As in platelets [181, 268], I also 
demonstrated that the cellular functions of CLEC-2 are mediated through its ITAM-like motif and 
that the receptor can induce intracellular signalling via Syk kinase. 
The ITAM-like motif of CLEC-2 shows a striking similarity to that of Dectin-1, suggesting that 
CLEC-2 may possess some of the functions of Dectin-1 [45, 181]. Indeed, it was shown here that 
CLEC-2 can trigger phagocytosis and the induction of TNFa, and it is possible that the receptor 
may also be able to induce the production of a number of other cytokines and chemokines in 
neutrophils [302]. Furthermore, it is possible that CLEC-2 mediated cytokine production may be 
amplified by co-stimulation through the TLR pathway, as has been shown for Dectin-1 [45, 178, 
208, 303]. Thus like Dectin-1 and CLEC9A, the data here suggests that CLEC-2 functions as an 
activation receptor on myeloid cells. These conclusions were based partly on the results of 
experiments using cell lines transfected with a chimeric receptor consisting of the extracellular and 
transmembrane regions of Dectin-1, fused to the cytoplasmic tail of CLEC-2. This approach was 
initially used in the absence of a commercially available CLEC-2 ligand. However there are 
potential drawbacks to using a chimera-based approcah for studying the functions of a given 
receptor. In this case I used the defined Dectin-1 ligands, zymosan or particulate p-glucan, to 
trigger signalling via the CLEC-2 cytoplasmic tail. Therefore these Dectin-1 ligands directed the 
chimeric receptor clustering which may have imposed steric constraints or lead to interactions that 
are significantly different from those that occur when full-length CLEC-2 interacts with natural 
ligands. Nevertheless, the phagocytic capacity of CLEC-2 was confirmed by the uptake of anti-
CLEC-2 coated beads by NIH-3T3 cells transduced with full length CLEC-2. This function was 
further confirmed by demonstrating the uptake of anti-CLEC-2 coated beads by peripheral blood 
neutrophils which express the receptor. The ability of CLEC-2 to induce cytokine production was 
also demonstrated using peripheral blood neutrophils stimulated with the CLEC-2 ligand 
rhodocytin. As mentioned previously this suggests that CLEC-2 can mediate cytokine production 
from primary neutrophils, however rhodocytin is known to be recognised by other receptors which 
may have contributed to the observed cytokine production [268]. For this reason, the chimera-
based approach was used to specifically investigate the ability of CLEC-2 to trigger cytokine 
responses. 
Cross-linking antibody experimets are an alternative to using a chimera-based approach to 











by CLEC-2 could potentially have been investigated by stimulating primary neutrophils or 
RAW264.7 macrophages expressing full-length CLEC-2, with Fab fragments of anti-CLEC-2 
antibodies. Although not detailed here, I made several unsuccessful attempts to express full-length 
mCLEC-2 in RAW264.7 macrophages and was therefore unable to take this approach. 
Furthermore, as mentioned in the results section I also attempted to stimulate peripheral blood 
neutrophils using antibody crosslinking, and antibody-coated Dynabeads, but specific responses 
could not be demonstrated in this manner due to high background levels of cytokine production in 
control samples. Due to time constraints I therefore relied on the chimera-based approach and the 
stimulation of peripheral blood neutrophils with rhodocytin to demonstrate the ability of CLEC-2 to 
induce cytokine production. 
The ability of CLEC-2 to mediate phagocytosis is likely to involve the highly charged cytoplasmic 
triacidic cluster (OED), in addition to the ITAM-like motif. This cluster is conserved in Dectin-1, but 
not CLEC9A, and mutation of these residues in Oectin-1 has been shown to abolish particle uptake 
[1BO]. Furthermore, although possessing an ITAM-like motif, CLEC9A does not mediate 
phagocytosis [253]. However, it is still unknown if CLEC-2 mediated uptake requires Syk in 
neutrophils. For Dectin-1, the requirement for Syk is cell-type specific; in DCs Dectin-1-mediated 
uptake involves Syk, but in macrophages this process is independent of Syk and occurs through 
uncharacterised, and possibly novel, pathways [177, 304J. In neutrophils, phagocytosis mediated 
by the unrelated activation receptor, CEACAM3, which possesses a traditional ITAM motif, was 
shown to involve Syk, but the requirement for this kinase was shown to be dependent on the nature 
of the ligand [305]. Although this study clearly demonstrates that CLEC-2 has the potential to 
mediate phagocytosis, the physiological relevance of this activity remains to be determined. 
Analysis carried out by Dr. Kevin Dennehy confirmed that the tyrosine phosphatase Shp2 also 
associates with the CLEC-2 cytoplasmic tail. Shp2 has been previously been co-isolated with Syk, 
and furthermore it has been shown that when Shp2 is recruited to the plasma membrane, it 
desphosphorylates numerous substrates, including Syk [306, 307]. Shp2 has also been shown to 
bind directly, via its SH2 domains, to the tyrosine phosphorylated j3-subunit of FCERI where it 
becomes activated via tyrosine phosphorylateion [30B]. Here it is thought to desphosphorylate p 
and V subunits of FCERI thereby functioning in a negative feedback loop that regulates this 
receptors tyrosine phosphorylation [308]. It seems plausible to speculate that in the case of CLEC-
2 signalling, the recruitment of Shp-2 may serve a similar regulatory function. 
One possibility that I have not addressed here is whether CLEC-2 signalling and phagocytosis can 
be uncoupled. I have shown for example that the cytoplasmic tyrosine of CLEC-2 is required for 
phagocytosis. I have also shown that cytokine production is dependent on the cytoplasmic tyrosine 
of CLEC-2. However, it is possible that particle uptake is required to initiate signalling. In this case, 
the cytoplasmic tyrosine of CLEC-2 would be required for phagocytosis as shown, but signalling 
may proceed via an alternative mechanism. This scenario could be investigated by inhibiting 











of macrophages expressing Dectin-1 however, this type of experiment has shown that uptake is not 
required for subsequent signalling [157]. 
The analysis of ClEC-2 expression indicates that high levels of expression of the receptor occurs 
only on circulating neutrophils, and that the receptor is only weakly expressed on bone marrow or 
elicited inflammatory cells. This suggests that its expression is tightly regulated and implies a 
specific function for the receptor on circulating cells. Although not analysed in detail, I also 
observed that expression of CLEC-2 could be upregulated on murine monocytes, following 
stimulation with Pam3CSK4, but not other TlR agonists tested, suggesting some specificity in this 
response. It is possible that ClEC-2 may be similarly regulated on human neutrophils or other 
leukocytes, which were not examined in this study. Why the expression of this receptor appears to 
be primarily restricted to circulating cells is unclear, and despite the identification of both 
endogenous and exogenous ligands, the physiological role of ClEC-2 is still unclear. 
like Dectin-1, ClEC-2 may function as a pattern recognition receptor. The expression of this 
receptor on neutrophils certainly implies a role in innate immunity, as these short-lived cells provide 
a first-line of defence against infection and are essentially required for the control of bacterial and 
fungal infections [302]. A role in immunity is also suggested by the ability of specific TlR agonists 
to induce ClEC-2 expression on monocytes, and the phagocytic capacity of this receptor may be 
important for the clearance of blood-borne pathogens, although such interactions have yet to be 
documented. However, other than rhodocytin, only HIV has been identified to possess an 
exogenous ClEC-2 ligand and rather than being protective, the interaction with ClEC-2 may 
promote transfer of infectious HIV-1 particles [275]. 
The primary function of ClEC-2 may be in the regulation of homeostasis through the recognition of 
endogenous ligands. One endogenous ligand that has been identified is podoplanin, a mucin like 
glycoprotein which is expressed on a variety of cell types including osteoblasts, keratinocytes, 
fibroblasts, airway epithelia, renal tubular epithelial cells, lymphatic endothelial cells and certain 
tumour cells, although podoplanin is not expressed on blood vessel endothelium [309}. The 
interaction between ClEC-2 and podoplanin was reported to be carbohydrate-mediated, and that a 
di-sialylated core O-glycan sequence on Thr52 of podoplanin is essential for recognition by ClEC-
2 [273]. However. as I mentioned in Chapter 1, Kato et al used recombinant glycopeptides to study 
the interaction between ClEC-2 and podoplanin [273] and it therefore remains unclear whether the 
oligosaccharide sequence alone is sufficient for ClEC-2 binding, or whether any of the flanking 
peptide region is also involved. 
During this thesis, podoplanin expression was identified on inflammatory macrophages, 
inflammatory neutrophils and stimulated bone marrow derived macrophages (see Chapter 5). The 
significance of this expression in terms of ClEC-2 function remains unclear, but will be considered 
further in Chapter 5. However, the interaction of ClEC-2 with podoplanin following tumour invasion 











tumour metastasis [273]. Metastasis is also promoted by inflammation, induced in part by 
neutrophils [310], and it is tempting to speculate that the interaction of podoplanin with neutrophil 
expressed CLEC-2 may contribute to this process. 
It is also possible that simultaneous recognition of CLEC-2 ligand(s) by both platelets and 
neutrophils contributes to the interactions between these two cell types and to the activation and 
cross-talk of the inflammatory and coagulation pathways. These interactions are known to be 
important for the control of infection, and for limiting inflammatory pathology, but are also involved 
in the development of disease [311, 312]. 
In summary I demonstrated here that murine CLEC-2 is expressed by peripheral blood neutrophils 
as well as on monocytes activated with selected TLR ligands. I also demonstrated that CLEC-2 can 
function as an activation receptor on these celis, inducing phagocytosis and inflammatory cytokine 
production. Furthermore, I established that CLEC-2 can recruit and signal via Syk kinase in myeloid 
cells. These data therefore demonstrate that CLEC-2 expression is not restricted to platelets as 











4 Investigation of the role of CLEC .. 2 in the respiratory burst and a preliminary 
examination of the mechanisms underlying 
this response 
4.1 Introduction 
4. 1. 1 Aims of this chapter 
Investigations using zymosan and Candida albicans have shown that Dectin-1 signalling induces a 
respiratory burst in macrophages, neutrophils, DCs and mast cells [162, 178, 180, 313, 314]. 
Furthermore, studies in Syk deficient bone marrow derived macrophages revealed an absolute 
requirement for Syk in Dectin-1 mediated induction of the respiratory burst in these cells [180]. 
Considering the similarity between the cytoplasmic tails of CLEC-2 and Dectin-1, and that I have 
shown that CLEC-2 is a Syk-coupled activatory receptor expressed on neutrophils [269J, I decided 
to investigate whether like Dectin-1, CLEC-2 could also mediate induction of the respiratory burst. 
During my work described in the forthcoming chapter, I determined that signalling via CLEC-2 is 
not involved in the generation of reactive oxygen species. This suggested that additional 
unidentified components, distinct from Syk, are required for Dectin-1 mediated induction of the 
respiratory burst in response to microbes, and I therefore performed some preliminary 
investigations to investigate the underlying mechanism. Before proceeding, it is appropriate to first 
give a brief overview of the respiratory burst and its regulation. 
4.1.2 The respiratory burst 
Superoxide, and other oxygen-derived intermediates that can modify organic molecules are 
referred to as 'reactive oxygen species' (ROS). Nicotinamide adenine dinucleotide phosphate 
(NADPH)- oxidase is the most characterised cellular source of ROS, however a number of other 
enzymes can also produce ROS including nitric oxide synthase, lipoxygneases, cyclo-oxygenases, 
xanthine oxidase and cytochrome P450 enzymes [315]. The generation of ROS is critical for host 
defence against microbial infections. The prevailing model for their role in innate immunity is that 
these radicals attack and kill bacteria through their chemical reactivity [316J. The vital nature of this 
mechanism is demonstrated in chronic granulomatous disease, where inherited defects in this 
response are associated with enhanced susceptibility to bacterial and fungal infections [317]. In 
phagocytic cells, ROS are produced via the multicomponent NADPH oxidase which assembles on 
cellular membranes [318}. ROS may be generated intracellularly at the phagosomal membrane 
after pathogen ingestion, or extracellularly in response to soluble agonists such as formylated 
bacterial peptides (e.g. fMLP) or activated complement. ROS are produced in a vigorous 
'respiratory burst' which is characterised by a rapid increase in oxygen uptake, an increase in 











may also be pathophysiological and have been implicated in tissue injury and inflammation in 
several disease settings [319]. 
4.1.3 Components of the NADPH oxidase complex 
In unstimulated cells, components of the NADPH oxidase are segregated between the membrane 
and the cytosol [320-322J. The catalytic core of NADPH oxidase is gp91 phox (recently renamed 
Nox-2), a highly glycosylated membrane spanning protein with an apparent molecular mass of 
approximately 91 kDa. gp91 phox contains NADPH and FAD binding domains in the C-terminal 
cytoplasmic region and two hemes in the N-terminal region [320-322]. It is the electron transport 
chain of the active NADPH oxidase complex which mediates the transfer of electrons from cytosolic 
NADPH to O2 to produce the superoxide anion, a precursor of other toxic ROS. gp91 phox is 
complexed with a 22kDa regulatory protein, p22phox, forming a mutually stabilising heterodimer 
known as flavocytochrome b558 [320-322J. Flavocytochrome b558 becomes activated after 
exposure of cells to microbes or inflammatory mediators as a result of translocation and assembly 
of cytosolic subunits with the membrane bound subunits (Fig. 4.1). 
The cytosolic components of the NADPH oxidase are p47phox, p67phox, p40phox and the small 
GTPase Rac [320-322]. p47phox contains a PhoX domain (PX) which is involved in 
phosphoinositide binding, two tandemly arranged Src homology 3 (SH3) domains that target a 
proline-rich region in the p22phox subunit, an auto-inhibitory region (AIR) that masks the SH3 
domains in the resting state and a proline rich region that mediates binding to an SH3 domain of 
p67phox [320-322J. The p67phox subunit contains a tetratricopeptide (TPR) region that is a target 
of Rac-GTP in the active NADPH oxidase complex, an activation domain, two SH3 domains and a 
PBI (Phox and Bem 1) motif that binds to a complimentary motif in p40phox [320-322]. In addition to 
the PBI motif just mentioned, p40phox contains a PX domain and an SH3 domain [320-322]. 
4.1.4 Assembly of the NADPH oxidase complex 
In resting celis, the cytosolic phox proteins are present in a heterotrimeric complex which is formed 
by the tail-to-tail SH3-PRR (proline rich region) association between p67phox and p47phox and the 
PBI-PSI interaction between p67phox and p40phox. In addition, Rac is coupled to GOP 
dissociation inhibitor (GDI), which maintains it in its inactive form bound to GOP [322, 323]. During 
cellular activation all of the phox proteins are phosphorylated. Phosphorylation of p47phox at 
multiple Ser residues causes the SH3 domains to be unmasked and allows interaction with the 
PRR of the p22phox subunit. In this manner, p47phox transports the entire cytosolic complex to the 
membrane during NADPH oxidase activation [324] (Fig. 4.1). Furthermore, Rac rapidly converts 
from a GDP- to a GTP-bound state, dissociates from GDI and migrates to the membrane where it 
interacts directly with the TPR region of p67phox [322, 323J. p67phox directly participates in the 
activation of gp91 phox by activating electron transfer from NADPH to bound FAD. The precise 
mechanism of activation is still unclear; however it is believed that binding of Rac to p67phox 
induces a conformational change in p67phox which may allow its activation domain to act on 
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Figure 4.1: The NADPH oxidase complex. Fol lowing cellu la r activation. 
p40phox. p67phoJ< a~d p47phox all become phosphory~lted which rcsults in 
their translocation, together with Rac. to thc membrane. The activated complex 
accepts an electrOl1 from reduced nicotinamide adenine dinucleotide nhosph~te 
(NADPH) at the cytosolic surface 01 the membrane ~nd don~tes it to molecular 
o~ygen on the other side of the memb .... ~e gener~ting a superoxide allion , 0,·-










4.1.5 Upstream signalling and activation of NADPH oxidase 
Activation of NADPH oxidase can occur via different signalling pathways and is an extremely 
complex and evolving area of research. For example, different stimuli induce different signalling 
pathways and different patterns of extra- vs intracellular production of ROS. Furthermore, certain 
stimuli induce different signalling pathways in different cell types. Many investigations use purified 
reagents, such as fMLP, in order to investigate signalling pathways resulting in NADPH oxidase 
activation. It is necessary to take such a reductionist approach when studying a complex system 
like NADPH oxidase that involves assembly and activation of a number of subunits. However, it 
should also be considered that it is unlikely that a cell would ever encounter individual stimuli under 
physiological conditions and several signalling pathways must be integrated to orchestrate an 
appropriate response to a pathogen. 
All pathways that activate NADPH oxidase converge at a point characterised by phosphorylation of 
p47phox and activation of Rac. However, the upstream signalling varies considerably [325]. It 
appears that a combination of kinases may participate in the phosphorylation of p47phox in vivo 
and PKC~, PKCI3, PKC15, p21-activated kinase (PAK), ERK1/2 and AKT have all been shown to be 
involved during fMLP- or PMA- induced NADPH oxidase activation [324]. With regard to fMLP, 
which signals through G-protein-coupled receptors (GPCR), stimulation of an inhibitory G protein 
results in activation of PI3K (phosphoinositide 3-kinase) via a complex pathway involving MAP 
kinases. PI3K phosphorylates membrane lipids leading to the accumulation of PIP3 
(phosphatidylinositol (3,4,5)-trisphosphate), which activates the serine kinase AKT which proceeds 
to phosphorylate p47phox [325]. Signalling induced by angiotensisn II (Angll) through its GPCR 
receptor, AT-II, results in activation of NADPH oxidase via a multitude of different signalling 
cascades involving the activation of PLA2. PI3K, PLC, PLD and PKC [326]. Investigations have also 
shown that G-CSF signalling through its receptor resulted in stimulation of the Src kinase Lyn, with 
subsequent activation of PI3K, AKT and phosphorylation of p47phox [327J. RhoG, a Rho family 
small GTPase guanine exchange factor (GEF), has been implicated in the regulation of Rac 
activation in response to soluble agonists [328]. It has also been shown that Vav GEF regulation of 
Rac is indispensible for FcyR-mediated ROS production in both neutrophils and macrophages, 
however it is not required for GPCR-mediated induction of ROS [329]. Vav proteins have also been 
shown to be critical mediators of LPS-induced MyD88-dependent activation of Rae and subsequent 
production of ROS [330]. As mentioned previously, the activation of Syk by Deetin-1, and in 
addition FcyR and CEACAM3, is required to induce the respiratory burst in a variety of cell types, 
including neutrophils [162,180,305,331]. 
As this very brief discussion shows, the respiratory burst is regulated by multiple factors that can be 
differentially activated by various immune receptors. Furthermore, the various signalling pathways 
involved are not sufficiently resolved. Here, I investigated the involvement of CLEC-2 in mediating 
the respiratory burst response and I further went on to perform some preliminary experiments that 












4.2.1 Expression of receptors on the surface of RAW264. 7 macrophages 
Signalling via Dectin-1 has been shown to activate the respiratory burst in macrophages in a Syk-
dependent manner [180]. The respiratory burst is an important anti-microbial mechanism in 
neutrophils, and as CLEC-2 signals via Syk, I wondered if this receptor could also mediate 
activation of the respiratory burst. To examine this response, RAW264.7 cells were transduced with 
Dectin-1 and CLEC-2/Dectin-1 chimeric receptors, all of which had a C-terminal HA tag to enable 
surface detection by means of flow cytometry. The chimeric receptors were previously used to 
examine the phagocytic potential of CLEC-2, and consisted of the extracellular and transmembrane 
regions of Dectin-1 fused to the cytoplasmic tail of CLEC-2 (Fig. 3.5, Chapter 3). The use of such 
receptors allowed triggering of CLEC-2 signalling using zymosan, a defined particulate ligand for 
Dectin-1 [290]. Anti-HA staining confirmed that these receptors were expressed at equivalent levels 
on the surface of the transduced RAW264.7 cells (Fig. 4.2A). 
4.2.2 Investigation ofCLEC-2 mediated induction of the respiratory burst 
Cells successfully transduced with Dectin-1 or the CLEC-2 chimeric receptors were compared with 
vector-only transduced cells for their ability to mediate activation of the respiratory burst. For this, 
cells were loaded with DHR 123 and subsequently stimulated with zymosan. DHR is a 
nonfluorescent ROS indicator that can passively diffuse across membranes where it can be 
oxidised by H20 2, an end product of the respiratory burst, to rhodamine, which emits a bright 
fluorescent signal. Flow cytometric analysis revealed that macrophages expressing the ClEC-2 
chimeric receptor failed to induce a respiratory burst in response to zymosan. Similarly, 
macrophages expressing the tyrosine mutant ClEC-2 chimeric receptor, Y7F, also failed to induce 
a respiratory burst. In contrast, macrophages expressing Dectin-1 induced a robust respiratory 
burst, as expected (Fig. 4.28) [180]. I also examined this response in peripheral blood neutrophils 
which I have shown express ClEC-2 (see Chapter 3, fig 3.28). As a positive control, these cells 
were stimulated with PMA which induced the respiratory burst as expected. However, stimulation 
with the ClEC-2 ligand rhodocytin, did not elicit an equivalent response (Fig. 4.2C). It is important 
to point out here that rhodocytin elicited a response from peripheral blood neutrophils in terms of 
cytokine production (see Figure 3.8, Chapter 3), although the possibility that it may have been 
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Figure 4.2: A) Anti-HA staining of transduced RAW264.7 macrophages, as determined 
by flow cytometry, showing expression of HA_tagged constructs at the cel l surface as 
ind icated . Pri mary antibody binding was detected using PE-donkey anti-mouse 19G. 
B) The respiratory burst in various RAW264.7 transfectants, measured by assessing 
the conversion of dihydrorhodamine 123 to rhodamine by flow cytometry, following 
st imulation with zymosan The dala are expressed as mean f luorescent intens ity 
(mfi). The data shown are the mean :!:SD arid are representati~e of at least three 
independent experiments. " p " 0.05 vs pFB ~ector control IStudent"s t test). C) The 
respiratory burst in periphera l blood rJeutrophi ls, determined as in A. following 










4.2.3 CLEC-2 does not induce a respiratory burst in response to particulate {3-glucan, nor does it 
collaborate with TLRs to induce such a response 
During my investigations there was a period where I observed a weak, but significant respiratory 
burst response mediated by CLEC-2 (Fig. 4.3). I suspected that this could be due to the use of 
different batches of zymosan. It is known that there is batch to batch variability in the composition 
of zymosan (G.Brown, personal communication), and to eliminate this confounding factor, I decided 
to examine the respiratory burst response using highly purified particulate l3-glucan as a stimulus. 
The data generated using particulate l3-glucan as a stimulus correlated with the results from the 
original set of experiments Le: macrophages expressing the CLEC-2 chimeric receptor failed to 
induce a respiratory burst, whereas cells expressing Dectin-1 induced a robust response (Fig. 4.4, 
upper panel). This suggested that some component of the second batch of zymosan may have 
been acting as a co-stimulatory molecule which in combination with l3-glucan ligation of the CLEC-2 
chimera resulted in the production of ROS. I therefore took a two pronged approach to investigate 
the possibility of collaboration between TLR and CLEC-2 signalling to induce the respiratory burst. 
Firstly, cells were stimulated with either zymosan, particulate l3-glucan or depleted zymosan. 
Commercially available depleted zymosan is obtained by treating zymosan with hot alkali to 
remove all TLR-stimulating properties. The inclusion of depleted zymosan in this experiment would 
reveal whether a TLR-activating component of zymosan was contributing to the respiratory burst 
response. All of the stimuli elicited a response from the Dectin-1 transduced cells. In contrast, the 
respiratory burst from CLEC-2 chimeric cells was not enhanced in response to any of the stimuli 
used (Fig. 4.4). The second approach to investigate whether CLEC-2 may function in collaboration 
with TLRs to induce the respiratory burst, involved the stimulation of cells with particulate l3-glucan 
in the presence of a TLR4 ligand (LPS), or a TLR2/6 ligand (Pam3CSK4). In this case, it was 
observed that there was no enhanced response when CLEC-2 chimeric cells were stimulated with 
both l3-glucan and TLR stimuli (Fig. 4.5). 
In conclusion, collectively these data show that CLEC-2 signalling via Syk kinase does not mediate 
the respiratory burst. Nor does it appear that co-stimulation of TLR and CLEC-2 signalling induces 
the production of ROS. The intermediate response mediated by CLEC-2 in response to zymosan 
observed in one set of experiments is not due to differences in TLR ligand composition and may be 
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Figure 4.3: The respiratory burst in various RAW2S4.7 transfectants , measured 
by asse!iSing the conversion of dihydrorhodamine 123 to rhodamine by flow 
cytom~try. following stimulation with zymosan for various tim ~s as indicat~d. 
The data are expressed as mean fluorescent intensity (mfi). The data shown are 
the mean tSD and are representative of at least three independent experiments 
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Figure 4.4: The respiratory burst in various RAW264.7 transfectants, measured by 
assessing the conversion of dlhydrorhodamine 123 10 rhodamine by f low 
cytometry , lollowing stimulation with particulate ~ -glucan, zymosan or depl<>ted 
zymosan (a ll at 50~glm l )_ The data are expressed as mean fluorescent intensity 
(mli). The data shown are the mean tSO and an> representative of at least three 
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Figure 4_5: The respiratory burst in RAW264.7 cells expressing the mClEC· 
2lDectin-l chimera, measured by assessing the conversion of dihydrorhodamine 
123 to rhodamine by f low cytometry , following stimulation with particulate ~­
glucan (p!,G, 50~glml) in the presence or at.sence of Pam3CSK4 (P3, O.1nglml) or 
LPS (l~glml). The data are eKpressed as fold difference in mean fluorescent 










4.2.4 The membrane proximal tyrosine of Dectin-1 is required for induction of the respiratory burst 
in response to f3-glucan 
The activation of Syk by the Fcy receptor, Dectin-1, and CEACAM3 has been shown to induce the 
respiratory burst in a variety of cell types, including neutrophils [162, 180, 305, 331]. However, 
studies have shown that zymosan induced Dectin-1 signalling in macrophages resulted in the 
activation of Syk and the subsequent respiratory burst only in a subset of celis, yet assembly of the 
NADPH oxidase on zymosan phagosomes occurred in all cells [180J. This data, along with my 
demonstration that CLEC-2 signals via Syk yet does not induce the respiratory burst, suggests that 
additional unidentified components, distinct from Syk, are required for the induction of the 
respiratory burst in response to microbes. I therefore sought to investigate the mechanism 
underlying Dectin-1 mediated activation of the respiratory burst. 
The most likely explanation to account for the differences in the ability to trigger the respiratory 
burst that I observed between CLEC-2 and Dectin-1, is that there are differences in the 
downstream signalling pathways induced by these receptors. Although there is a degree of 
similarity in their cytoplasmic tails, the full tail of CLEC-2 is actually significantly shorter than that of 
Dectin-1 (Fig. 4.8 and see Chapter 3, fig. 3.5). I therefore performed some preliminary experiments 
to investigate what specific components of the Dectin-1 cytoplasmic tail are required to induce the 
respiratory burst response. For these experiments I used previously generated RAW264.7 
macrophages expressing various mutant Dectin-1 constructs (Fig 4.6) [179J. Dectin Y15F cells 
were transduced with a Dectin-1 receptor construct in which the membrane proximal tyrosine was 
mutated to a phenylalanine. The Dectin Y3F cells were transduced with a Dectin-1 receptor 
construct in which the membrane distal tyrosine was mutated to a phenylalanine. Examination of 
the respiratory burst in these cells revealed that production of ROS still occurred when the 
membrane distal tyrosine was mutated, indicating that this residue is dispensable for induction of 
the response. In contrast, the membrane proximal tyrosine was required as expected (Fig. 4.7). 
I next generated three different chimeric constructs (ROS chimera 1, 2, 3), as represented in figure 
4.8, and verified their integrity by sequencing. These constructs consisted of the basic mCLEC-
2/Dectin-1 chimera described earlier, but with various sections of the Dectin-1 cytoplasmic tail 
incorporated. Assessing the ability of these constructs to induce the respiratory burst in RAW264.7 
cells would theoretically pinpoint the areas of the Dectin-1 cytoplasmic tail that confer the ability to 
induce this response. Due to time constraints, I did not complete the retroviral transduction of 
RAW264.7 cells before thesis submission. However, this work is ongoing and will form a major 



















Figure 4.6: Schematic representation of the Dectin-1 constructs used 
in these experiments demonstrati"9 the position of the various 
cytoplasmic tail mutations 
T""",duced RAW ee ls ~ pooicu a!e ~-Qlucan l~imlJ 
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Figure 4.7: The respiratory burst in various RAW2S4.7 translectants. measured by 
assessing the conve",ion of dihydrorhodamine 123 to rhodamine by flow 
cytometry, followi"9 stimulation with particulate p-glucan, The data are 
expressed as mean fluorescent intensity Imli), The data shown are the mean ±SD 
and are representative of at least three indeperKlent experiments.', p < 0.05 vs 
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Figu re 4,8 : Amino acid sequences of the cytoplasmic tai ls of Oectin-1 and CLEC-2 
with boxed s imilarities, and the chimeras incorporating sections of the Oecti n-1 
cytoplasmic tai l (boxed) into th e Dectin·1 ICLEC_2 chimer ic receptor w hich wi ll be 
used to study the respiratory burst. 
4.2.5 Preliminary ioontlflcation of proteins that 9ssociate W#ll Doc/IIl· I foiJowl/>g cBllu/9r actiYation 
To !dent:1y potent!a l Signall ing candidates that may be crucia l for Dect!n- t mediated indoJctlon of 
ROS I klol<ed for a protein or proteins that assooated di rect ~ or ·nd l rect~ with the cytop lasmic tail 
of Dectin ·1 during ce llular act lvatbn, but did not associate 'Mth the cytop lasmic tail of CLEC·2. This 
investlgatkln WaS carried out by perform ing immunoprecipitat iC<'lS from stimulated RAW264.! cells 
using tyros ine phosphory lated or unphosptxlrj' lated peptides, corresponding to the cytop lasmic 
tails of murine CLEC_2 or Dectln·1 I mmunopreClp~a!iO n s from the Iysates were resorved by SDS-
PAGE and sta ll'1ed w ith coomaSSIe blue (Fog 4 9). Subsequent MSiMS ana lys!s of separated 
proteinS was performed by Dr. Carol!ne jefferieS (Royai Co llege of Surgeons Dublin Ireland) 
From this anaiysi" a number of proteins whK:h associated specifically w~h De<:;t ln·t were identified 
(lable 4.1), and work is ongoing to Invesngate whether any of these candidates are involved in th e 
respiratory burst In a regUlatory capa city 
Dectin Dect in ·P CLEC·2 GLEG_2·P 
• 
Figure 4.9 , Immunoprecipitalions from RAW2S4.1 macrophages using the indicated 
phosphory lated (P) or unphosphorylated p"ptide$ were resol~ ed by 10% SOS·PAGE 
and proteins were stained w ith coomassie blue prior to MSJMS ana lsyi s , The CLEC-2 
peptides corresponded to the MQDEDGYITLNIKPR region of th e GLEC·2 cyto lasmic 
ta i l. The Oet::lin-1 peptides corresponded to the MKYSHIENLDEOGYTQLDFSTQ 










Table 4.1: Proteins that associate wth Dectin-1, but not with CLEC-2, during cellular 
activation 
1 TIP120 protein 
2 Ras GTPase-activating protein 
3 Heat shock 70 kDa protein 4 
4 Polypyridimine tract binding protein (PTB) -associated splicing factor 
5 Moesin 
6 Far upstream element binding protein 2 (FUSE binding protein 2) 
7 Dead-box protein 17 
8 Succinate dehydrogenase flavoprotein subunit 
9 T-plastin 
10 Lamin AlC 
11 EH-domain containing protein 4 
12 A TP synthase 
13 Tyrosine-protein kinase L YN 
14 Plasminogen activator inhibitor 1 RNA-binding protein 
15 Tyrosine-protein kinase HCK 
16 Heat shock protein 60 
17 Coronin 1A 
18 Tyrosine protein kinas CSK 
19 S-adenosylmethionine synthetase 












On the basis of the similarity between the cytoplasmic tails of CLEC-2 and Dectin-1, and because 
CLEC-2 is a Syk-coupled activatory receptor expressed on neutrophils, I was interested in 
investigating whether this C-type lectin is involved in mediating the respiratory burst. I found that 
despite signalling via Syk kinase, CLEC-2 does not mediate induction of this response, either alone 
or in collaboration with TLRs. There was a period when I observed a weak, but significant 
respiratory burst response mediated by CLEC-2, which I suspected could be due to the use of 
different batches of zymosan whose components can vary. I performed some experiments which 
eliminated the possibility of collaboration with TLRs. However due to limited amounts of the various 
batches, I was unable to compare them directly and furthermore could not rule out the possibility 
that the batch which elicited a CLEC-2 response was contaminated. It should also be noted that 
these conclusions were drawn from experiments using a mCLEC-2/Dectin-1 chimera. As discussed 
in the previous chapter there are potential drawbacks to using a chimera-based approach and 
further experiments using full length CLEC-2 should ideally be performed to confirm that it does not 
induce the respiratory burst. 
The activation of Syk by the Fcy receptor, Dectin-1, and CEACAM3 has been shown to induce the 
respiratory burst in a variety of cell types, including neutrophils. In fact, this response is completely 
absent following stimulation of these receptors in Syk-deficient cells [180, 331}. However, in 
macro phages stimulated with zymosan, the Dectin-1 mediated activation of Syk and the 
subsequent respiratory burst occurred only in a subset of cells, yet the assembly of the NADPH 
oxidase on the zymosan phagosomes occurred in all cells [180]. Taken together with the 
observation that CLEC-2 does not mediate the generation of ROS, these data therefore suggest 
that there is another component I pathway stimulated by these receptors, in addition to Syk, that is 
required for the induction of the respiratory burst. 
The most likely explanation to account for the differences in the ability of CLEC-2 and Dectin-1 to 
trigger the respiratory burst, is that there are differences in the downstream signalling pathways 
induced via these receptors. Although there is a degree of similarity in their cytoplasmic tails, the 
full tail of CLEC-2 is actually significantly shorter than that of Dectin-1. I determined that the 
tyrosine within the ITAM-like motif of Dectin-1 is crucial for the respiratory burst response, whereas 
the membrane distal tyrosine is not required. This is not unexpected, as the ITAM-like motif has 
been shown to mediate Dectin-1 signalling and is required for other cellular responses [179. 180J. 
Future work will involve the generation of various other CLEC-2/Dectin-1 chimeric receptors which 
will help to identify other components of the Dectin-1 cytoplasmic tail which are critical for induction 
of the respiratory burst. As mentioned, this work is in progress and the initial constructs have been 
generated and their sequences verified. 
To identify potential signalling candidates that may be crucial for Dectin-1 mediated induction of 
ROS, I performed another preliminary experiment which was designed to identify proteins that 











did not associate with the cytoplasmic tail of CLEC-2. This investigation was carried out by 
performing immunoprecipitations from stimulated RAW264.7 cells using tyrosine phosphorylated or 
unphosphorylated peptides, corresponding to the cytoplasmic tails of murine CLEC-2 or Oectin-1. 
Subsequent MS/MS analysis revealed a number of proteins which associated with Oectin-1 but not 
with CLEC-2. Investigations are underway to determine whether any of these proteins are critically 
involved in Oectin-1 mediated induction of the respiratory burst. Some have previously being 
implicated in this response, for example the Src family kinase, Hck, has been shown to regulate the 
fMLP-induced respiratory burst response in neutrophils [332]. 
It should be noted that it is also possible that Oectin-1 may function in collaboration with other cell 
surface receptors to induce the respiratory burst response. However, this is unlikely as the chimeric 
receptor that I used contained the extracellular and transmembrane regions of Oectin-1 and would 
therefore in all likelihood, participate in any collaborative receptor interactions that Oectin-1 may be 
involved in. 
In summary, I determined that CLEC-2 is not involved in mediating the generation of ROS. This 
finding raised questions about how other Syk-coupled ITAM receptors regulate their activation of 
the respiratory burst. A greater understanding of the underlying signalling mechanisms will 












5 Characterisation of the expression of the CLEC .. 2 ligand, podoplanin, on 
macrophages 
5.1 Introduction 
5. 1.1 Aims of this chapter 
When I started this project in 2006 there were no known ligands for CLEC-2. I therefore set out to 
identify endogenous and/or exogenous CLEC-2 ligands and I used two strategies to pursue this 
objective. The first approach involved screening carbohydrate microarrays with a soluble protein 
which contained the extracellular region of CLEC-2. The second approach involved the use of a 
reporter cell system. Using the reporter cell system a CLEC-2 ligand was ide tified on inflammatory 
macrophages. In the intervening period, two other research groups identified a transmembrane 
sialoglycoprotein called podoplanin as an endogenous CLEC-2 ligand [272, 2741. I subsequently 
determined that the ClEC-2 ligand on macrophages, was in fact podoplanin. Podoplanin 
expression on macrophages had not been described previously and I therefore went on to examine 
its expression on various macrophage populations. It is appropriate at this point to give a brief 
introduction and overview of podoplanin, in terms of its expression and function. 
5. 1.2 Identification, structure and nomenclature of podoplanin 
Podoplanin is a type I transmembrane protein which contains a short cytoplasmic tail, a single 
transmembrane region and an extensively O-glycosylated, sialylated extracellular domain [333, 
334]. Rat, mouse, human and canine forms of podoplanin have been described, although several 
different names have been used in the literature. The first description of the murine form was as an 
early-response protein called OTS-8, that was inducible by phorbol ester treatment in an osteoblast 
cell line [335]. The protein was also identified as a cell surface antigen called gp38, expressed by 
murine stromal cells and a subset of thymic epithelial cells [336, 337]. In rats, podoplanin was 
initially described as E11, expressed on mature osteoblasts and newly formed osteocytes [338]. A 
further rat homologue, T1 a, was identified as a developmentally regulated gene which was 
translated in high abundance in adult type 1 alveolar cells [339, 340]. The protein was also 
described as gp38P and podoplanin in the glomerular epithelial cells (podocytes) of mice and rats 
respectively [333, 341]. In humans, podoplanin was initially reported as a marker of lymphatic 
epithelial cells [342], and was independently cloned by several groups who assigned various 
names to the protein including aggrus, gp36, PA2.26 and T1a-2 [343-345]. Although, various 












5.1.3 Expression of podoplanin 
Podoplanin is broadly expressed in normal tissues (for details refer to Table 5.1) and is widely used 
as a specific marker for lymphatic endothelium and Iymphangiogenesis (formation of lymphatic 
vessels) in many species [342J. Expression of podoplanin in normal tissues is regulated by Prox1. 
a master control gene in the development of lymphatic endothelium [346]. Podoplanin expression is 
also upregulated in a number of different human cancers. including squamous cell carcinomas of 
the lung [347]. the oral cavity [345] and the cervix [34B]; mesotheliomas [349], dysgerminomas of 
the ovary and granulosa cell tumours [350J, subsets of tumors of the central nervous system [351], 
chondrosarcomas [352]. colorectal tumours [343]. Kaposi's sarcomas [342]. ameloblastomas [353]. 
follicular dendritic cell sarcomas [354-356] and a subset of angiosarcomas [342]. 
5. 1.4 Function of podoplanin 
Mice that are deficient in podoplanin die at birth as a result of respiratory failure [357]. Compared to 
wild-type mice, these animals displayed abnormally high expression of proliferation markers such 
as PCNA (proliferating cell nuclear antigen) in the distal lung, fewer type I cells, narrower and 
irregular air spaces, and defective formation of alveolar saccules [357}. This phenotype suggests 
that podoplanin is required for normal lung cell proliferation and alveolus formation at birth. In 
addition. these mice showed defects in lymphatic vessel pattern formation which resulted in 
diminished lymphatic transport. congenital lymphedema and dilation of cutaneous and intestinal 
lymphatic vessels [350]. This suggests that podoplanin is also required for the correct formation 
and function of the lymphatic vascular system. Podoplanin may function in this role by way of its 
interaction with galectin-B. a soluble protein which was identified as a glycosylation dependent 
binding partner of podoplanin [358]. Recent investigations suggested that galectin-8 and 
podoplanin playa role in supporting the connection of the lymphatic endothelium to the surrounding 
extracellular matrix [358]. Studies in podoplanin knockout mouse embryos also showed cardiac 
malformations and myocardial abnormalities, indicating a role for this protein in normal cardiac 
development [359-361]. A number of reports have also suggested that podoplanin is involved in 
mediating cell motility by promoting cell-surface extensions and reorganisation of the actin 
cytoskeleton [345, 350, 362, 363]. Interestingly, in squamous cell carcinomas, podoplanin 
expression is restricted to the outer cell layer of the invading tumour front [345, 363J. It has also 
been shown to interact with the cytoplasmic linkers ezrin and moesin through a cluster of basic 
amino acids within its cytoplasmic tail [364]. These observations have led to the suggestion that 
podoplanin may induce collective tumor invasion [363]. 
It has long been known that some tumour cells have the capacity to induce platelet aggregation 
and that this ability is associated with the tumours metastatic potential [365]. Podoplanin was 
eventually identified as a platelet aggregation-inducing factor on tumours [343, 366. 367]. and 
further studies described CLEC-2 as its physiological target on platelets [272, 274]. In vitro studies 
have suggested that podoplanin aggregation through CLEC-2 is an important mechanism of 
tumour metastasis [273]. As mentioned previously, it was concluded that the interaction between 











podoplanin [273]. However. recombinant glycopeptides were used in this study and it remains 
unclear whether the oligosaccharide sequence alone is sufficient for CLEC-2 binding. or whether 
any of the flanking peptide region is also involved. 
Notwithstanding the expression of podoplanin on follicular dendritic cells [354-356]. whose 
hematopoietic origin remains controversial [368. 369], this protein has not been previously 
described on any other hematopoietic derived cell types. Here I examine the expression of 
podoplanin on various macrophage populations. 
Table 5.1 Summary of podoplanin expression (M: mouse, R: rat, H: human) 
Cell type Location/Organ Species Ref 
Glomerular epithelial cells Glomerulus, Kidney M/R [333,341] 
(podocyes) 
Parietal epithelial cells Bowman's capsule, Kidney RlM/H [333, 362, 
370] 
Type 1 alveolar epithelial cells Lung RlH/M [339,356] 
Follicular dendritic cells Spleen/Lymph node M [356] 
ThymuslTonsils/Lymph node H [354-356] 
Pleural mesothelial cells Lung M [362] 
Cells of the choroid plexus Brain RIM [340,356] 
Meningeal cells Brain M [356] 
Ependymal cells lining ventricles Brain M [356] 
Ciliary epithelial cells Eye R [340] 
Epithelial cells Thymus M/R [336] 
Lymphatic capillary endothelial Lymph vessels M/RIH [342,356] 
cells 
Osteoblasts Bone RlH [338,371] 
Osteocytes Bone RlM/H [338. 371, 
372] 
Myoepithelial cells Salivary gland M/H [373] 
Breast gland H [374] 
Fibromyocytes Testis M [356] 
Perineural cells Spinal nerve roots M [356] 
Stromal reticular cells Spleen/Lymph node M [337] 
ThymuslTonsils/Lymph node H [356] 
Germinal epithelial cells Primary & secondary ovarian M [356] 
follicles 
Granulosa cells Primary & secondary ovarian M [356] 
follicles 
Odontoblasts Tooth M [375] 
Enamel epithelial cells Tooth M [375] 
Basal epithelial keratinocytes Skin/CerviX/Oesophagus H [356] 












5.2.1 Carbohydrate mieroarrayanalyses do not reveal ligands for CLEC-2 
As there had been no CLEC-2 ligands described at the outset of this project, the recently 
developed neoglycolipid-based oligosaccharide microarray technique, a unique approach for 
constructing microarrays of lipid-linked oligosaccharide probes from desired sources, was used to 
screen for CLEC-2 ligands. The soluble Fc-CLEC-2 fusion protein was used to probe the 
microarray for CLEC-2 ligands. This approach was previously used to successfully determine the 
precise carbohydrate specificity of Dectin-1 [155]. CLEC-2 lacks the residues involved in the 
ligation of calcium that are usually required for carbohydrate binding in classical lectins. However, 
there is still a precedent for carbohydrate binding as exemplified by Dectin-1, which has 
carbohydrate binding capabilities even though it lacks the residues involved in the ligation of 
calcium. Neverthelss, the results here show that none of the probes included in the microarrays 
elicited significant binding signals with FcCLEC-2 (Fig. 5.1). Included as a positive control was 
FcDectin-1 which gave strong and selective binding signals with 131-3 linked glucose sequences 
(11 mer and 13 mer) as before (Fig. 5.1) [155]. 
5.2.2 Generation of a reporter eel/line to screen for CLEC-2 ligands 
As an alternative to the oligosaccharide microarray approach described above, it was also 
attempted to identify CLEC-2 ligands using a reporter cell system. The reporter assay was based 
on CLEC-2 chimeric receptors triggering the expression of IL-2 and f3-galactosidase (LacZ) in 
BWZ.36 cells (Fig 5.2A). BWZ.36 cells are a T-cell line which have been transduced with a 
construct consisting of the NFAT enhancer element of the IL-2 promoter. They were then futher 
transduced with a CLEC-2 chimeric receptor which consisted of the extracellular and 
transmembrane regions of CLEC-2, fused to the cytoplasmic region of the CD3( chain. In this 
system, if the extracellular region of CLEC-2 interacts with a ligand, the ITAMs in the CD3( chain 
become phosphorylated and induce intracellular signalling. As a consequence, cytoplasmic NFAT 
proteins translocate to the nucleus and bind NFAT sites in the promoter of the LacZ gene. This 
induces j3-galactosidase expression whose level of induction can be quantitated through its 
enzyme activity. Endogenous IL-2 production from these cells is also an indication of cellular 
activation. This approach had been successfully used in our laboratory, and by others, to identify 
ligands for other NK gene complex receptors [137, 376-379]. Using flow cytometry, it was initially 
established that the reporter construct was expressed at the surface of transduced cells by staining 
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Figure 5.1, M icroarray a"a lyses of mCLEC·2· and mDecti"·j ·huma" Fc chimeras , 
Binding signals at 7 fmoUspot (with error bars) are show" for 326 o ligosaccharide 
probes arrayed. NO"e of the p robes included in the microarrays eli cited significant 
tMnd ing Signals wi th mCLEC·2 (the signol at position 146 has a large error bar and 
is not significant, NS). This is in contrast with Dt>cti" ·I . which gave bindi"g to ~1.J · 
l i"ked glucose seque"ces (1 1 and 13mers) derived from a g lucan polysaccharide, in 
accordance w ith ear lier data. Th" probes are sorted accordi"g to their backbone 
seque"ce and are divided i"to 10 main groups. Tooir a"notat ion is ind icated at the 
botto m of the figure. A bbreviat ions are as follows: Lac, lactose: LacNAc, N_aGety l. 
lactosamine: LNnT, lacto-N-neo-tetraose; L NT, lacto-N-tet raose; Po ly Lac, 
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Figure 5.2: AJ Cartoon representation of the mCLEC.2ICD3( ch imeric receptor 
and signa l transduction pathw ~ y in BWZ.36 reporter cells. Ligand binding to 
the receptor induce5 phosphory lation of the cytoplasmic tyrosines of the CD3~ 
ch ain, lead ing to recrui tment of Zap_70 and further downstream signall ing 
resulting in th e activation of NFAT and expression of ~-9al actos jdas~ and IL-2. 
B) Antj·CLEC_2 stai ning of BWZ.36 cells transduced with the mCLEC .2!CD3~ 
ch imeri c rec~ptor construct. showing upress ion of the receptor al th e c ell 
surfac e (fi ll ed histogram). Isotype control staining is indicated by the unfilled 










5.2.3 Preliminary ligand screen using reporter cells 
To identify ligands using the reporter system described above, murine primary cells or single cell 
suspensions isolated from various murine tissues were co-cultured with the reporter cells for 
20hours at 37"C. The concentration of IL-2 in the culture supernatants was then determined by 
ELISA. By comparison with reporter cells which were incubated with media only, IL-2 induction was 
observed following co-culture with inflammatory peritoneal macrophages, and cells from various 
other tissues (Fig. 5.3A). Cell which were stimulated with PMA-ionomycin were included as a 
positive control. These results indicated that a ligand for ClEC-2 was present on inflammatory 
macrophages as well as in various other tissues. To further explore ligand expression on 
macrophages, reporter cells were co-cultured with RAW264.7 macrophages that had been pre-
treated with lPS or left untreated. These LPS-activated macrophages also elicited a positive 
response from the reporter cells in terms of IL-2 production (Fig. 5.3B). The induction of 13-
galactosidase following co-culture of reporter cells with various cell types was also examined. By 
comparison with Dectin-1 reporter cells which were used as a control, induction of Ii-galactosidase 
was observed following co-culture of the ClEC-2 reporter cells with thioglycollate elicited 
inflammatory macrophages and cells from various tissues (Fig. 5.4A). Similarly, co-culture of 
reporter cells with lPS-treated RAW264.7 macrophages also resulted in expression of 13-
galactosidase, whereas untreated RAW264.7 macrophages did not induce expression of this gene 
in the reporter cells (Fig. 5.4B). These data further suggest that mCLEC-2 recognises an 
endogenous ligand on activated macrophages and on various other mouse tissues. 
5.2.4 Podop/anin is the CLEC-2 ligand expressed on inflammatory macrophages and activated 
RAW264.7 macrophages 
During the preliminary ligand screening investigations described above, podoplanin was reported 
as a ligand for CLEC-2 by two other groups [272-274}. I subsequently examined whether the 
macrophage expressed CLEC-2 ligand that was revealed during the reporter cell screening, was in 
fact podoplanin. Staining with a podoplanin specific antibody and analysis by flow cytometry 
established that podoplanin is indeed present on the surface of these cells (Fig. 5.5). Additionally, I 
probed these cells using the FcCLEC-2 fusion protein to confirm the presence of a CLEC-2 ligand. 
Using this approach I detected binding of FcCLEC-2 to inflammatory macrophages and activated 
RAW264.7 celis, confirming the presence of a CLEC-2 ligand on these cells. This interaction 
appeared to be specific, as similar binding was not obtained with FcDectin-1 (Fig. 5.5). As 
podoplanin expression had not been previously described on macrophages. I decided to 
investigate its expression on other macrophage populations. Analysis by flow cytometry revealed 
that podoplanin expression was negligible on resident peritoneal macrophages and on resident 
alveolar macro phages (Fig. 5.5). This was in agreement with staining using FcClEC-2 which 
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Figure 5.3: AI Fold differenccs in Il_2 production from reporter colis following co-
culture with various cell types as indicated. The data were generated from two 
independent experiments and were normalised to the media only control value. Error 
ba~ represent the SEM. (Thio_pM0: Ihioglycollatc elicitcd peritoneal rnacrophagcs) 
BI IL-2 production from reporter cells following co-culture with RAW264.7 cells or 
RAW26~ ,7 cells which had been pretreated with LPS. This data is representative of 



















Figure S.4: X-gal staining of reporter cells following co-culture with A) various 
murine primary cells and B) RAW2S-4.7 macrophages which had been 
untreated or pretreated with LPS. These data are representative of several 
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Figure 5.5; Anti·podoplanin and FcCLEC·2 staining of various macrophage 
populations, as indicated. In the left column, filled histograms represent 
podoplanin stain ing (light grey) and rigG2a isotype control staining is 
reprensented by unfilled histograms. Primary antibody binding was 
detected by PE.donkey anti· rat IgG. In the right column. filled histograms 
represent FcCLEC·2 staining (dark grey) and FcDectin.1 con1rol staining is 
represented by unfilled histograms. Primary antibody binding was detected 










5.2.5 Signalling through certain TLR's causes upregu/ation of podop/anin expression 
As podoplanin expression was upregulated on inflammatory macrophages, I investigated whether 
stimulation of macrophages with microbial agonists could also induce regulation of this protein. To 
do this I examined expression of podoplanin by flow cytometry following a 20 hour stimulation of 
bone marrow derived macrophages with a variety of TLR agonists. 80ne marrow derived 
macrophages were chosen for this investigation as they showed equivalent levels of podoplanin 
expression as alveolar and resident peritoneal macro phages (Fig. 5.6A). Stimulation with a TLR4 
agonist resulted in upregulation of podoplanin expression that corresponded to an approximately 
14 fold increase over unstimulated cells. Although treatment with TLR2/1 and TLR2/6 agonists 
caused an apparent increase in podoplanin expression, statistical analysis revealed that this 
upregulation was not significant. The addition of TLR3 and TLR5 agonists did not result in any 
upregulation of podoplanin expression and its levels on these cells were comparable to untreated 
macrophages (Fig. 5.68). Concentrations of TLR agonists ten fold less than those shown in Fig. 
5.68 were also tested and resulted in similar effects on podoplanin expression (data not shown). 
5.2.6 Cytokine regulation of podop/anin expression on bone marrow derived macrophages 
As macrophage phenotypes are strongly affected by the action of cytokines, I also investigated the 
regulation of podoplanin expression on macrophages in response to various cytokine treatments. 
To do this I examined expression of podoplanin by flow cytometry following a 20 hour stimulation of 
bone marrow derived macrophages with a variety of cytokines. I found that TNF, and to a lesser 
extent IL-10, were involved in podoplanin regulation and caused a modest increase in its 
expression. Treatment with IFNy and GM-CSF resulted in an apparent but non-significant increase 
in podoplanin expression. Macrophages which were treated with IL-4 had equivalent levels of 
podoplanin expression as untreated cells (Fig. 5.6C). 
5.2.7 Podop/anin expression on neutrophils and during systemic inflammation 
As CLEC-2 is expressed on neutrophils, I wondered whether podoplanin may also be present on 
these cells. In contrast to CLEC-2, there was no evidence of podoplanin expression on peripheral 
blood neutrophils. However, I found that podoplanin was expressed on inflammatory neutrophils 
(Fig. 5.7). It appears then that podoplanin is upregulated on neutrophils when these cells are 
recruited to sites of inflammation from the bloodstream. 
To evaluate podoplanin expression during systemic inflammation, a preliminary experiment was 
performed in which mice were challenged with LPS (11-1g, Lv) to induce a low-grade inflammatory 
response [380J. Using flow cytometry, splenocytes and lymph node cells were analysed for 
podoplanin expression 20 hours after challenge. It was found that LPS challenged mice exhibit 
similar levels of podoplanin expression as untreated mice which suggests that this protein is not 
upregulated during systemic inflammatory responses (Fig. 4.8). However, this experiment was 
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Figure 5. 6: AI Anti_podoplanin stain ing of bOM marrow derived macrophages, 
showir>g n egligibl~ e.pr~ss ion of ~h e prot~in at ~he c~ 1l surfac~ (filled histogram)_ 
rlgG2a iSotype control staining is represented by the unfilled histogram. Primary 
antibody binding was detected by PE-donkey ant i_rat IgG. B) The changes in 
podoplar>in expression following stimulation with TLR agonists as ir>dica~ed, 
quantified as d~scribed in Methods. The data w~re generated from two independent 
experiments and were normalised to the untreated control value. Error bars 
represent the SEM. C) The changes in podoplanin expression following stimu lation 
with various cytokines as indicated, qu~ntified ~s described in Methods. The data 
are representative of two independent experiments and were normalised to the 
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Figure 5,7: Anti-podoplanin or r1gG2a staining of Indicated cells. Neutrophils were 
identified by their expression of CD11b and Gr-l and density plots depicted here 
were gated on said cell s. Primary antibody binding was detected by PE.donkey 
anti-rat IgG. Percentages shown are indicative of the percentage of gated cells in 
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Figure 5.8: Anti-podopl anin staining of indi~ated ~ells, Primary antibody binding 
was detected by PE-donkey anti-rat IgG, Data is representative of one experiment 











I was interested in identifying CLEC-2 ligands and my initial approach was to use an 
oligosaccharide microarray, a technique which had been successfully applied to determine the 
precise carbohydrate specificity of Dectin-1 [155]. None of the carbohydrates included in the array 
elicited a positive response in terms of CLEC-2 binding. This is perhaps not surprising as CLEC-2 
lacks the residues conserved in other C-type lectins that mediate Ca2+ coordination and 
carbodhyrate binding. However, as mentioned previously, this approach was taken as there are 
examples of C-type lectins (such as Dectin-1) that lack these residues yet still bind carbohydrates. 
In the interim, other researchers reported that the interaction between CLEC-2 and its ligand 
podoplanin, is mediated by a di-sialylated core O-glycan sequence (NeuAca2-3Galf31-3[NeuAca2-
6]GaINAca-1) on ThrS2 of podoplanin [273J. Interestingly, this oligosaccharide was present as a 
neoglycolipid probe in the microarray used here, but was not recognised by FcCLEC-2. This 
highlights an apparent discrepancy between my array result and previously published work. This 
may be accounted for by the fact that in the microarray used here, the probe in question was 
conjugated to the lipid tag by reductive amination, which results in the ring-opening of the GalNAc 
core. Further analysis with the ring-closed structure would be helpful in elucidating whether the 
oligosaccharide alone is sufficient for binding, or as mentioned previously whether any of the 
flanking peptide region is also required. 
As an alternative approach to identify CLEC-2 ligands, a reporter cell system was used which had 
been previously employed to identify ligands for other NK gene complex receptors [137, 376-379J. 
Using this method, an endogenous CLEC-2 ligand was identified on activated macrophages and 
further exploration indirectly showed that this ligand was podoplanin. A subsequent review of the 
literature revealed that this was the first demonstration of podoplanin expression on macrophages. 
Although interactions between podoplanin and CLEC-2 have now been clearly shown elsewhere, 
future immunoprecipitation experiments using FcCLEC-2 and macrophage Iysates, followed by 
probing of associated proteins for podoplanin should be performed to directly demonstrate an 
interaction between macrophage expressed podoplanin and CLEC-2. 
Macrophages are a highly heterogenous population of cells with well-defined roles in the innate 
immune response, but also in inflammation, tissue homeostasis, resolution, repair and as antigen 
presenting cells [1]. Generally, monocytes derived from bone marrow progenitors circulate in the 
blood for several days before entering tissues to differentiate into macrophages [381, 382]. 
Macrophages in different anatomical locations exhibit various functional specialisations, suggesting 
that the tissue microenvironment is involved in the macrophage differentiation process [381]. It is 
therefore expected that the range of expressed proteins differs between the various macrophage 
populations. I explored the expression of podoplanin on various macrophage populations and other 
myeloid cells. Although I found that podoplanin was highly expressed on inflammatory 
macrophages; alveolar macrophages, resident peritoneal macrophages and bone marrow derived 
macrophages showed negligible expression of the protein. As tissue macrophages are known to 











changes in gene and protein expression, I investigated whether the expression of podoplanin on 
macrophages was regulated flowing stimulation with TLR agonists and cytokines. I found that 
podoplanin expression was upregulated following stimulation via TLR4 but not other TLR agonists, 
suggesting some specificity in this response. In terms of cytokines, TNF, and to a lesser extent IL-
10, resulted in an increase in podoplanin expression. Although not examined in this study, it is 
possible that podoplanin may be similarly regulated on human macrophages or other leukocytes. 
Considering the expression of its binding partner on neutrophils, and to simply investigate its 
presence on other myeloid cells, I also examined podoplanin expression on neutrophils. The 
results indicate that podoplanin is not expressed on peripheral blood neutrophils but is upregulated 
when these cells migrate to inflammatory sites. This is in direct contrast to CLEC-2, which is 
expressed on peripheral blood neutrophils but not on inflammatory neutrophils. It would appear 
then that CLEC-2 and podoplanin are reciprocally regulated in terms of their expression. The 
mechanism and functional significance of this is unclear; one possibility is that this regulation may 
be in place to avoid inappropriate cellular activation via CLEC-2 signalling in inflammatory 
neutrophils. Although not detailed here, I made several unsuccessful attempts to express full-length 
mCLEC-2 in RAW264.7 macrophages. This reciprocal regulation may explain why I was 
unsuccessful; perhaps there are mechanisms in place that prohibit the expression of both CLEC-2 
and its ligand podoplanin, by the same cell. 
Alternatively, it is possible that CLEC-2 is expressed on inflammatory neutrophils but that its 
detection by antibody staining is masked by cis interactions with podoplanin on these cells. Indeed, 
in the case of Dectin-1, binding of soluble ~-glucan ligands masked detection of the receptor by a 
Dectin-1 specific monoclonal antibody [290]. The possible expression of both CLEC-2 and 
podoplanin on the same cell is reminiscent of the Siglecs (sialic-acid-binding immunoglobulin-like 
lectins), whose binding sites are typically masked by cis interactions with other glycan ligands 
expressed on the same cell [383]. This possibility could be explored by exposing cells to sialidase, 
a treatment which would presumably cleave the ciS-interacting podoplanin from CLEC-2 and allow 
its detection by flow cytometric methods. Other approaches, such as Western blotting, could also 
be used to explore the possibility of CLEC-2 expression on inflammatory neutrophils. 
The significance of podoplanin expression on macrophages remains unclear. Transfection studies 
with cultured normal and cancer cells showed that podoplanin promotes cell spreading, migration 
and invasion [345, 350, 362, 363]. Furthermore, podoplanin is upregulated in the invasive front of 
certain tumors. Given this role in cell motility, it is tempting to speculate that podoplanin could be 
involved in directing inflammatory macrophage migration. In the future, I intend to investigate 
whether podoplanin has a role in inflammatory cell recruitment by using podoplanin deficient cells. 
For this I will attempt to generate podoplanin deficient radiation chimeras by reconstituting the 
immune system of lethally irradiated recipient mice with podoplanin deficient fetal liver cells. This 
model will bypass the developmental defects by limiting the deletion of podoplanin to hematopoietic 











It has also been shown that the induction of platelet aggregation by podoplanin promoted the 
establishment of pulmonary metastasis in both experimental and spontaneous metastasis models 
and decreased survival of the mice [384]. This suggests that tumors which express podoplanin 
have more malignant characteristics and indeed podoplanin expression has been associated with 
poor clinical outcome in oral cancer [385]. On the other hand, there are also a number of studies 
which have shown that the expression of podoplanin on certain tumors and tumor associated cells, 
is associated with a good disease prognosis [386-388]. The differences in tumor origin most likely 
account for these apparent contradictions. What would be interesting to explore further is whether 
podoplanin is expressed on tumor associated macrophages (TAMs). TAMs are a major 
inflammatory leukocyte population present in tumors and have been shown to promote tumor 
growth through the promotion of angiogenesis, matrix remodelling and suppression of adaptive 
immunity [389, 390]. Considering the expression of podoplanin on certain inflammatory 
macrophages, it is certainly possible that the protein is also expressed on TAMs. This is an aspect 
of podoplanin expression on macrophages and its function in tumor growth that it worthy of further 
attention. 
Finally, as mentioned previously, the simultaneous recognition of podoplanin on macrophages by 
both platelets and neutrophils may contribute to the interactions between these two cell types and 
to the activation and cross-talk of the inflammatory and coagulation pathways. These interactions 
are known to be important for the control of infection, and for limiting inflammatory pathology, but 
are also involved in the development of disease [311, 312]. A further indication that podoplanin 
may be involved in immunity is its recent identification on follicular dendritic cells [354-356]. These 
cells reside in primary B cell follicles and germinal centres of lymphoid tissues and assist in B cell 
maturation by the presentation of intact antigen to the B cells [391, 392]. 
In conclusion, I have shown here that the CLEC-2 ligand podoplanin is expressed on inflammatory 
macrophages and inflammatory neutrophils, but not on tissue resident alveolar or peritoneal 
macrophages, or bone marrow derived macrophages. I have also shown that certain TLR agonists 
and cytokines cause upregulation of podoplanin on bone marrow derived macrophages. Further 
studies will elucidate the physiological and/or pathophysiological Significance of this expression of 











6 Summary and future directions 
6.1 Review of the aims 
The three principal areas of investigation of this thesis were 
• The characterisation of CLEC-2 in terms of its functionality. 
• An investigation of the mechanisms underlying Oectin-1 mediated induction of the 
respiratory burst. 
• The characterisation of the expression of the CLEC-2 ligand, podoplanin, on macrophages. 
In summary I found that CLEC-2 is a Syk-coupled phagocytic activation receptor expressed on 
murine peripheral blood neutrophils. I also determined that it is not involved in the induction of the 
respiratory burst. I showed that its ligand, podoplanin is expressed at high levels on inflammatory 
macrophages and neutrophils. Finally, I performed preliminary investigations into the mechanisms 
underlying Oectin-1 mediated induction of the respiratory burst and generated tools which will be 
used for future research in this area. 
Here I will give a final summary of the key findings which have been previously discussed within 
the context of the relevant chapter. I will also briefly discuss and speculate on future directions. 
6.2 Summary of key findings 
6.2.1 CLEC-2 is a Syk-coupled phagocytic activation receptor expressed on murine peripheral 
blood neutrophils. 
Using specific antibodies, I confirmed that CLEC-2 was expressed on the surface of platelets as 
described, and furthermore showed that there are high levels of its expression on circulating 
neutrophils. In contrast, I found that CLEC-2 is only weakly expressed on bone marrow or elicited 
inflammatory cells. I also observed that expression of CLEC-2 could be upregulated on murine 
monocytes following stimulation with Pam3CSK4, but not other TLR agonists tested, suggesting 
some specificity in this response. 
Having identified CLEC-2 on neutrophils, I next wished to determine the function of this receptor on 
these cells. I first explored the possibility that CLEC-2 could mediate particle uptake, similar to 
Oectin-1. I initially examined the phagocytic potential of CLEC-2 using a chimeric receptor that 
allowed triggering of CLEC-2 signalling using zymosan. Expression of the chimeric receptor in 











To evaluate whether the cytoplasmic tyrosine of CLEC-2 contributes to this activity, a chimeric 
receptor construct in which the cytoplasmic tyrosine was mutated to a phenylalanine was 
expressed in NIH3T3 cells. I found that mutation of the cytoplasmic tyrosine significantly reduced 
the ability of these cells to internalise the zymosan particles. Similar results were obtained when 
these chimeric receptors were expressed in RAW264.7 macrophages. I also examined the 
phagocytic potential of CLEC-2 in primary cells and showed that CLEC-2 antibody coated beads 
bound specifically to peripheral blood granulocytes and that upon incubation at 37"C, these beads 
were internalised in an actin dependent fashion. Collectively these results demonstrate that CLEC-
2 can function as a phagocytic receptor. 
I next investigated whether signalling via CLEC-2 can induce cytokine production. Using cell lines 
expressing the chimeric constructs referred to above, I demonstrated that CLEC-2 can induce 
TNFa production and that this activity is dependent on the ITAM-like motif in the cytoplasmic tail of 
the receptor. I also showed that CLEC-2 on peripheral blood neutrophils can mediate production of 
TNFa in response to the CLEC-2 ligand rhodocytin, although the possibility that it may have been 
signalling through other receptors in addition to CLEC-2 could not be excluded. 
CLEC-2 signals via Syk in platelets, and I wanted to confirm that this pathway was being used in 
other cell types. I performed immunoprecipitations from RAW264.7 using tyrosine phosphorylated 
or un phosphorylated peptides, corresponding to the cytoplasmic tail of CLEC-2. Subsequent 
analysis demonstrated that the phosphorylated CLEC-2 peptide could associate with Syk from the 
macrophage cell extracts. I also confirmed that cellular activation results in phosphorylation of 
CLEC-2, by immunoprecipitating this receptor from pervanadate stimulated or unstimulated 
transduced A20 cells expressing full-length CLEC-2. The expression of the chimeric receptor in 
Syk-sufficient and Syk-deficient B cell lines and quantification of the production of IL-2 in response 
to zymosan stimulation, offered further evidence that CLEC-2 signals via Syk. Finally, confocal 
microscopy analysis of zymosan stimulated RAW264.7 macrophages expressing the chimeric 
receptor showed clearly the activation of Syk around the phagosome. Collectively these data 
demonstrate that CLEC-2 signals via Syk kinase in myeloid cells. 
6.2.2 CLEC-2 does not induce the respiratory burst 
One of the most surprising discoveries was the inability of CLEC-2, either alone or in collaboration 
with TLRs, to induce the respiratory burst despite Signalling via Syk. This highlighted the likelihood 
that there is another component I pathway stimUlated by Oectin-1, in addition to Syk, that is 
required for the induction of the respiratory burst. I performed some preliminary experiments to 
investigate the underlying mechanism of Oectin-1 mediated induction of the respiratory burst. I 
found that the membrane proximal tyrosine is crucial for induction of this response. I also 
generated chimeric constructs which will allow for specific identification of critical components of 
the Oectin-1 cytoplasmic tail. Furthermore, using proteomic techniques I identified a number of 











6.2.3 The CLEC-2 ligand, podop/anin, is expressed on inflammatory macrophages and neutrophils 
During the course of ligand screening attempts, the presence of a CLEC-2 ligand on inflammatory 
macophages was determined. This ligand turned out to be podoplanin, a sialoglycoprotein which 
was identified by others as a CLEC-2 ligand. This was the first demonstration of podoplanin 
expression on macrophages and I therefore proceeded to explore its expression on various 
macrophage populations and other myeloid cells. Although I found that podoplanin was highly 
expressed on inflammatory macrophages; alveolar macrophages, resident peritoneal macrophages 
and bone marrow derived macrophages showed negligible expression of the protein. 
I investigated whether the expression of podoplanin on macro phages was regulated following 
stimulation with TLR agonists and cytokines. I found that podoplanin expression was upregulated 
following stimulation via TLR4 but not other TLR agonists. In terms of cytokines, TNF, and to a 
lesser extent IL-10, resulted in an increase in podoplanin expression. I also examined podoplanin 
expression on neutrophils and found that the protein is not expressed on peripheral blood 
neutrophils but is upregulated when these cells migrate to inflammatory sites. This is in direct 
contrast to CLEC-2, which is expressed on peripheral blood neutrophils but not on inflammatory 
neutrophils. It would appear then that CLEC-2 and podoplanin are reciprocally regulated in terms of 
their expression. 
6.3 Future directions 
6.3.1 CLEC-2 and podoplanin 
The work described in this thesis forms the basis for a more comprehensive analysis of the true 
physiological role of CLEC-2, which remains unclear at present. An important tool not yet available 
is a CLEC-2 deficient mouse. When such a mouse becomes available it will allow for the in vivo 
investigation of the role of CLEC-2 in disease settings and/or homeostasis. There are several areas 
which could direct future inv stigations which have become apparent during this thesis. The 
significance of the expression of the CLEC-2 ligand, podoplanin, on macrophages is unclear at 
present. As mentioned, perhaps the simultaneous recognition of podoplanin on macrophages by 
CLEC-2 on both platelets and neutrophils contributes to the interactions between these two cell 
types and to the activation and cross-talk of the inflammatory and coagulation pathways. These 
interactions are known to be important for the control of infection, and for limiting inflammatory 
pathology, but are also involved in the development of disease. Whether CLEC-2 is involved in 
these processes is an area that warrants further attention. It is also tempting to speculate that 
podoplanin could be involved in directing inflammatory macrophage migration and I intend to 
investigate whether podoplanin has a role in inflammatory cell recruitment by using podoplanin 
deficient cells. For this I will attempt to generate podoplanin deficient radiation chimeras by 
reconstituting the immune system of lethally irradiated recipient mice with podoplanin deficient fetal 
liver cells. This model will bypass the developmental defects by limiting the deletion of podoplanin 
to hematopoietic cells and the immune cells that they give rise to. The reciprocal regulation of 
podoplanin and CLEC-2 on inflammatory neutrophils is certainly intriguing and implies that this 











functional significance of this reciprocal regulation is not understood, and this is an area where both 
the CLEC-2 deficient and podoplanin deficient mice may be useful for future investigations. 
Future work will also involve the precise determination of the expression of human and mouse 
CLEC-2. There is some evidence that CLEC-2 is present on DCs (Caetano Reis e Sousa, personal 
communication). The capacity of DCs to induce and regulate adaptive immunity has potential 
therapeutic implications; for example, in the design of vaccines to treat and prevent infectious 
disease by enhancing immunogenesis, similarly in tumor immunotherapy and in situations where 
tolerance needs to be increased such as autoimmunity, allergy and transplantation [393J. Future 
studies may explore the precise function of CLEC-2 on DCs and assess its potential as a targeting 
molecule in immunotherapeutic settings. It will also be interesting to determine if CLEC-2 
expression is regulated under conditions of infection and disease, and to understand its function in 
these settings. 
Preliminary studies carried out directly prior to submission indicate that CLEC-2 has fungal-binding 
capabilities. Future work will involve the specific identification of the fungal component that CLEC-2 
recognises, and the exploration of the ability of CLEC-2 to recognise a range of fungal pathogens. 
The availability of a CLEC-2 deficient mouse will allow the determination of whether CLEC-2 plays 
an essential role in anti-fungal immunity in vivo. Initially, the in vitro phagocytic and cytokine 
inducing capabilities of CLEC-2, could be examined in a physiological setting. 
6.3.2 Respiratory burst 
As outlined, the observation that CLEC-2 is not involved in the induction of the respiratory burst 
raised interesting questions about the mechanisms underlying this cellular response. This is an 
area which I will focus on following ubmission of this thesis. Future work, which is already 
underway, will involve the generation of various other CLEC-2/Dectin-1 chimeric receptors which 
will help to identify whether there are specific components of the Dectin-1 cytoplasmic tail that are 
required to induce this response. Using biochemical and proteomic techniques I have also 
identified a number of proteins whose involvement in downstream pathways will be explored. 
Based on the findings and to further explore the proximal signalling events induced by Oectin-1, 
computational methods based on protein-protein interactions will be used to construct an activation 
model. This will allow the determination of how exactly Syk associates with the atypical IT AM of 
Dectin-1, an aspect that is currently not fully understood. Particular attention will also be paid to the 
regulation of assembly of the NADPH oxidase complex at the phagosome membrane following 
triggering of ITAM-coupled receptors, as this complex is ultimately responsible for the production of 
ROS and previous studies indicate that it is likely to be an area of regulation for the respiratory 
burst. Ultimately the determination of the mechanisms underlying Dectin-1 mediated induction of 
the respiratory burst will advance our global understanding of antimicrobial immunity and the 
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cet<1.~.d -.'ith W!lu...cJ .r;,C~1, 2:\11 or ,"('!nl~:i .Ah",. Wi;;K 
it 11 nn:k~ of two badr.k:-cU. b<c;lit'l!\\"in{!. 
i h '" 4T, "","",un<! !>cod:< ""'" "",,,,"'«1 "nll...,fl"g~'i,.,. 
f"ftcn:oU rtu" grnJk::n1. {40:md 71)""l):i J.W.J C(::1 
trin.l.S,l,..u';lrL ~t!~~h~ in dlI!: presmncc OT alh~ 
n. W~ alki>wt'>l M })CL:U!'" ;;a1 JTC fQ.f 15 mitt. f;,:ucnul wert" dt1cL1(d 
with ..l Pt~oojlJ¥.atcd .t!lU~T-N;:l At:.~ £'I! d~bc'-! O1oove. 1.lr«1 enmuhlC)'lK 
FITC ~ t'".t':ll p:~uliCOti-m~~ .. "bleb hllod bound or intL:frY~i;I.cci: bcud:t '*""C::'t: 
:did ttx pcn;:t;V"~c dch:.m1int:d try- ~"CrnpLt<\ns 
." !be PI' ~ cell ""J"" •• ""'" 
f1JWn'JUl!l ;;yttl()SOfi biiUfillg. r<'spilUtor; bur.q, "lid C)'I ... killc 
pmJIk,li"ll ,Wi/IU 
h)' 1;Nftv.:ioceU itA ~'!~4. i 
$i)iubk jJN!JOC:lrn WA,. i.ktcrmiMU a~ 
(24). Tn c:,amine 1:1i.tlkiru: pnxhu:lidn from pri" 
_ry "",ri." ro<:,,:ropi!< .... cn pu,",b"d .. d_ribc.J :'00 pl.ted '" 
:1 )( u1- «Ibiwd I. C~Ih; wen:: ldt un:$tim~l,i,ttd f:c' ~i:mUi.ilf.c>::J "tid~: 1 ~ 
rh<><kl<yt1n, P",,".<1; "" at"",ibed i2K). ",. 1 ",!!1m! 
{SiemA\,.-\.hiridlt f~r6 h lJ 17"(". ~r.: supcm:aUdlt W~ IDJ.:~, 
"''''.;! •• ine the 0r-<UA """'M.: '[1\i1'0<1 ¥1.1SA """ IUD 1110«:><"""". 
the ~lru,lyg!.\ ni the Syk. .. sutfldcn-t anJ Syk.,d-cfidt::t:1 f~,'Cdll., l '", 
kan*:h.st:cd cdh W(lrC Mimuh.llK& with 'tQno-us ~"ff"'"c(,~mru:.kr,$- cf unb· 
ht:lk.d ryrr..(.jutJ U\i8m~"AI.drk.b) f",~ 16 b;,at :rrc ~rA 11.·1 SJ.:; .... rcl.crl irac 




tram.. cc.lll wt:.K Ju.Iclod whh Jih:¥.trer 
litt A final CO!!:'l:attr.v.lon of :2 SJ>.\t· A f;;(;T 
,TC with 'Y""_~ {25 151'-f/ml 
rhodocytin9 Of l my'wi PMA. J:.!} l~ 
rlnxiaminc "'l!:J a~e!f.K'.d by Jt:)'k" cyu)tnCtry . 
lllllfUllI('Pf't'dpiJalif.lllS 
r"'mcnol""~:i!,iwi,,"'-, ["'Ill itA W m~""'rb,g", 
K£:iiCtu',h 
~ doctin-;: P'ptiik"% h~"lt been 
! 19}. ror imnhJl'K.lp:rtX:tp ta.tUm~ ff;h"m A20 tclh. 
UA.lAgEoo venJun ti<fCtl-:C·2. 1 '''. 10'1' ",'db W't"fC 
HA AI! and tb~-!l j,umn.d..lLi:-d 1Aiili ~t'lfatt~.M.lt: ~fI 
"'(;;'k;fJtx:d j,6L Cdl IY1<;C;C4C ~'t:''''' iUkkJ :r.o UKt::p anJ,H';,ai; 
l).YM.bc<id~ .nd n..~ {QT 1 h ai1"C. nc.~to wtn: WA~t:d t-'lh::n~'tdJ 
t:K:"10rc .wAJyu!O: hy Wt::lkfn blou.ins __ Prutcirffl: ~Illht: imm>;JnJ'JpN..x:ipl<W:j 
w-c::rc d,,:u:c&i:i wlU1 Ulti~phn·=sphotyrt)£inc 4"d{J~ 4GH)? ·rr anti.Syi 
IS""w. Cru •. Jli="tl"I''S~-). {"Iloww hy 'PI""'fd.tt H~l'olln'<d ""Co, 
·uCiduy Abs (lw;::hiJn imrrH.mun~:~I$~h 1,,w,MaUtri.z*}. 
Resulli 
MuriAL CIEe·:! i,l' ,-xpresseJ c'll peripit.erai N",:id fWil.lrop/ril$ 
To expkwe thi1 c~rra;sioo.of CLEC-Z. Wi' gilllcmt,'d affinity puri· 















f'.U:liRE L mCIJ::C~~ i~ t:Xpn::$~::,d t~n the j:~r.u;c <Jf pc:':1ph'z.l.1 b>1f.\.I:.d m:Ulr{T'tt1t~ ..... 4 .• Amti~HA ~i.lir.jn! or ELi cdh, ll"% .;k~c:rmin(:d hy fhv.' 
qt.urnt:tr)·~ lUV:I·~.;b£ 1:xpn.:~s:inn nf H;'\·U.~Ft! :::nCLt-£:.2 (HEtJ tn,$;lo;J£t~) a: j""c ~d.i VJr.;~.u:IC, Th" ~~v..H'· .. t.nJ"i cl-.ru;rGi cdh. W"t: irHhc:u'!:cri: by ±-t 
I.mtHkd t-vi$U?gfW11. B. Thi.: :m.'.:Hl0tJO~aj ~Iid :Jfhh»F"Urif:.cd pnI)'dm:illl .Ab ~.l.!!~ .A.!1o.U1Ht C'Lr:Ch~ 1fi.~cHk.tHy n::C;~.fH1-C r<:fA .;;:di~ tr.k,~jU>:t:l wit':! 
HA"'Wt:,g~d meLEe·:! Wlkti et!.,;:t :It:..t ~"');)f.-{.mty ~-tlC'l.lt\:.!i ccJl~ {ucHkd b .. ~kj"!!!;Jtl'nj Q.'Ii &ktmin.::d by tl(~IA' :::y!nl!'t;.:lr~~N (~ mC1J~C.:1 i:, 
t:1if4'C»>ed:~}fI ;;:i'>",z ~u:rf~ j~ I'hn~k>;.~ (hikoJ hlfio~r.l1n\ D. E'tpn::~j{)n orrna.hC~: UidkJi t;jt~tagr,,"m) <::m (]») 1 I:< f-Ch'".· [ , reriri'icml 
blood ftCul.n:opb:iii> fr--ont n:\Lj~h:, C57HJJh .. Uld I2\US,,· mia ... ~ indk:~li:4. t_. mCLhC.l i.., vuly w>Z:.luy t:xPft.:l<Os;.c~;j i:<n CD1 :b""Cr- f .... b<m,,; ID..J.rr'0W 
cdl~ .Lad f'. elk-ked infI:;unmi1iii.C"it"} r_A"l.ftrnr~iH:<o. C. F, TtilO pdyck'flJJ Ab W;L{ '-;JM'.;j f'~-(t Hainin."i; I&f1d f1.-t~ly?C ,"~rMmJ ~-ru.inlT·,¥. if. indkt-lcd tly the ur.:$lkd 
~l}>t.n1!nrn. The ~',d; ~hi~',ll,in l.lr'C rt.:Fc",,'m.uth.:c ;-;.,f .1.': k..;ut 2,n;-C irutcpc:rnk'nt {;xpt:ri~rinl). '(;. R~!i!'.Jbtbm ;-:;·f m{1J':C~:! clpN:;'a.ien un rtt"utmf~':1th iU'ld 
M1nn.:~)'u:::r; (olh-:<'v,,>jn@ 1;::timu.b.ti<~r; wHh ¥"J.rlOLi l1J~ l.;!t)nls'!~, a~ "h:k:i:tu!. llYilh rnmux:km,~1 .;.wti-C1.r:Ch~ b» (i;>w C},.,1nrru:-wy Th--t J.MOI dww :rt"~Jft'!'i 
f1f PilL;; pot..'k-d (r;"m 1 ~ mice 
Abc> .... it, dem'm~lf'di1cd t-j staming EIA all, tf'J.Il!ldu.:"d "'11th HA· 
tlIKl1.cdCLEC-! flf "",,:tor'Dllly cflm.ml;; ll'ij1,. 1.4.). Anaiy;;!s !:lyllnw 
c}lomc1!)' dcmcoslfllllcd th.u b"th th.: JX1iydo!lal :wd mAo.'lX'· 
cit;cally r&oj!)tized ClJc'C·::; exprL"ssc'4. on tlK,,;c ;:ells (Hg, IS). 
tJ •. mg ~ Atu;. "" fir.it conlirruc'4 CI .. EC·2: c:>'p!".!S"i<;o 00 
f'!aiL'l~l" rund ;:,;"lld ,jclc><:i ~lpn.'$.~iIJO ,xl' thie. rcx-<>pI,'r nil the sm-
lace ,,1' (T)(,J"!'''SSC'''~ (,dh. :1-' previously dl!«:f1Ilx'(l. I.l H iFi['. 
1("1. To determine Vl1\elher CLFC·1 wal als<;) npn~sS1!d on i1Iher 
cd! type>, W~ then exa.'tlined PHts fwm HAIJllc mice using a 
.Mid), (<if marke'''' h, dlstingLllst! thi! ,'arious .::dlLllar lX'plilalioos 
(JO\ am! could ..:kllr1)' d~t c~f'ressk\ll of CtEe·1 nn Iht' rurface 
dCD11b'(:;r·,~ nC'ulforllilHFlg. If) anddlrta no! shUWll!. Tbc 
i!xpressinll (If thi.' nxept(lr nil th,;,;;,'! (dl~ wa, m'! uCf'!I'Acot (m tlw! 
il1t'tuse 51rJjn~ as 5irnilar t-e\'ds I,,'f( ~xpr1!ssioo w<tr'i? also del('<:~oo in 
other s(mins i.ocludill® C57BlJ'6 and i29.'Sv mlCe 4Fig. IfJL Wi! 
did Ill,;( dcttXi CLEe -1 Oil any other ,ell p!lpubtiorl in the blood 
• .;Iatn not S!1.'Wll .... ThUs.. thew dat;, demOflSlfall! lha! axpres.smn of 
CLEC-l Ls nc~ rC'SUicti!d to platelets . .lilt! thai tltis f!N:eptOf is also 
expressed ~ pefipi1eml blood neulInphils. 
Under normal CGodlUOO5. the n1l1jmi!y of IlcmOfilils arc kXt!ted 
ill It.,z lYYlte !rulrm"'. arid not} • :<nUll fm:tim of thesc (elis. is 
releaded inK' Ihe bloc"J. ffOm where thiY ('00 to? r{><:rnit~d 10 ~tes 
of lllilarnmali"!l nJ HO'A'cycr. ''''~n w~ charucteriuil CLEC·l 
e~prt"SsIDn III the hooe rnMft'l" Of ('n j 8·/1 thiGi1lyw!1 al~ £>Kl\i!,j 
peri~:ln€al lh.'Utroptll15. Wi! foond that expcessk)n of thiS HlCepmf 
wai, mocn ],;)WC( 00 Ihe:".: cd(S IFi.g. 1. J: .ar..l n Similar findings 
were (mttinoo ill all !t!n\lS<' !ilrains examined Idm rwi sh{)w(':· 
Thus. the:~ resul1s sUi,!gi!:U thal c:q:m."%£t>n t't CLEC·~ apf'lt:111< to 
~ up-regul:al£d uP;)lltllCutrupl:lIlauigmti'J!I (rum the b"oe Ill.lm'(lk 
it!le> In.: )X'tipl1Cf'JIl bI,x,.j. but O;)WIHq,:;ul1il.:d <l.l1."m (uU"WIlJg fC' 
cruilml!OI to Slie'S of in tlatmrml;o[t, 
Rt<)tMlutiL'\tf 'L!f Cl.J::CH l t'.tp·j1':!.thVf 
As O.EC-1 eJ;pr~ssiD!1 was dOVlll·rcgu.1alild on recruitl'4 illflam-
!rulto!), MtllIt'Pbils {Fig. t Ft. w~ ool1!ooine<l \,;b~thl"r 5Iimula.!",n 
fI( pcripilcrnl 1.>11:>00 fl('utropnils with mkml.>i211 agolliSiS ;;,'uld a);'I.' 
induce fc:!!ulath'fl t,f thi; ft!t:>Zpl!:)f. as has m'ltn l)eSCI"ib."Id for olh.:r 
ooclia·l elU.S!"f mt,locull'5. su;:h 115 MICL (31), Wi exam!n,\! 
C1J:;C1 "tpri!~sit'!l by flow .:ylome!!)' fr,,!lo"'ing a 1\ h 5Iimu!;If.>l1!1 
flf rilL, wlUl a vanely of Tl.R a£Hl,stS. bm did nt1! "hiCfYC allY 
sijJftilicwl reg:ulatioo ,,'Of SUd;U:2 ~llpressi(lrn (11 llellli"~I·cx­
pressed CU:C-2 iFi~_ lGk However. CLEC-2 ~xpres,%rm was Db-
!i!l!ffOO li:J iocrellSl!' 00 l1K"ltocylcs definoo by rsc and sse pmlil~s 
13(H. following stimulaW:ln with l'am:~CSKJ> a TLR::lfUH ago-
Ill>! iFig. let Thus. rnCle relults suggesl CLEC-::! is nO! dimaJ: 
regulated (1fj IIClllf(1phlls foll0'\\<'illg micmbial stimulation. but that 
tlrse ()ndilil.w41I can lm!occ uj>-fc£uIMioo Df d~ (('Cepl.nf Oil ('<ther 
I eultocjle$. 
C[E("·2 ffI<"liau.f phi1gr·,wo.<i,f 
Having identified CLEC·~ ml lIeulropIlil$, we !Ie>;! wi.;hed to de· 










.£A ,. We also ~oo!iIm.:;d that cellular ocllvillwfl resutti in tbe pIm!\-
pborylllt.ioo of CLH>2. by immunop£ocipill!tln~ lrus (ocep!Or (mm 
p.,r,.andatc slimulm:ed or unstimuLated Itl!m£duc~'>i A20 c~l!s c:\· 
fU\!!ising full-kmglb Cl..EC'-2 IFig . .l.lh In addjtion. liS we had dorul 
fr.'fI tltber m::i!ptoo; (6. 291. ... -e exptc:>lied lile chimerk recllplDt al 
i:\NIlparnl:4e hm!ls in £yk-sutlicifnl lIl!iI Sylt-deficiellt B edl hIleS 
\dall! mJII mo...li). and examilled me producdoo of Il-1 in M'r)!)1lSi! 
It) zYll1>:lSaIl stimulation. Althoogh ilddilioo of lyrrmsanlo the Syk· 
sulljdool c~lls ~xp!'~miln@ t:M ,bimcfll illduted me ~oo of 
lL-l. the Sl'k-ddkient ~cl!s did not :show any fCl!IxnlS(t to itlis 
partii:Wt {Fi:e. 4£",. Finally. w" alw examined RAW264.7 fIlJICf1)· 
phag..s c1\plJ.'SsinJ.[ W dlimuic ~ by l:ooi~"lli micro.sctlf'l'. 
lolklWillg a liIoJt 1-mil! cJ[p<!lIUl1! to Zymosall. Il!ld wuld dearly 
detect the oc\iyllttoll of Syk atOOlld t:M pilagoo:;me. as Il1CHlred by 
sWl1in!!; for plmspho-Syk I Fill. 4DI. Similar oclivati1:l1l ,~f Syk. WlIll 
absen! ill t:M cells expressing. th~ Y7F mllloot chimeric fOCepwf 
\dalll lbJt ~h"wl11. Thus. tJk,sc dala defllOn>llale that CLI'.C·2 sig· 
nal. via Syk klna.'Iil in mydmd ccll~. 
CLEe-I d,>{'.f na/ itldilU tile 't'spimlf'l'" m,nt 
Sigruillng "ia doctin-i ha:> been shown In activ,";c tile respirlllnry 
OOr.'~ 'II macn~gcs in a Syl;-d<.>pe!id>l!1I1 ll'IiUlllCr f :l'\ll, The respi-
mini')' bwsl i> an imP<ll1.'1IH anHmkrobial mechanism in ooul1O-
phil~ and us CLEC·! 5i gnab ,.ia Syk.. we w,1Ildered wbi!t:Mr lilis 
(OCeprol Wll<S aL';(~ mt'\ljali!ll! th,s activity. We l!xamjned this re-
spcm;;c in the RA W264. 7 Il1XI'l'1¢lllges transau(:ed with t:M villitrus 
dl.illlll'fk:' rt<Cepllll> folltw>ln!!; >tlffilliati('11 with lymm.lll. Some-
wh,,1 surpri.in.gly Ii_'ever. mocropl1ag", cXpI<.>ssing tbi! chimeri.:: 
mCepk)f' f"i.loo Iu indOCIl U r~'l<ir.'lil:"ry 0051 io nlspc"!flS,i! 10 tbcse 
part.ic!cs iFig. SM. III .cootr.l:lt mllC'rnphages exprer.Mllg d~\:j;n·l 
il1duced a robust re~ir.atory hurst. as expc<:ied 13'h f'll~rmore. 
this ruspoll.W was .iIl!l:) ~Ill in hlot>d neulmpbils rum· 
IImted wim food>;-.:tyill (Fig. 581. tMse dlWI sh_ ilia! d..~ 
sp.'te sigJl.1IIi€lg via Syk ki!l~. CLEC-l d>:x-s n.;:.t il1duce me respi· 
ratory bursL 
Dlst."USSlon 
The study of1he d&tin·j c1ustl!1'nfNK·!lke C'ly~ loctin l'l'CilpWI> 
hill- p!1.'vldc'>i irnp;wtanl illsighl$ into mc'Chanisrre underlying 1m-
me,ma~ and immu!lily 1.4. 1.L Argmbly olle !be rlk'Mt important 
discCi\'eri£s ha:>. beet! t:M idemificillioll of roc~'f!I0r:; oolll:.\lining cy-
loptasmic IT AM-liLe motifs wbi>:b (llil trig:;€! cellular "'ti"lIutlll. 
Thl!!ii! motifs possess 0011' a singhl tyrosine. yet acre able 10 filCfllil 
Il!ld sigw ,'ia Syk UII_ Ibl'C'lJgh a pnxeu whid! is 001 yet fully 
Imdffiil<!o(J,j (2'i. elO). (me roccp!or ",,,,~.,,,,.mg this motif i. 
CLEC'-:!. a rnoliXule pI~\'IDlI..qy Ibooght to 00 exd'll5ivtiy ~x­
p€essed on pia_ill and ;:apable of trigg~rin~ lhe activation (II 
1hese Ci1!l$ (Ill. In litis 'lIIdy. w€ ,no",. !hal CLL'C'-2 is .also oi':1-
p€essed on murine peri~ral bh~1d Mutrop/1ils. A~ in platelets 
n I. 15 i. we mo... !hat t:M ::dll11lN fU!lctio!ls of CU:C-2 are 111>.-'-
dialed mrougb h.~ IT AM· like rnJ.'llif and thai the roceptor;:iUI in-
dllce iatra.;t!Uular ~iglla1in;; v,a Sylo:. kinas.:. 
The I'TA~t·!ike IThJilif :shows a stnking ~imi!ml)' w tI'.al Dr dClC' 
lin·!. !\iUggooing lill'!l (;LEC·2 may p<'slK.'ss nUll)! of !he hmctkms 
nf i.W:lin·l 115. 41 i. Il1d~\t'd. "''' hav.' ~'wn liIat CUT·l em 
trig~j.!f ph~'lCylmjs linil the- in<tw:lioll nf TN!' ...... iIlld it is p;:'>Mhle 
!hal the fe<:J.'!ltW ma), also 00 able 10 iooocc mt' prndooioll of a 
C1l1mbi..'f of ,:4h~ cyl"*-incs aOO chemokines In n<'11Ifcopbils (3:&i. 
EuMffil1ofe, <..l.EC·;! mediated cytc,jdne prOOuclioo may be am· 
plified ,O!!timula:!ron through t:M n.R p1l1llway. as has, heel! 
showll d~'ctjn-I 06.n. 41. 42l. Thus. Ute dt."4.'till·' {~9. 411 
and CI.EC9A {til. C'LEC .. 2 fuoc!ron.~ as all ..:tivalioo rucep!t>f 00 
mydoid ,ens. 
-1155 
The ability "f CLEC-2 W mediale pll.1lgOCyt<lcSJ£ i. lili.dy 11.1 
involve tbe hit!!llly charl<!d cytoplasmic triocidk dll$ter iDEDI. 
Inllddilh'Hl In liIe !TAM-like motif. This duster is conservoo ill 
dcnio- t. bul !'lot CLEC'9A. and fI1Illtatiol1 .;:.f these residues ill 
dc;:tin-I has ooen shown to abolish particle uptake (391. fur-
thermtlfl!. altlmugll possessing all IT AM-like motif. CLEC9 II 
does ~t l11ediate phl1g;o<:ytilsis ,lSI. How~vcr. it is Slm'llnk.!lOWD 
if CU;C·l-l11oolated uptakll: fOC/uims Syk. in nemmphils. h¥ 
de."1ill-L Wi! requirement fnr Srk is ,ell-type ~dfic; in d~l1-
dritk Cl!lIs <ledin·i-mediatoo upl.lkc i'lvul ... "s S)k. but ;n m;;,:· 
r~hages this process is indl!pendl1'llt 01 Syk 1100 occurs throogll 
uncharaclerised. wd possibly Dovel. pathwJY' \16. 2ii)' III llCIl-
Ir~hils, pl:llI,gOC)tOSIS mediated by liIe unrelated ;I('tivatinll fZ-
ceptOI, CEACAM3. which ~se$S<!s II tt&<li.!iona! ITAM m.otif. 
was .,"-·WI'I] 10 involve S.l'K. bur tile requirement for tbi, kinase 
was shown to be dependent nn th~ nature of tho!' ligand \.1:1.1. 
Altbough w"" have dearly dem(lIl:>lrat.::d tllal CLEC-2 Ius tbe 
potential to ITh!diatc plwll'X;ylt»li:!.. th~ pIl ysir,j,,~ ka! rele~:tlH:~ 
nf this Jrli~';Il' r.lm.lin~ I" be !h!lcrrnil'H.'<I. 
Oll~ {)f Ihe mOM Sllfp€i.siDg d'llCI.We-rics .... 1I~ lbi! in .. bWty d 
cu,e-:! to induc'c the fcspirali1!) bllf:'t. d~spib: sigl1alin~ "iii 
Syk. k.ifl~. The a':li\'Jljjon of S)k by Lbi! F::~. dedin- L :!I11l 
(,EACAM) 11M beel! slmWII 10 induce the mspiramry blll1>1 ill a 
variety of cell 1~'fI<!$. indudillg Ill!lltmpbils L'I5. 39. ,t,;o .t,tl. 
III (a..'!. this fll:>pOllre is cemplCllel, absent fo!l~i!lg S1imumliorl 
of IbL'Se ru.ei!pl1JO in Syli:·dctkioJlll ;;ells (39. oUt in tllilCrophag\.'. 
stimulal;!d with :l)TIKl<'hilIl, 1w'"'"""'Cf. me aclh·atioo of Syk by dt.....--
lin- t and iii" SUbstlQlli!'!Il respirn.h;,ry bursl O<"I."Urred only in a sutwcl 
of ,.:1\$. y<!t IiIc a,'>scmbly of 1he NA DPH (!)uda.~11 on th~ Z)'IlKmJll 
pbll~"S<!ITICS occurred 'II illl cell, I}'H. Takil!1 together. the"., dllla 
ther~fo!1! SUggilst lila! t:h~re is 1ID00000000r ,;:owPOrn?otfpathWllY ltll'OO-
lalld by meoW fl!Ci!pt015. inllddidoo to Sy1. !hat is requiroo fOrlh.c 
illdoction Hi the m.>pirntory burst. 
Our analysis ,,')fCLEC'·l cxp<"\?~sioo ill;jj,;;lItil:>!hat lIi~h Wtvds of 
i!,~!<k'll ,jf the re(.'i!ptDf 0<:lCUrs only tm <:il.'t'ulating l1elllrapllil", 
~nd thaI t:M r.x't.'ptor i~ only wcakly e~f'res>i!d un bOm! I'lI<Im~'" ;';1 
eili:lloo inflammatory ':CI15. This StI!;gC$lS lMI its '''pt~ssilxn ;, 
light!y rI1gulilled and impl res a ~'Cioc fU!Il'lroll f(¥ me reccp!tlf ron 
circlllating ,dis. The exprel/$,ioo of eLEC-:! Oil oCllucopbils. !JQW-
i!v~r. ma;- only ocrur in mite. as we did nO( dctecl express inn nil 
lru!nari p!!fipilcral pcllymorphol'locJ.ear t1!uil;ocytes \illr1~ l:omm."f-
dlllly available Ab.; ldatil nct sbnwllk Almllul1b llO( :IJld!Yl.cct ir. 
!h!lail. we also ObSilflli!d tbat expressron (11' CU,C-~ coold be IIp-
reg.ulated 00 murillil m,;JCIoc}ws. followillJg stimulatioll with 
Pam.,CSK ... but !I>;)i. ottIDr TLR agooists tesl(!d sul!l!eMil'lg SDlTIi1 
'JX'Cilicity in mis re5ponse. It is p<."'~lbk< mal CLH.· -1 may he 
simiiJUI)' mg'lliatlild 011 hillnan p"lymorpliol'locli.'ar ICIII;...'lC~1l!$ m 
Olili?f Ietlkocytl!\l,. wbich wern nu! ex.amined ro Ibis study. Why the 
expression of mit rt<CJ!pIor appeal> til he priflW'll} rcs!ficl . :rl to 
circlilating cells is UllCleJU. aOO despite me idemification of bolb 
cndo@OOOll$ IIlId e';4)J,lcnnIlS Ii~allds. thi.! physi4;IQ!!ical roJ.;: of 
eLEe'·:! i> ~liII IIIllmo ..... n. 
Ld.c olh~f rcn'l'l()11\ in til" d!.'.ctin-l duster \.t). CLFC-2 may 
funetiotl u;! a paUct'li t'1!('ugnitiofl n..'*Cepte~r. The c1pn!~$-ioll of 
Ihis fe<.<''Ptor ..,n nC"IHn.1pi1ils ccnain!~' impli,,~ 3. mlc ;n inoD!;! 
immunity. as thcl'l! sn<;rt·liv<,d ci!lI~ pnwidc 11 I[!'ln--lilk! nf !h!-
f"flsl! a£.'lins~ inh.'Ctnlll and arc L"£M!lllially I'\.'qllircd for tnc C<1D-
1m! of lxiiclerial and IU!l]1.,,1 ml"'''('''05 i.'iS). A role in illmnmily 
is lllw "ugg<!:>.teJ by liIiJ ability of sp~'Cin.: Ttl< rlg'''l;'!.;; to 
induce CLEC-2 ellpressioll on 1Th100c~'!es, and lhi.! pIlagocytJc 
cl'I{lll(ily of this reci!ptc.r may be impc1flal11 for tb" de"ranee of 
blood-b<"mc palb~cns. alwoo~.h socII imcr.KtiollS 1m..,,, yet to 
bot doCllmeJl\lId, Hnwc\!cr •• ::>tner than rb(,.jocY1in. OIIl)' HI\' ha, 
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ralh~r than th:mg pn.~tive, 1M inleradinn ¥otth CLFC·~ may 
prnmDtc trlm!fl'f of infe;:li('u~ HIV·I particl<?s (}71. 
The pdiltll'Y f1JllCtinn M CLEC-2, h('w~'1.'!", may be in lite reg' 
ubuon of homeosta.."ti5 through 1hc rec(1~nitioo of endogenous n-
glUld$. Ol'li! illldOf!eRol.l$ UgNill Ih;a OM OileD ideoofied is p..>dopJa, 
Gill, a mucin· I iK!: prn!e,n tbat is exprel""o on J vJriely Dr c~Ji t).pi!S 
tocludm~ ('stc,,'.j}las.L~, ~i1f1jtinocyt~s, iibroblasts, aMWay epithetia. 
f<?llal tubular epithelial Ci\J!5, lympllJtic ~nd()tbdilll cdb, lIJld CC1-
tJlifl tumili ,.:Ils, although podoplM.in is om upr\l$:>ed on bkkXl 
\'C:..,.,~1 cl'xh:yJ'tetium l.iS), Tlms. under I}ormal CifCI1ITh~t;:UK'i~t t+r M 
eubliag llculmphils and pk'lw:!cts wr.'ffl1d n,ll wme illl';) C(ifltoct with 
thi. ligan.;!, Hr.}WC'ii!f, the inle:rm;'1ioo oj CLEC·2 with p.:xIoplanin 
f(\n(1l~'ing Hltnl,1f inva.,!Cil0n has bc-e-n P'f{':f'<.11€'-rl to promt)fi! pbtdet 
1I£'tiHtil>n and aj),gregllbnn, whiN:h rnay be 3l!sociatoo ""ith rumor 
meia;:w;i:; ( I l. D I. M2wt;c;i~ iF 3150 PWflUlIk'd by iufiamlrultion. 
jrn:!oc~d ill part by fli!lIln;.p!JJ!S i 46, 471. ar.il it i!; rem~t!lli 10 spec-
ula!.: thaI th~ mler<l<:lk'll Df podoplallin ""'lh nt'tllrnphil-i!~rr"sSild 
CLEC-2 mllY ,'ofillibuw (1) this pr(lt"'" 
Hnally. til<: simullanec.![s """'Pfl1lj,," of ('1.H.',2 lippilllS) by 
hoth pblelds llod ncul!Uj)!lil> rnay ;:"!'ItnbuI0 In th'" inlcl'llcliull, 
helwc'>:n 111€'c two edl lyre. and to tbe ~t!'i"lhm and et<)5.!Halk of 
theillllilmmlltnry and l'X)Qgulllti,m pathway'. The", iolc'racliolts 1lSl: 
koown E) Oil imp<1rt:lll1 far lite cpntml [If infection, !I!Id for limiting 
ml1ammalnry patb;;!QjQ', 1'111 i.lf0 nlso inv<'ivc'd in tM di!W]OPl:1l0nt 
of di.'''·;t,~ I .1.S, .t'h WI111n, currently detumining whetMr CU:C,2 
I'> invnh·ed in t!t~SiI procel>!ies, ll!ld tli<1 !''i';;sJbLhty that L'lis fOCeptt\r 
f,:xngntb~$ otht!r ~ndog~nn.ls and exogenous IigandfsL 
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W'.::;;;h..;;lt: ~ w",L.;,)''''Jae T.ftlS'; i"c" !~h,~"'l.t 
Syk·coupled C-typc lectin receptors 
that mediate cellular activation via 
single tyrosine based activation 
motifs 
Su~: WI,.","J dem,.;",:: ,,,:u (rc) ",1>,...", "''''' dm""" 
Jlu~.ixm;« .;:estU, bct,-ffi lfi Fm h)' f.h~Jr drll"f:muul UV'~S;')(',T2 p-X'!-f:fi1 
~*,'u'l2;)nrfi.'l'f40F. (P'RR't). C4l~ mm. ~~ ,a:ps) ,lrt- 1 grvtff" 
of ~,"; 'txp.r'f.:r;5-t';; hV r:..c.~ lnd <¥d:tel'1r-.l}"fda.d >rn'lb Wt CHt :recoFjl':~ 
endc\;~~ bRm.-±: ~ well!1;:';l. wid<!'r,mg~o'fn:~'1l~~4'!!'i :~rn,;;:ru:rt"'JF~ 
M'l1 on p~!:'U·>.W'nXt, IJtuJ r.:ief'£ 1%1 h.('~~~u uta ttr.UftUIU:Y lu'\~ r~(-::n 
d,f1t¥.Xll~f4rd 1;;"tT J.:":<1TIp. i'Oe:m~ ·::·r i.m.~ T~1i4,;y tJmlN, l..ll']:r.-ly due ~.5 
!frt:n e:lId<X')'\!oC' ilituh::'}' l.nd ::nl~~ .'ST*Oh.x::: ~~::.'alC<n.. rx:: -r.JCfI'~ C1Jt .. 
h.H"'!:-bten m-t" ftt-v'mi tJJ :Jilim1ic.:lm l..n:lgt:n·:n:ri:~tl:ug:ml<.b~, A rfumwot' 
CIlb; tlt:na l~;n ~':J1 tM r~ >';)f ~n.J1Jn;: 'f'U J,~.:.u.rE .... "fl Vrt1!.b lrr.m:m.OCtN'i 
~'Col q,'!',(:><;uuo>w.'>«i Id1'\'1i'il(:Il m'::>1lt (ITA.).!) >t'{'..<n:tunm~ J.dlt~ 
PTC">1MR1t Cth:r-n i\.nnu.m ITA..'Y ll'lXl"d rnn~i": r'f' lr.cmU;'f¥'>,~" rrrc~ 
:!;IM.·~~ mJnrnt:a')' lTIf,Tn% t1TTM%} m 1~:Jr (')'1<:r-l».l'mt': :m.d,,," J~ ~ 
:fin"'l>rWcnt .. 1ut:ir...m.tC>!:: mtr.a~jlu.u.! .a~tm.~ via J ~n~~~~"".:rLn~.b.l.N. 
ITA:M·hn: mMf-l.:nd fug·h.b~h! ;hr;1:rT<t-~~;In,,-~.l.t\ 1e:rlf't; ·{jff)( trL1J<:t>t.Jl 
li:r!yw"",,,: ?"""'" """tP- "'''''l''"".C tqt .i<Cn\ h~i alta""", :~'" _ 
!""J'ilf 'fEll,. ;"'01 ",,_.,. "'''''> r~=. J 
J:).cndmlc udh (C'I:::'J an'" hi"!<?tOg€l\"OU< fUlllly ,·f klli;,xyte" 
!i:tu .,.t<: a?xlfr;tl~t jnvoJv<~ ill rhi' TY~n,J;tl1,.,n of lIm"'W lJ1!u 
... '1"puve Immunity. Th~ tuncrk1l1!l dlw.nlty lk dcpend" ..nr (>11 
v;.riml:l DC subtrT1i:!i whiCh <i1l1!!1' mk,e:ukll.l, Otv,}kl'Hl1Uir .. d 
hlli",ry, "mJ !p<~liz,;dfimui'm. In g"IH'ul. [)01::'; funiTKfl1 pi!' 
nHally trl '''prote, pt{)«-S~, uld Jlfe.Mll! ,mtigms ro T .:dk Tnt 
p.lrt1u.t.s DC !1t1l" mil w; :octintlon ;t~[( deu,nnme ¥ .. hfrllt'J 
.Illtigi"!! pl'fScmcl1on ro rul,;: T <;:ll, l""ulrr m Illumm .. mI'" 
plM.>I<m 01 anllmn" xUY.M:km ( l). Fm cDmplc. iVlf·,ml1g>.'T, 
Frr."-'!IHi'd Iw DC, In !Iv' .h>m~£ "f mn,.,. ,1gr",k l"li.li\. 
illdu,'!,§ !;} if:UI"!(.k. ,llld Lf~lkq1l0lfJy II III l!, Jilllbl'lt Jicr, ~1r't. C<>n· 
n:t<lcJy, III ;::;:yuill amrnll >nCh.,5 p.;trhogen inV,llh,U m mg· 
'ilV':> cdl dt",h, 'lllmluJlNltH SlgJ,,,k ,rlm.l.Li!.:> DC llHtuY"n0n. 
",:nv,uhm, "no 1ll1gJ411il11 J() dnmlng J}111j1h n,)(1." wb",,, lllt't 
f\l£s.etlt .u1tlgtn<; m n:an, T cdh .ald IlldtJC~ 











DC, CXjllt:SS .. Lu~ l~r"'lroiro of <Jell :;UlEta!. l~a!.ptClf"i 
whim hdp them w p4!:lfi)lm tb~jl v~riou, function,;. III p.mk· 
uin. p.uUll'll lerognitkm m;;<!.pt<Rs (PRRs) .ir<!. nllld.i.m<lllul to 
DC biology. A«ariling tOJ.!.lRW"y'S <n1gim:l hypntllesil. PRP..s 
evclved t" rE'Cngnj,le lTIlcwhi ... J hg.nds;md fUllfri()J)OO !(fdg· 
rillguish 1:Ilf~,"inu" n(s)·sdf fiZl!ll nC~I·ml~,crtnu, .~df vmh til" 
remltl:nt lnltUtwn of ld.>.pnve itnmuniry (+. i). Fm ... long 
nme this theOly ,,~~med to hold rm.,. ~nd H!pm'ts ~m.~ged 
thll! v;niol1s PRR" such ;1.4 Tcll·Jjh lootpt015 (ru~s). C·t}'pi': 
loctin r~repu.it~ (CUls). nud~CJIJd~·cljg(cn"ri2ll!nn domJJn 
(Nod) ~1.k~ H:oepr.<11" (NI..R.<;.). loo rmnok ... dd·mdudbl~ gm~ 
I (RIG-I)·Jlh rereptm~ (!.U .. n.,). did le::ognl1~ polth<'>gCIH!;$O' 
olrod mol4!cul,u pmi1fnJi (I'A.'vIPs) lnd conldtndoc;J immune 
re;poIHH. TI..R., _.re th~ tlat d.ass of relll1l4! PRR, deS(l'il1>.'d 
md .ue pt~m It th<!. cdl sUJfk~ at v.ithln mdQlomei. Th<ly 
H.::ognlJle microbUl components JaJd pt.y J. Cl'llCW 
l<ll* m InlIDunlty molt h.1S ~e!l Ie"'" .... ''''''' ",.xtemlvdy /!1;.;!-
wbme (Ii. 7). CLI\., c'-lmpliS!! bc;th ,,<lIu ble ,And II ~nlIDemhl me 
l«:cptms md em 1~mgn!7.~ .. wj~ flns .. of c4!b()bydl"~re 
stfucmns on p.Mbogtns. NI..R<. ,llld Rr..R.~ .!Ji' mn1.<:clluln cr.o-
"ill'; li!«ptors lIlvolved pnn14!ily in !,h", di',i'Ctit)fl of b.lCre.rl~ 
md .imse; lcsp.-,crivdy (Il-Ifi). A,sour uoo~l':'L\ndil)g of tlw:>e 
l>OC>0pr.<115 his ,izepe.fJoo, 1! h~ h"mn-.r n,,£l('s,,;wy to W(~I,ldi'l 
J,u:..!W,lY\ migm.d the,,!y, FOl mstm",. it is row LTJOwn ID.lt 
lh,' b .. c{aW bgm';:.; h;cnglliud tty n.Il.s ,IN, Ilf,! unklUt' !<) 
p.tthoger,; but He "ho r«(,sem (oil cmmnmw mJo'(,o:tg.!ll 
Isms. Fa exmlpll!. ,rudie~ h;"vi: leV\~4J"d th,&!: TI.R s1gr.ll.hng 
mducoo hy c()mm;1n~l b,;cwr!" hJ6 .. 11 ""jIf:!ltl;d ml.e in moUn-
utnlng "plmcli.:il homzos.t.lsi..~. md pt,)wction fl<1m dir<la q:ll-
the boll Il:qmy (i 1 .... ; 7). Fmtbenn",,,. gro""ng ~vidi'nc;; 
mgge5u r1'.01 ~ 1"'Jl<Jl1d t<l €ooogenou£ Hg.mdi whim J:/<o 
rcle4l4!:d fft.-,m. Of' j!Xjl';)6.ed on th,~ ~UJb.:<'! of d\ing aU>. F<H 
eXJ:mple th<"! ClRs. Minck md G.EC9A. \""€H: b0th shawn m 
r«ognjlfj' lig~nd> nn n,xrooc cell,; ",ilh the )'f,mlUIlI "mH' 
tiOIl {,f .. dqmve immullirr (lB, !9). II hJ.~ •. )so b~n d<!.ll¥!ll· 
str,&!:ed th4I TI..R.< em re5~md :<) endogenous ligmdi whkh 
Me tcl.e.l&~d dllrtl1g h';;POI1~ md ll<SI.W 
dlm:tge. ()n~ eumple is the inducriol1 of ~jgrujjl'>g aoo DC 
JoCrtv.l.ti('!n ",,a TI.R2 .. nd!ol TI.R4 l~rogl'ljtiOI1 of hy .. JUfOU.lr, 
(lO·-22J. Fin;dly, l'r Iii b"o:nnll'>g jTOCH-aMl'>gly "pp.uem ID4l: thi: 
h'!C;)guirkill of ~ndc..geu ... :JU; I1g .. ndi by' ~luJn I'F:.R.i mm:rlt:.-
uti!;; Ul lmmUll<: h.-nlco:'iU!i.i:S.. ThH H p,lltlculnly .rppall'li! In 
lh!' col«, .. ,f CI..R." (B). A «:lea ex .. mpll' 1s DC· SIGN. wlw:.h In 
lddlrtoo to I;JQ'gnjzjng !1evel'_d PJ.thogens, .. Ii,) btuh 
mll.l< proWUl!> md iu thH w...y medl.;;.ws Jodllol'slOO b"tw>r~n rX":, 
.!lId md(;thdld odk dul'illg DC mlg>:.illon, .rnd h<€:rw • .en IX":> 
md TaD, dmmg antigen pn~nt.u:l<}n iN). Wi! h .. w J&H~d 
.. tri!mmdous ;;mollnt .hom the immune s}-:lrem m th€: 
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20 yerm; !line;: Jam,way pmpo:'>ed the jd~ 0f PRIl., llld 11 h;l.' 
h~mm;J de» thoi! hlS hyp0th€si~ d~~ nOl mH1Il1p.l£' .Jl ",;;. 
n~rtn". Hnw("iu.;I., RUi,J,.n M<dl'J:mmr IHmlly' put Jr, 'no lhl< 
OJ}' is eWI <:ompl_ an:! (th!1:) pol rre:m H:cognltion c(,Jr,cllH 
"'ill omunu" to t.volve IDd ...,~n,ud!y lUkgr·.I(' WITh mha 
concc:pn llltO .. moti' gen<'1J;j thea,y' (1'». 
Thl! rea;pta~ 00 whim Wi': v.,JJ fiXllS In thh 1eo.1ew ... >e man· 
bel'!' of the C·ryp;: l"aln !iIlp;:d:.rtn1ly. Th~ tam 'C-<yp:')ecrJn' 
wu migin.illy usoo to desolr,e ;; gInUp of 
c.uhOOydr.u" nmdlng pl<ymn,; mutunmg J. IXlnw"V<!cd c»bc}· 
hydure lecognmon d'ID1.l1n (16. 27). OthCl pwreim COOUlU-
ing tll.- ",m<' rlom.un WO'l! ,ul>w.'lu<'ntiyldi'ntiti"d. bl1l 
c,llbs'lby-dt,U;'! ligLoos h.we noc oohln ldcntl'&d kll mmy 0f 
~~ protein,;. To this mlbigulry. tbl! t~rm C·ryp;: I~c­
un-Jllre d,)m.lln (CTID) w~s l.nn'()du~d to Id"l W sum 
dm-mln, (18. 29), The CTID if, a StrUCtl.lI.J nK,tlf whkh W;l.' 
<n1ginJ:lly id('.fitilled .IS .1 pt('!t('in tOld In the collboo}"'dnre He· 
ognltion dom.un of mmno:",-nmding k:ctln (10). The C -<yp;: 
lecrin sup;:lf..lmtiy 1$ naw d!<6noo .15 ..I tu-ge group ;of plO!eil1§ 
th,1t ~le m.:llJ.acl"iud hy ,hi' Ph-s.'IlOc' of our m mOl(, en.1X 
Borh S;C,hlhk .. lld rl""l~mcmbt.,;ne G.Il., Otl,<;! J,nd :h~ mpcrf.lll1·· 
lly U divided inlO 17 gh')UPS ro:'>ed .;m mi/l,i! phylogeny ;md 
dOlTUln OJ g;mlz ... "1tm (J t). 
f>e'pite tlll' jW","'IlCC of" highly COIH,lv<,d d(Ul~ill. CLR;; 
ne furli:ti{lIuDy di'(~,l~.e .md tuvr b.ea. l1npl1c.I!ed m y,ul<)u< 
pwc,;;sr, includillg ( .. JJ ~dh<l£im. ti.~ue inlegroll1<ill ,md 
rml1ooeling, pJ,uclG :u:mr.:mnll . .:nmple.m<llll.lCllvJ.uon, poltlh:j-· 
gm lemgnlnnn. endxytosl!i . .:md ph;;gnq10>is (n .. ·3.6). A 
ptYl/nJuent!Ole fiu CLI\.~ 1n immunity WJ" ,mgiuJJly l&ntill,cd 
in n.mmJ hiler (NK) c.::lb.. wM.re th!!y Wet f! lmpllcxM ITl 
cnntwlling h'X nlTOC1l0U in re.spc..n>e to tf'lud;11moo £rid vildly 
Illf~croo a>lh (37). nl~ jim''1:km~ ofNE: (.e.Us wu~ found t() 
b-r rontmlk:d hy paiad ClR, wblcl:\ delivel~d .ld,,~tl<ll1 ~nd 
illhUlltmy s:ign .. l>. the b.tlmCft of whim coorrolkd NK Cf:n 
fllnCtioo (38). The ldi'ntllic.au"n (f all" on mY01md rell, 
l~i"",d the pO~Slhil1ry WI the>t- mzy ,elW! Slmilu funct\Qm ill 
cmtr'oDing rellulJil ~aivJ.TIcJU in thiO\e cclls. H:lW~yet, eLR 
funCTIon ,XI mydoid cells now .1pP;:JJ'£ w be mum nhl!*' am· 
plo1X md th"5& l-emp!.tAl'" have h€:m lmplk.lVoo m ho::t. lmnlU 
nlry ,~nd ht:.rnc,-,;u,;js.. This dwJl.ry in fimnh1fl is h"",'d (., till' 
'''l',..:try nf nuny CI.R~ to recoglllu t.-dl endog<'Il(AJ, .mel 
exogencills hgmds. It Lti,...,." irnel<snllg qutstiOO. lh"U! the 
(·v(Jh.mon of such ru:rplm« ,;nd Si.IJl"!oU (',,·,Mon. ~m(mg nth 
~lS. h"" sptt:uJ.ned W! the furthet tdentit'lc.ttion of u),bge-
nm:rs lignd, .. nd :in incle,l>lug olp,pH·dol!KID of ~,m",»ulk 










nnmune <ymm ;,.< 'prjInMHy .. phySl<'lbgic d.~l'U:l1lhtL1n (62), Thi> ~rn\',lnon m~y be k.?pt m eh",>: h~' 
'Yftll1, "''lm d.::li:.n~ ,),1 ;';";1:0riLuy, ,llhd! 'ilL&], Ilnmuno:reC>2p!01 1)'U1'ljne-b.:~d inhibit01Y motif (!TD .. {H:nn-
(39) , 
Hen' w(, fen"" (~I el1"" m"t 4ft:' ''1pHs.u;d Oil rx:" PC,! 
~ll1pi<!, DEC 20S 1$ ~XJllffi$Rd Dr, ~ nllmtJel of suffi{!!>; .u 
high l~vf:l\ (jH Ul)'l)1t: mooull.l1)' DCs (CDlic" CDS'!, md 
;ruh,."" (,fp"l1phn,,,j DC, (CD! Ic" CDR· 'ph:nl<,/'l}'ll1jlh nodi' 
['!.:;, danuliinU'lsnnll DC,<. xnd Llng~hJ;fl.> ,:d, (4fi, 41) 
DE{> HI>. <I.d ''''''iilll ()!h~ C-1)-pt: lKlim ,uch "-< DKtlu, i. 
MIa. ':,11£1 tho1 MR !0 nJoJnil hll! Jo j~w, Mi'; J.l;l() i!XJlJ1l)$!\0d nn 
,;thel mydojd cdl f)iP"" ~Plrt f1'om DC, (3.',), HW{<1w:r, :wmIC 
Cl.R~ ,lH": rn;:')f-,f> h:~n'('trvf>}'i ~xpre~.'Vi;"Yi and J1~ C{"1I1~id:.'\<'l'~d 
m.ut('f" 1<)J llOIll1011;a DC 'i.lj~1:I. Pm .. x""n1''''', BD('A·2 [" 
\\<"lddy 1i:Oi:ptlOd U ~ iip«i.lk nurkln tnl humm 1'J4lim1i:)i'Wld 
DO; (pDC,) (+2.). CLEC9A h :IekGP,rdy 0XpU'SM.j hy th~ 
Cl}B:. ... IK ;mhwl I.n nl1..e :Hd m th·~ BLl<:::;"~~ pm .. !] V" ht~lUn 
<"111iv;&Ji1tnr D(\ (4-3-4,). 1..lh'i;f1m, whl>:.h W,lS Initl .. Uy 
hdwv~d 1£1 he unjqll~ HI l.J.ngelh"r1£ cdh, i$ nnw kno\'m t<1 
r,;:: i':Xl]r~~"d hy ~ P"]lul.gh·m of <:li:nnll Des (4!>-49). 
ITt·,rl s-if,;ir.g 
In il'V,'.!'..J m>:.moe:'C, OR flllh: lk~:' Ius h,,*:l1 1m k",'! tn It." prt~£· 
ina of,l ;;jgruh~ mcdf ill itc; cyk,rdu:nic Ull OllQ ,m .. hllity 
U1 cClll1'k ... ith dgn.lling cbJ.:ir,,1. fm cumpk 'ldlllCle, Decill-
2. l'!L>CA-l ;ald DC4.R, whid, dlO.n<mb"l'> (If rh£ 'Thxlln-l 
f,!THill" of Cl.R, (~j)), h.lV,~ .!lJ r,;::,m ;;hc(wn TO '!'~5,:.ci,l1~ \\<il'h Fe 
l~:e>2pt61 ./ dujn (Fe!R), m )mmlllY')"iC:CCfK<'1r 1)'lnQm:-bJo:'Vtd 
... :tlvlIlon n1f.'lUf (!TA.\{I cOllummg ,l'ilptf!! (t 8. 51-.'.4). Au 
ITA.\1 CJ;Jt~N·t{ al' J. d'.l{)u :ln1inD .1Qd 1W~U~'!Tlor; con~jng a 
dtlpllc~ of the :"':'1"''.11<.:" Yn:I..i£ 'I'mh ,1x U1 tv,"l:'jn lmi'.t'ven· 
itJg l~,idllb lYxxI.·'l.x(," WI:rHf' Y 1s rym:<m«, L 1> 
kudn;~, I h L'(,~i!ume IDa x 15 ~Ily lilSlaue J (S 5-- 57). Thf! mn-
""IVOO 'P".iln~s ~n'; lrudll£'/I"~rlJcm., l't's:idll,". ,md the 'Pl'" 
ing ho'lWHIl ttli'm "l~ "mkd 1"11 the h!nkljl:lt:,l;J f'DKrlOIl of ~n 
ITA.\>! (5.81. T:rnmuu<-U€r.:I':ptm£ wh)('n .. ainU': imncIClhlLu :lig· 
ruling thlnugh ITA.\1s mdudi: ,[·cell ,;.no 'Ef..ccll J1lugm l'<':Cqr 
!()H, JJH! Fe fe"'pt,;lIs. oJ", well E th" my1tlQld la:ep,ou 
n ... ,ntkmrd ~bClV", Slgm.Hng vu lTA.'!' H lnstig .. ti'd by lig;n-,d 
hmding wni,h lI.duc." 10('.(>pt'iI dmu:nng .. nd plh),phcwylJ" 
tino of the !TAM 1)'l{)Sln,~> by SIC kio4li<!S. Thi; phOi' 
phf.>tyuuon pr{lfI1,~,~$ h::ClUlTIn~ll of mt'mhus of ID<l Syt 
i:"'m1r nf pw!dn rpo'Clllt km .. ""., (7.AP·70 m Syk), whu:h 
jniUJ;!<1..H Hmi!'i ()fd:)v'tn£tI~m SlgtlJ:hng ev~m; b"', 51). 
ITA..\1 ,'lglHbng ofr<ID l~,mjrs in tho1 :1a:i'Nitlon or ~llulJol 
''':clp-m'l.el, Indud 'ng reB mlgn!lOn ;md .. dhlO£1m (S 9), pullif 
,nti,m aru dlfi'€lcnn.llu>n (00, 0 !), "md phJ.goo::yr<1sl5 md 
wlllng l~r.:i';ptr1l:S (:;0, S7). An l'ITM n,.:l cyrcplJ.smk SNjlH:n;:,: 
romi£ting f,f the .. mmn Jdd 1<'.>la1l<'» l/VlTiSxYxxI:l.iV, 
whe!e i is i,olrudnc., LIs kudne. S l:l s4'line, Y 1$ 1)'l,-:.;ill4', 
md x h ,lny ji1ti\due (b3. 6+). G,·,neulJy, !TIM c,~n1J.ming 
nyeptm" 4'" 1)'H"m~ ph""phmll~"'d h'y St-:: km;;>,'.s til 
HSP<ll't;;.,e to 1mlJ1uno~t:cpZtlr i:]'~glgtn)£!rft. ThB msult; In 
H'Ll1Jllmtnt ma .c.tlv.l!i'!ll of p!o~m tym$lne ph,"prutJ:;,,,~ 
q>::h :IS Shp- ,wh.idl mhibit ,,,l]uh) ;talv~llarl by d:,ph.:",. 
phoryl.l!ion <If V;UlOm imll1unoK:':';PW1-H'gulJ,red mb:m:.::e$ 
(63,64:1. 
TIl£: all:r:qJ! of p.th·",d n~prc.", on(: .,-:rlvnmy .;md rt,,· 
ntho11 lrihil:mol'V, "":liking in oolhl:k'tl"tlfm m rnsU!<i: (Dn-
rl'{l/1",d c..tlul..., H"P(~l""~ W.h p,,-,vJ.l.'nt f"3· 2 .Iong time Xlld 
".""ms ~ p!.Au,;lhle modd <,.of l(cgu)"tj{D" (6Sj. Thg m(jd:~j ,,'I 
uinl)i .w,,;a$ to hnld nu~ wtli'n '1I'1~ COn<;ld~lS th~ right lJ'flill-
I"non <1f NK ~ll JUnt'1iol1 (8). Ht)\wn~, In locmt y~"H " 
Ilumh.~r of cumpk" h"v€ '.\mcrg(rl wbldl h.lv€: qll2$tk:,md 
th" p~I:i,:bgm (S6. S7, 61'». P<:li In'U.Ile;?, It h;"i bum ;!J".,,,,,'T! 
th ... ! lTAM :rigtl..lhng undt:1 <Xlum (:()n::iiriml.> c;m mdllct n.::g., 
rtw le>p()THe:L Ol'l~ ,,,ampl,, 1$ TREM,t (:l'lggel'lJ"g lOC~ptm 
i!lqnes;ed ('.I!l mydOld ,;:ell; 2l whl,;:h ,!;'$(lCI:.::e:, V,1th til" ITAM 
,..-,maining .od"pi:ii,t' nAPl 2 (1)NAX AalvHing Pr<'~dn (£ 
t2 kDJo). TREM:-llDAPt2 dgn1.1mg W;lS .illoWTl K, mggel 
nime oXldie pwdudon ~ m .. aophJ.glOs (07,1, cyu>l"lIlt: pto· 
docticru, dlUgen uplJJ.e ~ru m!l1ll211ol> m J:)G (tiR, 69), dId 
djlfCl-e.ntl"n,lIl of n:H.",;eli:'.s (70]. fuw"'~'i<tl. n W:I:, ~!,<" 
,ho",,'T! th':H In o,ru.m cnmUli, 'I'REM. 2.tDlJ'11 :ngtlahng em 
n,',"g.;ttivdy regnhu rm . .l.Ild Pq'Rqgnating lU m.o::l('lphlg.~" 
.md lIlhlb1!mJ1J.mm.a,ary cyroJdnIC p1<1dlKl1on (71,71). Tt.'J" 
.uf'. r!l5~'~ ~.!t.4J.)''ipie~ af ITTh4·· ... Y,n!>11Ulng h".("f'1'((H''''i rh.ll funakm 
Hl ,;crlV~ cdlLllu II'''pOn""" Pf. m,t411C<', TF'J'.lJ·hl;" tfdl' 
=i1't-! (TLT·!) W .. , showll K.o entHn,.~ Fn:RI,mool.rtoo oj.· 
dum "gtllllng, ;m 011UDm,' whk.h w,;.~ d"l',md.:m on jt< 
"'i$'(l<jnion wilh SHp··l (73). n'j ... id Jim:h~)' {oml'Mxiry 1<:1 
lTA.\1/ITIM 'lgJl:llillg ffi:'ldeh, lTA..\1-lJb; m(mf~ whleh V4ry 
ff'<1m tbt 't:l,,,di:Vm.J COOSin<;US ;o:qnence juw: T1-.'lW bi"en 1<1l'n-
rtned lTl.l Tlllmbtt of re':qlt05. 
rT!\H·~;c s~"'in;i{ 
Dernll- 1 ex<1mpliliilS Jr. !TA.\t-hki' m,'flf C<fll'lt.lIT.ilng l'"(;0pt<'!t. 
II "onuins TWO :Yl'o;;!llC< In in; 9ml'I~"iinK UlJ dux .;ui' P,,\j 
ti,)nt:d in ,!T, .. :nmga:n.:m simllx; 1,) the n",llthm;,.l ITAM bm 
ll,)t COnf(Jl"lmng lOud}' w tho' consensu;; ;;"luen"c The IWO 
1)1\1;ilne$U~ If'pmpnJ.mlylp.!<:<ld, hu, th,~ N-f£ltmn:il l)<"M,dn,) 











J6 the lung, gu;, .i:lld £pJ~n. (133). On€ In'n!>ngJitlon (on· 
dudro tI .... I "[!\tenn· ! w .. , ~xp,e«ai ""dmlvcly em (j)~~' DC:' 
(Ill), but .. numoo of otblu '.:pmt\, have dem(".!Tlsll.l1ed its 
pre"q,uI"!on bnth ms,,' md mS:t~ (77. I.B-!H). Furrbf!!" 
mol'''. !J!>CUll' i We ide.mUit'd or, ,ltin·d",rlvNI mlg1' .. wl"y T.JC, 
In Ip"llph noo." dr41ntng th(.'. skin (48. I! 1. I V,). Ahh:mgll 
nd: ~.XJtmin".d in OC" ir no:; ~en ;rgJWT. thot! th" 
c:!ptw."iOO ofIRa:il)··! Qn be ,nfluenocd by vmom q:vlktn", 
,md mk:rollj.iJ u.:tms (130. 133. n6. 137). F,·.If europle 
It·4. It·n, ,!.T.d GM·CSF c.:msai !)z:a!n·! "-Xpf."ssion to he 
highly Wh€l",.H It·! fl. LPS. ;"nd dex.m"thJ.SM<' 
01)",<:1 dw,'TI"llgul;;uo{) .. :f n.-.::nrr\ ,n:.pte~!lIon (116). 
SlgmUng from !)zctin·! f£,Uawlng ligmd binding c .. n 
iuduce many "".1 lulill re<;pol"e, Inc! lldmg til". "I';:sp Ir~!my 
bur~t. DC m..rurJitlon. lig.md up~ througb progocyWii< 
,md arlocytrHis. the puJduaion af u.lc.hjd~njc meubaliti"!j\ 
.!lld v;ltjou; cr"!41i:m<s ~OO dr:mdkirliH ,\Xh Ji!i T'NF. C:XCL1. 
It·H, It-", IL-l •. md It·IO (138). In r«tom YilU;l., IDai': luve 
b<t:n !;Cv.ud Ill:.:!!,,; whkb h.-y" \('mgtt: m di!clphkJ the I:\<oc. 
tin· i indU:::i\d signalln g plIDways th~ r und!!rlk Vlnou£ ccllulll' 
ttsp'Jn$i~;i. Ekfor~ dl;;.al~Slng ib", trndlngs b<:lmv. it is w(lIib 
nol1ng lh;.u '" <:vidm<:r. cd" cro","ulk .. nd hlilrl\~hmg In V.U1<~KlS 
"f,~n"fl Is nnl'rgtng. the trJilltiond n;lll.ilb.l!lan (If ~ line .. } 
>lgnllmg p.;uhwly is givtng wJ.'f Ut th~ loMli7 .. riW th.rt rh~ 
pJ:!hw .. y< .u.: In f.:orl mur.h ll1(1H' jnmc.l!~ (139). 'fhi;; IlDkh 
tTl,,; fm Dealn· t mduc .... 1 'lgn.Julg, which in ",.n~ C,tl..:" em 
U'iggel' ;0 l>t'pnnse. direx:uy but in OChl""f C..,,,S :te'luil(;;, Ct"!<:.p€l:l-
uve slgllJ.!ing With MyDIl8-cooploo TIR,. A rurthG' of 
romplellity was H;'\t,u.l(;d by f{,cem ~'idf:.u:::e whkh shows va· 
l.thility In J)zctin·! jlgn.lling In dltrerkm mye}md ,,,,11 lYpi!" 
(l4O.14!). 
Sigll.tllng irJltuted '1M n.-.::t:U:r! l<SUl!S In acr!H.!km of 
NF-,d' mroogh bnib ibe Ch$$ICM ,md .llt£<tnJ:tive p~lhw"}"11 
(142. !"H). Th€' t:!"sc\k" ... lOl ,)l.mllk ... J p;Hhw:.y h mroiuro hy 
JCuv.l1ian of m J:ll:X (IMl hiUll of KB kinue) mmplex whICh 
C!ull'''~s the pbc.sphOl"'fl.ltlOO of Ildls reSlllring in th~l1 uhiqui-
~·I.£l'j(Li md subsequent degr.od"uon. Thoe rel!:,t,r.ed NF'I<R 
dnne» n:an.-;joQ!e m 1:Ir: DUck1H .. nd .ocrtvJi!e g<!:ne tLlI"lsoip-
riml. In DCs, ibi. p.lIhw~y h iniuJ;t£<d by HgltlOO of Decr!n·! 
whldl rt1gg0~ Sylt m4i runil<!:l .lctlv.m~:\ phcgpl:ic1lip.,sc-Cyl 
(PtC),l). le.!ding to the mg,ogt!mm! of mr; c.l$r",sr; lecnllt· 
ll);,m dcm .. ln (CARD)·comJJning pr<lh'ln. CARIJ9. which 
togt!th,-:r with Bd 10 "nd Mal!! >lgn"l flU .Ic.!iv.a:\all of th" 
rr.mscriptloo mtm NF'KR (!42. 1+4. !+5). The slgmling 
~Vt""t.> ~t lmk PLCt 1 "dntl,,!l m CAP.Ii? leil'ultnlCl1! J.l",~ 
"till UO! \:ooWTI. Hw""vcr' in lymphoc1l0~, >lgn .. hng ibmugh 
ITA..\4,u.«:Itunmg jlI'atcln~ 1,,""& to leo'ultnlC1l! tyTa;;jne 
hr,J.i<!$ thlt J£UH1€ Ptey, whleh 1n rum C"l.ll't'7.~' !t;: hydl,)· 
340 
11"'lj,; ,>I' moembuTh'.' ph"elpbolipj(j,; geneuting dj;"':rlgl)"·Ct~Hll 
(TMC,) .1'10 ino<;;\)ol, 1.4. ~tnpho"ph.ltl' (II';) \ 146). D."c, ad· 
nws PKC hc:&:ll'lu$, which tb~n .. alv .. re !hi! C..A!<D9 lci.HOO 
pUUln. OltMA t. ibe wmn .. tim of .. :ngn.tling cctn· 
ph"!X """I"lng of CAR.J.1AI. lk1l0 .• lind M.tlllfJ (146). l! h 
Hk<.'ly th.il ~ ~lhwJ;y .m,d<>g(JlH to rhis Oil!' CUlmillltillg In 
CAR..\Vd .. cr!V.Hion in l')''lnpl.:'!cyws l-e~ull" In '.::ART-'" ",nvJ,-
rion in l1'/)"ooidcdl,; (1+4), How dgn .. k .. re n .. ml1lmed fr0tn 
ibe CJ\.RD9/l!Ii:l!OJM.oJtl comple.x ro NF'KB 1, .oJS() nm Y'" 
d;'JlCtiiled. HOWI!VCl. [fom: look.>\.J;g .. [n to .;Imned p.uhWJ.Y; In 
otbn "".lk, it ,eam le..,ombl-e to ron;]d". th;>! ,be dll",,:! 
Inrer",:uon ofM.illrlO "'1ID m~ J;.j.lf't~s Tl:1fl :md 1'1',11'6 nuy 
leold VJ .. alnu;"li"' of" lXX, whICh In lympooqws reSull$ tTl 
n .. m.lo(..lti,;m ,If 1-.'F·Kfllf! the frudeu$ whn(' i1 lnilufn<:£, fi':l),> 
tI.tm<:liptiOn (!46, 141), 
It hit> le«ntl1" C<'JIl"\~ to 11gb! ibJ.! !)zain·l MgI·l.lllug vi" 1:Ir: 
CARD9 f.;Hhw;;y de:ro1h,-.1 J,b(JI,"tt j~ dlff(;lt!.nrtllly It!:gtlbud In 
mY<I!lrnd c.eJls (1 +0, 141). Fm i!x.lmpl~, Ix)!)" m.!!!"I'" dill1vro 
OC" l\C,ldcm p"lton(,;d "",Ii> ;m.;l .. lv<'nlJl' mJICwph"-ges .. al 
V.He NF'Ii:B a.oo d11Y(' T'NF:x pFJdu::non J5 dils01hro .. b.-..vc. 
whel~5 000" lrurNw derivai tll.lClnpbJ.ges. thiogJycnll.lt<l! 
~.I1d!€,d 1Il:'Cf<~,b.'Jl!?$ .. ,nd FI!Rd"lvotd r.x:, {.iU Kl de) 'Ul. Tbt. 
Ll.llu"K' te. dr1'1( pminthmm:.tm-y q'wl:lm pmducH:m b III 
lplW ofDealn· l iIlduoiYd amVH1{"lQ of thi! (',;ud'JI/l!Ii:llO/M:ild 
,jgrullng oompln (40). Thh v<iri",hlh~' 0, T;."ain·{ >lgll.il 
illg ill dlttrlHll Ct~ll p"'I'ul4l1(Jll'i l' pc>!.~nrJ.iJly ~ nwd m~(h~· 
llism by wbich my~lald (Ells em hi! M"ttJi .. (j t(l Hgnb!t 
J:numn:ot resf>:)Tlse; J.nd molY row Impllarton; fOJ' tbt.nptlll1c 
11;;£.»(140. (+l). 
In .!ddith'm tel .lc.rlVltlng NF'KB vi~ :br d.l;S.'iJal f'J.'hw~: ... 
!)zain· I j$ JJ,o ib" M: PRR ;,110'10'1'1.\ :,~ manee Syk-depi!ndmt 
,.alvnioll ,'lfNF·d~ m DC;; vi.!: tbi! "lra-n.mv;": pllhw.!.1" ( (41). 
In Ire .. l!ill"ll.iUve. or ll<'iI"l·{.loonjal p;u:hW.l;Y, ReJa-p51 dima~ 
tiJ.llik,caT£ ro Th~ Iludtus following 1m, <ll((,'S<;;\¥" ",~!v:Hknl 
of NF·KB--mdu:::ing kim"", (NIK) md lid! kin,1.\"·:X (J:ll:X:z) 
(1+8). l"ltV101lily . .llwrflillllve otCtivJ:tion of Np·dl rod h,~en 
yepmted fm <July ~ t"-w mcmb.;Ys ,11' fre T'NF l€(ltptol ruP':3' 
flmlly whl(h do !lO by a Sylt-mdi!p4:'ool!nt m.xmnl.'ill1 (149. 
t SCi). '!'h~ inn'KJCle; of Tt~ palhw.l.y which l~by5 'lgn.us fUll)) 
Sy),: 1<1 thi! JiCtiV.lti(Jll of RelB-pS 2 dimen Jernain undefin,-.1 II 
pl~m. 
A.~lt ft"Om .t('.!1VJ.!ion "f NF·..:Bin DC.>. li!:,H1Dll of Den In l 
.. 1> ... tligget~ ~riVJ:ti(1U ofth~ ll'J.n<Olptkm f"(IDI NFA'f 1n 
mJ:Cf{lph.ogl'$ ,md l)C; (14.>. ! ~I.l. T'ha 10k ofNFAT .. oo the 
g~qU~11CQ '" f '~.V<:'llts. k .. dlng !O 1t> J£:lJ v:mon J.l\~ lJ)(l!1 wd 
ddin(·i! in T cd!';. The. slgn.llmg l'"rhw"y indw::ai hy ITAM 
{("G1Uinlllg T>cclll"ttPl<'lI:\ m Iymphocytl'$ (dl>:Ctl>~d .. t.we) 










DAG Ifiln;Ui£" C:,l;'i..:.;;.dc (,f ""~nL' uSIlJring m rh" ..!cr1nn,jf, of 
NF'ld'J, Th.' "cnon (If IP, 1IlI1ht,'$ .. moth"l slgnJ,hng pa.thw.y 
hy mgg.~rrng ITe I>i:)e.l"" of'.:..loum VitH (C.,l+) fwm Iml.iCi!J-
lulu '!OIC! whidl In rum nigger$ tl:v2 opommg of c., , .. chm-
l),'h jn rhe rum);!. m,,'mhl-;m,' li!slllring in fl,e m;clnttJHll(lt of 
1bt~ IOtl("M.!i>£-:d k:v(:k .ri lnn'...«.i'.liuljj' (:t: .... , Tht'i h';·~Ult..; m the 
l4:rtv~tKm d'tnc pl")$pb;u ... ~~ aldnr;min which d~phoipbClty­
bows NFAT ttm:I-Cllpuon fM:t<'lt"i. ]eiding ffi then nocl(;H tran,,· 
hCJ.ti,on ,IDa H:gllbtion of gene .e:qlte".<ion (!!il. 153). 
AlrrEmgh roc >.ign"lng {!Vel1ts li;r.l:1ng Deml1' sJgn<.!mg WIth 
NFAT aCl1vHkro in myeJoid cdJ, OCCllI", via ,); juthw.>Y.<D..I.k" 
gnu; to the (jn~ dc:,C/lr.::d lor T 0i:lk. Thh i£ .ill the mOl'" Hkdy 
<iIK'- '}111os<.n h"" h,"'l) H1JQn{'d tn nlgg{'j cildun1 !lux .llla 
De.:: tin- h tn<1W!'! ~:) '1g1l.lJ vL Syl m nncropbJ.gffi IDd DC, 
{t+S. h+.'55j.Deain·! moojJ.t<\d.u::nv;itj(lnofNFATI~n' 
1.11)(:, CY'doOxyg"ruf~2 ~nd proouglmJll'l fJh1duaion m m..:-
lOprugts.lnd rb.: mduCtioll "f rL·2. It·ln. md rL-B In Des 
(hil_ 
l! h;l£ .1.)$0 be;m ,~h(J\Vll thJ:l C£lt.;!Jn ;;cJlul.ll r~'P')ru;(", con· 
noiJoo Ily Deain·V~-l: £igtl,jJing :.Ill: nm d!!pcndim on 
CAE])9. F<n nmlpk. In r>c, tto<'l~ is ~·k·d'l'«'j)din! .. -::.1".1)('", 
of ERE:, " mlt0g>ell·"crlv"ttd pK>,em l:m; • .., (MAPK). thl~lllgh 
J c".rill9·mdcpelldr.nt pzhway (t 56). Anorr.cf e=pk of 
this l}I'~ of slgn..!tng h in<: in<1uC{i(m (If ph"g.:)<)"1os:h 'fl~ 
Ikrun, m DC:,. Almnllgh thh pom",,,,)' b ml fiJU~- m¥l"'J' 
';tDDd, Jt I, kno"""IT."1 l! js 3yt dq:oeoot'nl hUI One> nel{ 
l>::qUll;: (,..ARD9 (77. 142.1, III mJ£Wph"g>e1. !l<)Wew1. Denill' 
t ·m£di,ncd pb"gocr1mi, u llldua:d m .. $y.k·lndcpmde1)[ 
m.mml (5,e~ hebw). An'l1'tlfr.w ~y'N1l1. ".,.111<:h dem:m50:mxl 
the ph,gOcytK ap;,wjty of De<:tm- ! hy CXjJleSlJng th<: l<':Cq:ot(!l 
m mmwly m1l1'pl:u~;)C)'tic I1t)1ohLt.,t>. ilinw<:d thz De.::rin· i 
>1gll.lJmg Q.tl!<td aCtiv.ltkm m Cd::42 ;md h,t triggmng 
;;tun poJ~'i1erb .. tnDIl ,.00 P~u&-.lIl<',j ,;XW1!ll<ll ,ll<:Hloo m~ 
f"ltide (76). II ,1l$o,boW"d tiul: pwrun kixuse C (Pi:C) Wi' 
wqUlJ~d. Th." Pl~c1;l~)Ok of f'KC m ph-lgil<:yiOSH l!i ullde.l1; 
mw,~m. me (If 1I:I ,ubitt.ll',15. MARCKS (mym.mylmd . .it;!, 
run.,.,l1ch C·k:lll"'«: ,ut":H.~). P("'~_' "crifl (tC.I!-s·hllKtng 
XtiV1tY th.lt t~ ln1t<lNCd In Z)'n):'15.l.'fl plUg<h::Y't<:)f}15 (tS7j. 
De.::rin·\ 1> ll,><1 apa.bJe ilgmllng 'fl" Syt'lndl!-
ptnd.~m p1.thways, In m.lI::m:rru~,s, !1g2UDTI of De.::nn, t 
i'C,uh ill pJug(:C~T"':<iI!i-. ,uld rrl" 1""1)(4""'" "'quit"" the ITAM 
hk" motif MId" nUddlc nm "<"lll<l)ct' hUl dn,,, nor U''lUirt' 
Syt .uri i$ fK):i:lihly pt<)f'"g..!,ed hI' a nc,vcl kin ... ,," (74.76.77). 
rbi, 1, in conn' .. >! m rh~ Syk "'qult~mm! [.-,t rX:cr1n·! m"cb, 
.u;,d prog"',)!',,>;l;; by DC.<, diKm:«:d ~av", fu)ccntly, It W,lS 
f()1lJHi th"l T>ocrm, Iludlle:£d .. 5igll.lJing p1.thw~y thwugh rr.e 
kim:,,, R~, :to,,! w JS m('kp'~ndffit <) f th~ Syk p1.thw .. y hm 
ItH<:glJ.wd '1\-'lIh It '" thi! lev,,", ofNF·KR ;).ctin.tlon f,;)t H:gul.l' 
pmducriol1 (14-'>j. 
Cm:llJlluing l'<~,ach in rr..) fidd of r,,:hog',l1 "":i:oglli:k~l .lnd 
the :reQ[!Pt<>~ low"Wid in 1Ill1diJ.ring illlnl11rw Y"''P<n"", h.t$ 
hlghbghud trot l";;~ptot ml!"hm\atwn J:\ "'ppo,<rl 10 lCC£p' 
ml~; 1n im..1tion 15..11) nnpdlt.nlr fJc£:.1 (,f (lemon], 
ling tnfocrkm (liB. I S9). ThH mId; 011<''. £<-11 rX'(!in '. whldJ 
,IDtl·my,:oo&:tillul lnSPOIlSaI,. In "ddnjon l>:J ali"" 
.de .. numb<::r ofPAM1'l, III ::he <~JJ w.ilh offu!1gJ :h.u £ii: lir· 
ognl?,'d bf ""Vl':l..u i'RRs, wh{",~, Nx1p"unon J, l~'lll!li'd £<',1 
dUOi'm ;mn,fimg<.J immnm Ht'POlli{\:, (! 60), De,;:nn l hE 
h""n dll)v,'1l to wlboh('>tm WIth ru;:;; f<"lf '"ptini.iol qtol::in,t 
pmdocti,)n ,1I1d ~nlUlK..emt,n: of r1',,1 H~aJlll~,)ty hmsr. 1'b15 
mllJlb(luti(ll) dcI'mds on ~lJ rype, PI',! I:!x,ompl!:. Ul m. .. ao .. 
proge:;. coJJ;ili,jf~tI'f,,;;Jgn,jJjng Ily itR, .lind DH!in i )i 
u:qniH.:! fi)l TNF:x pwducri,JI) (IS. 79). In OCs. Deam-! ug· 
n.l:!ing ll<),.., Q.ll nlgg.11 TNF:t.md IL· Hlj)t(ldu.:rioo, aJrh<,ugh 
()(,Uibcu,i"" sigrioliling with TLRs N:dlJ.ll(S lh,~ H'~)0"''','' 
(ISS, !t.!). III m""mprog<", it wu :;,/'o sht,M11 :to..;: :t.:: SY'I; 
l:mJ:le p1.thw .. y l.ngg>el.~d bf L'IOCnn-t 1'.Ia'Juu\':d fC'. coll;;,bo .. 
utlVI' ugn.!lmg With TIR,. willeh 1I1dll<x,d 'll5.'Umfd r~ll 
d<:g:rJ.runnn. 10.<ulting 'iII ~nl:w.netd nuck.;"1 !lJlls,bGHlm" at 
NF-.:B (! SR). In ("".!. r>octill-! em lmeu.a v.1ili "",wI;;l 
MyDBRcoupkd TI.:R., (TI.Rl, TI.R4. rub. TUz7. TIR9) to 
mdiJ()t ptocluGioll of 1U1l11lr!le q-:<)l:1n.~:; (Ull. [58. t 62). In 
&ddm<Jn v) $)"1:, In'''''lr'''Ii<m of TI.R or,d De.::tln, t ;igmlmg 
H"lniH$ rrl~ .. rupt'~l R .. f·! (1431. Functi<'1IlJJ W')T"'l',j;,yll'l 
berwi'el1 De,;:ril1'l md TI.Rl h .. i ll.h) bi1!i'l1 j)$t.mlishcd dtmng 
progoq!!ct;is. ERK!/2 MAI'K J;Ctiv;mon or,,:! tbe S£C'lm<JI'l of 
pl<)·tntllmrn,llmy c}'mlill~ by mKf(~',b4g,,,, dulkng<rl "'irh 
my".ob..u:u!.r1.l (i 21- t B) Inde~d, ~ qudy wbid, "Ullll:ru:d 
bon~ ffi.J:U(JW dnlw:'<:l 1l1.l.:!OPtug>i's chJ;n~n~d with .l,.1}'~l.!e, 
J1um ~_; m zymos;m ilinwrd til.\! ,De.::nn·) phf:;kllly 1m-a, 
';;:1:\ <lId colo<:iJB6 wlrh TI.i'U (II! J. 
Ap4lt fU'llTI the rul.>. ["erin, I &hn COC!plnu:s With 1. num' 
b"" of (J!h.~l r!la:mu In<i;mbunl! pHltCJm. In humm DC~. mm· 
mt!l~n,m of r.l>i>::nfl, i .ind DC ·SIGN !l1ggetS th", ,nu:hld,'lllk 
Jt.:ld ¢:4&Qt:k: (t63). En nUflYiph.tgrs f>Cerin" ~ .ll~) rof'K'J)ln~~ 
Witb SIGh'll. t, the muw)~ !l<.:i1ohgu" nf DC,SIGN. duru"g 
n,mOpWfJlC IHngnltion c~f ye.,i.it (l1>+). In &ddiriOll Ie p.m~m 
t!xogmt.oo J<'<X:pl¥lr:'i. rx-ain·! <au UJlf:l.IC! "mh ren."'p4l'in<. 
J; f,unlly of pro-WIll< th.ll h,,',,~ bI1l!l1 ~blW\'l1 trl moduJ.ll<: :<iIgna! 
tlm!<ducrklfl hy Int<'r .. mng Wlth nlJJ1Y ott"'l tlIDsm .. :mbl.:m~ 











memtl1.:;n" ~!"S). ~ctill·l a-'lWO.ltes WIth Ihf.: llbiqulwu$ tet· 
IJ..~p<IDin (J)63. FunnerTllOl't. it w ... ,ho,",,"ll th.:u pil.;gocyt'6ls; 
of ]I>!":;!: p.utid<l' hy DC, W.);5 J.<x;onlpJalied by 1. deaus" in 
(J)63 ClPl":i6ion. whkh w,;.~ inhtllll .. bk by W soiuhiR ~ .. glu. 
<:'>ll. l~nll1l.llin (166 J. Alm,mgt. the fllncam:iJ cI1gnllir41ICt of 
.. ~.all'l+·(l)63 llltt'r4(![OO 1lJ.£ nm y(~ bN'fI cln<jdJ:!(:d. 11 
mly T>cpH'Sel'n PJl't of", :lignJ.!mg complex th.rr muk! mfiu!!lla! 
phlgocyrai,. Dartin·! .>lID illU:TJlCt!i v,.,th thA' immunf cdl 
~rrJ:ip,min (IB7 N$ulting in $otiliHi:;.l:!lm ,)f~ctin·l 
in the «>11 n",mhY"n!! .u1d jnhjbitioo of lR.ctln .. j medj;,;u;d 11· 
.. pTy;dllfflClll in les]Xln~ to zymaw:n <.! 67. 168). \'I1'.cth"1 
lh<! ~rr.);5p.min·~~tin·t ITJt(j'JoCti£HlS ,u'e involved ""th Dar· 
tin .. t Qllhbat.l nan "",th TI.Rs 15 nor knmiD. J.!thoogh thii!fe 
h"" N'A'.n sl',,,,ulorklh th~l reo ""f'"nllH nu y dlnaJy Jm!. the 
~ctin·! ,ind TLR signJ.!ing pathways (i67). 
futn-I and 1'lnale '('IY'IKr,<ty 
IS-gluans an cmstilUw up m 50% of fungal ()fJl w 4.11£ md .a 
rm,ntimH:d. ~tin- I r«ogni1lCs JI nmrili~r of 'f'edcs 
by W4y of itt Sp«ltldry mchH:llng Cdillthld. P:loeilllll(!~. 
!~. SoIo::hdlOOlfw, ~6Il1il" Cxcidhl6 .md P<!flic'Ollim (79. !69~ 
& 76). M~ny studies hove >I1o""n !:l:u! del«tI<"lft Of'Mlcl<'!lls om c 
g~J 'J ... 'd('s by ~cr1n· I 1""-UJI.' III th" iuitl4t1(m of prot<?ctive 
unmun" n"pnnif$ sueh ,i;\ fimg~l llpuke ,md killing hy t(1J[k 
Wdcr.Nt (':ryge.n 1Il1~.ml001;rt~, <illd the prnducti(Jo nf J't(}l«c 
n1l'C mfL.mmJllc.y q1<>1;:1n,'< .. nd dlcllml:m;'". including 
TNh. CXCL2. l1·tri, II.·!:'1. eCL3, GM·CSP. G·CSF. IDd!L6 
(74, 177). ~aln-I ;olio indu.:esthe f'lodll<:UOn ofl1·c 2 md 
!L. ! 0, cyulklne:;, w1'.<)sc 10k In fnngJ.! infectio!) 1$ kss dleX!'_ 
!L-( 0 in p.ntku];u hA'l he~n ,hawn to have inhlhn"l1i dfoclS 
on mti·fung;;l immun~ n:os.]Xlnv" (178). The:!£' cyt"kiUl's .. 1ro 
oontlihur<'! to the dev'l!lopmmt (.if legulJrrary T celk ('i'regs). 
thi: unpliGUlm.> of which J.Y<t dt«:l11Si'd ht;:l . 
m .ivl> ;;rudl.:::;, .<hl¥mgh oo! wholly ,on • .iSU':11t, h.wl' sup-
p,'gtOO "WI ~vv.lmc.., rh..rt ~ctin-! phys,i role in J,ntif1lllg;J 
lTlmmnlty. 10:;:,> of Dartin-! in mi.oo with ,i ! 2 'is\'' hadgr'ound 
Hsulred tn InCN:.l!ll:d 'iIl~ptih!llty !O SY5IX:mH: Inkc!I<lI1 ",,1th 
.. m:n\4:qu~n{f d InfumnuuHY def~<:t~ IDd d,~ae~d fung.u 
Jdlllng (tn. t 79). I:nwl>e~!lngly, k"$ d~ctin·! in mice 'WIth 
.1 C.'>7BL6 bJitkgri:lund ~ru~d no jnc:re.l~d iim.cq:Hibiluy to 
C. /ij,i:a.,,;. hIlT did exhibit mo ... ,~d sll'ICi!ptlbil1ry m l'mmll)'::I':rn$ 
ollllllJ dUl? H> dd·,.,;:t, in It.it repir.unry hUMl (170). This dis .. 
p.uity is mO'>I likcly ~am" d W ~n"tk h:.d:groonds of th., 
deJ'klem mt~. bur u/Uld .. 1m he due. 1(, dlff"l<'!.OC<:.S til the. run· 
gal $o,.ln$ md/Ol Wl111o< (Jf inkction u,,",.::L FurJlu' "vidence 
1<) 5Up]Xlrt a l<1ii: t<'1 [lectln-! 1n fung.1linfi'Oions 15 th',li'.Cf'.nl 
ldmtttiatlCln of .1 poly1nmphiim in hmn.m rkctin· I thaI is 
312 
2.smd~~d Wllb <ill incH,,,,ed ('t ll .. nd g.4'itl<1inmtlnal (fIlOO1Z,/,-
tion w1thC_iJ~ \p<'Cl~~ (ISO), 
III "ddUl<:ll1 m trlgge'mg lrmare lmmllll~. N"POlH<!<. DH!1n I 
~jS'1"J.l111g Qll .ill", i.udutt ctd.iprtv>; lllmnmlty .. lId '11'4' Ih~ fll,! 
non·TI.R PRR ~hnwn tr.1 do !i<), Darrm-! .. ctivJ.wrl dmdll!K 
cells " ... n 'In;nun' the. dlfli-remiJ.tlon of T h€lpu t 7 (Th! 7) 
,lll(1T helpel I (Thll CD4" T ('.ells ind.-:pendi;ntly (JfTI.R ~jg­
n.<Hr.g in respoo~ to CAl""" md M~iRlI &ll::aruhslf 
( 161. lSI). It h,l$ been shc ..... n th .. t RJI-l sclgtlihng hy Ixccr1n c 
t IS J. aumJ di;t~lin .. ru !D th~ indlXtion :me! l'-.oguhuan of 
tb~ Hdennt ]Xlj.u\zmg cltt<1k:lne.'i (143, I 6 ! j. Whllil 1t IS gill'" 
ilf;Jly ",cc"l:'t<?d !:l:u! th~ gell<'r.lllil£l of .. Thl ·a:ll lCe'P(Il"'~ " 
lilqtljl'ed fr)J pl(l(oc!kSl agJJnst lmoctl<JIl in h<'.l.lthy 
hmrs (i 82). rh~ 101~ ,:1£ Thi 7 cclh in mn-fungJ.J tll1mumry IS 
l.lUlC! mm~ umtlOve.nlJiL A HllIut.itr of ~rudjes IHve ,h{lWl1 J. 
delllm"llt:il h.l£ far !L-t 7 in J:Iltj.fungll immunuy (i8';, 
! S+). In mu!!.!;;!, mia? lhll de UU.lhle to mount Thl7 
l'espou9l)s J.l1I: vcry ~u:Y::)CjWihk to omphu')'"llg.r:al c.md!dhSi;; 
(I8S, IS6). FllTWfm(lr~. 'I'M? del'ldcncl' in hum.m .. l.<..d,<, 
USOd .. 1Ni ",,1rt. lHcn4M'd "us<~p[lbijjty to C. dJblCll*~ lllf.,,~tI(Q) 
\ UU. ! 8S). C<'Kldtl1am sIKh .s r<llllC of inf«tlon :md 11l(,o.lJ~ 
used nuy ;;,::mum lin !he obi;ervoo difikrGlce;; howi!V('!. 
It 17 hire nthi" .::y,okln~s an 114w: OPPO<ill!llOk, III dl<i'J.'\i' 
Fmc I'LI!l1pII:C. 1n l"'fiod ... m,l1 diiU:I<' It! i mJ.Y bio 
dthn OOH·prote.alVe OJ cie.U11,,:tjve. depeudlng on hnw 
chlunk .:nd ,{"f.ere thi'! diS;::';'!Je h (t90, ! 9 i ) _ It t.., .. k<,) h.:rn 
"flown th.u vJoCon,Ati()I}-jn.nlCf'.1 It·17,plOducmg T ccll!; clll(' 
clitial fm the U Pld reCtulUn<illl of jW'ol«tlve (lx ~ T ce Us 
llf'OO ,:luD,cnge wlm M. t\ll::aa:klsls (in). ThIs lind!ng mggl'S{s 
thn tho! Th 17 r<spCJflSi:, induced by Ul gctillg ~a:1n - t m" y t.~ 
pathngcn. 
~r.:ti!l .. 1 W,i;\ rocmdy Idmtined as motha Syl:/CARD9. 
coupled a.R th..rt lnedUl>M DC ~ti~non IDa lndufflr.m of 
Th t 71mmunll)i tn re'f'0n.,,~ m C. uolh:all> (! 'H J. f),)fUll·1 M, a 
mtcdl.1t .. , J;;',)OJ.ttal With :1'." ITAl!.i,cclDulning F.;;Ry dum 
.mo llbw$ coopling m the Syli: pathway ('I9J)- ~£pite ,blS 
di,nn.Ol diffl>lmCl> In Syk l"011innmt. D<lcr1n- 2 IDd D~<:rm·l 
m .. y be r;:>pUS"IlU!jV~' of.1 lh"lm .:1"-,, of mydoid 1':1I]H",-;OO 
lNlef'UlI"!l which <.lJ:1u! V!.t SrI: ,.nd C'.ARD9 W Uliti4U' immll 
ni,,', ,U th~ Jruthot" f>',jnlOO out ( t 9 J) . 
Aalv .. tk>£l of DC, '1'14 rJ.:crJll·c lOll .. 1<0 «»)v~n SC:kCli'd 
poplllm{)m (Jf Twg C!':lls mto 11· I 7 ·prodm:tng T ~Jh th..r 
CJXllWI: h" cl.H'iilled a, elthe- Tl~ OJ Th t 7 (dl~ {!94.1. 










Ul Tl,,!: ~xp,ahi<ltl JJld funCJ{ln (!9S, 1(6). TIegs mpJllc;;!; 
T<'ffirt()) n·ll~ "md 11.1,<, ph'hxnv~ ,{r,~ct1 in (<'lUiu ir,f~CJ<m$ 
hy U1ff;<J:l.; ()f th(jt J.ntHnfhullU.Hmy nmcrwn (! 97). Thly 
JuH~ ~jw be"n Sh(Nil\ 10 bi! e55milld ~omp{)['tnL' 0frh" m"m· 
Ol')t Pl(~(:ctiw jj)'omml1Y lX' Ct'ItJrtl' p«th():ll"lH \! 'Ill, ,9'1). On 
!.l:.e ()th"l how';, Tl,~!? W,'H~ di:mml>n.<l<x:i ~, !llllmmo.<mppN+ 
SiV'J d1.lung drSlcmlnnea c.m:hdl,;st, f, 1(0). Th",,~ ad.1.ptiv~ 
mll'flllrH~ h'SP<lIls(:, meedllted 'i1,. Th-.:tin·! lmuin ;i<)!newhJ.t 
l)[,dLU In ton:m;, of !.l:.eil <':()llrrl!:n.:rWIl to h,:t<;, ptma::u011 m 
IHlIllUIlOPJ.t hology; hCJ\ .. ,,:vex, t! rru y !Hill m1! ,rut Di:-;:tir,-! 
mlbmnumr),; lHpOn;ie.> during 
In lddnion m drlvlllg CIN~ T·cdl {hili:H'nuJ.tiao. I:m:tm-! 
"rul)uLrtJol) ('..lB .• dS() tndn~>t (j)8+ T·.;:>;~lll~:5J)(Jn:';..i'$. OC~ W'hi<.h 
W.~h" .'rl1mll,,]?:d ""1th cmdkn. J. ;;eJOCtlw: f~··glocJl'J lll')fJEt. 
WIlI~ £1UOO m pUlin·.1I€ tbe "xpill.n':lll .. ml -difi:ZHlTJ!l1.tl<,n of 
<:Y1<l:(,Xi<. Tlpujlhc.:y,", (CU.) l",~cun>(ll" I" vm. (ih). Th~ 
PH';Q£.e u:dll? <~;f t-:TIs ln dn eo Jf$pcm,~ 15 unCk!J.l; 
rKrv~i\~IfO:. "it h.J..'i t:a~en SfK"fWll ItUt cr;s- T edt, .Ut:,: .tt~:tl1;";.lt.{~.d 
during rnfe::tlnn; .lUId an Fd~y Jo Jll<ltHllVC t01j! jn ,mne 
Q,.,,, (Wi-204). CwdLm W.l;; abo f,'lUnd r,o ... :r,H ~ p"",:m 
ld)llV.lfir £ion (.:it {~o'i~n~innng m 't1lt>. ~lkn)ng 4 'T'tOt(,J'gk 
""I")Tr;~ lh;.u W"" ,nllj,::lem w p,,'(~n .tgJrtn'l rumor d:uJ!mge 
(t h). ThiS m~y e;rpLHn ::he mtirumol:' .a:m'lry of p··~ltIGtlli. 
wtach 4)';' l.lio::d In ,::<1-'::,'1 rhil.lJ'l'· 1n ;Krnll' ronDO U;, 0.0'>). 
Alxj lhis ,;n'ar ""!:g<SB th~l f.l0Clln I "grllll,., m~y be benet'}. 
t':u.l ~'lmmlll'lorhfl''>f'-'lJrlC "g~,m", Annlx:.dY-llH;di&!ro wgu-
Ing "r I:k!crm- i .1.1;';1 It;%1.lJu~d ill dH: llldll<:tion of en 
l"ip.~mc; a.i wdl 4' CD4-~ T-ed .!.oo anlln.-,dy l<'Sp<ID1H 
(t i 1). ThiS srudy d6roon'lW.HNI ttlJ.t ,,,,1 gl!:lng to djjf",,~m DC 
;lJb!itt'> mJr.g 11.;a:p!<Jl}; <'.all jOOUUt qwHunvdy dlf!h€'nt 
jmmun£ msp:m;;a, WIrb Jlnt1·I:m:nn· t pl'.e.ti:lt~ntiJJly lJ'jg~l' 
he implKJ.Rd III V,J:tlO1li <"ulel ~umjmmun" db",,-;t5 m fum.!'" 
( l3g). 
The ,'xp'res;;iofJ of I:m:tin-, on L'C $\lh;;'~5 .ill.;;)\\> kit the 
re::ognm<'lll of timg.!l .iOO myeoblCtllll.ll ,patJ"s ~lld :hi': 
;mh'-"<J1"ern mducnm of .in rn.llKhes of ldlpnv-':: lmmlmjry. 
I:k!ctir,,, i W;l£ thi' fit};! Syt .. roupkd nOl)·TI.R f'RR d·"."Ntl t,) 
driv~ mer. H::IpOm<1S, md i1 Itl.iy Ix: tb" pr'O!Oli'J''' of .• n<1W 
d .. " furthetmom. I:k!cnn· t was the firI: '~JWmpk 
"f.a PAA thn mdmX:llnn .. :clluln StgruJlng \'l.t a ;mgk -1)N--
"In-: D4't"d ITAMlU:1.; ll1(ldf. furthi"l H'S.'&!'<'b Into the mk ,'It-
Th!7 100 THl: ftsfl>:'lI'l5tiS m fl111gl.l md lnycohlCt£11.l.J mfa::· 
non j:, r;!I.jUirl!d lx,t('H~ w" v.r1lJ fUlly undet-,n.1n.1 l.h" mk d 
f>eain - j In ,Il"", llnmtnl* h'<p(jn .. ~'. tlilt ndks -mgg.::S! ll:a: 
I:k!am- j i, pOf<'nliJ.lly.lUl inlllluj){>t:hcUp.~Jtic 1.l:rg.:1. 
CLFC9A I;;. l :YF" IT tlJlHIDcmbfJJ1C prnl:{!jn "Vlth a ,ingle 
CTID . .1 namm-emln.m" 'li:g1Dll .md" ~ylOpl;;\'lmC wi {DTJlJJn-
ing ~n IrA~1·bk~ monf ,im,lJ., VI ttllt ofDtctin--1 (44. 4-~). It 
b." ~tm h"'XI d.''£nbed "''' DNGR- t (DC, NE: kctill g1<lllp 
lOCl.;ptOl~ i) (4-S). In 1:01<:£, .JJ!>!m"tin _;plkmg gml!:llWS ,H 
],,;ar five i;;otonm of a.F.C9A. Simllu In uJ. ... d Cl.'R!.: (iJl't nf 
th(,,~ b.-. f.:mn, {(lIlt.Un;; "11 ~XOllS. ;u:.d this fium h ~.:I 1",,-(:$,.-;d 
.. ~ .. lK,n-gIY"iuYllri:d m("lh)n~l 41 !ll@ e,'.JJ :nu·!J.cc (#). COl'l-
v~.l$\~ly. a: -ii:V>t'$l i'X(Jl) veJ:\ktn whici) ~~)I'H,un:\ :lU "H.klitk1TlJJ 
;;X,]fl tn ::hI'; CTID H '"llJlIC;i,.~ J._> J. dm"::J in rbe Util _IUl !J.ci' 
(4~, >1-51. The V,lliou, lnUl1n1.; 1;';)£11mS !ll"y dHp.l.ly diffHflH 
phy\Jok'liPGiI fnna'j,)!u md cdlul:n d1,mhutiml • ...Jthol.lgh th" 
bl:> OOl 'let been "'lUlhln"d Inn;;tiglrinfl c,f,;:"lJuj"l dl£rihu-
lng ,l 0''>+- i-cd r"'r~)ll';'" hut ~lln"DEC,lO$ 
!ion of.l CDJ"" T,~lJ H,~l{lllM.' i 1 t 2). 
indue- don h;l.\ only beiTJ CJi:nl00 om f,)f rbi's-eV\lI1 "lW:O ve;r:;;inl'l of 
mlll'lnt CLF.C9A I: w,,-' found l(J be i'Xpl<:<.,,~d JJ k,w 1<-."I>(m 
pl.:lSmlCYIaid lY2, md on CD&:x· IX:$ m the ,;pleen. l).·mph 
nodt_s. JcOO rhpl1lH (43.4-5). n-,,, CD!b:+ OC~ .iN: spectdlZ<!d 
dll'iing ~U!<llmmunH:y. S;':G inK". which ,ll" g.::n{;d,:,JJly £u_" 
"'fl(lbk to dew10p ;.mlmmmlll"~ J.nmll:l>, did not devdop 
'<''f;J<. "hlm.c .alhnw;ln rhcs<: .llilmJ.l~whichc(JIl.ldh(;lnhih 
jtl'rl hy hla:k:ing fX'(lnl I (21'11». ThiS m"y IH~ H.!. l<:Wlr of 
~>I~guJ;u,,_d g<~l'h:nuon of lL-17 . .!. C)",oi:iIle whKll hg 1''''''11 
shm.·,m In bt jn"(,!.,,,d in tnt pJcrn0g<'ll1'_,l< of ".ainm J.Ulnim· 
IlllllH' dl-"''''''''' In mk.- (207). FunhHmm'l'. blorbge ",fDt<:· 
un-l GlUld ple-lY:n! nJ'llIime_nuJ ~U1mm:rmme m'HH€tinll:is, " 
Th 1/Tt. i7 .:ll."~.i:;" •. nd H h.!., b,>m !.ugg.:stotd tt,J.t I:k!ctill' 'l'nll 
pqmd.,; on!vtH:: d.1.>, I ID,)I.:.::ujt~. " raO'1i'5;, IT,0WU ... , ClC"·;-
Pl~mclu:Jon (l n. 1 d, 21)8. 1.09)-
In bllITl.'lh.'. CLF.C9A (hCLF.C9A)ls pu""m 1$ ~ gly';:"'ylJ.v.d 
hlo.:idly urs,:s:'Rd "-< .!. <mgl" llJ;Il<<:Iq)! ill m(~·1 "'1:g41', '.'.1:h 
hlgbiSt "lIJ1h'!S:;i(jll in hrJJn. lhrcmu< And Spk"';ll (44). In 
pllllpbel...J hh,)d. ha.BC9A <e.Xpl<'!i,ioll is resniCted to BDCA.'i" 
1)(;';, .. SllHUmbMt of O')14+- CDII> - m,'Q)("r"'<-. JJj umdi:.nn-
fii--.; popul.mclll of an >I- ",Ill !h "CDM + cd!>. md II o-;ll< 
(4~w4'». Little is tmo.'l'StCJoa ili<'lUt tbe BL'>C • .t,.."- pOfAlhnOll, 










th(}Ughr to he imm~Ul:'" PUOllS>flE of inre.:rv.:irbl DC" 
(1 t O~, 2 I 2), TtJes(: ~lls £150 Gqll ~il'i bIg h kv,~15 af (:D6 2L Jnd 
it h.s he,;n \U,gg;~51ed th4.t tbH m.,ty m,i\u"te the mjgr~tl"n ,'If-
RDC.A3~ DCs &«on !h~ hbod lnm iymphilld tl'C\U(, (H2), 
~d on th~ mcpresskrn of CLEC9A ,IDd ~vcul odlel 
,;MJt.:C m,nw5, 1l: li hcljevoo tha: llDCA l+ OC", n11y repl"""'nt 
.. DC Jjn~ .. g>t "'1uivJdmr to rh~, mmirll,' CDlb:'" OC 
,uh!>e! (+'1-4;, 92. 213). CDl4+CDt" m::mocyres ue 
{,£:lfl5i<1.'loo ·d.:s.sk.l;! monocyre,' ,IDa ~w h,,~v~,d !(j mJgure 
ta n~~ of intl"lmruri<ID whee DC dll'f,,!t:rn:lJ;1ion occurs 
(11+,11<;), 
A~ nl('mloll,;d. a.F.C9A ront.Jm m ITA'\f,l1\;(> motlf in ir~ 
CYlf~'l4;:"nlc uti, Y:o:L. ,",nd H mduC£:'l mtrJe"UuJa;r ;;Igrullng 
via l<>::lUlrmcm of Syl: (+4. 4!». his po""ible that Syk JSJMJC1-
oU"" with CLEC9A in .. ,tmll"'l W.ly 10 lh .. ! which m< heal pt"" 
patd fm r.l<~\-tiH' I; vu .. I:uidgtng iml'l"crJ(~l b.':Weal tw'Ct 
CI.EC9A mol(;Cnle~ {n. aOi (Fl~. I). Sp~dli<: ligJ:r'ci£ lO1 
CIK'!A b<w~ yet to h" idmtitli:d. Hr!v,'X!vo. it WJ.'> loerently 
aenloDsllJ.lOO tm. Cl..EC9A JeC!£ .. s • firi:p'!:(H f"r nocu;oc ccl15 
JJ'Hi it 1> 1htJUgb! !ha: this it In*dl;ou,d by y;,mgni110n of :. 
ubiqUlt<-~H plcl"anllNl ;Add-1J.hlJi, lig:;nd(i) tha: is Donn..JJy 
$equ<\\ger~d in h4l.l1thy crJh but b",mmll!i 6t'{)llI'A follawlng 
di'lT1lpth'lT' of ~mhr'lnc inregnry dunng nHmfiis (i9). 
CIK9A .d!iO l!"J:nl~U!'> th~ CTO>"'Pf<:'S('J)tHlfJll of di'",1 (Y:H'''''6n" 
cured mngen$ in ,l Syk-dependmt maTiOOl (! 9). ThIs i:nn£n-
thoU llthough aIC9A I, not lNluhorl for upub 
"f n<:<1m1<.: C~n m,lrcrt.l. it is nl:Q~5"'ly felt "flkjml':1''''<r1l:~' 
S<Xlurion of deld,.;:clll.'i50ci"lCd J<nl:lgelli by (:DS:!" Di.:" (! 9), 
In .oddlti(!() t;) CLEe9A ... mlhel 5rJ.;·c<1upl~d (-type le:nn. 
Minck, hl.<; ;1110 he",n slwwn TO 1;'<"ngtlix oocmth: celt, (HI), 
A, mmlioDoo, Mlnde a .. membu af tho! J)!;crm-l fJamlyof 
a.R" .illd ht;~ J)!;crlll 1. It medJ.J;!'" SrI.; ,ign .. bng b~' ;l~'jd ... "" 
ti(m With tb£, FeP,/, dWJl (18), t1 m .. y he IhoU CLFC9A ,mo 
Mind~ JJ'i! p"n af a umily of S~'l.:·>touploo protclm nut 1iJ~ 
'jnw'!'t'X!d in ,,'n~mg ,>nd m~di;ol1,ng Ih" r""f":>llii<.' 1<:1 <1('.;.d cdl< 
FUfd''-:l"Juole. Mind!! h.,lS r«,;nlly 0,>'.1) d"Mlihed «$ l 
r<>::fptOf t.'n th~ fungus lI&J .. i:H",b "nd w .. <; ,bown !(j phy 40 
crud,,} mk ill the b:romm" U:s.P<'JIH"S !(j thh p:.tlwge,n (21 6). 
ill 11gb! of re<:;mt dboilveril'£ toega!dlng a..EC9A, J)!;ctin-!, 
Ikmn·l JJ',d Mmde, it .iW<i'Air£ thlt J. p.ll.:.dlgm k emaglng 
ofSyk-coupled l1l)'~k'ld (;lq}H!"aed CLfu 11..<t 111ltdbtt recngnl-
Ikm ... .1 Imn_ ceUllI"r l~;;pon""-s to p..lthngem ,mel nl!Cloti<: 
Q!lh. 
B«,ulse CLEe9A j, J.H (:ooocync l'£<':;'PU,! ID,u h lu'gely 
1£, bath huffitn ;lnd mica. It MId! ian~ pr('JIDiMe"$.!: Undidi.M 
f';,l deUvt.ly of antigen> to DO. This T.:lttrn:laJ was ~plored 
loOCemly by tWO independem gwups:, S;me.ho ,md collugue:; 
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d!':mon:m.<t~d thlt .. mtig.;:n qmope" cov;;-"mtly c-nupli'd I:CJ ID 
ann.cLEC9A moncldoll;u mobody weN ,;ek~"l:lvcly a<l$S -pn!-
,entoo to CDS" T edk J:< ,~,' "n.1 mdu::oo lV~11l (11. 
H"p;m~:~ In th~ pr~n,'lt of .. djllV.1l11 (4,,», They .;1", dNa 
mined th~ mgenng of ,kl)ngell U1 DO VI .. CUX::9A did 1'>::.1 
Ht$llI! 111 pW!i¢n!.ilu{ln by pOC.s, ). re:mE whif.:b lhI!:y lmlbulOO 
to tb.~ f,HI th~l CI.EC9A i5I!%pf~"",~d "" v,'JY low j"vd;, on tl-."", 
cclJs i&fld th.<t ne __ the:Je$~ pTJC., JJ~ und,'11\!(){:..:! to he lrufli, 
cl"m Cl(165·pr~:''':!I'ltlng APC:; .. They thm pl<x,.~dcrl to aplow 
wh"the: CLEC9A Ulgetlng could he m .. >d 1',1\ UIDi(J( lmmuno" 
th"I"PY, In .. an«llllood. ti!ud the "f ..Intlgw 
Lugeting vLl c:t.l'.C9A lit) d!hiel' Plf''I<!1)t <1T 11 .. ,,1 tulmJ<.ln th<'11 
model. mm(ll' d"rlVl'.d pepud{!'C w,,!>t o;.v.i!cml)' mupk.i Ttl 
;mri.cLEC9A :ind .1dm:mt5!~~d k~ mle", in the pr~!iO!ll« ('J! 
.. h!>en;::~ ("t .odju1,QmJ> C,ltl~l' bctoli: 01' ~f!""j lUmOl ch.Jlmg~. 
They found th£1 lhr C11. N'Sj"otI;W5 mounted 1<5U1loo In b(~h 
mm,)l eudlc.mnn md rumm prt:vffllkm (4S). C'.J.mm,dil.1.nd 
cc~l".l:gu.a> .. !so ~hOWN1 ibJ.! u.tget"d .u.l1vel')' of mrigens 10 
Di.:, mmg ,l.oo ... CLEC9A l1Y1Dodoru! mOho.:!l!)'; indue.:..:! .. 
,mung enhln<:i!mcrn of humol'.i! immunlty ... nd e:n!l .. occrl 
CD4 mel CDS T relJ pIC~jj(,l .. rlV€ le;:p,!rj)W,jl ( ... ll. 1'IlMl(:Stingly. 
.oJ! ,:l th~ NJiH)Il.'i{es in tins iIlYe:!.ug.orlon Wfflft (,b;e:rv<rl m U'Je 
.. h!>ence of J.d:hli-nrul ",a)UvJl'J~. 
A, m"ntic«h'd "oove, CI.F.C9A h 01<,,' <If two Syk .. ormpl,;,d my" 
low aR" tm! mrotlU!'> N~mgnltKG\ ,)f n£Q'{',ru: 
cells. Stmtl,u to f)ecnn'!. CLEC9A al"" ,ngruh ,1 ... m ITA'\1, 
11k" mmlf. T! Wi.ll h". inlX:l!es.rlng to ",,-e whi!tha a.EC9A lU1TtS 
om to ronrrl,Q] 1n p .. rbogen lemgnirl<>D ... b;;s h<:£ll dit$<~llh,rl 
fc~ rxeainl, Docnn 1:, .u:..:! Minck:.. Th~ <;rudi,,< &>"O'lhoo 
"oon whlr.h mil aIC9A to t.1l!get .mrtgens to th~ CD8l:~ DC 
:ml-",('! indica!" rh.lil cr.a:9A j~ ;0 promi~jng !.ugH f,~ th,:n 
p",uUe applic.<rJons J.lld hmhe.l l""".u"eh in moose modcl, 
c£!Illd p,:.;"jhiy nm;;l.ltt 10 ,m ImITl1mcj{h.'l.!:p~1l!k ;'U.l.t0jiY I'm 
cm<:lCl 1Ilchr>lc.ll ",mng;;,. 
CL£C-2 
CLEe· 1 1:\ .. trll€ II n .. r"memhl .. nc H'o:prrJl dI'pl.o)o1ng .11!. 
e1GIJl::dlul.or CTI.D, .. sillgh' u:>.mm"mbr .. nc 10jiklfl "lid ~ ,hr.JI t 
cywpl .. smk wi U'J.lt ,,:!;{) coi1tJ.im J.:n IT A.\<! .. 1lb'!;lgn.lling 
mon[, ,lmil.or !(j th.<t d!: .. o;m boo. f,1/ Decrtn· I J.nd aIC 9A. t! 
W.15 ongmJdly jdenr!ll~d through .. mmpULlU<"ln .. J ~'T,,(:n (If 
myeloid ccl!> fc,!' C .. 'trpt kd:in-hl:xt rec"llton hom .. ll"'!r'll.> t<j 
thoS<t expl£'«OO by NK cd, (117). RT,PCR :JJl..Jy'$iJ at' full 
ltmgth hum .. n aI(>l ,MWt{j ::ru.n:,£Iipts m PBMC. h(l1l1': 










cpU don;" (1 t7), In 11llC€. rw" lim!.'l spll(;' "ui;alLS In .!ddl, 
oon v, the full-kngrh vell;JOn hav., bem ldmtitled On~, 
lum<rl meLEe, ll'i. bcb Cl«m 2 wbldl ':lK""!.'" til< llam, 
llltml:a;;ll(: u-gkm, Th" n!h,,". lLllll"d mCLF.C2C, ],,,:b (,xnns 
2 :md 4, whl("ll ,4l).i€:,\ .l fnm'<l£hlft "nd gm{:1~MS m open 
l'I!J.dlng fr;m"Je of only B2bp (218), The v;abu:i 15of,.JI1n, of 
roCLEC·l mowed d1ffaent eYprtsswn pr<)fiks and mhcdlul:u 
bc1l1zauan. All thre~ J:n!lSCl1ps wex,; expre'Mld 1n PIn",;:! 
md mannqN:\, How"va, only nx-:LEC m J.no mCLF.C·1C 
W'i:Jf' d,,,cc,,,d in .I l' ·"ell hnt:. ;,. ~o1:Jl lme . .tn,;j 1. In.l.o.aphJ:g<: 
a:lJ line, md Iimh~lm"H:, (JUly mrue·IC m p"'f"i!;onC'.tlnuc· 
IOf'h .. g<·' .l.n:i,. tlbmhlJc"ir.:<dJ line (21 8), fn 'Hrl1<f«:b~d fihl(,' 
bl;J;;<ts. hID kngt:11 mCLEC,l W.t:< eXf'",,,,,d on lh" ~11 "ltc'"". 
wfAIt mCLEC·lB .nd mO.£C-2C wele ItUlrl"d In th.1 q,o, 
rd.l.ilfL Thb lS CfU1:;l'i!.en! Vi'1th tbt'l: CY10plJ.'Ql"tK t«eJniliJ) Df 
<"t.hn 1}1H' II !U'hn..-,mtm.Di.' f"''"if/lm,;. wtlldl ha'l' t.;"n 
~",m"l1wly sphc<'t1 Ul gmo",:e YJ.lUJH:\ ud,ing th" n~m~ 
n."mhl;m~ l~gmn. j,'H t'umpk, hmn;a) Dcal ... I I$rimm E 
(LU), Surfk" itxpH;;\sbn ofCl.EC-2 h ... , hem deU1<u:'lm:1l<'d 
on p,"lph~ll bloc,;:! neutrophil; Jlld 00 pLu<tla., Wlli:lt' It W~, 
,h""",) to unOeigo diff",,,ntW gly,""Jiiyl~tlon (2!9, 210), 
Th;ll" IS ,JJ", ,,'ljI1~ "vldl":!"C<1 tIl& CLEC·2 h pri'SH,t (,n DC, 
(Itch ~ ~u:'i,1 C, Ilrl>C>D,:;j mmnllmiatlon), ,mgg<:S:1ng :J1.1: It 
H'uy IUV(; » nm.;;n(,n~ l{l]~ {n', dh"'" odb, 
rnCLEC·l Gin he cle .. wd by ,,,,nm, pf"le:!!i~$ r.::li!Lq:lng :i 
;;oJuhb fCllm nf th.~ l"':~P!{)L Thh ,';lrob]" Y,~,i{)n hkS h.,.;,n 
,bOV<1l w eldM 4' dl;;ulfidiJ,li1'lh'rl hnmodimf:ls WhKll led 
m th,: 511gge;;t;:k,n tbJ! nlll-l,mgtll meLEe,! ,.!;;n ,)ld,ts .IS 
bomochnwri. .lltllough this h.s nm h,){:n dtl'l!l.:Uy ,ht)wn 
(2 is), In fJr<:l, th., ,tnlauIw of tiw 0lIT,,;;,~Uulzr dDllum Df 
bCTEC· 2 h,,,,, b""m ,{l]ved .md arulysl£ H,vmlild ,h,u 
hCLECl apI"'oOl''; monomelic (121), H:n\,,·wl ... ~ h !Iii'. 
'4"" \\c1!1l O1:hf:'! CIA" >!Jcll H MlCt. 11 mJ,y 11.: dut tb,;, 
mmine ,m,j hum,ln 1<"lrmi diffn In Klm.' of th,~1 mm"yl.l"· 
nm 'J;p.;rnlilh'" (222. 221), 
Ibth 'lJ<k-g,'ll()lli ~l:~i Cl(>g('WU' hgJlr&i, t,f c!.B.~, 1 ruv" 
hr(ll Idennlltd, Th,' nlSl ":1V~.!!'?n"'l"i lig.md diJ:.cnhoo W.H 
tlwO:,<:ytln (210), ~ roxm pmitloo hom lh:, venom af It,,, 
1vllhyan piI npct CdlJc'lci!lZUd d.JJd.mid. EXP'l:>Il"" In 
lIKR"kxynn 1i'J.d, t:J ryw'>rm ph0"f'h<lIylJ.tinll of til" CL£C,]. 
ITA\!·lilc IMliJ( ;md Syk·d"pend.cnt pjCkule! ,lcjYal100 (DO) 
It h,u hren ;pernlMed th& JS IhodoC)tlm Ii fl)ul!in~ri,;;, hgmd 
hmding fl)"'Y inid,lt~ sulun, dtH!~Ting of rue-Ion plMelet\ 
causmg l", .. tlz.l!:ion d C}1<Jpl";lm.: ,ignalmg dOnl,j:im md 
mgrn"m.h"ic;u nfdgtl.l.llnn;ducthn (n! L OECllS likf.ly to 
l£cogrllz,;; l pr"WlUct10U; liglOO <ID rho;:k>1:t)'in,.l'i !h~ VIlnOl1l 
prO!Gn H nO! glyc(.;;ylJUd whkh ntk:s aill the p<Vl>lhlH;y nf " 
rue l'Qlt'<lh't\1nt~ lnlel;J;a:lOn t nn· 
P(),;joplll~n. ~ lun,memhr.lm $'lab<.ykclfll;.xdn mvop",d In 
J:UmUl ccll,mduood pj.1!$I~ 19l',l>eg.ttkm. J:U'jl)Gl met.Jd;:JS!', 
md l:onph..l.llc v.:,ss'>':i f0ll112,tJOn. WH leQtmly id"nrtfud J5 HI 
~r.1{)gen:'l15 lig;.u:d ft.ll r:tFj,~, 2400 it h,., b"mo:ugg(;;:<!j lb,i,l 
their intt'l:l"tion m.y b" l11\'olvoo In nJll1O! gtn\v1:h .md/m 
fl)€u;r.:t,!s (224-226), tJsing r€<:omhin.am gly,op0pnd,% to 
5mdy thi: irJ1jHJCrkm fIf heLle -2 ",,1:1:. p.,d.'lpkmn. Lu) It! .1 
(US) .::oocrodoo tlurthe imt:lllakll) W;lS c,,"rhohyd.ta!£'n~d\' 
~Md •• nd th"l "ciisl<Jyh.!oo (nt''"' Ct'g!p,;'" 'l1"lU;:;lltP on Th "2 
of po.:ioplmlTl w,,; {-$~ln2:.1 rdt H'Of!gtiil:h1n by CL!'!;::':L Thl$ 
tlrodmg 1,; in .<grecm<"!m; .... itll a wmcrm.u Slloldy :h,lT mdKJ.l€d 
th,z .m .~nd(.g""oU;; l1g;.nd is !ltdy :0 he ~ pr{)1<'in \Vlth ~ 
pI\'dnUlin;altly llfg,krivdy dUI.!!".:! bindlng '1l:11f~Cl:' (U!.J, 
HCllwtv,;,t, it r<:mJilffi UndL.tl wh~rr.n trill dlgn5J.C,Jurid~ 
""1uaK" .u(,1lC h 'i:ufi'id,:m f(ff OEe 1 hlnding, OJ whtlhn 
;a)} "fdlC fl..nhng JH:!pl1ikH·gwn.ls JJ"" m\"~ved 
G.EC,I w';$,.b" jd.~lmfii'; ,.,,~H!V,1 ,l!t:.<:hml'mtJ.::!mtlu: 
m~y cCkpm!>, ,.,ud n~rnf€l' lli<::a:lml, HN,! In>.:rop€lJ.!10il 1A1th 
DC·SIGN in phtckl$ (217), 'ft.: ;;uu.::ruJ,"; H'mgn'i~d hy 
CLE(>l on HIV, I l1il)'!lde; ne 5D til" UTm:kndh<;d HCM'''''':), 
hlnding of HIV, f ,<1 CLEC· 2, <X allred in 1:1'. .. a))",m;", of til,;, 
HIY01.ap~ pf',~:in which ltd U! the suggestion th-iT ruC2 
mJ,y n;,<:,.:tgnlZ" :1. ce,Dnlxt f.ldC4' whlet. is jYY.fllp<xJ.ted Inte) thi'. 
vi;oll ennk1)~ uI',m hudding &(8'fl Jnf(:(:Lld (clls (2:1). l: " 
w"ll kn:J""'1 tl:ut .1 Y.lJ;t l:n .. y ,)f b:)st PIOOeJIH (.on be ifKOITXl' 
fmc .. plm:dbli: IdiJ.l: thxt CLEC·); may nmgmu: J:n HIY· t 
inmtp0l,lled hfl&! f,h:;<)l, In fJl.:t, thl!re 15 t:yjdmo.~ th,ll I-:ry.( 
an ird-oct let:UJ cd:, wh~m podopJurln j;; expvss.:>d ;aId lllus 
h~n ;;llgge;wed !rut pO(hJr~"nln m~y b" lJ.:orp<x.l.N,d 111m th,; 
bud.chng vlljon k.!dmg Ul ra:',:tgfllnan hy o£e.;:" (12+, BI), 
Bt ,1, Th,: "~Jtt"3,;hn of (lEe)' <m DC:, :rzj~ til" !vJiisihlUrr 
thM OJ,(:1 nuy he i1'lVY,)w"d m Hrl'·j C.'p!llH' hy rx~, hk,' 
.;)!b<:t C11ts; induding DC·SIGN md ungel1n. '.'llll" tile mech· 
ml£llH zrf! mlllmdc.!l. lh~:tli' j, ~ gmoJJ J,('Cl\jlT;U'Ci> thea L'C, 
srGi'~ H'c,1gnmml of Hri' enhzrK'''; Dlf,'Criro of r .;:dh oy b:'s 
m !1~n> on, 131), wb"l;>l, Lmgnin,m"dJ,z<,d J>tmgrdtlim <'If 
HN, j prot«:H .. ~m$J: mk.<:rioo (13+), 
A num her of ,mdi€, h,lVt! aplm>2d ltll' dOWT,sm:,un ,ngll.llmg 
poitllw»ys jmtioiL~ hy hg.,;,thn of CLEC· 2, A,., lm~HVjn",,1 f'lfeV',' 
ml!ily. I: WJ.' SkiWTl !lur CI£Cl slgn.llmg H altkJlly dej>'n· 
d.'''1 on h<ih SHl dOlnlm:s of Sf t, :tinulzr tn Decon· (/Sy t 
;;lgn.i.ljng (SO,!. FmtrJ1Umol>e.l: WJS PJ(~h)s<:d thll d :tingle Syt 
m€~''Cllb f(Jum ~ to idg<: beTWeen rVlw CU.C ·2 leGfl1m>. )£1 I", 
n1!frn ,;ugg<:sw:d kit botll Dcctinoo! J:nd CLEC9A (44, lHl j, rt WJ.:'. 
d£o .ihown thn In JddJrtnn to Syt ph<)'pb.:lIyhnoo, :ulmnh, 
rion of CIllC,! '",:,111::, in rY,,)5l1l(: ph:upboryl.l!:ion (,f T'LCi,·2. 










dciidmtl:r.Syk, J.l1dCLEC-I trJ.l1sfeaed T-edhdclidi!ntin Syk, 
Etk (It Pl.ey! filled 1<) resp,1f)d ro llx,df.cynn, dcnwnmlting l 
01tlo.! mk for Tnt,;,) pU4~11> in med".:ing Cll'A~·! '·igulling til 
ph!~ l!':!$ (iI{), nn). On the om01 h;}J)d, J. tlUI dIm til 
l$be<ll·~sJYJIl!&l of CUC 2 Tl~rufuctoo T <ells to rbadocynn W:bii 
ot:.;uvoo in rb~ ~'fnce ofBL1>lK (ll ID'I", d<TilOnstI1UngmJ.l 
OEe. 2 lsooly f .... !tully (i!:p{,OO(mtMl mi: SIP· 76/11INK f,unily 
of .d!.pwl PWf£IDS f.in 'lgnJJlng (SO, 2H). Pl .. i':Itti w.:Jdng 
IUd dhpl .. y :w:wrely JlnPUlOO CUe. 2 dep~OOi:11I JCtlv:uI.:m 
d<1!non;n .. tiTl'~ .. role for ml~ RM:: GTI'J;'i<! in CI.EC-2 Slgrulmg 
(B6). 
OW~1<p",~,joo of CI.EC .. } in .. ao.ll Jh,,~ g<'ni'l:UOO ~"IHnru 
tlw. ,1 gIlJ,Hng Vi .. SK .. 00 Syk kin"",,, !n .. kd to hlFA T .iC!lv;ul(>ll 
(237). CO.~xpt"f~on of m" IT!M·ronw.ning pl .. elet p111",ln, 
C6td~, l€llUitOO ln lnhlhlnon ofbr,rn mmururlVl' Lnd agonl'icl-
indu<?<rl CLECI ~lgIl.lllng. 1l'", ,nnh,,,,, ,;, flhk srudy sptruh:~d 
lh41 mh lnJ.Y f\"'PH"';!nt ".n impOl"t.lnr role of Grib-B md arhH 
rnM ronUlmng pl .. !;?);!! :recqnOls 1D Inhibition of phle~l Mtti-
V,ill0l') wh.1£h H,an e$~mti .. l component of phy,k',jogk.;11 hI",,)d 
flow (B7). A fiIfth"l srucly u,amiu~d th>r df~.;:t of Jr,otilr.l 
ITIM·muuming pl.lrolet p)<,roin. PEC.A..\t-I, "Ill CI.EC- 2 'iJgn.!l-
ir.g U;Ul'lg b«h PECA.\t-! d .. fidmt miC!! md mtihooy CIDlU\-
linl::ing of PECAM·L TIm Win>:: demoonrJ.l4\:d m.u PEC..J0.1-\ 
Jl,,;, ha.s~n jnh:ihl!my~ff;!a (.Hl O.oc-l !iignJ.!mg. alm,rugh Ih~ 
rcsult> $uggfSred ih4l thi> inhibil:«,), dli;C! 13 mild .md unltkftly 
t,~ be phy,;lo!nglally rclnml (B8). Thesft srudie;; rJ.\~ the 
p"'J'i$jbillty m.n CI.EC -2 slgn.lling in D;!ur,ophlis md DC" jil ibo 
1 cguh red by ITIM-«mtiinlng l"ec.tp'klf COunie:tP,I1U 
Dtctln- t :md CI.EC··1 h~V<': m i.lelllk .. J ie'l'lfnct Cflll;Wltll'\g 
of four '.mUla add r~.S!du(S DEDG. pu;a::ding !.l:.elr Ylln 
m(l!l('. AnJ.!y,j$ 1n tun,feru:d B c.tJ], revu.kd rr"r mu:ltion 
of rh(, glycln" ri'"idll>r of O.Pr.··! '>r,ulT~d III 4. ;;lg1lttkmt 
u,juctlnll in ,igl1«hng tn H'$p<gl~ m rhodoq'llJ:! d<"1Il(!Il!lQJ.I· 
mg thi;! m<t gj'fcm~ lJi!$idn€ H impofum tar CLEC- 2 'lgmhng 
(SO). III 4 ,1milH will. m1.uncm "fmls highly ch.&rgtd dus;W)" 
III ~.:till·l w,os iMwn to ~hd:j'ich puticl< ' upuke (78). Glw!ll 
rr,~ of tilc glyCITJIC h'Sldue in CtEC-l sigruHng, 
th{· r'i;tjuiH'm€m of tilc OED dlH16' fOI r.>octi,,· t mool.\t"d 
plug<lqta\Ciol, md tbr. d.:mOll:itl:.nial'l mar (1.EC9A which J •• d:., 
sum .J. wqlltllC!' oo<ts, Ill)! m"di",lf.' plu,gocy1mls (44). it :>rem, 
highly likely th .. tbr. .. l:nlitl' of o..E(>'2 10 TMdiut phlg<l0V)-
.m iIl'i'olV'i!l ml$ hIghly m.l1gfll duSlO'. 
Al!:l:l(}ugh m.my of m" CLEC·::' ,igI)J.!Jngs.rud.<, W"l~ C.Jilliirl 
om in pI;;it;kt". lh" impntlJJlc<: elf OF,C.l fco pI<ilY.,k! ¥lJV4 
tic)n dnl1ng h>ellmW51$ ,md 1Il m~ COULle of mmmhanc €venl$ 
WJd nor ddlntd mmi ''''Iy roc,·lntly. M.ly rt ot1 dmlOI'IiOJ.wd 
lha! JJHjoody· w·gmng of elK· 2 u"lllu,d 10 (Xn:Cipl,;", ~ ... i 
highly kJ,,$ of m~ rec€pr<ll III Q1C\.1l41lng pI.;u,,)eti kit 
s.i:w.ul day, (B9). ThIS srudy d.tmoll,u..red Ih .. ! eLEe,2 j, 
not n::<jl.lilOO f(if .J.dh~SjfID of pJ.u.~1"t5 to mll.lgtl'l dnring 
thrmnhu$ f(.ltTtlJtlif41, hur t;; n«e;l,;uy fo," !illt,;,equell! ,;uhk 
.. ggreg.;w fOl'm;mnn. FUl~h.~l"lnOh'. mnh,>dy·jndncoo OK 1 
d('flCj"lXY rf'.<lll!"d ill m,7",.,.,d nnHS of mla:: mdl' 
c.mng th.lt CLEC-l pJJ.y!l a tignifianl h-M rot nannJ.! oonclsUr 
sb (B9). Th~.", f;",ul" ~Ilggt:;r th .. , eLEe! mJ.Y !l!':pH'.:<em 1. 
nnvcl IDnlb.N~nhJ;rl<: t,lJ5!"!. 
We ,",,,rolly O&momn..u:d th,.: o..EC·} h .. prugoc'{th:: 
l>:cepr,:g np:re,,<rl on neun·op!lJh WhKh all mediate U"" pu, 
dl.lctl(lll of CY'U'lblliS (219). Ahng Wirh tt.~ 
H:parr;:;d <'!XpltlOjon on DCs;. mh implie; .. rok for a..£(:·1 In 
immllnity, Fl.lum; smak, w1Jlundoubrodly O!plm~1 me PK!<:l:l<' 
f'unctioo ofCtEC· 200 OC, md ,lSi,!;" iu por.muJ.! .15 l wgtl· 
tllg mol£cllll! in lmml!llOm<i1.lptunc <;;!!mngs. 
We :;pccu!.He m.at tbr. Syk-roupkd ITA.\t-lU::e a.Rs d""'llhl!<l 
heH~ .!lC m;!milc15 of J lllg<' of my'l:hld "XJlres;oo 
H,,~pt(JI$ whldl !i1gr ... 1 '1.l. ~'k u.:! (,.ARD9 to InItl."U· a:lluLlJ 
J.C!l'i'''tK.lIl. It bas heer] <ktm,JI):>.rrmd m;u ,,)me "f me!i~ re;:"p--
toM loc('>gnl:r£ hom p41h)~ns md ll6:1oo<: cells. md 11 b, 
Ub:l}' Ih,.l Mho udngtoo\l$ ligon';, will .1,,·, 1:0;, 
lev""l,,;. TI"" dllf!:fa-t!bl r:<l"16"1'~iI" of th,,~(, CI.R;;. Oil DC <ul; 
!I.~!S m"y h~ u~i.il fi,n wgmng by,mrihodk!;, md by speelfic 
ltg:m<k. 1Il0&«d ;<;<:Im" ,mdi.~, n;;v,~ J.!1~J.d)'· yidrl<:d l'tommng 
l",ult'l ,'lim U'g,ud to rUg<,rmg thi-f<: reccptC!l$ fOT immunn·· 
rrH~U'py, lnt;c:rel1lng rnsigh!> into lmlll1ln€ fullcunn h~ve h<:rn 
lCY'<1.tlOO ", <'ill} un.lel:lunding ,.,f me~ H,aplon hJ5 
expmd<rl. jn P.lluruJ.&r mi! lmpatt.lnCe of non-TLll. l'P.Rl1 tKLh 
in imu~lllity md t",m.rtH1J$j5. 
1, ~f"'"A~ JU,L 1-"':a.e:c(";:mm cd Xmt1"l.1ti~' ,rid 
x:l~!.tc!a:: lr'f d('fi.±i;::( c.e2. P¥:t,: 1!io: 
(r.~f iOHt,!Sl ,~¥Ai1U 
~'I:B'r..o~ lC.')~J Rt'''' !:::tL-rutnd Wi#il,I6_ 
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C-type lectins and phagocytosis 
Ann M. Kerrigan. Gordon D. Brown'" 
lllstil"t~ of hil,Yllolls Di,.'(/s,' <lfI.' !If"I<'m/",. Met""I'''', Cl.s. i'iwdl y ,.If Jleallh SCWIU'CS, Unirenit,!' of c"f>! T"~"I!. Ob.'WrW{,I1',L 
C"P'" 1rm'll 7Q25. Smtih Afrim 
Abstract 
T,) re{")gnise and respond 10 pathogens, g.:rm-line encoded paHem recognition receph)fS (PRRsl bind to CHIL';eTved 
microbial slru.:tures and activate host defence systems. im:;ludmg mi.:mbial uptake by phagoq·lOsis. Phagocytosis is a 
complex process Ihal is instrumental in the control of extracellular pathogens, alld this activity is mediated hy several 
FRIts. including a number of C-type lectin.~. While some of these receptor.; have clearly been shown to mediate or 
regulate the uptake of pathogens. others are more ctln!elllious and are less well understood in terms oflhdl' pnag,lCytk 
potential. Furthermore. very lillie is known about the underlying phagocytic mechanisms. Here. we revlt.'w the 
phagocytic mks of the mannose re('eptor, Dectin"I. dendritic cell-specific rCAM grabbing n()n-integrin IDC-SIGN). 
Del-]. manHose bmding lec!lIl and surfactant proteins A and D. 
f :2008 Elsevier GmoH. All rights reserved. 
I II t rod IlctiOll 
l'hagol--ytosis is an actin..Jependen! mechanism by 
which celh (phagocyte,) ingest large particles Ihal are 
usually greater thlm O.5!Jm In diameter (Aderem and 
Underhill. 199';11. Phagocytosis is phylogenetic<llly con-
served in mammals and has evolved inlo a remarkably 
Ahbri'1'iarU*f7X (,OPD. ~b1"tmi~ t")~qru~tivl' put'nOti.;lr~ d1SVf(!i!r~ 
CTIJ). C ·r'yp< lectin~li.ke donuin~ CR, compl~m\!nt ft'ccph)C [X:, 
d>;?-miriti,,: 4..dt DC~SIG~. He 'lifA!('trl..:- fC;\\1 gr<lbhir-;g nun~lnt(!gtj.n~ 
J-'c!"R, PCl rlX'~r{flf. ftaO. iturm,l[$t,?lnbclin (;; ICA\l. int~I''iX'th:lbl 
a.dht!'"~ion 11l.Ple;Uie; iTA M~ lJ.nnlUtA)f«>eP{Of 1)ri-'J"im~hased ,K'1jv;3£,k)O 
rn-out'; Lt'S. lip(\r"nly.~cd'mru.le. \1:\5", ~tBL·~s;.sr!('t1'hXl ~dnc 
MHL. ln3UHO;e h!ooin~ leet.in; ,\1 R~ rUltnrwst.> recept.or, 
p.-tth,,"gen 3'lQ1ciakxt rncd¢cuJar rattem~ I~R R, fOCOf.~ 
n!tlon h,'\,:cp-I{)r~ ITfX+ p'enlTaxiu~ SP+ surfa>..i:;wt Jwptein, tpli·like 
roceptPf. 
*O)rrt'SJlL1nfl.Jn!! .Jutl:wr. TeLf.u.: '1 27::1 <MJ66(",~4. 
f::'mall "diln.',';.."'.,' g~H·df.'n,brl'Wn(j~ Hl'A'Cb.c,o.z~ in, D, .flrm,\-1)j. 
01 7) +2~J{5.--S~ ~~ frotit. m airel' :i~. :Wo~ Etftt"ner (j!nbH All rtghtA re~f\,¢{.t 
(kli:HUfH.6 t.lmf-,in.~bl)~.J 1,00:; 
inln.:;,l!e process. Ehe Meldmikoff was Ihe firsl III 
dell::ribe it ill 111.1;: lale nineteenth century and be was 
awarded the Nobel Prize in PhYSIOlogy or Medicine in 
190R lin his discovery. One hundred years laler, 
Metchnikofi's cellular lh~'()ry of immunity has stood the 
lest of lime. but we are now aware thai the phagocytic 
process is much more complex than originally envisioned 
und we are only just beginning to decipher Wi vurious 
mechanistic and molecular workings. 
Phagocytic ~'el!s Me involved in a number of 
biological processes. inc! uding the re.:ognilioll and 
coll!ml of lm'ading microbes. Innate pathogen n;~lx)b"ni­
lion is mediated by a series of germ-line encoded pattern 
recognition re('Cptofs (PRR.~) that are either soluble or 
membrane-bt.,,)lllld. The~e PRRs recognise .:onserved 
microbial structure;;. su(.l1 as OO(."Ierial Iipopolys:m:hlH-
ide Of fungal p-glucaus. that are known as pathogen 
aSS{)t1aled molecular patterns (PAM!'s) (Jane\\'ay lUld 










medlanb,m fm fcc.tgnition "f carl:"HhyJnllCl> by Dt:c111l-
1 is still unclear, hi)w<n't:r, it is km>w"I1 that at leas! two 
resid W:5 flan kin 11 a shallow J1Tlliwe un the pmtcin 
surface. Trp121 and His:!!:!. are crllCiall1:>r ft-g1uelln 
bindil1!\ (Adl1dli e! lll., 2(lf14). By way of ib 1I-1,-lU= 
"f!CCificity, Dectin-l can .tCilJ,.'!1i"e a number of fungal 
:>pecies, including C: alhiam.f, I' air/niL Sao:har(;my(~s 
n!reri:riai', Couldioides po:wdavii and A.rpwiJiillLf fum!-
gams {BmWTI et al .. 2ill3; Genuk et al .. :M)06; Silljn 
d al .. 2(17; Steele ;:t 111., 2!XJ3, lIX)5; Tayl"r et lit. :Miff; 
Viriyaku';'''1 d aI., 2Ot)5). 
The presence of an IT Al'.'I-like Tm>tif in the q1nplas-
mle tilll of Dettin-l initial!}' 5uj;ge>ted similarity m 
Fe/Its. Durillg FC'/R-m<:idilltW intemaliSlltion. !<TC ki-
na.,c:;. phn"pllOrylate tbe tyn>5ine re"idue~ within the 
HAM leading In retTuilmen! and l\Ctivatinn nf Syk 
kin=. Syk activllti(ln then initiates a fk ... xi of siJ;nalling 
event;<. that ultimately .e"ul! in various cellular re-
indudin_s: philgot)·tmi~ IGilrcia-Garcia and 
:M:~):!J. PI-.! kina~ is required r"r ~udnf!od 
extensi,ln and pha~~mal clo'!iure during Fc')'R-
m~diated uptake, ;u; well ll$ the p~'iml"ly mentioned 
Rbi} and Ok4:! OTPa.."l!:>, which are required fur ill.:tin 
Te{}rglmisa tion 0: i1'. 2.1. 
The ligation nf Ikctin-l at"'l tri~er:; inlr'.K:dlulru-
:>lgmllling resulting in a variety uf t-ellular T~rues, 
indudinll phagocym@>. in contrll."lltl uptake by Fe/It. 
huw<:Y~r, phagucytosi~ by lkctin-l require" phusphm-
ylatiun of only the m:mbrane pr<'llimal !}Tul>ine of the 
ITA.M-like mnlif (Herre el III., 2!X).I1. Src .kinl1l<e'; ilre 
nnly partially Ti::sponsible for Ihh, aJ< Ihe inclusion uf 
1'1'2, a :'ire kinaJ.e inhibimr, in intem.alisation experi-
menm, did not eause complete inhibitinn nf uptake. In 
;wdilitm. Syk was nm required I'm f)e';'1in-l medillt<:id 
f1'hagflC)11>5i$ ill macrnphage", indic.ating the e1isLencc: of 
novd signalling pealhwiI)'\sl (Hem el al .. 2f)(J4), On the 
(Hher hand. Syk is required. at le.a:r.t in pJm, Ihr Declin-l 
dependent uptake in dendritic edt. and in NIH-lD 
ccil" , sUgJ;e>ting that ~i,! .. nalling events initiat<:id from 
Dectin-l may differ depending uo cell I ype {Hare ct al .. 
2004; Rnge~ et al.. 2(1):)1. [lectin-l abo has a highly 
chargoo triacidic molif (DE!)) in the ITAM-like nmtif 
whidl i" requir<:d fm uptake (Underhill el ,d., 2(,05). 
Inhibititln studies h;J.vl: slwwn th:11 PI-3 kinll.'ie wns n"t 
~ntial fur f.)a:tin-l m<:idil1l1::d phaJ,'OC)tiY@S, whereas 
PKC Wll5 required. In addil];:}n. the use of dt>minant-
nega live cons Iruct~ ha VI: shown that C.lc41 and Rac-l 
arc illli"lveci. hut nut Rb" (lkfr.: .:1 al., 2004; Ucyamlt 
et nL. :!())4). The ruub: nf inlracdluiar processing of 
lkctin-l may depend nn the mnlecub.r nature vf the 
ligand, wit.h the receptor directed tn !yMlMlm"", dunng 
uptake (If th.: particulate liglmd 1)1TIll!S.ln. but rct.')·cled 
to the membr.me during uptake "j' the sHluhl;: lijzand. 
llU11inarin ()tem: eI aL, 2(1;)4), 
Other mtllc('llleli may also associate with Dectin-l 
during phagnqtl'l$is, For example, immunoprecipitatitm 
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experiment;; halie ~h{}wn thai the tetnu;;panin, CI)bJ 
ul.JCillle:> with D«tin-! {Mantegarnt el aL 2004). In 
additino, phagtlC}tl>sis (,f YCaJ.I partides by Des was 
au:umpeanied by a d¢:CTe~ in Ci){,:; eltpre!i!iinn, which 
was inhibitable by lmninill'in. Although the furu:;ti<m;tl 
~igl1ificance of a l:kctin-I-CI)b3 interaction ha$ n,'It yet 
b<:en duodall:d, it may reprc!I(:nt part .,f a silznalhng 
c{,mplex that .;:mud influen.::e phag!l<:ytU'sis I,nmwn, 
2(XJol. Dectin-l alst> rectl1,'lliscs nplitmised partido>, 
l'entruin-3 (PTX-3) '::4U~ i!!i!iregatiun ,'f 1:}11\.>J.iIn. 
leading t ... the l)cclio-I dependent illtemali~ti.mHfan 
incnas<:id number of ?.)mo;;;an particbl (Dinl7 ct aI., 
2:0(14). J>.loroova. macruphag..", e:qtrcss hilzher levels nf 
PTX-3 in the presen<'(! of ZYffi(l$l1ll and it ha" Ixen 
Miggesied that during fungal infection, J.ecreted PTX-3 
may enhan(r dcaran~e b}' <1p',nni~inl!! the l',athngen and 
facilitating im upt.Lke by Ikctin-l (Dim? <:1 aJ.. 2IJi:>l;1. 
DC .. SIG:"Il (C0209) 
IX-SIGN is a type II tran:>membi'ane f'mtein tlut is 
daJ.slfi<:id as a Gmup It C-type lectin. It a.msi~~ of an 
extracellular ("'-taminal ('Ttl), a repetitive .'>talk regi{'n 
which mediate;. n,.:el'H,r multi1'l1l:risatinn. a "ingle 
transmanbrane reJP<ln and ll. eytf'plaJ.mk IlLil within 
which a numlxr of intcrnaliJ.l1ti,m mutifs are fl'resenl 
!Fig. .n Its e~pres;~inn was. initiatiy be5c\'<:id to be 
re:l>trictW Iv immature dendrili<: cells, hut il is nHW 
KntlWn tn hc c:xpre:..-;cd on endt,thdium and scb:ted 
macruphi.lJ!ll: ilUbpopulatinns lGeijlenlxek et ill .. ::!i10ilb; 
Krutzik et aI., 2((),; Lai d al .. :lO1l6; Suilleux.:1 aI., :lilO2:; 
Tailleu.x et al .. :l:fJ051 IX-SIGN expre:~inn iii mainly 
induced by !lA, and Is negatively reguialoo ily IFNi. 
TOFt!. and de~metha5(}ne I RelluJ.(' d al .. !I)(J~). 
DC-SIGN w.a:r. origimtlly identified /1j, lL receplor fi.lT 
intercellular adhesiun mQklcuk-3 (teAM-3) that focil-
itate~ DC-mooiall:d T-o:lI pmlirerntivn alld bind~ H1V-l 
iGeiiten~k d al.. 2(J{)Oa. bj. It ha~ since Ixen fep<>rted 
that the recepH>T interal.'h with II range of path<>gm,", 
including At. rubi!rC:u/(!,fis. C albicOTu. Jlt'licobaat'" 
l'dori. S,histo.Wlffia nUlI'w'mi ;rnd A. /umiqatlls ( Appel-
mdk dill., 2t:(l3; ClU11bi et ,LI .. 2t~)S; Gdjlenbeek; et :tl., 
20ilOb. 11;)(13; Serranu-Gumez et aL. 2:OIJ4;!ailieu., et al.. 
2:1.).1; \'1Ul Die el al .. :!(~H), IX-SIGN T<:cogni_ bnth 
intermd mallnos.e hrand-Ietl ~truclure~ and tenl1inal di-
m,lIlnnses_ and the receptnr forms tetramern aiding its 
~pecifk;ty fI,r high nnnn<>s: ,}liJ,'nr.acch;uid..", (Mitchell 
el at. 1illl). 
DC-SI GN is nften described aJ. a plugtx;ytic receplm. 
·Ibi. is ennceivable given ils interoction,. .... -ith pathogenr; 
and the T'1'<:'I<n:e <>f in!ernaJi:<alioTI mntif", fdi-leucine 
mntif: tri-acidic duster. ITAM motif) in its cyk'pl.:umic 
tail {L.lmu et al .• :!OO6t Hnwever. m dall:, the cviden.::e 










inJm:"1 and ~tiU n<red" In he J<!nm!l~tmtoo c<rndusj~dy. 
Fur e.Y..l1npk a ;,tudy by SerrJ.l1{l-GHm~z. et al. ~hnw, 
tluL DC-SIGN mediilte~ d"ikiml hindinll HI" A. jumiya-
tu". cHnidia Ln immature amI mature l\.fDDC (Serrmn. 
Gnm<:l. et ;tl.. 2(04). In thi~ study, intcrnaliS<lti,m ;t,.,'i.J.y~ 
in immature /l.unx: re;>ulted in C{1nidial uptake in 
\'e."jde" IIl;'!'1 s[llin.:d fl'l}.,iti\'dy f"T DC·SIGN indicating 
il f'"renti:.d mle fm the rd:epl,lr in uptae. It ha, also 
he.:n ,hu,\\TI that OC·SIGN is present in AI. tubacliiasis 
~'a~1Jol~~ Iff !'.U>lX fraill~u~ et al" 2('(U) , Other studie~ 
hliV': "jmil;lrly mnwn cnkKaliSilunn ,,1' DC-SIGN with 
{Camhi el aL. ~lOii; Geijtenb<:ck el aL 
The de1l1{}n~trati"n of phag{>;;}ln~i" h}' u~ually 
Ilun-pha gilCyl Ie cd 15 I ran,;,ducw wit h LX: -SI<.1 N "",.mld 
he a m<'re direct way In e:tamine the phago,-)'tic 
f1' l tential nf the rea=plnT, Thi~ type nf appmoch has 
hem us:rl hy Lhlinj! et ;1I. whcre they indir.:clly 
demon"traled inkmaliSiltii10 ,.f a. m,n-pllthogenic strain 
{If F..u'/v:rio'li" wl! hy HeLa celh tmrv.fected with DC· 
SIGN (.Lllan!! ct al.. .l){JO), Inlere.;.ull,!!ly, mutatit1l1 {If 
the l}Tn"ine in the ()' tupla"mic dumain of IX ",';;ION did 
nnl affe~:t inlemali$lltinll nf E, foli i.n the.;.e a$Slly~, In a 
$uNcquen! "Iud)' , tbey used the DC-SIGN !ran:>k:ck"d 
Hd...a cdl, to demtm,tralc uptae of Y.vtTim pestis 
lLh,J.ng et it.! .. .ll(J!i). The.;.e studies gn some 'Aay ttl 
irnplirnting l)e·SIGN ail a I'hlij!<lC}1ic nxc'I'tnr, h{'lw-
ever, further w •• rk in alternative cdllines is warra.nted. 
,IS Y. p.wris ,tiM' hinds 1<> hepzml n ~ulphatc pnrleoglycan 
=plnr HIl BeLa <rIb. whkh cuntributes In ih 
inknuli>.al it,", 
I'herc ha'l:! b<:cn nn l':.'p{,rl> HI a Ilk!(;hanbm fiff IX:' 
SIGN mediakd pllagtx.')'It'l$i", HnWe\-eL activatilJn (If 
DC ·SIGN trijlger~ Rh,l-GTi-'ase (Ht.x:lga. ct :II.. 2.f)071 
making it cnnc<!i"ahl<: that Rhn cnuld he invnh-cd in 
plMgoc')'tmis mediated by this receptor. Further studic'5 
are rcquirecll<l confirm the ph1l1"{lcytic ability f DC-
SIGN ,md ducidate the underlying m.:chauisrn,,'1. 
DnA «('0302) 
DeL-l is a recently d.:><.:rihed type I tran!'JTIembrane 
jJ'H>tcln which was identified a.' :i genetic fusiuu 
"f human DLC·lOS in H.x:lgkin'h lymptH.>mJ! line" 
and i~ da..~illed as a GnlUP XV C-I}'pC! h:ctln ! KillD et 
aL 2\)lJ3; Leim"ky and Gready, :),105), The name DCl-1 
is derived fmm DEC-2.fJ5-_-.ueiakd C-Iype Je"tin·l and 
the receplt>T cmlSls.l~ Hf a singJe extrocellular CTtl), a 
short ~pao:;r r •• lk>wed by a tran.memhrane regj,-'n and a 
c)tnpla.'mic LuI cnnminin£ a pulli!i,'e tYToone-ba.;.cd 
illft!rnaJiti.,J.tion motif I Fig. 3). Human DCl-1 <hDCL-1) 
j, cxpro;;eU ,m mun'l(;ytc: .... mocmph.ages. gTanukK:yle:S 
and dendritic cdh (Ka t;1 d at .. :::\)071. The 
n.>! CHTItmn the amino acid. thllt 
dcpendent 'U,!l;aT binding in uther C-t}'pC! 1«:1 In', 
~u£)!l:'sting that it doe" nul h.a\,= cia., ... ic sugar bindinj! 
caplldty, but no endogenuu$ nT "'<>¥l!nHU' tij!and, have 
yet been id.:ntified, A r<'.Cent "too), has sht1wn that cdl 
lines trl.Ll1~feCle:d",ith I1I)CL· L efficiently phagi"-')'l",,e 
micwheaillo c{lated witl1 hDel-1 mnnocluuaJ antiho-
diC'l>. Hnwe,-ef, mOll!:H.')'k" dmved rnacmphage~ dl:r 
played rdatlve~' inefl1cient binding JlnJ ph,lj~n,;ytn"i~ 
Hf the~ autibcrly-cnated micrnhe:tds ,KaIH d ;d .. l((fi). 
Further in ritra and in I'iro ;;Iudicsare W!eded in order tn 
clanfy the f1',tmtial ph;tgflCyti..: mle nf naA, 
Soluble ('-type let'tins 
MannlJJie-binding lectin (MBt) is a Ciruup III ('-type 
1'.!\.1in helonging it} the c'lli'.!\.1ins {I{.,illl"knv et llL. 
l(Xn,l. which arc a gruup {'If ,*,lubJe ulignmmc pmtelns 
ccntaining ccIlJ!l(el1ou, regi.ms and CTU>s. MBL is 
;,e..:reteJ inti' the hk"x:l stream as a large Illultim<:rlc 
c<lmplex and is pnmllnly prndua:d by the liver, 
although t:!ther "ites of proou,1i<>n. :<uch liS the inte;>;tine. 
ha,'e been rmpnsed I Llemur;t el ;tl.. 2.fJ02j. 'rhe hasi..: 
fum;tinmu unit nf1l.H~L is a lmmutrimcr. ....,th each 
mom>mer uf all amillf}-terminal cy,sleine rich 
domain, a kmg d,'milio. &1l:l1·hdk;t.i c • .>ilod 
,,<,ii and .a single cruJ O'il!. 3), Olignmeri"atinn "I' 
trimeric ~llbuuit!; create. 11 "'.>uquet-hk.:: ,tructure and in 
>efUm. MilL cHn",i"'b ,i <>Dj!omer:" r;tngiug rmm dimer" 
In hc'{amers, It rocngnisa. carbnhydmte:\ such a., 
manm»e. gluu»e, l.-fUU11;e, ;\' -acelyl-IllJlnTH11;!Jmine 
fl!.tmNAc), and ,'\.'-a<rtyl·gluc~"",mil1<! fCiIcNAn Oli· 
gomeriMtinn of MBL enables high avidity bmding to 
repetlti\'e carbvhydrate ligand", $uch ll.' tht",/: pre>enl nil 
a "ariety "I' micmbHu surface", im:!uding f:. mg, 
Klehi.fi'lla a<"1'{Igtt!US, NeJ:uaia meningitides. Siaphyl<l-
O:lCt'!Lf aUl'<!IIB. S: pm:umo!!ia . . 4. lJlmitJa/Us alll.i C 
abinms {I),tvie~ el al.. l(t(J; Neth CI at .. 2()f){t, Schd,:rv 
ct aL 1995; l'ahnlla d aL 1'J'.15: van limmerik et aL 
l~J. 
MEL ha.' tnl:! a1padly It} mix:lify the efficiency flf 
upluke und the expre"",jon of olher pi1J1l-wcylic .",,:=""-,. 
Activatinn of the compkment ~y"tem ~ia 
ciJlteJ !~rim: pmte<lSe> {MASPl> I tDJlhl et ;11., 2fJOl; 
Kltw,!!<Uki et al .. 1%<;: Mitlsut.hita lind fujita. 1992; 
Stnver et al.. t99'.l; Thiel el al.. 19i !,!), result" in 
deposition of compkm<!nt on the micn,bial surfllce that 
call lead. tn uptake ~ia complement rec<:pton;; i Fig, I! 
{KIIWlLtiai et al.. l'IS9; Neth eI al.. 2002j, UHwevcr. 
inhibitiun of _terial gmwth a.,,,,>;;iale:d with the 
Mnl-MASP JlCtimtiull "r <wmplem(!!1t has .11:1", he.:!l 
un:ICrved, without IIny !:nbam:emenl of plla!..',(lC)tt':,;i~ 
(Ip lind lau, 2m .. rt. Thi .. inJicato; dUlt the specific 










mllUTC of Ihe memo;a! tngeL MilL can mM'influenu: 
ellpn-5..~ion of .. ther PRRs.. lL~ dem~mstmled by the 
ability of~HU. to augment the uptake .,f .'i: ml.MUf 
through the up-rel,'ulati<lU of 5QV<:I1ger receptnr A (SR.-A) 
\On<> et ;11 .. 20)6) Wig. Il. 
MIiL ha~ mso been pm~d t" function dire"tly as 
an n~njn by binding It> ~aroohydr:tle:s {l11 palhomens 
,and thell interocting with 1\ffil ~qltnrs on pllligoc:itic 
cdls. prnmotinjl; microbi,d uplak<: and :;.timulating 
immum: n:spnnscs (hg. tl. This was lirs! de,;crihed 11). 
Kuhlman et at. wnu ol:t:c:rva:! Illli! bindil1j! of MBL 10 
Sl.I1rnmwJ11.1 montevideo ftsulted in IIll Mill-dependent 
uptake by m.,llocytCc\ (I\: uhlman et ;11.. I <}g9). Thll-" 
Mill can interact directly with recep1or(S) on the 
surfJlCe nf mnnoc:ytcs and severm potential Mill 
receptms llli'"I: sin:e been pmposcd. although thdr 
liketihl>od is Mill debated ill the literature. Calmirolin 
hn., emermeu as the main camlidatc (Malhulm <:1 m .•
199()). but further studi<:s are required 10 cnnlirm its 
interactinn with Mill and iL, mle in the phaglx:ytilsis f)f 
pat h"gens. 
A =nl study hn.", s!l"wn that 1vmt m<1ditles 
C}1uli:ine rel"pon.~~ throug h a nnvd Cl.ll'penL ti"n with 
'fLR.2'ii\ ill thepnaJ,,'t}some {lpel!lL 1i)()b.~ Althuugh the 
Mimulati<>n <If the inflammatory respnnse was not 
c,!uscd by enhan\:eu phagnt)'t.u.is., lllitterial engulfment 
was requirat This "'Iudy therefore demnnstratcs the 
impmtllJlce of phagocytvMs in prnvidinj! the appropria Ie 
cdJu!ar ellvinmllleni 10 Lu::ililate CH{)perali,m b.:\wO!'Il 
ml.>l~llles (ip et a1.. 20(11). 
Surfactant protein .. 
Surfactant protons A and [) {SF-A, SP-Dl are aL'iO 
colkctinli within the Group III C-I)"flC lectin;;. Their 
basi;: structure is l'cimilar It> jI,.·ml and include" an 
amimHerminai cysteine rich domain. a cnlJagenoll-.. 
dmnain, an ~hetical coiled coil and a single CTlD. 
Th.:y are al;,n asscmhled as trimeric subunits which form 
oligomers. 51'-1) [OIT!l5 dodec.!l.nl':TlS that are ellliue-
lrosa:! 11)' a CI1lClfnrm ~lllipc (Fig. 3) lCmm:h el aI., 
19~). SoP-A I:!> prescnt mainly as {!Ctlide\:amen;; with a 
bouquet-like structure similar Iv thal .. f \>flit uli£<,mers 
(Hickling ct al.. !99S). SP-A and SpoIl arc primarily 
synthe:Soll\eu in the lun1¥> by type II alva~la. and Clara 
cd!;" fLu et ,d., 1(t)2). They are S«Tetcd intu the alveolar 
5J%l.Ot: w~re they an: the main pmtein ClHlslilucnh nf 
pulml'nary sllli·actant SP-A andSP-IJ ba."C been shown 
to interact ..... ith a wide variety {If carbohydrates and 
glyonjipi<h, but both recccptms ha~"C "mnmon and 
dj"tin.;.t ligand. .(!Cognition capa\:1tla>. For example. both 
pmtcins bind t{l gltlOO'JiC lind rnlLllnmt, hnwevcr. SP-A 
bind5 prderentially II' l.·fIlCi~S<: and ."l-acdylmanmtsa-
mine 4Haap'll1an ct ;11., 191>7; Haurum ct al.. 19'H), 
where.as SP-[} di"pJay" prefe,renlial binding 10 glUX:m.e. 
maltl-w.: and im:l1>iwl {lim el al., 1~94: f'en;.nn et aI., 
199m. Thmugh these al.bohydrll.te reco,l,'TIiti<lllll.bilities. 
both pr"!!:in.,, have been shnwn tn hind 10 a wid.: range 
nf pathnj1ll!ns. including 1'.'leuthll1umt/s dl!mniTlil,.;a, P. 
ctlrinii, ,4, fumigtwlS, M. ruh''1'cuio"fis, 5;. J»IeUI'IWI'IiGll! and 
K. fi""!lI1umi(l (lbrt>h.}m et a1., 19':18: Khuoch.lll:ldani et 
lIL 2(:.11: Madall ct al .. 1991: M.lI.riencneck et ill., 1','1':1; 
Oli:k et ill .. 200 I; Pasula el m., 1991; Yonl! el ill .. 2(xJ:\). 
L1nlike MBL, the :surfa(1ant pmtdns dn nN a(,.11~'ak the 
cnmplement ~y1>lcm. Bnwevcr_ they can fu.nction 
directly as oju,onins by binding tn microbial c.aroohy-
dnileS and interacting with l>urfactll.nt T'C\:qltOrl' nn 
pha.b"x:yticoells(LeVine eta!. 19')9; Mariencha:k ela1., 
19')9; Ofek et a1., ;Xliii}. A number t>f otndidate 
recepkm, including calreticubn have been described 
and are reviewa:! elsewhere {Gardai ct m .. ZO()J; I(j"hnre 
.::1 ;11 .. 20(6). 
Surfactant pmtdns can dm cal.lSC lIggregatii>n nf 
path,,'gens, which, d.:pendinJ!i on the pathnmen invnl\"ed. 
can ather en!l,ll.llce or inhibil mia •• bial uptake. Fm 
eumple, agj!Tegation of S. pn.'llfflonim: by 51'-1> 
stimulates mi;:mbial uptake (llarbilurn .:1 ;d .. t W8). 
whereas5P-l>medillted of P. al.riniiinhibib 
phag!JC)1nsi~ hy a1','ehllar macrupbag<.lii (,Y' on!! ei aI., 
20n.1). 
Similar tn tl.HJL, the "urbctant proteins can msn 
indirectly influence pnagoc)'tn~b by regulating expres-
sion of other p.hagtK:ytic f'nr e:rumpk. SP·A 
il1ereas<.lii the: ex-pres.:siun scavenger reoeptnr A 
r<:iilliting in an enhancement nf uptake ,~f S pnelll1wniali 
!I\:uf<muma et m .• 10(';.1-'1. SP-A can ills<' enhance FeR 
alld CIU·medi,ued phagoqlusis through unknnwn 
m:echani~m", leadinJ! I .. it« de.cripli"n ,I" :111 :1ctiv;ltiun 
ligand (fenner <!t al.. 1<),,"9). 
We have ,;o:ell Illli! a numocf nf C-I)"flC 1<:I:lin:> are 
inH>lwd in pMgndY{l!'is. Th{;'.!><! mnl«"Llics can li.m.:tion 
as pba£<1C}1ic reu:pton. as direct fir indired <>p$o"lniru.. 
and IlOme .:an a1"" mudulak cxpre..",j"l1 of i>ther 
re<:eplttn;; (Fig. lJ. In (1ertain ~S:.~, theindhidual C-
lectin fulfil", mi.re than onc ufthe>c mles. Although 
nilt in detail hen::, C-!)"flC lecuns can al"" 
c"uremtc: with nth.::r molecule:;., ;1:" in the cal;(! of MBl 
and TlR2 mcnti,mro here. In j!meml, the mechanimu; 
of pM£OCytosis by C-typc l(!Ctin." are nut >"l:T). well 
charllC.leri~a:! bUllhey arc cblrly cOlllpi:ll and "ppellr IH 
be unique tn ellCh ro::eplur. Out <11" no::e»ily, must 
stud.ies han! focu:!iOd iln particullLr receptm:, in isulation. 
but we dmuld remember that the mechanism i,e uptake 
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11$.1 INTRODUCTION 
The mnate immune f~'Sl,Xlft5(' 01 vertetlratt'S is tfIggeft'\llf a pathogl..'fI brellehe£ thi.' physkal barl1l'H 
of the host It provides a rapid but noospecitic response and i, thc first line (If defea\c. The functions 
of innate immunity arc- based nn a variety or germline-dlcoded rcceptors. \he pattern rec:ognltion 
R"\.'t'ptO[S IPR Rs) [Ij. PRRs are PIU~ins e:qm."Ssed by Ct'lI); of \he j nnale immUfle syslem thalf~'Coli­
nil2 (;Oflserved rl'lolecul~s a5sociated wllb microoial pathogens. These cnns.erved microbia! struc· 
tURS are lmmvil 1L.~ pathogen-as,socialt'd mol~1JJar pallerns (PA..1I.1Ps). The f~ognjtioo of PAMPs 
enaNe£ !he immune system !O djstinguish foreign organisms fmm cclL~ uf the ho:>t and iniliati."S a 
rapId inflammatory fl"SfAJfise. 
'Ioll-Iike receptors rn .. Rs) are a family uf PRRs invol';ed in the [tK'tll!nition 01 a broad rang.: of 
microrial structures and they :He the major m{\iecule.' through which mammal" sense infectiun ::too 
activate infhmmalory fl'Sf1(IflSes. For t'umple, TI.,R2 plJ.ys an important role in R'('ognltion and 
resp(1n.-es to fungal pathogens [2,3jandTLR4 is critical fon:iete..'tion and deartmC'e ofGram-oogati\e 
bacK'lia [41. There are Iilw several ('thee non·TLR receptors that have role" in mk.'fobial det.oc!lofl, 
including complement r~ept()fS. pentrnxins, scavenger recepKmI., classical and l1onclas);iea! C .. type 
lectias and colk'Ctins. In genernJ, hOlO'ever, the exact i'!.mcti!m of the nOfl-ll..R PRRs in the control of 
infection remalns unclear. 
An exception to thi.> is Ihe nondas1'.iclll C·type lectin receptor, Dectin·l. Dt., .. ctin·! is involvcd in 
the innate immooe (~1iponse 10 fungal pathogens;md hlL~ !:lei.'Il shown 10 bind many fungal spt'Cies, 
induding SllaFt.unm'ices 111. Candid" 151. CoccidioideS [6j. I'nel1mo0'stiJ lUll. and /u[leruifluJ 
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to mooiale fungal bin.jing, uptake. and killing 113.141. and the production or numerous cytokines 
and chem,,1kine5[2.7.t5.l6]. Studies using Dt>ctin-!-<lefidenl mice have established the essential 
mle of ~-glucan f .. 'COgnition in the development of an antifungal inllil.mflUtory response and the 
control of fungal disseminatioo in vivo [5.8]. In fa.;:L to date. I>ectin-J is the on!y example of a non· 
TLR PRR thJt can mediate it, own inlfaccl1ulaf signaling!n induc.\! a protective immufl(' response. 
This chapt .. '1' will focus on indcpt'1ldent and ClmpCfau .. ,c Signaling by Dectin-I and ilt)'W the cutren! 
Itoowk'dgc fits inll) the overall paJadigm of immullOfl"Ccplor liignalillg and pattern recognition. 
18.2 DECnN~ 1: STRUCTURE, EXPRESSION, AND LIGANDS 
Dl.'Cun-1 was originally il:k.'1ltilled lIS 11 dendritic cell specific fel't"PI.Of thal modula!cs T t'ell function 
by an unJdentilied ligand 00 lymphO<.,'ytcs 117.18). It was reidl'fltijled llS a ~glucan 
fec~ptor a "creen of a murine macropbal}~ eDNA expre..<;Sioo libra!)' with lymosan. l!. 
p-j,lUl:aJIl-m:1l extraet of Sm::tlJt1m~(es rern'is/ill' [1:2]. 1l-GIUClUIS are c1l.foohydratc polymilm with 
well...:,tuu·acl:eri.l.ro immunostilllulaWry activity that life found prifllafily in t!w cl'!lL waLls or fungi. 
but alsu in pLant~ and some bacteria 119]. Othl'f receptors such lIS eompJemem feCl..'P{Or 3 (CR3) haw 
heen implicated in ~-gluc3fi and fungal recognition !20j. However. studies using spt.'Cilic lonta· 
gonists. !)locking monoclonal antibodies. and knockout mice hav<J clearly srnJwn that Dectin-[ is the 
maj« Jj-glucan receptor 00 primafY macrophages, dendritic eells. and neutrophils [5,8.2 t i. 
[)ectin-I is a membi.'f of the noocias.sical <. ... type lectin family. It is a type II t:ransmcmbrane protein 
c(losi.sllng of a single eXlrlICellulaf lectin-like domain connectoo to a siflj,\le-pa~s transmembrane region 
by a stalk and acytop!a~mic !ail. which contains an imnll.ln;;Jf~I{)<ftyrosine·based lICtivatj{~ I.HAM)· 
like motif (FIgure IIU). It ha., a similar structure to other mcmhcrs of the noocla.~~kal C·type lectin 
family. with two signific1l.fll cX'ccpliilt1S. Firstly. there aft! 00 ~·~tclne residues in i.ts S!al~ region. imli· 
eating that it OOots n<.'II. dimerize. Secondly. the t;itoplasmic HMI-Ilke motif is 1.100$00.1 as mQl;t other 
knfl\,\'o activating nnncla."ical C·!ype If%..''tin receptors. socb as Ly490 (IympOOc}te antigen 49Di. 00 
not contlil'l cytoplasmic ITAM·like motifs. but rruller a.swciate with signaling molecules. socII as 
DAPI2. to carry out cellular actlVatiOCL 110\\1\.',,<,'1'. C-type Ioctin-like flwptOf 2 ,CLEC·2). an(J4her 
! 
ReURE 18.1 Structure ohlli! !}-glucan rnccplOf Oedin-l. D«tin·1 coo.lains an €Xtrnl:cUliiar C-typc 1..'CIin-Iikl: 
carbOOydrul~ rocc..gl'liooll domllin (0.)' ;;tillk regIOn. !l1\flslMlllbralle domain. and cytop{;mnH: tllil thlll oontllilU 
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receptor that is ellCOtk"d within the $llflli! gene clustLy as 1)a'1Jn-1. does nave a similar ITAM -Ii Ke motif 
to Dectin-l. and has aloo bet.--n shown to induce cellular lICtivation 122]. 
Oiigosaccharide micmarray tochnology has shown tilal Decun-I specilka!ly binds 13- 1.3 -linled 
glucosc OIi£rt1mers [231. Otht'f members of the nonchLS!,ical C-type lectins 00 not generally recognize 
cl.trbohydm~s_ as the:- lack th~ conserved residues im-olyed in the ligatioo of calcium that cO(1fdi-
Ilale" carbohydrate bind.ing. [Jt'Ctin-1 aiw blCks lhe,o;e conserved residues and its Ca:'-inde]J\!fJdent 
mt'Cnanism for H.'«lgnltit'fl of carboh),drate:; is still unclear. HOWe~'L'f. a stmly. whkh lnvol,OO bllld· 
ing analysis Qf 31 point mutants, revealed tllat at le~sf two residues. Trp121 and His:!:!) in til.: 
eUraceiJula.r regiilfi of Decl.in-I. are crud aJ for f!-glucan binding {241-
The !lluri!l~ form of the rt.'eeptor is t!xpressNI by' many t'eil types. I!lChH:!ill~ l1l11cmpl1llge;L 
dendritIc cells. monocytes. neutrophi!$, and a subset of splenic T cells [2:'5J. Therc are lit least 
two isoforms of murinc De-etin-I. C'ncooing the rull-Ien~th receptor and a stalkle;;.s vershll1. 
Studies have ,,!;own th;1t lymohlln binding by the .. maHer isoform is significantly weakened at 
IH'.;;er tempemtufes and them are ll!"O difference~ in tile levels of cytokine production indmx-'d 
by !ne t,,,,o isoforms, These studies indlcllte thai Declill-I isoforJ1]" are functionally distinct and 
may r,'present a m.:aos whc-relly ('('Huhr responscs to fungal inre-~!ion can be regulated !2n]. 
Structurally and functionally ~imHar uuman hoomlogs have been identified. Th", expression of 
human D.:ctin-I dlffers sligh!!y in that it is also expressed on BccUs and eosinophil£. Human 
Dectin-l mRNA is also altemaUvely splin,-'d. resulting in eight boforms. of which only two are 
functional for ~glucan binding [27J. Of the two funcLionalliuman isofnrms, the mn.,;l predomi-
flant lacks Ille stalk region [271 I Figure 18. n. and similar to the mouse. there are also te-mjJt'l"a!ure-
de-pendent differences in zymosan "inding [261. The two major human imforms a.re ~xpres.se-d 
differently in \'ariou.s cell types although the signilicance of this remains undear. It ha.'I alMl 
neen .. hown that the level of Dcctin-l expression in murine macmp!;agcs can be iniluenc(-'d by 
varinuscytokincs lim! microbial factors, Fur example !L4. lL-13. and GM -CSF cau,e Dt.'t:tin-! 
expres~i(ln to be highly upregulared. In contras.t IL-W. LPS and deumethasone callse down-
regulation of Dectin-I expression [28j. 
liD SIGNALING THROUGH ITAM·CONTAINING RECEPTORS 
Studie.> of molecules contai fling ITAM motif" h~'I'e conlrihuted lar;;:ely to Ihe etuC'i (filti 00 of patterns 
of immunorocep(of signalillg and are lJelpful woon coosidering signaling thfOl.ll1h the lTAM-Hke 
motif of l)('CUn-l. TheT cel! fi..'I."C'ptorffCR)-(.1)3 complex, the B cell fl'Ceptt)f and Ig Fe fl't:t'ptOOl 
j FeR) all signal via SfC and Syk family lj'fi)!iine kinases. phosplJatac'iC;,;, and a lIo:!.! of adaptt'r protL'in:> 
that "erve as molecul.ar linb to downstream signaling pathwa)'s. 
The activllory Fq receplors are characterized by the pre.o;eflce of an n:A.M motif in 11ll accessory 
.:nain that a.'iscdates with the feel'plor. When Fc reL'eptnOl inti.'flIct with their immunoglobulin 
ligands. Ihe extracellular oomains of the l\.'Cl'PtOI1\ aggf~att'. Tlli!i result~ in tyrosine pllosplwryla-
lion of tile ITAM motif by mem~ of the Src-kina..'iC farruly and subsequent recruitment of SH2-
• .xmt2iniog kimL't.'!i including me-mrers of tne Syk-kiruLo;e family. These early ~ ... enl~ Ifigll'er the 
initiatlon of downstrellJ11 signaling cascades that ultimat~ly lead 10 cdiuia.r activation 1:291. Such 
events include phospl,orylation and activation of pr.osphoJipa.'W C I PLc). which leads to Ca~' il:u 
and activation e·f Iloc~ar factor of actiV:1t~ T cells (NEAT) tr:mscrlpUon factor. In addition. activa-
tion ilf pro~in kina."e C iPKC) iiioform, couple ITAM-containing rec('ptnr~ 10 the ':l1,p:tse recruit-
men! oomain (CAROl proteins such as CARD 11, Such proteins form complex.:" witll the adaptors 
MALT! and BellO. k'adin!: to thl: recruitment and activation of TI"F rt'L't:ptOf aSst'lCiaK'd {ru..1or (-; 
lTRA(6). whIch in tum 1x,upics to illnibitofofKappaB kinases flKK). Activation of the IKK com-
plex ll..'Sulls in phosphorylation of an inl1ibitory' protein J~B.I~B is boone in:l complex with inact]"e 
NFtdi. Once h;B is pho.'pllofylated. it dissociates from NF .... B. 1I1l0\l.'ing the tf:ll1scrip!ioo factor to 
transtocate to the Ilucleus and induce various genes POI. The TLRs. also activllte- NFtdl. bet IltilifJl! 
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The functional TCR complex is equipped y,ith 10 .!TAM); that are pihosphorylated by Let. a Srr 
family kjfl~. fill ft'<.~"Plor engagement This allmvs rccruitml.'nt ofZAP70. a Syk family Idnu.se. ami 
phosphorylation of the adaptor molecule'); LAT and SLP·76, as wellll$ the en7}·mI.'.~ Vay and PLCyl 
1311. PKCG is subsequently recruited to the JUt.'mbrane and activall.'d. Thi~ event :lppears 10 be a 
sp.."Cilic link to the l"KI(B pathway. PKCe activates CARD II b)/ phospbt'fylating spt,'Cilic serine 
residut.'s [32]. This in tum leads to recmitment of BellO and MALTI and aetinUofl ofl"FICR 
The traditiooallTAM motif is dlarl1l1eri,R'ti by a ,·OIl.'IOO",U$ Soii.'qu~ that includes two tym.if\JeS. 
usually 10-12 amino adds apatt: Y nllLxu;.wY xxI/L The signaling rnotif or Dcctin·' is only £li gbtly 
differenl: fmm otner activatory receptol's and, ron.siMs ofYxx.:d/Lx, YnUL Given thi~ llkelif1t'£s. it was 
originally !houghl that Ilectin-I may iJgnal ill a iiimilar m:mnef to ITA~f ..... "'.Qntaimng roo.>pffirs S.UCR as. 
those de.sclibed :trove. Stud.ies have sirk.":C Sbo'wfl that while parallels can indeed be drawn between 
signaling 1Jj' I)ect.in-l and other activatory receptm. such as FqR ami TCI<. there are aL~o notable 
ditTerences (Figure 18.2). As previoo:dy nlL'l'itioned. in vitro Similes have snt1',l;n that ligand binding by 
D;,octin-l can induce many celLular respolLWS. such as pI'lagocytusis. pbos.phuiipase A2. COX2. the 
respiratory buBt and cytokine production. These \'0000'> aspect, of i)ectin·j function will be discussed 
in more detail in the subsequent sectionr;. Signaling from Dectill·l alone llppellZ'l\ to be sufficienl for 
many of these respooscs, 001 others, such as the induction ofTNJ.~ require CiJ()jX!ration through n.R2 
and signaling via MyDS8 [2.1.5.(6). While many activ:ttory receptors are known, to a&m;.i:tte with Syk 
kinase. l)ectin-! is presently the sole non-Ttl< PRR shown to signal via Sy~. Furlhermore. the as..'>iJCia-
!ion between Dectin-I and 5yt occurs via a novel illteraction im'ohing ooly roe tymsine 1151- How-
<'''''-'1'. some cellular responses induced by l:let,'tin-1. such as pll~ytosis.. do not require Syk. The 
presen~:e of Ttl< and S yk-d'l.'PL'I'idI."I'I1 and-indept,"fld.enl pathways highligh~ the ,.'omph:xity of l:let,'1in-1 
signaling. The elucidation of the signaling mech:misms ofDectill-1 has. polenllal j ~ic.ations for (1{her 








RClIIE 18.2 COOlplU'iJI<lIl 01 NFIICB activlllioll pa~s througb De .... tin-L Tl.R2. and the TCR Ih1in·! and tlI>i! 
TOt use Syk fllltlily ki~s Ie Ct'Ollpic tn !he CAROO and CARl)! 1 adaptor.!, _]Xlcti\cly. k'Willj! to Jl:5SCnJb!) ill 
!.lle TRARi cam~:\. OOj)'rndatioo o!'ltcB and NFt;H llCtinrioo. Tl.R1 Ulili7.es Ihe ~ MyDlIE aoo MAL. and 
LRAK klllllSe> tD couple 1:0 lti! TRARi cUlllpia and NHcB 3Cti·,a1ioo. Oocti!l-I aoo TLR2 cnll~iw _pooses 
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llU PHAGOCYTOSIS 
Decl.in-! tri£J:i.'rs cyto:;K('letal rearnl1lgem('1l1s Jeadin!! to particle internalization. Figure IS..' 
illustrates a Dt'fUll-l expressing celt internalizing L.llldida albicans. This phagocytk activity of 
D('Ctill·! is deperulent on the ITAM-like IOOtif in tlk! c)'topla.'imic !aBIDJ. A:& previously men-
tiOfl('1i. Ihe &ignaling motif of [){>CUo-1 dUft.'fs only slightly from the traditJonal !lAM motif {1! 
activatory receptors. However. tllis diffi.'fcnce appears to be sufficient to warmnt an alternllHve 
mechanism of internalization. It is Widely accepted that the Sfc-ITAM-Syk signaling pathway 
results in phall()(~ytosis by FcyR [34]. StudIes usinlr macrophage> deJieient in various Src li:ina.<;es 
suggest that there is a high level. of redundancy fOf t.hese enzymes, lIDO Ihllt all ofthem:lft' required 
during activation of phagocytosis by FcyR i2'U5.36]. 1l'Ie phagocytk capacity of Di.'Ctifi-l 
depends only on its membrane pmximat tyrosine residue within the ITAM-!!I\.e motif 1131. 
Declin-! beroml'S tyro.'iine phosphorylated at thi, residue upon ligaoo hindjng. However. in con· 
tra.~t to Fc-tR. SK kinaSe.> appe:lf to be only partiaHy responsible. ;,1., was shown by using PP'2. a 
SfC k:inase inhibitor wilt,s!:, inclusion in internalization assays. did not cause complete inhibition nf 
uptake I! 3J. This sug.ge&t5 (hat other kinases may be im;o(voo. Furthermore. in macropbages. 
D<.'Ctin-l-medialed phagocytosis d .. -.es nol ft'quirc Syk. This indicates the !)xistcocc 01 a nov.:! 
slgna.ling pathway flW DL'Ctin-l-medjatoo phagocy!o:>is. in macrophag("SIL'U5j. II has also Dt.>ell 
&hmm that pho~ph()ill()sitide-3 {PVI'! kiMSC is n()t essential for Dectin-l-mediatoo phagoc)'ta.<;is. 
whereas PKC. ra.'-relaled C3 I>otutinum toxin ~u!lstfale I (R:iC-I}. and Cdc42 are fC'luirN [13], 
On the other hlnd. Syk d()es have some influence 011 Dectin·l-medJated pbagocytosis in dt.'fulritk 
cells where the tin:Lw is recruited to the membrane proximal tyrosine of Ikctin·' [16). 
Dt.'Clin·1 is also involved in !he uplal;e of opsoniz,oo l)'ffI<:lSan. Penlr:lxin-?i (PTX-XI !:lind}; 10 
zymnsan md it has bct.'1l shDwn that internalization of Pl'X-3 opsonized zymosan is dependent on 
I)ectin-I [37J. Macfophages actually cxprc,.., higher Ic·vels or PTXJ mRNA in the presence of zymo-
"an and it h:iS been sllggested thal during fUllllal !nf(.'Ctinll. the PTX3 gene is actiraloo md secreted 
PTXJ may enh:illce the c!earnflC-c of the p3thog~n I :nj. Th.'Ctin·1 can al:;..'1 ft'Cognlr€ expos~d 
FIGURE tit) (see color insert imlowing page uxJ 1K'Ctin-1 mNiatl!S phagocytosis ofCartdiikJ aibicatl.l . 
... N!H·JT.; cdl e.lprc!i.,ing Pectin-, plt.1P:OCjtllS.ing Fl'rC-laheil-a C aINfl1!fS. Actin h!al1t~nts omd phaYP':YIlC 
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~-glucans on cOOlplelm.'flt opsonitA!'d zymosan and Hllas ~"Il shown that Doctil1- J IS necessary for 
infuunmalmy fL'$ponses 10 opsooizro particles [381. 
Other molecules may also associllle with Dectin-! during intemalil.ati{)n of yea.~t For example. 
it has been reponed that the !etra.~panin CD63 is imemalilA!.dwfyeastp!lagiX.ytosis.amiimmuno-
jlfecipitatioo experiments tllive shQ\\,ll that it lL~sociates with l)atin-i 139). Althoogh the functional 
significance or a Decllll-l-CD63 interaction has not yet b.."en eluddat.."I1. il may represent part of a 
st!l;naUng ('omplcx. A timctional inlel"actioo between another tctraspanin. CD3? and De;.'tin-I has 
alm ilL'Cn reported. This study demon,traied that rn.n inhibits signaling pathways leading to 
Dectin·j·medi:lted cytoline production {40I. As cells of the immune system expreM s.cverai PRRs. 
sil!nals from the ~'ariou" receph){S must be ~Iltegrated to produce an appruptiate immune respon;\<t.~. 
TIli" \.'tIfl be acliic'l'l.."d by dust..'fing immUn{)fOCL'PtlJlfS and signaling mnk."<.'Ules j aID compk'Xes using 
tetraspanins. 11:<trnspanins em laterally interact with immuOOfC'Ceptors to .. Teate ',elraspanin micro· 
domains" and cons.l.'quently regulate dowfltltream signaling {41-43]. The Docun-l·CI)6) Of CD) 7 
compiexe" are therefore quite ilkely to form pm of a larger complex that in!t.>grare, signaling frmu 
other receptors! 40j. 
18.5 CYTOSOLIC PHOSPHOLIPASE A2 ACTIVATION 
AND CYCLOOXYGENASE 2 EXPRESSION 
Zymosan lia~ long been used to investigate arachidonic acid release and metaoolism [44045J. 
ArachidorJic acid is relea",,"l1 fmm rell lTlL"IlliJnn('S by cytosolil: phospholipase A2 (cPLA,). afwr 
which it is. available for the jlfoouction of the inllammlilOry mediators, leukolriencs, and jlfost;!-
j£landins. MetliOO!ir.m of free arachidonic acid by the :S-!ifl()lyg~n3se (5-LO) pathway, or the 
cyc\oQxygnase {COX) pathway, results in the proouction of leukotrienes Of prostaglandjns. 
respectively. Recent work has shO'W'1l that Dcctin-l has 11 role in cPUl activation !l)' zymosan arul 
C. albicans 146,47j. Ligation of Dectin-l by ryIDosan and C. a/bit'.IIls also increa . .'les e~pre.ssl()n 
of CDX2 and consequently pro.'ltaglandill production. The cytoplasmic tall of Dectin-I is required 
for lymosan·iruluced arachidonic acid release alttmugh internalization is no! strictly necessary, 
Aracnidooic acid release and leukotriene proouctlon stimulated thmugn Dt.'Ctin-1 ligation is 
TLR2-independt'fll bul requires Syk. Src kinases. and PI3 kinaJie !46A7j. In contrast COX:' 
expressioo and consequent prostaglandin production are SylH!epeooem and panially TLR2· 
de(!<."fldent i 461· 
Uto RESPIRATORY BURST 
The s.ignaling cascade initialed Ily FC",R-medialed pnagocytoi>is results in activation of the respira· 
tory burst The respiratory burst involves pr()ductioo of reacti'le olygen specie., {ROSl that combat 
invading microorganism:>. and it is initiated by 100 ~ADPH oxidase enzyme. feR signaling in neutro-
pi'lilH3.USeS mi~ratioo of the varioos subunits ofNADPH oxidase to the phagosome membmnes and 
sul:ls.equcnt activation of the complex 1481. V:mous ptotein kin:l~s have been reported to activaw 
NADPH m:idasc, hut the initial signalin:;r ('Vents tm place aklllg the Src-n/\M-Syk pathway [291, 
The generation (if intracellular signals by Dt'Ctin-1 following ligand binding also result in the acti~'a· 
tion of :'-iADPH oxlda.,e and production of ROS 13. \51. It also ",,'Cms that Dectin-I can c.ooperal~ in 
.IDme way with TI.,Rs in me jlfoductioo oJ ROS. For example, ROS production Induc.ed by lymos:m 
can. be enh.anced when. cells are preslimulated with TI..R ligands, indicating that the Decttn-l· 
triggen.."j response can he primed by TI..R activation 1151, There i5 also iii requirement for Syk in 
ROS jlfoouction try macmphages foilowinj! Dt.'Cun-1 ligation t 14]. Howevl.."f, thL~ respiratory !lUl'Sl 
does 1lI:.>t occur in all macrophages. Evideru.--e wg,."'t':l<ls that macrophage;; can exist in two statClI. tlnc 
that i" Jl'!'rmis,s!ve to Syk activatioo and ROS production and one that is not, These c.e!ls Ihal initiate 
1I respiratory hurst repre.~11t a specialized su!Jpopu!ation of macrophages that are f>omelluw prtmed. 
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18.7 CYTOKINES 
Activation of Dectin-I f(','mlls in the pnxloction of Ilumerous chemoitiflt:'s and cyloj(lnes. such a.~ 
TNE IL-IO. fL-:::. IL-t2.IL-6. !L-In. Il-ll1. MC?-L and \>UPla [2.5.\U5.49J, The most welJ stud-
ied in relation 10 Dt'Ctin-l ifll.!uced prodUi.:tkm are de",,:ribcd below. Cyloki.llC' pmdllCtion Wld other 
resjXlllSC's imlu\.'('1l b" [x'Clln-! are summarized in FigUfC IliA. 
18.7.1 TNf 
Tumor m'crosis factor \Ti"FI is an c.sse1ltial proinllammalory cylokine requirtxl Ior the successFul 
ct'ntm! of many fungal pathogens (50·S31. Thcrcfore. it is no! sllfJ)riging that Doctlo-l ligation 
by zymosan :mdlhe fungal pathogL'IlS induces TNI" production [2.151- In fact. Dectin-! iSI.tlC' 
!1flit non-TLR f('Ceplof identified as being invol'ilxl in the generation of a pminl1ammatory 
response to fungal pathogens. Studies using cell lines expressing Jl truncated version of Oeclin-I 
lacking the cytoplasmic tail demonslrated that the Dectill-I cytopJas.mk tail is rt'qllired W 
induce T.:"-IF production in response to 7.ymOS:atl !2.15j. However. particle intemalil:ltinn is n01 
ft.'quimd. a~ cell Iinco!; expressing Dl'Ctin-l still sil(y;,.' e!t!Y:lI.ed levels of TNF production when 
phagocytosis i~ inhibited 12J. TNF production induced by Dt'Cl.in-1 also ft:'quires the recognition 
of another compollCllI of lymosWl by TUn and signalinl.; through the MyD88 pathway [2.! 51. 
II is well established tllat :;;!.imuiation of TlRs !ead£ to activation of :'oll"idl and produClhJll of 
pminflammatofY cy!oldfiL's such as TNF. However. the specifidty of these rCli-prMl.Sil!"s is not 
clearly understood and it is believed lhat other immUnOfet'ejJ{(lfs cnntrioote to their indoc!ion. 
This appears, to be the case for 11..R2 and Dectin-I, lL' tile simultWleO'u& eng3ltement of both 
these receptors greall~ enhances TLR::!·mediated TNF production 12.151. Gross et at. ha"!!' 
recenlly shown that bone marrow derived dcndrjtic cells (HMDCs~ from CARD 9-de!ld~nt 
mk:t:· displayed SoCY'erely defective TNF prOtluclion induct'd fly zymosan [:;41. CARD \) is. a 
CARD protein that is related to CARD! I which is mentioned prevIously_ In Ihe same study, 
indusion of sp!."Cific inhibitors of Syk aoolisoL'd zymosan-induced production of' TKF by wild-
type BMDCs_ Thls w\rt shows that zymosan-iralured prmlllCtion of TNF is highly dependent 
on Syk and CARD 9. GrogS l't al. al:;.o provide evidence to support the idea Ihat CARD 9 
operates upstream of HellO ami Maltl If.) transduce signals lor NFI(B activation and cytoll:ine 
production [54j, 
Dendritk: oolt Phago...--yroma Il- j 0 
Macr~ge: Phag()o::y1Oma 
IL-2 
TNF,IL-12 .. ROS 
Il-'!2 
flGUIlE 18.4 Rt?~r·ons"s .n.dun'd b-f n"CIH1-! dod Tl. FI2 .ignaling r",lthway~. fungal slimulmiou "f 
Q1!1l:Urilic ;";'<1llsim.llJc('s IL-to through the Oectm-!-Syk p,;!thw:lY, ilnd HA~ lnruugh the TUU-MyDSg 
piUh·",'a,. !)<:!C'lin-! and TLR2 collabi:oratil 10 induce !L-l in dendritic cells .and TNI'". UA2 am! ROS jJl 
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18.7.2 IL-12 
Doctin-! also enharu:-eJi 11..,.12 j:Woductioll induced f)y TLR2 stimulation [151.1l~12 ptays a critical 
mle in ThI-bas<.'CI resp<mses. which have ht.'f'n llnkt'd to resistance to fungal infection r5~1. It has 
been suggested Ihat De..":ti n·1 rec~)gnitioo of ~g!UC!llL~ in fungi may sme to focus Th I-type It'sponses 
thmullb pwductioo oHL-12115J. lJnllke TNF. tbe proouction of 1L-12 is CARD 9-iooependen! [5-11 
and only partly dependent on Sylt. as shown using cells from CARD !)-detlcient mice and Sylt-
deficient mke 11654]. 
18.7.3 IL-10 AN!} Il·2 
ZYIOOS1ln also induces signilicant le"e\so! Dectin-l-mediau.\lIL·1O and 11..,.2 prllductioo [16A9]. l11e 
production of 11.-10 is, stmlewllat surprisinll given tbat 1.1.-W eOllnter'd.cts the effects of [L·12. 
IL-IO prOOllt'tioo Ila$ advantages and disadvantages for !he ho6! durin~ fungal infection. It impalr!i lbe 
antifungal effector mechanism.s of pba.~1e5 and !he secretion of flfoinft1l:lMlatory c}tctines. Hov.'-
e\'ef. its anti·inflammatory action may be beneficial late in the course of infection to aid in !he f(!(i(llulJon 
of !he inflammatory It'spome 1551. TIle prOOuctlonofIL-lOby dendritie cells isTLR-irn:k.~ndent 1161. 
but It'Quil\'S the cytoplasmic tail of DI.'Ctin-l. Like TNF. lJc\4:in-J -medioo..ed IL-IO prOOuctioo is dcp..'fl· 
dent on Syk and CARD 9154J. 1L-21las an essential wle in tbe development lind jX>flpbeml activity of 
l\"gulatOfJ' T cells [56-58J. which are rcpurtailu have an Ci'\sential role in prolocth'C memory immunity 
to fungal illfectioo.~ [J4 ,591. Production ofIL-2 It'Q uires the cytoplasmic tai! of Decti n-I and is depen-
dent on Syk and CARD 9154J. MaximallL·;! syntbesis also requires signaling \'ia Myl)88 116]. 
18.8 CONCLUSION AND FUTURE DIRECTIONS 
Tht:! disco\'(!f)' of DecUn-1 as a rt'CCpkJl' till' fungal pal.OOgens lias chan!,<N !he way !hat we !hlllk 
about 000-TIJ~ PRRs lind opened up a ne'iL' fl!Cel of innate i mmuoology. 'The 1l.Rs are dearl~ key 
components of the innate immune system that rerognilc a wide range of microbial plltbogcn5 .. How· 
ever. !he efll<.'fgent.".e of Dectin-I as tbe first example of a Signaling non-TLR PRR ha~ !\b(lW n thai 
TLR.~ do not flloctiofl alone. Furthermore. th/.!' collaborative signaling betWt'ell 1x.'Clin-! and TLR! 
has provilil"1.l !he sli.eletoo of willi! may be 11 valuable model for othef roceptor~. 
The immune re:>pon.'ie i.> 13uoclled in response to micrnbiallt'Cognttlon by a complex ne(WOfi;. of 
It'Ceplofs. The specific cl'lluJar res.p.ln,'ie 10 Ihis recognition is dependent 01'1 functional cOIJjX'rntion 
of do\!tnsrream signals initiated by It'Cep(Of activation. Dectin-I colllllxlr.iles. with 11_R 2 to tailor the 
immune res.poo.se and ioouce proouctioo ofTNF.IL-12. and ROS via a nO\'el inll!fllction involving 
Syk and other unknown mol...cules. Future feS<!'Mch into the nature of Dt.'ctin-l ami TLR2 collabora-
tion will deline this fuoctlonal cooperatioo and provide insight into coUaboration between (Jlher 
im.munofl:."Ceptors. DC{~lin-1 is therefore likely 10 be the first of a number Hf flon-TLR but Sylt· 
("mpled PRRs til at are critical (or the oolltml of various infectious agents. 
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Complement C3 Plays an Essential Role in the Control of 
Opportunistic Fungal InfectionsV' 
S. \lid,:) Tsoni.! Ann M. Kerrig,an/ Mohlopheni J. Marakalala,l Na.rl.'11 Srinivasan,l Maureen DufflcJd,2 
Philip R. Tllylor.·' Marina Botto,4 Chad Steele.' and Gordon D. Bmwn u ,* 
1",1,;,,/£ of hlf«J;o"s lJisel/iSl! ilma Moif!t:"iar M~diciF"!, D",~ of Immwlolq;:;'. 1 and DepUlmmt of AlUtftNtkical P"th()J<?;~'.~' 
crs. UHi'_i~' ol Cape loom, (ape l'i:M.l 7925. Soulh Africa; De"smrtJ'lti of Med.cat lJiochemiUr)' and ImltJ''''tllagy. 
Cardiff l1>li.l'iT.'ii1Y ScJuJol or Mt!1.1icim!. Car{lij CPU 4Xl\i, United Kj;~'$i(.'ml; Imperial ('(J{te'?!f. PQcul/y oi 
."-f",die;" .. , Hamme11lmilit ('Jilt/PUN, J..o.Jdr.m W/1 ON!\~ Ulliltd KHlS¢(Jtn~; IH~m tlf Med'd'l/!. 
Urii:.'lY'!i.')I of JlJllbarl1i!l M Bim,it;gllam. Bimmllfiwn, .4~~: ami Al~'n:iml FUitjpJ ~ S«ti"",; of 
l~' ,'lItd b,frr:tMJn, Di~ qAIJ{ii.ai Meriice, hwitulit of .~al Scie"ce<. Far/'1l1erltili, 
u.:i.~ at Al:>mm~ .1benJ~t A1U5 27JJ. UttiJ,td Ki'l~!£JI'ri' 
The illlWill: recognition oJ funpl ptttbogen~ is a crucial lin.l sl4~p in til'" lnd.uclion of prult'CU"'" antifungal 
Immunity. Compl_~nl b Illoogiit 1(, IK! nne Iwy C'Il>IIlp(IlIrnl in lIli. pnlCCH, l"adlitAtilig fu.ll'~nitiollllnd 
indudng ~arfr infuunmalion. H_llVU. Ihe roles of'tlte individual eompleltllfnt romponenls han lint lK!i!u 
£xlmlined alt'UJ>iwly. Uere !IU ~ used mel! lacldng L'J to namlnt it!! ~DI£ inlmtnunity to opportmUstk 
fungal pttlhllgt>m and sh_ Ihal 'lib tOmplemelH rnmpancnl Iii: eJlSnltial for r~llrntc w iofectlims with 
t'mutide /Afbieem and CMdidlZ glabmte. We dt'ftloostralt that 11K! lIbsellCt of (:) impttir~ fullglll dl:arlilnCIt bul 
d~s not a&1:I int!.timmalory rnponses. We also lib_that the presen« 1111' C3 ronlributcs 16 IIlC!I'taIlIy in min! 
challmgcd wilb ftry higb diYsltS of SfHXfwl1H!fl)lr~ curvisillt'. although tmse dl«15 wen! found to be mullS!' 
strain dl:pmdml. 
Over the la~1 fe .... dec,ldes. !TKmm medica! pra«ice and 
"''luir<XI immul1odeiiciend« haw: cxmtribulcd to.l >Ollmlanli211 
increasc in tite incidence of illfcctkm. with normltlJy rommen· 
sal N nonpathogenic fungi 1)2). prompting a renewed inlelQ;! 
in our undemanding nf (be morhanism". underlying 
PW!,,;;:ti''C immunity. Identi!>':.a[;on and dJaraclero.alioll 
of the. rca:plnrs invnlvcd in the innate recugnilion of !bcse 
organisms are ni parlkular imp<>nam::<:. il6 these ~pallern re.-
,xgnilitln !'C':':P!')!1>" Il4) m,t are responsibk for mediating 
(Ile recognition and u(Jl.3:ke by phlll:cJoi.ytes but ai-.;) 
initiale ~1Id direct tite re5tilta.nl immune response \ 17). Wbile 
nmm:mus nnnopsnnk pattern r~';iJgnition re('Cptors Inr fungi 
n.llvl! been .. eli dlMi!>::kriled. induding """'cral member" Qf the 
C -I)'P<! kt.1in alld Toil-like receptor famili<.'S (far felXn! fe-
vi<!'o\'5. sec rderencea 10. 11, and 32). less is known uhout the 
op&onic mechanisms of IUllgaJ reoognitlnll. sucllas thrnc me-
diated by complemen.t, ot:Spitc the CSliC'nti211 mk of tllest: syll' 
lem~ in arttiflHIj;,dl immunity (141. 
The (cmpkmc,l'd .ystem consist; of more than 30 ""rum alld 
ce nul:!r rurtace proteins Jnd is activllted lhmugh r.h Tee IlllItll 
wU(,-", the dasJ!kal, alu:rna1ive, and lcetin pathways. Tri£l1cr. 
log of these lhtre p"t!t\HIY' initi~1l:'5 ertlymatk ~a,"-ade, which 
G>rivcrgc on Ihc thir.:! oomplement component. C1, wh(JI;!C 3.(-
li>,,!ion leads to microhial opS<Jf1 if,aiion, !be n:leaJiC 
,. (·.ofr..:·!ipt.wdil<t:g HUlhtnr, 
Infcctkm., Room .1.2:0. In.~tiu!~ 
A,,~ro'c R".d Wcst. 
.j.!··1?:.l-55.9,"", F~x: 
CIa ;lJld C5a, ,md the geneI" 
3c~m:1ll ,,f lmmll!!litv and 
lJ IlWcmrr Of AI>-
Kingdom A1l25 
"''"'-,:0:1'''' .... E-maiL gordon 
atiun Hi II m~mhranc atUCk enrnplex (!>.V,q (1St.. AClWaril1n 
(If the da<i<>ic"j !"ItDW.), < ... 'curs pnm"!'ily following the hjnt!ing 
tlf ('tq tn ;:mtioo...4y'ltntigcn cm'l1pk\es. .md .'llthiJU£h iOY(ljn:d 
in Ihc aml <If the immune ~J1;!em, this r.atbl>.'ay j" al$o 
try' n3lUnti ;J;tllihodics, thereby mn:rlhuting to the 
innate ,eQ)gmuon of fungi llll). Inilia/bn (,t th" allC!1tati ... : 
pathway c'll:UIU throogh the sporuaneous actiyation I1f CJ nil 
miant>iai !ilH'frn:«. and the lectj~ pathway is initialed t<y the 
hinding of the manoosc·f>im:Hng lectin W "'lrrohydld!eS Ull 
mi,,,,nb! surl~ 124.1, 
Ali three' m theM: pathwll~~ lire induced. hy op!l'onuIlL~!k 
fllng:!.1 pa!lmg):J1$. im::ludin;g C,uuiuiu ,1iNru",r 03, 15. ~4), iJJ· 
though tile aitemative pathw,,: maylx:: th.:: mlm uilkal (7,15), 
Tile pmlecai,·c role f!f c':lmplem¢nt in immunity tn these p;IHw .. 
gens bll$ largely been determined in mice treated with cc,bra 
vennm focMr {C'Vl'l, .... lliIch depkles liCrum wmpkmenl fry. 
(orming II pOlent C3 mnvcrlase. or in C5-ddkil:ml m')Usc 
str:tim .. such lioS A'J <11 DBA1. ",111m: fungal op"onilation reo 
llllIins intact but the anim.ais lack the ability to Il'!oaate C5a elf 
the MAC (b. 7.9. W, I'l}. W!lv G-defkiell! mke an: SUl'(CP-
tibk L~ still Ul1ci¢!l.T. but is likely t\:) !>e due tel a!>eHant illna.'Tt, 
maim), re"pn~, a~ tbe MAC ha.~ liltle ¢lfec! Oil the \',,,bili!y 
of fungal i 15, J9). Although the roles of each ni the 
pathways il!.:li'llllticm rune been relatively 1,,-,orl)' 
examined, re...'1!n! stud,!)!; nave ~Iarted In :tddrcQ; this issue. 
Ion king at tile mh: of factar B. Cl, Clq ant! maIll'l\.lElt-binding 
lectin in Ille control of systemic candidiasg 1.11). 
C~ is ~ 'Celltral l1Jmp.mcnt in aU ni the ~'omrlemcm patl!· 
"''')''. as de""ribed arnl'le. but it na.: n,M bren studied in [",,13' 
lion with respect to !ullll:l1I infection. Sludying the ml.<: of tbis 
wmpkmen! o.lmp.;lnelt! in isolation is particularly relcyant, 
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1Mft IL" MeP.1 11..·1. IL.10 1flIl 
flG. 3. C1 C. f1J!>M:_. C3' '. lIOO wild'~'j)I! role<! "'~"ff ,moooo i.p ..... itb I x lit CHJ 
of C aj!}iCiInJ. (1).""Wa00i! fJi irohu;:,d pcliwliRal ftUlid !~' hlsmgrmn) or 5Cf\llll (unfllk'll 
~ml wltlI C/lfwiidil atfunms k-ad~ W C\ d...'f'OOi00i! {'O The diin-gray ponioo or the !li!itogl'll.m roiClil .. '" ulmsIDcd panid(s 
P"coOOa."l'-<1Il1y e,)ljU'lll}. (II> RCPfI.""GUtr:" rk,:,,' ':Y1ll.'lmlrit: . sboo.-mg In" ~! .. ;,; u,;cd (25', ro identity t.:auilcd !>clll~bit (Nf)) am! 
rn<!(I''';:~lC!ma<:n'P~~ (M"l P'JPUlaU£O!'15. (,.1 ddr.;l'dlt), dncs _ alk'\:! cellular IlXi'WilII;:m iWlld 1)1"'. 5.71 x HI" 4 .. 11 "- W'lOW ,db/mI) 
(C) 0f fcdoo:' inllam:lllilmry ~ll)kin.: prnliKli<>n (l}i fDlkw.illl! Lp. &ilmmim'iUIDn ,,1 C Il/bi..'fm!;. Tn" frr til.!: .... ;kll~'P' ar.: iI$ (ollows: 
R.<\NTES. HI'; ~ 1.0 p§"m!; G-CSF. 2.-2U!: .\34 pg<m!: granulocyte eSF {G~H:SF).19:: :. ma.ropilaF' illhihiwry pl\l{cin 
!" .MINa). JI} .: 36 p";ml; Ml!>:,r r!<Xliliiis fa(ror (TNT). 2! I !lA, 6.1(,1, 1.1(,9 pg'11:l!; mdoocylC dll:'n-.:%UI!3ctam r-rotdn I 
(MO'·I). 5J~;1 , 1.41 pj!l'oll; IlA" ,11- J Ii I'jIj'ml; H.·I\f, .~ ~~'fOpha!!C irnhib!tl!'1' prnl.:m til ,MTI'·]!!). lh' 
12 pg:d VJlu<;s for die wild tYfIC vtl'S1!.1 ute ~ fcliOw1; Ct;t.Wfl. I .j(.~ ;;; M I Il\!.'mt, KC. 5Ji, • 1 n '"rsw; U ZJ -
fJ!lImt ~nd It.· Iii (Il ·11l), 77 , 14 ,.-:i'SU,~ !2!l ,; 11 C\ ddkh:>~ akn hasoo'CIr((! .}1I imilam!ll\a[iol! folk""n!! i.p. mdCt1.klrn 'IHtli bighCf 
dnw, .: I , liT! CFt' flf C m\bO:""" '. "'lid 'YI". x • 931 " to' ,m"J ,,,cU\'mtl. •• I' <: H.fl" (" " [, an;",,,ls I'<'r gr''''l!, f"'r c"p,:r,m,,,,,) 
The dalJ $1Y",.11 m IWlci C arc pooled from UIJtCC il:dq:'''~rll "l!"-"fim":lITh. liars jlldk1l1C rru;"n ,';;.I"e'1\ III the <lau.. 
"tI~ dclickllt ill Cl lIll.' ~lts«'ptlble to :OYSkllllk illfectloo 
with Cglabratn. We also examined the roLe orC} in Iii<: <:or-Lml 
of C. glabro.llIt. annther organ ism .., hleb hall been :lIlIl'lociatt:d 
witll infections in immun.ocClmprmnil!Cd host.>;, For Ib~ e,· 
perimenL" wild·tY11'e and C)·delklelll! micc WetI!' infl!'L'tOO Lv. 
with 7 X 10' Q'lJ and J;W'ViVlll WJlll> monitored Cll'er tim<:. [n 
O.')otra..t ttl the wlld.type mke. which "'-efe fully resbltant to 
inic<.1.i(,fj with C. glDbf(Uii, ll.' cxp.::clCci (1). all of the 
<::3 <'~ mice bad succumbed to inJectit;fl with urg:mi~m 
(fig. 6). These flail! therefore rlcmollstr~le llul C3 is ;:SM:!l' 
lialty required for resistance to infection .. Alh C !!JaIN-ala. 
CJ dclidtnq protects mice agaill,;.t high-dOM! Inh.'Cooa wilh 
S. urniullt. Although 001 IIf)rmally 1:onsidcred II plithogen_ 
""'alC1i ')1 S. cNf:vis.ae ha',-e been linked to d~se in ;mmu· 
!loc<)mp1'tlmj,;ed individuals. an elke! which may be related to 
changes in the cdl wall of the tlfganism (3!). Furthermore. 
clinical strains o(S. c'Oltvisill£ ha~c oct!n :!howo to am.": lethal 
ioic;:lit1llS ill C5---dcftdent mioo ("'t. and we thereuli'e cliplorecd 
the possibi!iry that D would be important {m resiWUN:C to 
inkdinn with a nonpatbogenic wain of S. rerevisill .... FOf th~liC 
experimcnts. WI!' ini<:!:tcd wikl-lypc llIIld ('3 mice Lv" with a 
high do.e (l )( 10" Cl-lJ) ,'f a ialmr .. tof)· strllill of So ccN!visMJe 
and monitored slJrvi"llIl uver time t.Fill. 7). IThi)re 
than 811% of !he C.5illLi6 wild-type mice 24 h 
following Lv. admin istration of this organiom, wnrm:as the 
C\·i animals aU !ru!'\1ved !he ini«bon. We (lIs<) cuminc..:! 
blgtHfuse infection in DBN2 mke, which lIfC circlkicflt in Ihe 
C;; component III O.')ml'kment. and ,m,'el'llCd thai these ;lni·· 
mali, "''ere also fully fesiJ;tanl leo high. dose inlo.:li4m with S 
cHf!,i'lielf (Fig. 7). Huwever. we foulld that inlc"timl witb this 
do!;e of S. clfM'isia£ inooced only 14':"", mortality in wild-ryp.:-
BALB!e mice. suggesting thai the kvd oi this TCSfl'.!Ilse is 
depcmlcut on Iii<: mouse strain badw"und i.hg. 7). Overall 
these results; i:kmor>5trate that CJ aln "'<'lntritJUte to mortality 
upon infedion with hi"h do;;e:oe of S. UfrYi!iGI!. 
mSLiJSSION 
lin important rule in im mu!l iI,' tu m;1"Y 
pathogens;: killing through the formation of il MAC, 
by JIl.-ting lIS· op!>(lniJlS and {Militating microbial uptake. and by 
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TNF IL-1i MCf'-l IL-liB 11.-10 MlP-11! 
1'1(;, .1. Ci ~lft>.' iJlC inl1ammilwry r~1if'1fl~~ In C ,,/bicllJlli<, f'J"i ~OO \"'if4.ryp.: mk:': W\:r~ inft>.,cd 
1Il11,am;wl;ofY rdflOn~;l W\'''l'~ m~;;sW'oo <II doy .t. v'l.} RtPf,'Sl'l1tam", Ill:... pmtii<-
l".x:ruilc4 IIWd'l1ph.ill!l~'. dctkkllL) d('<.'11 lit'l alr':'1 cdlular r(.'t:flli~1'lI (II) (If "''' .. m'''''R'''~ 
adt:nillisu.,t.rlfl C lilbia",.<. ValUe'S wiM lypn"rMlS {J' '. foUtlW>; U I': x 
llw wiW ~'jX an: RA1'fn::s" M ± G-CS!". ~n .. 
CSF ,GM·CSh Ll . 1)3 pg;ml: lL·m {1l.·lbl. lIJ.1} , ".5 inhibitory pl'(1I£m \" 
(aoor(rNF!. 115 : ~"pg,'ml: !1'(', 2.1 ' U pma:ifli ,11.4(11.1 
11,· til, 53: L': aoo illitCI0pllitgC ~$ " U) P1li1nL ., l' <: In >-
n~ data panel D ;u., pt'oIcd fmol !he;;.: OJ:pcrilJX!lL~ ll<.rs l!!iliGu( mean values oJ the 
to trigger complement aCli~aljon since :he 1911f);' and hav" 
!xcn used \0 help dell"e tilc a(."ljvatiim p,athwaY'12.). Although 
fungi apfl<!ar W be resistant h1 mmpiemcnt-mediated killing. 
pr.:sumably bccau:;c at tbeir thkk cd! ... a.ll~. the (~jlSmlic and 
inillJ.mmi!wry compo.,ne!lts of n>mp!cmeot are thought t() play 
a central ri'l4c in amifungal immunity I, 15. 211). The role of 
complement has. il;;J\\'C'Ver. largely I:x:en determinoo through 
the l:l."o;: of CVE although C5-ddident mice hllve a&1 be<:n 
examined. niven Ihc thmmbin-depend.:nL C'·jndept'ooenl, 
plith .... ;ry of C5 acti'l'ulinn ( ! 2. Jj)). we undrrtn()k ll) examine the 
rule of ('3 ill immUrlJlY to sew:ral ()PporH.mistk ftmgal patho-
gens using C3-sullkien! ood CJ..dclident mire. 
e o/tlk:altS ".n trigger all three path .... a}'s I..-.f cnmp[cmelll 
aClhation. leading lil the rapid depo.1sition of CJ 011 tile surface 
C<f this organism and fadlitating its uptake by phagtX,,}1cs I,! 5}, 
Animals irea!ed witb eVE or h,t"illg dcfkklh."}' in C5, Me 
mor~ SU,liCcptiblc to bnth ~'Ystcmk and (>..I IanctHlS candidiasis 
(! ~). lind here we 8lmW Ih~t C} i~ 1Il'<i1a11 eSj.cntillll oompone!l! 
of protccth't' inllate immunity 10 C albiCt%P.JI. 1.0000n! ChesullS 
in inm:a,t'd $U.""eptihiHt)' lil info.timl with thil; organism Wig. 
1 oou 2), ",hidl hs due to defects in dearance iFi1; 5) but 
not dcf!:"tiv!:, iniLimmllttll)' results therdore 
sUj!.£est thai tilat the inflammation seen ill the kid-
neys and bb;)(xl lit :I days (fig. 2} is due to higher fungal 
hurden. and not d)'SfcguJalmn .;)! the infi:tmma(nry n:spoll."'!. 
lnde-ed, although nollru I)' represcn!all\'" oj s)~mic ink..:tk'l1, 
using a pe riwncal model of c,mdidiasi>. '\OIC .,)U!d dl!'monstf:J.le 
that the inllammaLol)' re'P"~~ in C3·ddkicnt animal" Were 
equivak:1t 14) tilllSC: d)!er.'oo in II>'ilrl"lyp<: mke (Fig. " lUlU 4!. 
Gil'en that su=plibility dut' 10 C5 d"tidc[Ky' results (mm 
aberrant inftammatmy !'e5pn!lses (!'ii. thcS<! results suggcst 
thitt C3 is !1D1 c~!1tial!y required far C'i activation. Under 
conditions of C3 deficiency, C5 artivatioo is presumably _. 
diated through the thmmbin pathway (11. 3(1). 
C gJatm.uiJ b another spcdcs nt Ctmdida \\' hkh has heen 
j,naea;ingiy a,.'5f.)cia!ed wjlh (l'pl,,)ctunistic inlcctioll.'4 in immu· 
m~wmpmmiscd indh'iduab:, yet reialj"dy Ii!llc is knm',rn llb;nJI 
the Imst factors whleh mediate immunity to this organism. 
Colillc: C aibiCQ115, C. glabram does T.o{ induce I< lethal phe· 
in immunocompetcnt mi;;:e, eyen al higb inllcuiums 11). 
thi,,, (lrgllflbim can inducc the allermlo"c pathway o! 
eompkm.::nl 1lI.'1i"·ittjon f5), th.: role nf complement in lhe 
rontrol of e glabmta il.as mit yet !'lee n e:t:.1mined. Hcn:: we sh.;)'I' 
tll.at milX' dcikil:nt in C3 are higbly sus,-cptlNc 10 .ystemic 
infection with C. gfabrata, demonstrating for the first lime the 
I:SlClltial role of compiement ill immu.nity til this 
S. t::erIfYiaifU! h mlt normally ,:oMi&:red to r.:: a 
it bas heen rt.:Jhlrtcd tn ClIU5I:: inf;;:t:tiuns under certain settings, 
sLlch as immllnosupprcr;sioo !l5). 1n mice. thc ;rus.;:cptibiHty of 
C5·de.fident animals follo"i"g Lv. adminl5trlltion with rome 
dl"kaJ iw!ates ha;s ocm(mstratcd tht.: impc,'ftance "r til<: <:nm· 
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FIG, 5, C3 d<'r!o:1cClCY d .. '1aJ~ hlfllPll C t ' .aru!wihl-!ypc mireWl:N milXlcd is, with I " HI' CHJ orC'. a//liClfj,rr, and 
rn '/",uiotl, Ofg,ilIU WCfQ li:wrmincd al lA.. and n t, ' .. I' <: tUB (" - 6 BlI~ indicate fllCilll 'i1IllOCs 1.1! lib;: dalA, 
14-11 ",'lid 1}j!C 1''i.'1lllI~ \:3"" arc <ii, (nl[.;,...: b:,'an. 2HJi,' Wi 'l'i.'1'ltlS :11.155 ~ IU!lJ!.1'i12 ' IO~ Vl'ftU~ HZ, 
11 W1"!W.':17 (,,~ CFUig. main, zn !, {,Ii "cnru~ 9(", ! 36? CFUig;qlI~n. 1.50:< " 1.911 
LS(, ~' " (,.(1 ~, I(~ CFllig. Valll\.'S for 4S-l! .... 'ld!JPC \'crsw; CJ .. • .. !l!'C lij fult;VO\'!I; 1;11 ,~ 
~ 100 CFlYg,lwcf, 12& ,: 13 vetlU>::11 ), brain, LOOi' " Wi ,,,n;w; 22W "' 
57,W2.1 ;t :!I,,~I~ 'CmlJi J,1I Ji)', Hi' CF·l.Ji!J. Valu.c,; fUf i:·h ... iO:J !?!'Pt ¥C1'ltiS 
1oog. <100 926.t tifft, 112 " I~ Vii:rws 211 ,,6, CI1J!g; vrain.. 
J.()71 ;! 7'n and tidllq', i 5.!G versus ~'!" 1')' '~ 4.4 .f; I!l" Cf1J/g, 
Ofb'liinismlI (4,. Here we explored me deci uI C} delkieoll' 
upon administratkm of very higll OOW5 of It standard i.abora· 
tory strain or s.. cen ..... <ilJ.e, witb the expecta.tioll lllat the lack of 
fungal cleantnre caused b,l' complement I:Iefkien.::y may pro· 
mote susceptibility, as we hoo OI)IiCl'\'OO for C. ttl/:licam, Sur· 
prisingly, we r,nmd Ihlit administration of high doses of S. 
cf!f't,iiitu caused the rapid death (wimin 24 11) nf C'SiB! i(, 







{) 7 14 21 
-- tlme(d)--
FI(;. (" Cl ikikj~Il.") iocf~J&i!' SiIISOCptibi,i!yw in(~(!l<1(l wilb C 
I)inm/D, C'57nL¥'> '1Itild"IW:: (e) "au C~tkicnl mke WCfl1 in· 
["''tcd "Ii1h 7 Hf (Tty ,'l€ C l)in~jQ Lv, 1I.Il<l mooiwft"U fnr 
!ijU'\1"a,l (lI'i:f 21UaY' as .;1escrJb..."lf ill Mliwriah aDJ M~ll1(>ds, The 
~1liJw!llltc piYJkd fmm r".'O ind£pcmkm cxp;:rilOC'l'lI£, +. P < 
wild-type mic.: and that deficiency in C3 aoo C:< was, ill {lILt, 
pro!e>.'tive uooer tIlese rooo.iuons {I'lg, h Inocula1ien of a 
high dose of C. afbicl1<lS has arm been moW!! to induce rapid 
klhality in mice, and in line "llh our findings using Succharo-
myces, tile. lrnw> of compkme,1l1 fUIll"l.ioll 'ilia> prote,ti-,e ill thi, 
!Mdel (81. These ft1l'ullJi therefore suggest lila! oompicm.:nl 
S.~.lae 
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FlG< 7. C3 and (5 d£lidcncy klhalilY irnllliCC:;Z 
wi!h S. wild-cY[IC or Cl· 
mic.: WCft tnfcaed .,.'lll 1 ;.< ll)" CFt' 
ill :£ c/!I"eV<\'iae and WL'1'l! munhnroo [N ~W'\'ival mw ~ I thvl., :as 
deuitx:d ill Mali.'flltb a.nd Mci.llodL 'II>;) data sh(!'I'I'!l arc p.:';li:,j lmm 










ESSnmAl Iml!: OF C3 IN CONTROL OF n;l\CAI INIHTIO;';S 
it,elf oct~ in " tleietetious faMlin!! up,m high dnse ir.'1l{:uialioll. 
irr<:"PC>:Ir.'e ,.)1' the fungal spedes; h,JWewf. the mech,l1Iisms fill' 
these etreels "rc still uru:kar. Panku.iady intriguing is the ap. 
p.arent ,tr;!ill sp<:>;:rtidty in this rcsponsc [the .-1'1'<:,,1 WlI'> fM Ie", 
marked in B/UJV.., mice Ih4fi in C'i7Bl,b mi,~>c). 
In .·ondusion. the usc of g;ene.Jehdellt mk;e h ... \ proviJ<'d 
mVlliuabk mSlgh b i n(" Ille fun>:lhm;> "j ind j.'idual C<>fllpiH'IenL, 
d m,my bi.llogk",l 1'",:x:eSM:~. We have :;;h,""n here that C3 
plays iL'l c§cntw role in the cOIHrul of opportunistic fungal 
ink_linn;>, bUI it may al",) ({,"tribute Ii) mortality under .:ertaill 
conditions, Although our studies willt C di)')ic6Jtn suggest lhat 
the primaryl1.1!1.:titlll ufC:' is ill mediating fungal dearam:e.lbc 
eltact role Hf lllb; c<)mplement component in the Cimlroi of 
other fungal I'atb(~genss!ill neoo5 1.\.) be cxplnreti, 
,ilJm. Ilk ;'O<lllatl .. d!iIV fOf C<ir,' "r til.: i!lliillldr- <ls<:d 
In 5!lIily Fk;j: fOf belp ",'Jln Itil~okil!:" 
We' lhlut); tlli; Wdkomc Tnm 1;1( fuOOing. Thi> \\ult Wil,\ alro 
!IDWOffcd by grant> frern thc Parkr Il Fr,wds F'~rnla!ltiO, (bi: Amer-
icM LUll!! A,,,,,;!alion. and NlI! HlJtHll> Ii !II) CS", (; JJil i;; 
a Wdknfile 'i.:niaf 1',::11"", in Africa. 
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Syk kinase is required for collaborative cytokine 
production induced through Dectin .. l and TolI·1ike 
receptors 
Kevin M. DennMy1, Gerben FerwerM, 111l$. Far.".7HJufude1, flwira ~'lil, Janet A. Willment1, 
Philip R. Taylor",:l, Ann Ki'rriganl, S. Vicky none, Siamon Gordonl , F'ri£derike Meyer.Wentrup4, 
Gosse J. Adema4 , Bart·Jan Kullberg:.!, Edina Schweighoffer. Victor 7ybulewias, 
Hector M. Mora.Monte-li, NellA. R. Gmt,o, David L Wil1iaJllJ~ Mihai G. Nelea:.! and Gordon D. BroW/l1 
J Institute ,If Infectious l)lse&SC aml Mok-cular M<.'<:lkine, Clime;;! LcoonltUIY Scicncr:s Division of Immunalu)1;Y, 
University nf Cape 'fm1<n, Cape Town, South Africa 
2 Ueparl:!1:1ent nf lnterrtal !>.k"hdne and N~ltlt'11iCn Univer>1tjl (;cnter for inf{.'Ctious Di'sc~" Radboud University 
Nijru<'1lcn, Nijrru::JilI'n, The Netherland,; 
3 Sir William Dunn Schon! fJf Pathology. UnhwsllY of OxfiJrd. Oxford, UK 
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Recognition nf microbial. cUmpOtlL':tlU by germ-line enL"-xkrl pilttt.'nt recognition 
rt'l"t.'Pturs (PRR) lnitii!tt."S i.mmunc to inft.x"tious agents. Wc and ot.hers have 
propo;:ed that pairs VT se:ts of I'RR hm'! immunily. One ~llcll paircompriscs the 
fung-"l ~-glw:ml rcteptor, Doclin-l, which collabun.ltcs Ihrough an ululefin<."(). 
rneCliarrismwith 'foU-likc teccp!ur 2. ('1'11<2.) tn indUL~ optim;;l (:ymklnc te~f,'lJnsc, in 
Vole show here that DOl'tin-l signalinj{ thmll,.l<;h the "'Pk'Cl1 tyrosine kinase 
(Syk) is required for this colJaoorl!IUln, whiclt can IlL<;£) occur ... 11h TLR4, S, 7 
and <), Deficiency nf either Syk or the TLR adaptor 1\.1)1)8J.'I .lIoolJshed col.J.&borath", 
rcspon;SeS, which include TNF, jl,llP-lu and J;.fiP-2 pruduai!Hl,and whicll .. rctompiir .. ble 
to the previnWily dClicrib.."(). ~ynerlO' between 'flJt2 and '11,1\4, Collaoor.ltltm of tht~ Syk 
and l1..R/MyDli.Rpathw;l'iS rt'~1l1!S mSU>'tJllntxl dt"li;radatim of the Inhibitor"f kB (IkE}, 
enhancing NEl:f1 nucicartratlsiucation, 'l'hese lindin,:;:s C$l;;]}llsh the fir>1 examplc of Syk-
and Mybss-<:oupled PI:tR CtJllalmratiun, further l>uppurtinx the roru..'L'Pt tliat paLrtxl 
recepwl'S ;''{lllab-urare to {~ontTol infcrtiow> agents. 
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indicates that the defect in these animals. is due to the 
lack of collaborative signaling from the Deetin·l path-
way. Receptor collaboration may also expl.lln the 
previously observed synergy between mannans, which 
may be TLR ligands, and P.glucan fungal cell wall 
components in the response to these organisms [7; 201. 
These results thus highlight the importance of receptor 
collaboration during inft.'Ction as opposed to receptors 
functioning in isolation, and further support the concept 
that pairs or sets of receptors collaborate to control 
i ntectious agents. 
While Syk has been implicated in the modul,ltion of 
Till responses in other systems [l0. 21-24]. the 
interaction between Dectin-l and Syk occurs through 
a novel mechanism [91. which is likely to be represen-
tative of other receptors involved ill pathogen recogni-
tion such liS the HN-l receptor Q..EC-2 and CD66d, a 
PAA for Neisseria gonorrrweue and Haemophilus infiu-
eru:ae [25-28 J. Recently. it has also been proposed that 
the adaptor CARD9. which is downstream of Syk in 
myeloid cells. plays a role in TLR Sign..1ling [291. We 
propose an alternative explanation in which Syk-and 
CARD9-coupled PRR collaborate with TIR. Stimulation 
of TLR9 with CpG, for example, induces lL-12p70 
production that is dependam on Syk [10], suggesting 
that an undefined Syk- and CARD9-coup\ed PAA 
collaooflltes with TLR9 in this $}'Stem. 'l1lefe are 
therefore likely to be many more examples of Syk-
coupled PRR that collaborate with TLR to control 
infectious agents. 
Materials and methods 
Reagents and rnioe 
Al111.R ligands were from Im-ivoG<!n (San Diego, CA.), and the 
production of highly Jluri!ied particulate fl-glucan and soluble 
~-glucan (glucan phn~phate) have been described else\,;here 
[15, 30]. BAUVe. CS7BL/6 and C57BL/6 MyDlI8-!-, 129/$v 
and 129/5" Dectin-r·r··17) mice were obtained from the 
animal unit of ihe Unive.rslty of Cape Town. BALR/c SyIC-
chimeric mice were generatro by the transfer of SykI " fetal 
liver cells ill.!o imldi.ted BAl.B/C recipients as described [9]. 
AU prol.'edures were approved by the University of Cape 'Iown 
anhnal eihies eornmitlee. 
Cell stimulation 
Murine Ihbglyrolla!c-elicited macrophages were plated 31106 
celWm!.. in RPMI medium .::omaining Hl% FCS (Gibeo) and 
iru:ubated overnight. Mrojum was replaced, and cells wefC 
stimulated with JO l1g!mL particulate f)-glocan or 10 ng/mL 
Pam,CS14 unless oiherwisc indicated. fur 3 h. Human 
peripheral I'IM)Jl()cytcS were p"cparcd as de .... "ibed [20, 31 J 
and stimulated wiih 10 flg/roL particulate fl-glucan and 
relevant 11.R Hgaruls for 20 h. CylOkine s~n~lioo was a.'lSayed 
{} ;;008 \V1UY- VCH Verlag GmbH & Co. KGaA. Weinheim 
1"'""fA! immunity 
by IiUSA using kit~ from !lecwn Dickinson (MoUIlLain View. 
CA), R&D Systems (Abbingdon. UK') or KOMA Biotechnology 
(Korea.J. Data were analyzed using the Student's t-te,~t. 
Syk and SLP-76 phosphorylation 
RAW 264.7 t-dls expressing Dcctin-l [12J (lO"l'eJIs in 100 jiL 
HBSS) were stimulated with 10 jiymL ltlluble fl-glucan 
(g.lucan phosphate) for 1 min at 37C before addition of lysis 
buffer (l % Nl'40, 25 mM 11'Is pH 8, 10 m.lI,i EDTA, 140 mM 
NaO, 5 mM Nal', 1 mM N3"VO •• 5 mM iodoll<.ctamidc) 
comaining pt'OIease Inhlbitol'5 (Roche). Lysate supemlltamS 
were incubatro for 2 h wilh 30 ~ streplll\'idin-agarosc beads 
(Flub) preCOOled with 25 11M biotinyl.aled Ocain-} phospho-
peptide to precipitllte Syk [9] or 30 I'L protein G-Sepharose 
beads (Amersham, UK) preCOOled ",11h 5 11& 5L1'-76 mAb. 
Beads were washed with lysis buCler, boiled in 50 I'L SD5-PAGE 
sample buffer, and samples wct'c Western-blotted and probed 
wiih phosphOlYfosine mAl> 4GIO (!leeton DiCKinson) and 
antibndies to S>,k or SLI'-'i'6 (Santa Cruz Biotechnology, CA). 
For phospho-Syk staining, 129Sv thioglycalJate-clicilCd macro-
phages were stimulated with 10 fig/mL particulate fl-glucan 
for 6 min, fixed with paraformaldchyde, blocked and p<",mca-
bilized with Tr itoll X-lOO. Cells were stained with anti· 
phosphoSyk (CellSignalling) followro by donkey anti-rabbit 
Cy'J (Jackson Immunoresearch) and analyzed by fluorescent 
microscopy. 
IIIB degzadauon and NFIIB nuclear localization 
RAW 264.7 cells exptl'Ssing Dtcx,ill' 1 plated at 2 , 10' celWmL 
were stimulated with 10 flg/mL particulate ~-&!ucan and 
10 ng/mL Pam"CSK. for 2 h, or the indicated tim!". before 
lysis and Western bloning ofwhoJC-l-cl.i lysate;; with antihodles 
to lkB or actin (Cel!Sigllaling , MA) as a 10adinl! control 
Nuclear 1}'SlItes wcre prepared aflel 20 It stimulation as 
described [32], followed by Western blooiJlg with Ilmibodl"" 
to r-..'FkB c·ReI or USF·2 (Sama Cruz Biotechnology) as a 
loading control. Band intensities "''ere Ijuamified using 
Ntlllmage software. 
NFi1B nuclear translocation 
CS 7BL/6 thiogl}WlIate-dicited macrophage. plated at 2 > 10" 
cells/mL were stimulated willt 10 llg/mL Pam,CSK. for 
\10 lnin followed by 10 Ilg/mL particulate ~·glucan for 
60 min, fixed with parafonnaldehyde, blocked and permca· 
bllizro wiih TIitoo X·IOO, Cells were staint"tl with Boechb1 and 
Ni'kB c-Relamibody, followed by anti-rabbit IgG..cy6 (Jackson 
laboratories. USA) and analyzed by flUOfeS«1n microswpy. 
TIut'e independent fields conmilling > 100 cells were cowRcd 
for each stimulation type, and data were analyzro using: the 
Student's HesL 
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